

Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	May 12	EXTEND option available in structure searching
NEWS	4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in Caplus
NEWS	6	May 27	Caplus super roles and document types searchable in REGISTRY
NEWS	7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12	AUG 02	Caplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS EXPRESS	JULY 30		CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:16:34 ON 14 AUG 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:16:43 ON 14 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 AUG 2004 HIGHEST RN 726125-61-7

DICTIONARY FILE UPDATES: 12 AUG 2004 HIGHEST RN 726125-61-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>


Uploading c:\program files\stnexp\queries\10823809.6

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 Cb,Hy

G2 N,CH

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full

FULL SEARCH INITIATED 10:17:08 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 39580 TO ITERATE

100.0% PROCESSED 39580 ITERATIONS
SEARCH TIME: 00.00.02

152 ANSWERS

L2 152 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

155.42

155.63

FILE 'CAPLUS' ENTERED AT 10:17:15 ON 14 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Aug 2004 VOL 141 ISS 8

FILE LAST UPDATED: 13 Aug 2004 (20040813/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2

L3 32 L2


=> d l3 fbib hitstr abs total

L3 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2004 ACS ON STN
 AN 2004:41461 CAPLUS
 DN 140:93789
 TI Preparation of substituted anthranilic amide derivatives as VEGF modulators and methods of use against cancer and other disorders
 IN Huang, Qi; Chen, Guoqing; Li, Aiwu; Rishi, Babak; Tasker, Andrew; Yang, Kevin; Yuan, Chester Chenguang
 PA Amgen Inc., USA
 SO PCT Int. Appl., 204 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 PAN CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005279	A2	20040115	WO 2003-US21601	20030709
WO 2004005279	A3	20040311		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004087568	A1	20040506	US 2002-395144P	P 20020709
			US 2003-615809	A 20030708
			US 2003-615809	20030708
			US 2002-395144P	P 20020709

OS MARPAT 140:93789
 IT 645418-48-0P, N-(1-Acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-(4-fluorobenzylamino)benzamide 645418-50-4P, 2-(4-Fluorobenzylamino)-N-[4-[1-methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]benzamide 645418-56-0P, N-[3,3-Dimethyl-1-[(4-methylpiperazin-1-yl)carbonyl]-2,3-dihydro-1H-indol-6-yl]-2-(4-fluorobenzylamino)benzamide 645418-64-0P, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-(4-fluorobenzylamino)benzamide
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 as (drug candidate; preparation of substituted anthranilic amide deriva.
 as VEGF modulators and methods of use against cancer and other disorders)
 RN 645418-48-0 CAPLUS
 CN Benzamide, N-(1-acetyl-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)




RN 645418-64-0 CAPLUS
 CN Benzamide, 2-[[4-(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)




IT 645418-65-1P, 7-[[2-(4-Fluorobenzylamino)benzoyl]amino]-4,4-dimethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 as (preparation of substituted anthranilic amide deriva. as VEGF modulators and methods of use against cancer and other disorders)

RN 645418-65-1 CAPLUS
 CN 2(1H)-Isoquinolinecarboxylic acid, 7-[[2-[[4-(4-fluorophenyl)methyl]amino]benzoyl]amino]-3,4-dihydro-4,4-dimethyl-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




Patel

L3 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2004 ACS ON STN (continued)




RN 645418-50-4 CAPLUS
 CN Benzamide, 2-[[4-(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 645418-56-0 CAPLUS
 CN Benzamide, N-[2,3-dihydro-3,3-dimethyl-1-[(4-methyl-1-piperazinyl)carbonyl]-1H-indol-6-yl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

GI



AB Selected substituted anthranilic amide deriva. (shown as I; variables defined below; e.g. II) are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving cancer and the like. Although the methods of preparation are not claimed, approx.139 example preps. of I and approx.80 of intermediates are included. For example, II was prepared in 3 steps starting from 2-nitrobenzoic acid and 4-[1-methyl-1-(1-methylpiperidin-4-yl)ethyl]phenylamine and involving intermediates 2-nitro-N-[4-[1-methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]benzamide and 2-amino-N-[4-[1-methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]benzamide. Compds. I showed inhibition of KDR at doses <50 µM. Some of the exemplified I inhibit VEGF-stimulated HUVEC proliferation <1 µM. Compds. I are active at doses <150 mpk in a tumor model. For I: R = (un)substituted 9- or 10-membered fused heterocyclyl, -(CH2)1-2-R3; R1 = (un)substituted 5-6 membered saturated or partially saturated heterocyclyl, 9-10 membered bicyclic and 13-14 membered tricyclic saturated or partially saturated heterocyclyl, and phenyl; R2 is ≥1 substituents = H, halo, hydroxy, amino, C1-6-alkyl, C1-6-haloalkyl, C1-6-alkoxy, C1-2-alkylamino, aminosulfonyl, C3-6-cycloalkyl, cyano, C1-2-hydroxyalkyl, nitro, C2-3-alkenyl, C2-3-alkynyl, C1-6-haloalkoxy, C1-6-carboxyalkyl, 4-6-membered heterocyclyl, C1-6-alkylamino, (un)substituted Ph and (un)substituted 4-6 membered heterocyclyl; R4 = H, C1-2-alkyl; addnl. details are given in the claims.

<8/14/2004>

L3 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2004 ACS ON STN

AN 2003:950836 CAPLUS

DN 140:16722

TI Preparation of 1,1-disubstituted cycloalkyl derivatives as factor Xa inhibitors for treating a thromboembolic disorder

IN Qiao, Jennifer X.; Pinto, Donald J.; Orwat, Michael J.; Han, Wei; Friedrich, Sarah R.

FA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 686 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003099276	A1	200311204	WO 2003-US11893	20030505
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
			US 2002-379357P	P 20020510
			US 2002-415367P	P 20021002

OS MARPAT 140:16722

IT 630385-55-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 1,1-disubstituted cycloalkyl derivs.

as factor Xa inhibitors for treating thromboembolic disorder)

CN 630385-55-6 CAPLUS

BN Benzeneacetic acid,

4-[[[2-[[[5-chloro-2-pyridinyl]amino]carbonyl]phenyl]amino]methyl]- α,α -dimethyl-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

0-2 carbonyl groups, and there are 0-3 ring double bonds; P is fused onto ring M and is a 5, 6, or 7 membered carbocycle or a 5, 6, or 7 membered heterocycle, consisting of: C atoms and 1-3 heteroatoms = O, S(O)p, and



N; ring P is substituted with 0-3 R1a and 0-2 carbonyl groups, and there are 0-3 ring double bonds; alternatively, ring P is absent and P4 is directly attached to ring M, provided that when ring P is absent, P4 and M4 are attached to the 1,2, 1,3, or 1,4 positions of ring M. One of P4 and M4

is -Z-A-B and the other -G1-G, provided that P4 and M4 are attached to different rings when ring P is present; G is consists of 2 fused rings D and E (ring D, including the two atoms of Ring E to which it is attached, is a 5-6 membered ring consisting of carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O)p; E is selected from (un)substituted Ph, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl; alternatively, ring D is absent and ring E is selected from (un)substituted Ph, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, thienyl, and thiazolyl; G1 is absent or = (CR3R3a)1-5, etc. A = (un)substituted


C3-10 carbocycle and 5-12 membered heterocycle consisting of: C atoms and 1-4 heteroatoms N, O, and S(O)p; B is Y-R4a or X-Y-R4a, provided that Z and B are attached to different atoms on A and A and R4a or X and R4a are attached to the same atom on Y; Z = a bond, -(CR3R3e)1-4-, etc. Addnl. details including provisos are given in the claims.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



G1



AB The present application describes 1,1-disubstituted cycloalkyl compds.

and

derivs. thereof (P4-P-M-M4; variables defined below; most of the examples contain 1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, e.g. the trifluoroacetate of I), or pharmaceutically acceptable salt forms

thereof, which are useful as inhibitors of factor Xa for treatment of a thromboembolic disorder. Although the methods of preparation are not claimed, .apprx.240 example preps. are included. A number of I exhibit Ki's of

<10 μ M towards factor Xa; also some I are direct acting inhibitors (Ki < 10 μ M) of the serine protease thrombin as indicated by their ability to inhibit the cleavage of small mol. substrates by thrombin in a purified system; the specific compds. are not stated. For I: M is a 3-10 membered carbocycle or a 4-10 membered heterocycle, consisting of: C atoms and 1-3 heteroatoms = O, S(O)p, N, and N22; ring M is substituted with 0-3 R1a

and

L3 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2004 ACS ON STN

AN 2003:913147 CAPLUS

DN 139:381477

TI Preparation of 4,5-dihydro-1H-benzo[glindazole-3-carboxamides as IKK2 inhibitors for the treatment of cancer and inflammation

IN Lennon, Patrick; Bonafoux, Dominique; Oburn, David S.; Wolfson, Serge G.

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 312 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003095430	A1	20031120	WO 2003-US8917	20030319
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
			US 2002-379090P	P 20020509
			WO 2002-US39774	A 20020919
			WO 2002-US29774	P 20020919

US 2001-121423P P 20010919
US 2002-379090P P 20020509

PATENT FAMILY INFORMATION:


FAN 2003:242305

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003024935	A2	20030327	WO 2002-US29774	20020919
WO 2003024935	A3	20030821		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			


L3 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 US 2001-323423P P 20010919
 US 2002-379090P P 20020509
 US 2002-247096 20020919
 US 2001-323423P P 20010919
 US 2002-379090P P 20020509
 EP 1444207 A2 20040811 EP 2002-775879 20020919
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 WO 2003-095430 A1 20031120 WO 2003-US8917 20030319
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2002-379090P P 20020509
 WO 2002-US29774 A 20020919
 OS MARPAT 139:381477
 IT 503555-09-7P, 1-((1,3-Benzodioxol-5-yl)-8-[[[2-[(4-methoxybenzyl)amino]pyridin-3-yl]carbonyl]amino]-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of 4,5-dihydro-1H-benzo[g]indazole-3-carboxamides as IKK2 inhibitors for treatment of cancer and inflammation)
 RN 503555-09-7 CAPLUS
 CN 1H-Benz[g]indazole-3-carboxamide, 1-((1,3-benzodioxol-5-yl)-4,5-dihydro-8-[[[2-[(4-methoxyphenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]- (9CI)
 (CA INDEX NAME)

L3 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 AB The present invention relates to substituted pyrazolyl deriva., compns. comprising such, intermediates, methods of making substituted pyrazolyl deriva., and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis. 4,5-Dihydro-1H-benzo[g]indazole-3-carboxamides (shown as I; variables defined below;
 e.g.
 II) were prepared via conventional and solid phase synthetic methods as IKK protein kinase β (IKK β or IKK2) inhibitors. Although the methods of preparation are not claimed, 480 example preps. and/or characterization data are included. For example, reaction of 7-nitro-1 tetralone with Et acetate in the presence of Li bis(trimethylsilyl)amide in ether gave the 1,3-diketone (87%), which was cyclized with 4-sulfonamidophenylhydrazine-HCl with HCl in MeOH to give the Et 1H-dihydrobenzo[g]indazolecarboxylate (69%). Amidation with NH₄OH in MeOH provided II. In IKK β resin enzyme assays, I exhibited IKK β activity with IC₅₀ values ranging from $\leq 1 \mu\text{M}$ to $> 100 \mu\text{M}$. Thus, I are useful for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis (no data). For I:
 B is
 a 5 or 6 membered heteroaryl, aryl, (un)saturated heterocyclic (un)substituted with R₁, R₂, and R₁₂; W is a 5 or 6 membered heteroaryl, aryl, (un)saturated heterocyclic. R₁ = hydrido, halo, alkyl, aryl, heteroaryl, alkenyl, alkynyl, haloalkyl, CN, NO₂, OR₅, OCOOR₅, CO₂R₇, CON(R₆)R₇, COR₆, SR₆, SO₂R₆, NR₆R₇, NR₆CONR₇, NR₆SO₂R₇, NR₆SO₂NHR₇, and SO₂N(R₆)R₇; R₂ = halo, hydrido, hydroxyalkyl, alkyl, OR₆, CN, NO₂, SR₆, NHR₆, CON(R₆)R₇, NHCONR₆, CO₂H, and haloalkyl; R₁ and R₂ may be taken together to form a 5 to 7 membered (un)saturated carbocyclic ring optionally containing 0 to 3 heteroatoms N, O, or S, and wherein said ring is (un)substituted with R₁. R₁₂ = hydrido, halo, alkyl, and alkoxy; R₁₅ = alkylsulfonamide, sulfamyl, alkyl, alkylthio, alkylsulfenyl, alkylsulfonfyl, alkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, halo, acyloxy, oxy, formyl, haloalkyl, cyano, haloalkoxy, acyl, carboxy, hydroxy, hydroxyalkyloxy, phenoxy, nitro, azido, benzyloxy, dialkylaminoacyl, thioalkyl, aminoacyloxy, thiocyanate, isothiocyanate, alkylidenoxy, hydroxyalkyl, alkylamino, alkylalkoxy, alkoxyalkyl, alkenylamino, alkynylamino, alkenyl, alkynyl, dialkylaminoalkyloxy, and heterocyclic; addnl. details are given in the claims.
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI




I



II

L3 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:665525 CAPLUS
 DN 139:345320
 TI Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching
 AU Furet, Pascal; Bold, Guido; Hofmann, Francesco; Manley, Paul; Meyer, Thomas; Altmann, Karl-Heinz
 CS Oncology Research, Novartis Pharma AG, Basel, CH-4002, Switz.
 SO Bioorganic & Medicinal Chemistry Letters (2003), 13(18), 2967-2971
 CODEN: BMCL88; ISSN: 0960-894X
 PB Elsevier Science B.V.
 DT Journal
 LA English
 OS CASREACT 139:345320
 IT 618359-41-4
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (identification, synthesis and structure-activity relationship studies on a new chemical class of potent angiogenesis inhibitors (anthranilamides)-based on conformational considerations and database searching)
 RN 618359-41-4 CAPLUS
 CN Benzamide, N-(2-fluorophenyl)-2-[[[4-fluorophenyl)methyl]amino]- (9CI)
 (CA INDEX NAME)



AB The vascular endothelial growth factor (VEGF) tyrosine kinase receptors KDR and Flt-1 are targets of current interest in anticancer drug research.

evaluation PTK787/ZK222584 is a potent inhibitor of these enzymes in clin.

as an antiangiogenic agent. The development of a hypothesis concerning the bioactive conformation of this compound has led to the discovery of a new class of potent inhibitors of KDR and Flt-1, the anthranilamides. This could be achieved with a limited exptl. effort, which only involved the testing of one archive compound and the synthesis and testing of one appropriate analog.

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2004 ACS ON STN
 AN 2003:551370 CAPLUS
 DN 139:111679
 TI Combination of microsomal triglyceride transfer protein (MTP) inhibitors or apoB secretion inhibitors with fibrates for use as drugs
 IN Thomas, Leo; Mark, Michael
 PA Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
 SO PCT Int. Appl., 220 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN, CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003057205	A2	20030717	WO 2003-EP57	20030107
WO 2003057205	A1	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10200633	A1	20030724	DE 2002-10200633	A 20020110
DE 10256184	A1	20040609	DE 2002-10256184	A 20020110
US 2003162788	A1	20030828	US 2003-339088	A 20030109
			DE 2002-10200633	A 20020110
			US 2002-353397P	P 20020201
			DE 2002-10256184	A 20020110
			US 2002-435386P	P 20020120

OS MARPAT 139:111679
 IT 486436-62-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)
 RN 486436-62-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 1-methyl N-[[4'-methyl-1,1'-biphenyl]-4-yl)methyl]-4-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS ON STN
 AN 2003:551181 CAPLUS
 DN 139:117339
 TI Preparation of substituted arylamine derivatives as antitumor agents
 IN Elbaum, Daniel; Askew, Benny; Booker, Shon; Germain, Julie; Habgood, Gregory; Handley, Michael; Kim, Tae-Seong; Li, Aiwen; Nishimura, Nobuko; Patel, Vinod F.; Yuan, Chester Chenguang; Kim, Joseph L.
 PA Amgen Inc., USA
 SO U.S. Pat. Appl. Publ., 106 pp., Cont.-in-part of U.S. Ser. No. 46,526.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN, CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 200314836	A1	20030717	US 2002-197960	20020717
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
US 2002147198	A1	20021010	US 2002-46526	A2 20020110
			US 2002-46526	20020110
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
WO 2004007457	A2	20040122	WO 2003-US22276	20030715
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2002-197960	A 20020717

PATENT FAMILY INFORMATION:
 FAN 2002:539663
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI WO 2002055501 A2 20020718 WO 2002-US742 20020111
 WO 2002055501 A3 20021219
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2002147198 A1 20021010
 EP 1358161 A2 20031105
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 2001-261360P P 20010112

Patel


L3 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2004 ACS ON STN (continued)



AB The invention discloses the use of fibrates for reducing the hepatic toxicity of MTP inhibitors, as well as pharmaceutical compns. that contain an MTP inhibitor and a fibrate. Compound preparation is included.

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 US 2001-323686P P 20010919
 US 2002-46526 A 20020110
 WO 2002-US742 W 20020111


OS MARPAT 139:117339
 IT 561297-65-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of substituted aminopyridines as antitumor agents)
 RN 561297-65-2 CAPLUS
 CN 1-Azetidinecarboxylic acid, 3-[[2-chloro-5-[[[2-[[4-(fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 561297-60-7P 561297-61-8P 561297-62-9P
 561297-63-0P 561297-64-1P 561297-66-3P
 561297-68-5P 561297-70-9P 561297-71-0P
 561297-72-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted aminopyridines as antitumor agents)
 RN 561297-60-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1-(methylsulfonyl)-1H-indol-6-yl)-2-[[[4-(fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

<8/14/2004>

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 561297-61-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[4-((dimethylamino)acetyl)amino]-4-(1,1-dimethylethyl)phenyl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 561297-62-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[4-(4-fluorophenyl)methyl]amino]-N-[3-[[1-methyl-2-pyrrolidinyl)methoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 561297-66-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3-(3-azetidinylmethoxy)-4-chlorophenyl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 561297-68-5 CAPLUS
 CN 4-Pyridazinecarboxamide, N-[[4-(1,1-dimethylethyl)phenyl]-3-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 561297-63-0 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[4-(4-fluorophenyl)methyl]amino]-N-[3-[[4-(trifluoromethyl)phenoxy]methyl]pyrrolidin-1-yl]- (9CI) (CA INDEX NAME)




RN 561297-64-1 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[4-(4-fluorophenyl)methyl]amino]-N-[4-[[1-methyl-1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 561297-70-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3-(3-azetidinylmethoxy)-5-(trifluoromethyl)phenyl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 561297-71-0 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[4-(4-hydroxy-3-nitrophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)




RN 561297-72-1 CAPLUS
 CN 3-Pyridinecarboxamide,
 2-[[[(3-amino-4-hydroxyphenyl)methyl]amino]-N-[4-(1-
 methylethyl)phenyl]- (9CI) (CA INDEX NAME)




IT 442847-21-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of substituted aminopyridines as antitumor agents)
 RN 442847-21-4 CAPLUS
 CN 3-Pyridinecarboxamide,
 N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinylmethyl)-
 1H-indol-6-yl]-2-[[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-,
 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 442846-17-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[6-[[[2-[[[(4-fluorophenyl)methyl]amino]-3-
 pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-,
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-22-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-acetyl-3,4-dihydro-2,2-dimethyl-2H-1,4-
 benzoxazin-6-yl)-2-[[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX
 NAME)


Patel

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)




IT 442845-77-4P 442846-13-1P 442846-17-5P
 442846-22-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (target compound; preparation of substituted aminopyridines as

antitumor
 agents)
 RN 442845-77-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3-fluorophenyl)methyl]amino]-N-(4-
 phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 442846-13-1 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid,
 2-[[5-[[[2-[[[(4-fluorophenyl)methyl]amino]-3-

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)




IT 442845-71-8P 442845-72-9P 442845-73-0P
 442845-78-5P 442845-79-6P 442845-80-9P
 442845-81-0P 442845-82-1P 442845-83-2P
 442845-84-3P 442845-85-4P 442845-86-5P
 442845-87-6P 442845-88-7P 442845-89-8P
 442845-90-1P 442845-91-2P 442845-92-3P
 442845-93-4P 442845-94-5P 442845-95-6P
 442845-96-7P 442845-97-8P 442845-98-9P
 442846-00-0P 442846-01-7P 442846-02-8P
 442846-03-9P 442846-04-0P 442846-05-1P
 442846-06-2P 442846-07-3P 442846-08-4P
 442846-09-5P 442846-10-8P 442846-12-0P
 442846-14-2P 442846-15-3P 442846-16-4P
 442846-18-6P 442846-19-7P 442846-20-0P
 442846-21-1P 442846-23-3P 442846-24-4P
 442846-25-5P 442846-26-6P 442846-27-7P
 442846-28-8P 442846-29-9P 442846-30-2P
 442846-31-3P 442846-32-4P 442846-33-5P
 442846-34-6P 442846-35-7P 442846-36-8P
 442846-38-0P 442846-39-1P 442846-40-4P
 442846-42-6P 442846-44-8P 442847-23-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (target compound; preparation of substituted aminopyridines as
 antitumor
 agents)
 RN 442845-71-8 CAPLUS
 CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[[[(phenylmethyl)amino]- (9CI)
 (CA INDEX NAME)




RN 442845-72-9 CAPLUS
 CN 2-Pyridinecarboxamide,
 N-(4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)
 <8/14/2004>

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(9CI) (CA INDEX NAME)




RN 442845-73-0 CAPLUS
CN 2-Pyridinecarboxamide, N-(3-fluoro-4-methylphenyl)-3-[[[4-methoxyphenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-78-5 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[3-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-81-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[2-bromophenyl]methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 442845-82-1 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[4-(trifluoromethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-83-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[2,3-difluorophenyl]methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

Patel

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (continued)




RN 442845-79-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-fluorophenyl]methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 442845-80-9 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-84-3 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[[[4-cyanophenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-85-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[[[2-cyanophenyl]methyl]amino]- (9CI) (CA INDEX NAME)




<8/14/2004>

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 442845-86-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-[4-(2-methylpropyl)phenyl]]- (9CI) (CA INDEX NAME)




RN 442845-87-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-88-7 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-(methoxyphenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 442845-91-2 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]]- (9CI) (CA INDEX NAME)




RN 442845-92-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3,4-dimethoxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]]- (9CI) (CA INDEX NAME)




Patel

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442845-89-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-(aminophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]]- (9CI) (CA INDEX NAME)




RN 442845-90-1 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 442845-93-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[phenylmethyl]amino]-N-[3-(trifluoromethyl)phenyl]]- (9CI) (CA INDEX NAME)



RN 442845-94-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-(chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]]- (9CI) (CA INDEX NAME)




RN 442845-95-6 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-(bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]]- (9CI) (CA INDEX NAME)




RN 442845-96-7 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-(chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]]- (9CI) (CA INDEX NAME)

<8/14/2004>

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442845-97-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,4-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-99-0 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,6-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-00-6 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,3-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-01-7 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 442846-02-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,6-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-03-9 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-04-0 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-05-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-[3-[[3-(dimethylamino)propyl]-5-(trifluoromethyl)phenyl]-2-[[[(4-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-06-2 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3-(dimethylamino)propyl)-5-(trifluoromethyl)phenyl]methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-07-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-08-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-bromo-2-fluorophenyl]-2-[[[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-12-0 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-[3-[2-(1-pyrrolidinylethoxy)-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-14-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[2-(1,1-dimethylethyl)-5-[[[2-[[[4-fluorophenyl)methyl]amino] 3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-09-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]-2-[[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-10-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-fluoro-3-[3-(4-morpholinyl)-1-propynyl]phenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-15-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(1-methyl-4-piperidinyl)-1H-indol-6-yl]-2-[[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-16-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[1-[(dimethylamino)acetyl]-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl]-2-[[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-18-6 CAPLUS
 CN Carbamic acid, [2-[6-[[[2-[[[4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl 1H-indol-1-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 442846-19-7 CAPLUS
 CN 2-[[[2-[[[4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-23-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[3-[[[2-[[[4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 442846-24-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-[(1,1-dimethylethyl)-3-(4-(pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-20-0 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[3-[[[2-[[[4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 442846-21-1 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[2-[(1,1-dimethylethyl)-5-[[[2-[[[4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-25-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-[(1,1-dimethylethyl)-3-(4-(pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 442846-26-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-[(1,1-dimethylethyl)-3-(4-(piperidinylmethoxy)phenyl)-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-27-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-((2R)-2-pyrrolidinylmethoxy)phenyl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 442846-28-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2-[[4-(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-31-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[3-((4-piperidinyl)methoxy)-5-(trifluoromethyl)phenyl]-2-[[4-(4-fluorophenyl)methyl]amino]-N-[3-((4-piperidinyl)methoxy)-5-(trifluoromethyl)phenyl]]- (9CI) (CA INDEX NAME)




RN 442846-32-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-((1-methyl-4-piperidinyl)methyl)-1H-indol-6-yl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (continued)




RN 442846-29-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[1-(aminoacetyl)-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-30-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinyl)-1H-indol-6-yl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-33-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinyl)-1H-indol-6-yl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 442846-34-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-((1-methyl-4-piperidinyl)methyl)-1H-indol-6-yl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-35-7 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[4-(4-fluorophenyl)methyl]amino]-N-[4-(1-methyl-1-(1-methyl-4-piperidinyl)ethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-36-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[4-(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-2-oxo-7-quinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 442846-40-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[4-(3,4-difluorophenyl)methyl]amino]-N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 442846-42-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]-2-[[4-(3,4-difluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-44-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]-2-[[4-(3,4-difluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-38-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-5-benzofuranyl-2-[[3-(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-39-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-2-[[3-(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442847-23-6 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[4-(3-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 442845-77-4
 CMF C25 H20 F N3 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



GI

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The title compds. I [R₂ = (un)substituted Ph, 9-10 membered bicyclic and 11-14 membered tricyclic (un)saturated heterocyclyl; R₈ = halo, NH₂, NO₂, etc.], and their pharmaceutically acceptable derivs., are prepared and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. E.g., a multi-step synthesis of II, starting from 1-dimethylamino-2-propyne and 3-bromo-5-trifluoromethylbenzylamine, was given. Selected compds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below

50 nM. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

L3 ANSWER 7 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:454323 CAPLUS

DN 139:22501

TI Preparation of glycinamide heterocyclic derivatives as factor Xa inhibitors

IN Pinto, Donald J. P.; Han, Wei; Hu, Zilun

PA Bristol-Myers Squibb Company, USA; Qiao, Jennifer

SO PCT Int. Appl., 451 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003048158	A1	20030612	WO 2002-US38239	20021127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003232804	A1	20031218	US 2001-336994P	P 20011204
			US 2002-304070	20021125
			US 2001-336994P	P 20011204

PATENT FAMILY INFORMATION:

FAN 2003:454257

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003048081	A2	20030612	WO 2002-US37212	20021118
WO 2003048081	A3	20030912		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003232804	A1	20031218	US 2001-336994P	P 20011204
			US 2002-304070	20021125
			US 2001-336994P	P 20011204

OS MARPAT 139:22501

IT 536759-14-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of glycinamide heterocyclic derivs. as factor Xa inhibitors)

L3 ANSWER 7 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 536759-14-5 CAPLUS

CN Benzamide,

N-[5-chloro-2-pyridinyl]-2-[[4-[[[dimethylamino]acetyl]methyl]amino]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



AB Compds. P4-P-M-M4 [M is a 3-10 membered carbocycle or a 4-10 membered heterocycle; P is null or a 5-7 membered carbocycle or heterocycle fused to ring M; one of P4 and M4 is -2-A-B and the other is -G1-G, where G is (un)substituted (fused) (hetero)aryl or (hetero)cyclyl; G1 is null or (un)substituted optionally-functionalized alk(en)(yn)yl; Z is a bond or (hetero)alkylene; A is (substituted) 3-10 membered carbocyclyl or 5-12 membered heterocyclyl; B is a functionalized amino group (with provisos)] or their pharmaceutically-acceptable salts were prepared for use as inhibitors of factor Xa. Thus, 1H-pyrazolo[3,4-c]pyridine derivative

I.TPA was prepared by reactions of 3-aminobenzamide, 3-hydroxy-1-(4-iodophenyl)-4-(trifluoroacetyl)-5,6-dihydro-2(1H) pyridinone, chloroacetyl chloride, and dimethylamine.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:454257 CAPLUS

DN 139:7167

TI Preparation of glycinamide heterocyclic derivatives as factor Xa inhibitors

IN Pinto, Donald J. P.; Han, Wei; Hu, Zilun

PA Bristol-Myers Squibb Company, USA; Qiao, Jennifer

SO PCT Int. Appl., 448 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003048081	A2	20030612	WO 2002-US37212	20021118
WO 2003048081	A3	20030912		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003232804	A1	20031218	US 2001-336994P	P 20011204
			US 2002-304070	20021125
			US 2001-336994P	P 20011204

PATENT FAMILY INFORMATION:

FAN 2003:454323

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003048158	A1	20030612	WO 2002-US38239	20021127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003232804	A1	20031218	US 2001-336994P	P 20011204
			US 2002-304070	20021125
			US 2001-336994P	P 20011204

OS MARPAT 139:7167

IT 536759-14-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of glycinamide heterocyclic derivs. as factor Xa inhibitors)

RN 536759-14-5 CAPLUS


CN Benzamide,

N-[5-chloro-2-pyridinyl]-2-[[4-[[[dimethylamino]acetyl]methyl]amino]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


Patel

<8/14/2004>

L3 ANSWER 8 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI




I

AB Compsd. P4-P-M-M4 [M is a 3-10 membered carbocycle or a 4-10 membered heterocycle; P is null or a 5-7 membered carbocycle or heterocycle fused to ring M; one of P4 and M4 is -Z-A-B and the other is -G1-G, where G is (un)substituted (fused) (hetero)aryl or (hetero)cyclyl; G1 is null or (un)substituted optionally-functionalized alk(en)(yn)yl; Z is a bond or (hetero)alkylene; A is (substituted) 3-10 membered carbocyclyl or 5-12 membered heterocyclyl; B is a functionalized amino group (with provisos)] or their pharmaceutically-acceptable salts were prepared for use as inhibitors of factor Xa. Thus, 1H-pyrazolo[3,4-c]pyridine derivative


I.TFA

was prepared by reactions of 3-aminobenzamide, 3-hydroxy-1-(4-iodophenyl)-4-(trifluoroacetyl)-5,6-dihydro-2(1H)-pyridinone, chloroacetyl chloride, and dimethylamine.

L3 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I



II

AB The title compds. [I; Ar = II (wherein Ra = H, alkyl; and R1 = H, perfluoroalkyl; R2 = H, halo, alkyl, alkenyl, alkynyl); or Ar = 4-pyridyl and R1 = perfluoroalkyl; R2 = Br, I, alkyl, alkenyl, alkynyl; or R1 = H, and R2 = F, Br, I, Et, alkyl, alkenyl or alkynyl and their N-oxides and salts, useful for the treatment especially of a neoplastic disease, such

as a

tumor disease, of retinopathy or age-related macular degeneration in the human or animal body, were prepared and formulated. Thus, reductive amination of 4-pyridinecarboxaldehyde with 2-amino-N-(4-bromo-3-trifluoromethylphenyl)benzamide (preparation given) in the presence of NaBH3CN

afforded I (Ar = 4-pyridyl; R1 = CF3; R2 = Br). The IC50-values that can be found for the compds. I are in range of 0.001 to 1 µM in test for activity against VEGF-receptor tyrosine kinase.

RE.CNT 1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:376824 CAPLUS

DN 138:368777

TI Preparation of pyridyl-substituted anthranilic acid amides for treating neoplastic disease

IN Bold, Guido; Furet, Pascal; Manley, Paul William

PA Novartis AG, Switz.; Novartis Pharma GmbH

SO PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003040101	A1	20030515	WO 2002-EP12445	20021107
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR		GB 2001-26901 GB 2002-12917	A 20011108 A 20020605

OS MARPAT 138:368777


IT 524729-00-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridyl-substituted anthranilic acid amides for treating neoplastic disease)

RN 524729-00-8 CAPLUS

CN Benzamide, 2-[[[3-[(methylamino)carbonyl]phenyl]methylamino]-N-[3-(trifluoromethyl)phenyl]-9CI] (CA INDEX NAME)



GI

L3 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:242305 CAPLUS

DN 138:271675

TI Preparation of 4,5-dihydro-1H-benzo[g]indazole-3-carboxamides for the treatment of inflammation

IN Bergmanis, Arija A.; Bonafoux, Dominique; Clare, Michael; Crich, Joyce Z.;

Fletcher, Theresa R.; Geng, Lifeng; Hagen, Timothy J.; Hamper, Bruce C.; Hanson, Gunnar J.; Houdek, Stephen C.; Huang, He; Iula, Donna M.; Koszyk, Francis J.; Lennon, Patrick J.; Liao, Shuyuan; Liao, Subo; Metz, Suzanne; Mohler, Scott B.; Nguyen, Maria; Oburn, David S.; Owen, Thomas J.;

Partis,

Richard A.; Scates, Angela M.; Stealey, Michael A.; Tollefson, Michael B.;

Vazquez, Michael L.; Weier, Richard M.; Wolfson, Serge G.; Xu, Xiangdong

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 331 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003024935	A2	20030327	WO 2002-US29774	20020919
WO 2003024935	A3	20030821		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		US 2001-323423P US 2002-379090P US 2002-247096P US 2001-323423P US 2002-379090P	P 20010919 P 20020509 P 20020919 P 20010919 P 20020509
EP 1444207	A2	20040811	RP 2002-775879	20020919
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK		US 2001-323423P US 2002-379090P WO 2002-US29774	P 20010919 P 20020509 N 20020919
WO 2003095430	A1	20031120	WO 2003-US8917	20030319
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		US 2002-379090P	P 20020509

Patel1

<8/14/2004>

L3 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 WO 2002-US29774 A 20020919

PATENT FAMILY INFORMATION:

PAN 2003:93147

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003095430	A1	20031120	WO 2003-US8917	20030319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2002-379090P	P 20020509
			WO 2002-US29774	A 20020919
			WO 2002-US29774	20020919
WO 2003024935	A2	20030327		
WO 2003024935	A3	20030821		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001 323423P	P 20010919
			US 2002-379090P	P 20020509

OS MARPAT 138:271675


IT 503555-09-7P, 1-[(1,3-Benzodioxol-5-yl)-8-[[[2-[(4-methoxybenzyl)amino]pyridin-3-yl]carbonyl]amino]-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (IKK2 inhibitor; preparation of benzo[g]carboxamides as IKK2 inhibitors for treatment of cancer, inflammation, and inflammation-associated disorders)

disorders for treatment of cancer, inflammation, and inflammation-associated disorders)


RN 503555-09-7 CAPLUS

CN 1H-Benz[g]indazole-3-carboxamide, 1-[(1,3-benzodioxol-5-yl)-4,5-dihydro-8-[[[2-[(4-methoxyphenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



AB The present invention relates to substituted pyrazolyl deriva.. compns. comprising such, intermediates, methods of making substituted pyrazolyl deriva., and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis. Title compds. I [wherein A = (un)substituted (CH2)m; m = 0-3; B = (un)substituted (hetero)aryl; X = N or C; Y and Z = independently N, C, CH, CR3, S, or O; R1 = H, halo, (halo)alkyl, (hetero)aryl, alkenyl, alkynyl, CN, NO2, alkoxy(carbonyl), carbamoyl, acyl, alkylthio, sulfamoyl, ureido, etc.; R2 = H, halo, (halo)alkyl, hydroxyalkyl, alkoxy, CN, NO2, alkylthio, amino, carbamoyl, ureido, CO2H, etc.; R3 = (un)substituted amidine, alkylamino, aminoalkyl, carbamoyl, NH2, or acylamino(methyl); R4 = H, halo, alkylsulfonfyl, alkylsulfonfyl, CN, alkoxy carbonyl, (halo)alkyl, hydroxyalkyl, haloalkoxy, heterocyclyl, NO2, acylamino, (hetero)aryl, alkenyl, alkoxy, alkylthio, sulfamoyl, acyl, ureido, carbamoyl, etc.; R5

L3 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

H, or (un)substituted (aryl)alkyl, (hetero)aryl, (hetero)cyclylalkyl, or heteroaryalkyl; R11 = H, halo, (halo)alkyl, CN, alkoxy carbonyl, alkenyl, alkynyl, alkoxy, carbamoyl, etc.; R12 = H, halo, alkyl, or alkoxy; with proviso; and isomers, tautomers, carriers, esters, prodrugs, and pharmaceutically acceptable salts thereof] were prepd. via conventional and solid phase synthetic methods as Ix8 protein kinase β (IKK β or IKK2) inhibitors. For example, reaction of 7-nitro-1-tetralone with Et acetate in the presence of Li bis(trimethylsilyl)amide in ether gave the 1,3-diketone (87%), which was cyclized with 4-sulfonamidophenylhydrazine-HCl with HCl in MeOH to give the Et 1H-dihydrobenzo[g]indazole-3-carboxylate (69%). Amidation with NH3OH in MeOH provided II. In IKK β resin enzyme assays, I exhibited IKK β activity with IC50 values ranging from $\leq 1 \mu\text{M}$ to $> 100 \mu\text{M}$. Thus, I are useful for treating cancer, inflammation, and inflammation-assocd. disorders, such as arthritis (no data).

L3 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:42101 CAPLUS

DN 138:106502

TI Preparation of biphenylcarboxylic acid amides as inhibitors of microsomal triglyceride transfer protein (MTP)

IN Priepke, Henning; Haeufel, Norbert; Dahmann, Georg; Thomas, Leo; Mark, Michael

PA Boehringer Ingelheim Pharma K.-G., Germany

SO PCT Int. Appl., 193 pp.

CODEN: PIXXD2

DT Patent

LA German

PAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003004020	A1	20030116	WO 2002-EP7215	20020629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			DE 2001-10132686	A 20010705
			DE 2001-10132686	20010705
			US 2002-187860	20020702
			DE 2001-10132686	A 20010705
			US 2001-304584P	P 20010711

OS MARPAT 138:106502

IT 486436-62-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of biphenylcarboxylic acid amides as microsomal triglyceride transfer protein (MTP) inhibitors)


RN 486436-62-8 CAPLUS

CN 1H-Pyrazole-2-carboxamide, 1-methyl-N-[(4'-methyl[1,1'-biphenyl]-4-yl)methyl]-4-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I

AB Title compds. I [X1 = CR1; X2 = CR2; X3 = CR3; X4 = CR4; with 1-2 of the groups being a N-atom; R1, R2, R3, R4 = H, halo, alkyl, etc.; A = O, S, NH, etc.; R5 = (un)substituted Ph, 1-naphthyl, 2-naphthyl, etc.; R6 = H, (un)substituted alkyl; R7 = (un)substituted alkyl; Y = 1-2 carbon atom(s) bound to (un)substituted 5-membered heteroaryl] and their pharmaceutically acceptable salts were prepared. For example, coupling of acid II, e.g., prepared from 4-hydrazinobenzonitrile in 5-steps, and 4-phenylbenzylamine afforded biphenylcarboxylic acid amide III in 86% yield. In triglyceride transfer protein inhibition studies, compds. I exhibited IC50 values $\leq 100\mu\text{M}$. Compds. I are claimed useful as inhibitors of microsomal triglyceride transfer protein (MTP) for the treatment of atherosclerosis.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:22869 CAPLUS
DN 138:89806
TI Preparation of arylpyrazoles as soluble epoxide hydrolase inhibitors for treatment of cardiovascular disease.
IN Ingraham, Richard H.; Proudfoot, John R.
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003002555	A1	20030109	WO 2002-US18752	20020614
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2003022929	A1	20030130	US 2002-172457	20020614
EP 1406892	A1	20040414	EP 2002-739870	20020614
US 2004092567	A1	20040513	US 2001-302066P	20010629
			US 2002-172457	A1 20020614

OS MARPAT 138:89806
IT 483342-21-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


for (preparation of arylpyrazoles as soluble epoxide hydrolase inhibitors treatment of cardiovascular disease)

RN 483342-21-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[phenylmethyl]amino]-N-[4-[[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI




I

AB A method of treating cardiovascular disease comprises administration of title compds. [I; R1, R3 = CF3, halo, cyano, alkyl, alkenyl, alkynyl, (substituted) cycloalkyl, heterocyclyl, etc.; R2 = H, halo, Me; L = NHCO, NHCS, NH, NHCH2, NHCOCO, etc.; R4 = (substituted) alkyl, alkoxy, alkylthio, alkylamino, alkoxyalkyl, alkylthioalkyl, carbocyclyl, heterocyclyl, etc.; R8 = H, NH2] (no data). Thus, 2-chloronicotinic acid in MeCN was treated with EDC and then with 1-(4-aminophenyl)-3-(3-pyridyl)-5-trifluoromethylpyrazole under ice cooling followed by stirring for 1 h to give I (R1 = 3-pyridyl; R2, R8 = H; R3 = CF3; L = NHCO; R4 = 2-chloropyridin-3-yl).

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:603273 CAPLUS
DN 138:122629
TI Synthesis of 1,4-benzodiazepine-2,5-dione derivatives
AU Ho, Tong-Ing; Chen, Wen-Shiong; Hsu, Chi-Wei; Tsai, Yeun-Min; Fang, Jim-Min
CS Dep. of Chem., National Taiwan Univ., Taipei, Taiwan
SO Heterocycles (2002), 57(8), 1501-1506
CODEN: HETCYM; ISSN: 0385-5414
PB Japan Institute of Heterocyclic Chemistry
DT Journal
LA English
OS CASREACT 138:122629
IT 489446-50-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2,5-dioxo-1H-1,4-benzodiazepine-3-carboxylate derivs.)
RN 489446-50-6 CAPLUS
CN Benzamide, N-(4-methoxyphenyl)-2-[[[(3-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



AB A synthesis of a series of 1,4-benzodiazepine-2,5-dione derivate with a carboxy group at the 3-position is realized in good yields by using Me malonylchloride as a key reagent and intramolecular nucleophilic substitution as ring closure reaction. The synthesis of 4-(4-methoxyphenyl)-1-[[[(3-methoxyphenyl)methyl]-2,5-dioxo-1H-1,4-benzodiazepine-3-carboxylic acid

Me ester was described.
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:539663 CAPLUS
 DN 137:109210
 TI Preparation of substituted arylamine derivatives and methods of use as antitumor agents
 IN Chen, Guoqing; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Huang, Qi; Kim, Joseph L.; Kim, Tae-Seong; Patel, Vinod P.; Smith, Leon M.; Tasker, Andrew; Xi, Ning; Xu, Shamin; Yuan, Chester Chenguang
 PA Amgen Inc., USA
 SO PCT Int. Appl., 253 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CHT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002055501	A2	20020718	WO 2002-US742	20020111
WO 2002055501	A3	20021219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002147198	A1	20021010	US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
			US 2002-46526	A 20020110
			US 2002-46526	P 20020110
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
EP 1358161	A2	20031105	EP 2002-717324	20020111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
			US 2002-46526	A 20020110
			WO 2002-US742	W 20020111

PATENT FAMILY INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003134836	A1	20030717	US 2002-197960	20020717
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
			US 2002-46526	A2 20020110
			US 2002-46526	20020110
US 2002147198	A1	20021010	US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
			WO 2003-US22276	20030715
WO 2004007457	A2	20040122		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-13-1 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[[4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentaffluoroethyl)phenoxy]methyl]-1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 442846-17-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[6-[[[2-[[[4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, ML, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

OS MARPAT 137:109210
 IT 442847-21-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of substituted aminopyridines as antitumor agents)
 RN 442847-21-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-[[4-(4-fluorophenyl)methyl]amino]-1H-indol-6-yl]-2-[[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




IT 442845-77-4P 442846-13-1P 442846-17-5P
 442846-22-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 [target compound; preparation of substituted aminopyridines as antitumor agents]
 RN 442845-77-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-22-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-acetyl-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-6-yl)-2-[[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



IT 442845-71-8P 442845-72-9P 442845-73-0P
 442845-78-5P 442845-79-6P 442845-80-9P
 442845-81-0P 442845-82-1P 442845-83-2P
 442845-84-3P 442845-85-4P 442845-86-5P
 442845-87-6P 442845-88-7P 442845-89-8P
 442845-90-1P 442845-91-2P 442845-92-3P
 442845-93-4P 442845-94-5P 442845-95-6P
 442845-96-7P 442845-97-8P 442845-98-9P
 442846-00-6P 442846-01-7P 442846-02-8P
 442846-03-9P 442846-04-0P 442846-05-1P
 442846-06-2P 442846-07-3P 442846-08-4P

<8/14/2004>

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


442846-09-5P 442846-10-8P 442846-12-0P
 442846-14-2P 442846-15-3P 442846-16-4P
 442846-18-6P 442846-19-7P 442846-20-0P
 442846-21-1P 442846-23-3P 442846-24-4P
 442846-25-5P 442846-26-6P 442846-27-7P
 442846-28-8P 442846-29-9P 442846-30-2P
 442846-31-3P 442846-32-4P 442846-33-5P
 442846-34-6P 442846-35-7P 442846-36-8P
 442846-38-0P 442846-39-1P 442846-40-4P
 442846-42-6P 442846-44-8P 442846-46-0P
 442846-48-2P 442846-50-6P 442846-52-8P
 442846-53-9P 442847-23-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of substituted aminopyridines as antitumor agents)


RN 442845-71-8 CAPLUS

CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 442845-72-9 CAPLUS

CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[[[4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-73-0 CAPLUS

CN 2-Pyridinecarboxamide, N-(3-fluoro-4-methylphenyl)-3-[[[4-


L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-78-5 CAPLUS


CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[3-(trifluoromethyl)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-79-6 CAPLUS


CN 3-Pyridinecarboxamide, 2-[[[4-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442845-80-9 CAPLUS

CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[4-(trifluoromethoxy)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-81-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-bromophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 442845-82-1 CAPLUS

CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[4-


L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

(trifluoromethoxy)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-83-2 CAPLUS


CN 3-Pyridinecarboxamide, 2-[[[2,3-difluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 442845-84-3 CAPLUS

CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[[[4-cyanophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442845-85-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(4-chlorophenyl)methyl]amino]-N-(4-cyanophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-86-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3-cyanophenyl)methyl]amino]-N-(4-(2-chloropropyl)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442845-87-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-88-7 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3-methoxyphenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-89-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3-aminophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-90-1 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-91-2 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-92-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-93-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(phenylmethyl)amino]-N-[3-(trifluoromethyl)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-94-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3-chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442845-95-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(4-chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-96-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(2-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442845-97-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(2,4-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-99-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(3,4-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-00-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(2,3-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-01-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(2,6-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-02-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(2,6-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-03-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(3-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-04-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-05-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[3-(dimethylamino)propyl]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Patel

<8/14/2004>

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(trifluoromethyl)phenyl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-06-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3-(dimethylamino)propyl]-4-fluorophenyl)methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-07-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3-(dimethylamino)propyl]-4-fluorophenyl)methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-08-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-bromo-2-fluorophenyl]-2-[[[3-(dimethylamino)propyl]-4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-09-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-10-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-fluoro-3-[3-(4-morpholinyl)-1-propynyl]phenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-12-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-(trifluoromethyl)phenyl)methyl]amino]-N-[3-[2-(1-pyrrolidinyl)ethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-14-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[2-(1,1-dimethylethyl)-5-[[[2-[[[4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 442846-15-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(1-methyl-4-piperidinyl)-1H-indol-6-yl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-16-4 CAPLUS
CN 3-Pyridinecarboxamide, N-([2-([2-((4-fluorophenyl)methyl)amino]-3,4-dihydro-4,4-dimethyl-1H-indol-6-yl)-2-((4-fluorophenyl)methyl)amino]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 442846-18-6 CAPLUS
CN Carbanic acid, [2-[6-[[[2-[[[4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-21-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-([2-([2-((4-fluorophenyl)methyl)amino]-5-[[[2-[[[4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 442846-23-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-([3-[[[2-[[[4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-19-7 CAPLUS
CN 2-(1H)-isoquinolinecarboxylic acid, 7-([2-([2-((4-fluorophenyl)methyl)amino]-3-pyridinyl)carbonyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 442846-20-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-([3-[[[2-[[[4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-24-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-([2-([2-((4-fluorophenyl)methyl)amino]-N-(4-(pentafluoroethyl)-3-((2R)-2-pyrrolidinylmethoxy)phenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 442846-25-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-([2-([2-((4-fluorophenyl)methyl)amino]-N-(3-((2R)-2-pyrrolidinylmethoxy)-5-(trifluoromethyl)phenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-26-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-piperidinylmethoxy)phenyl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-27-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-28-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[4-(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)




RN 442846-29-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[1-(aminocetyl)-2,3-dihydro 3,3-dimethyl-1H-indol-6-yl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-30-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinyl)-1H-indol-6-yl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-31-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[4-(4-fluorophenyl)methyl]amino]-N-[3-(4-piperidinylmethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-32-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-(3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-6-yl)-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-33-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[4-(4-fluorophenyl)methyl]amino]-N-[3-[(2S)-1-methyl-2-pyrrolidinylmethoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-34-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-[(1-methyl-4-piperidinyl)methyl]-1H-indol-6-yl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-35-7 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[4-(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-39-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-2-[[3-(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-40-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[3-(4-difluorophenyl)methyl]amino]-N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinylethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




Patel

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-36-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[4-(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-2-oxo-7-quinolyl)- (9CI) (CA INDEX NAME)




RN 442846-38-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-5-benzofuranyl-2-[[3-(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 442846-42-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinylethyl)amino]phenyl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-44-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinylethyl)amino]phenyl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-46-0 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[2-[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

<8/14/2004>

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-48-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-(2-pyrrolidinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-50-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-[3-(2-pyrrolidinylmethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442847-23-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(3-fluorophenyl)methyl]amino]-N-[4-phenoxyphenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 442845-77-4
CMF C25 H20 F N3 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




Patel

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-52-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(2-pyrrolidinylmethoxy)phenyl]-2-[[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-53-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[[[(1-methyl-2-pyrrolidinylmethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title comds. I (B1 and B2 independently equal C or N, wherein B1B2 form part of 5-6 membered heteroaryl ring A; R1 = one or more substituents selected from H, halo, oxo, (un)substituted cycloalkyl, phenylalkyl, etc.;

R2 = (un)substituted cycloalkyl, cycloalkenyl, 6-10 membered aryl or 5-6 membered heterocyclyl, etc.; R3 = (un)substituted aryl; R4 = H, alkyl, (un)substituted Ph or aralkyl; X1 = bond, alkenyl, alkenylene and alkynylene, where one of the CH2 groups may be substituted with O or NH, wherein X1 is optionally substituted with OH; X2 = (un)substituted N containing linker, e.g., -NHCH2-, and there pharmaceutically acceptable derivs., are prepared and disclosed as agents effective for prophylaxis and


treatment of diseases, such as angiogenesis mediated diseases. Thus, II was prepared via arylation of 1-dimethylamino 2-propyne with 3-bromo-5-trifluoromethylaniline, hydrogenation, amidation with 2-chloropyridine 3-carbonyl chloride and chloro substitution with 4-fluorobenzylamine. Selected comds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below 50 nM. The invention encompasses novel comds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical comds. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

<8/14/2004>

L3 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:171853 CAPLUS
 DN 136:232201
 T1 Preparation of cyclic amine derivatives as CCR3 antagonists
 IN Morihira, Koichiro; Inami, Hiroshi; Kubota, Hirokazu; Yokoyama, Kazuhiro;
 Morokata, Tatsuki; Takeuchi, Makoto; Takahashi, Toshiya; Kaneo,
 Masayuki; Inaoka, Takayuki; Torii, Yuichi; Iura, Yosuke
 PA Yamanouchi Pharmaceutical Co., Ltd., Japan; Toray Industries, Inc.
 SO PCT Int. Appl., 92 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002018315	A1	20020307	WO 2001-JP7321	20010827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001080187	A5	20020313	AU 2001-80187	20010827
			JP 2000-257451	20000828
			WO 2001-JP7321	20010827

OS MARPAT 136:232201
 IT 403477-79-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of cyclic amine deriva. as CCR3 antagonists)
 RN 403477-79-2 CAPLUS
 CN Benamide, 2-[[2-(2-chlorophenyl)methylamino]-N-[8-[(6-fluoro-2-naphthalenyl)methyl]-8-azabicyclo[3.2.1]oct-3-yl]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:11104 CAPLUS
 DN 136:69743
 T1 Preparation of pyridyl benzamides and related compounds as Factor Xa inhibitors
 IN Zhu, Bing-Yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Erick A.; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
 PA USA
 SO U.S. Pat. Appl. Publ., 259 pp., Cont.-in-part of U.S. Ser. No. 663,420.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002002183	A1	20020103	US 2001-794225	20010228
US 6376515	B2	20020423		
US 2003162690	A1	20030828	US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
			US 2002-126976	P 20000229
			US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
			US 2001-794225	A1 20010228
US 2004097561	A1	20040520	US 2003-687334	20031015
			US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
			US 2001-794225	A1 20010228
			US 2002-126976	A1 20020422

PATENT FAMILY INFORMATION:

FAN 2001:208239
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI WO 2001019788 A2 20010322 WO 2000-US25196 20000915
 WO 2001019788 A3 20010809


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2000074867 A5 20010417
 US 1999-154332P P 19990917
 US 2000-185746P P 20000229
 AU 2000-74867 P 20000915
 US 1999-154332P P 19990917
 US 2000-185746P P 20000229
 WO 2000-US25196 W 20000915
 EP 1216228 A2 20020626
 EP 2000-963452 P 20000915
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

BR 2000014076 A 20021015
 US 1999-154332P P 19990917
 WO 2000-US25196 W 20000915
 BR 2000-14076 P 19990917
 US 1999-154332P P 19990917
 US 2000-185746P P 20000229
 WO 2000-US25196 W 20000915

patel

L3 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The title compds. I [ring A = (un)substituted heterocyclic ring, etc.; X = bond, O, CO, etc.; ring B = Q1, etc.; ring V3 = hydrocarbon ring, etc.; W = CH, N; Y = CO, etc.; R21, R22 = H, halo, etc.; T1 = (CH2)n; n = 0 - 2; ring D = (un)substituted aryl, etc.] are prepared in an in vitro test (for CCR3 antagonism) using cells, compds. of this invention showed IC50 values of 0.001 µM to 0.45 µM.
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 JP 2003509406 T2 20030311 JP 2001-523368 20000915
 US 1999-154332P P 19990917
 US 2000-185746P P 20000229
 WO 2000-US25196 W 20000915
 NO 2002001229 A 20020521
 US 1999-154332P P 19990917
 US 2000-185746P P 20000229
 WO 2000-US25196 W 20000915

FAN 2001:208248
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI WO 2001019798 A2 20010322 WO 2000-US25196 20000915
 WO 2001019798 A3 20011025

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2000074866 A5 20010417
 AU 2000-74866 P 19990917
 US 1999-154332P P 19990917
 WO 2000-US25196 W 20000915
 EP 1216231 A2 20020626
 EP 2000-963451 P 19990917
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

BR 2000014078 A 20021231
 WO 2000-US25196 W 20000915
 BR 2000-14078 P 19990917
 US 1999-154332P P 19990917
 WO 2000-US25196 W 20000915

TR 200201413 T2 20030221
 TR 2002-200201413 P 19990917
 US 1999-154332P P 19990917
 JP 2003509412 T2 20030311
 JP 2001-523378 P 19990917
 US 1999-154332P P 19990917
 WO 2000-US25196 W 20000915

NZ 517828 A 20031031
 NZ 2000-517828 P 19990917
 US 1999-154332P P 19990917
 WO 2000-US25196 W 20000915
 NO 2002-1230 W 20000915
 US 1999-154332P P 19990917
 WO 2000-US25196 W 20000915

FAN 2001:561391
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI WO 2001064642 A2 20010907 WO 2001-US6247 20010228
 WO 2001064642 A3 20020502

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

<8/14/2004>

L3 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
US 2000-185746P P 20000229
US 2000-663420 A 20000915

FAN 2001:661392
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2001064643 A2 20010907 WO 2001-US6255 20010228
WO 2001064643 A3 20020404

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, DE, DK, ES, FI, FR, GB, GR, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2000-185746P P 20000229
US 2000-663420 A 20000915
EP 1259485 A2 20021127 EP 2001-918257 20010228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2000-185746P P 20000229
US 2000-663420 A 20000915
WO 2001-US6255 W 20010228



FAN 2002:522631
PATENT NO. KIND DATE APPLICATION NO. DATE
PI US 2002091116 A1 20020711 US 2001-794214 20010228
US 6632815 B2 20031014

US 1999-154332P P 19990917
US 2000-662807 A2 20000915
US 2000-662807 20000915
US 1999-154332P P 19990917
US 2003-387927 20030312
US 1999-154332P P 19990917
US 2000-662807 A3 20000915
US 2003-600695 20030620
US 1999-154332P P 19990917
US 2000-662807 A2 20000915
US 2001-794214 A1 20010228



OS MARPAT 136:69743
IT 358659-62-8P 358659-63-9P 358659-64-0P
358659-65-1P 358659-74-2P 358659-75-3P
358659-76-4P 358659-77-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridyl benzamides and related compds. as Factor Xa inhibitors)

RN 358659-62-8 CAPLUS
CN Benzamide, 2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-63-9 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino(methylamino)methyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-64-0 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-65-1 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-morpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-74-2 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-thiomorpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-75-3 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperazinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-76-4 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino(4-methyl-1-piperazinyl)methyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-77-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-hexahydro-1H-azepin-1-yl)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R2C(NR3), (substituted) Ph, naphthyl, heterocyclyl, etc.; R1-R3 = H, OR5, NR5R6, alkyl, alkenyl, etc.;

R1R2 or R2R3 = atoms to form (substituted) cycloalkyl, heterocyclyl; R5, R6 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted) alkylphenyl, alkylphenyl; R5R6 = atoms to form a 3-8 membered (substituted) ring; Q

bond, CH2, CO, O, S, SO, SO2, NR7, SO2NR7, etc.; R7 = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, (substituted) alkylphenyl, alkylphenyl; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, O, S, SO, SO2, alkylcarbonyl, etc.; G = (substituted) alkenyl, cycloalkenyl, phenylene, 3-8 membered (fused) (aromatic) heterocyclyl; J = bond, NR9CO, O, S, SO, SO2, CH2, NR9SO2,

L3 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 * (substituted) Ph, naphthyl, (fused) heteroaryl, were prepd. as
 antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl)-2-
 aminophenylcarboxamide (prepn. given), 4-cyanobenzoyl chloride, and
 pyridine were stirred overnight in CH₂Cl₂ to give 70% N-(5-bromo-2-
 pyridinyl)-[2-(4-cyanophenylcarbonyl)amino]phenylcarboxamide. The latter
 in MeOH at 0° was satd. with HCl and stirred overnight followed by
 solvent evapn. The residue was refluxed 2 h with NH₄OAc in MeOH to give
 70%
 N-(5-bromo-2-pyridinyl)-[2-(4-aminophenylcarbonyl)amino]phenylcarbox
 amide.

L3 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:661392 CAPLUS
 DN 135:226888
 TI Preparation of pyridyl benzamides and related compounds as Factor Xa
 inhibitors.
 IN Zhu, Bing-yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman,
 Erick; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
 PA Cor Therapeutics, Inc., USA
 SO PCT Int. Appl., 322 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001064643	A2	20010907	WO 2001-US6255	20010228
WO 2001064643	A3	20020404		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 2000-185746P	P 20000229
			US 2000-663420	A 20000915
EP 1259485	A2	20021127	EP 2001-918257	20010228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2000-185746P	P 20000229
			US 2000-663420	A 20000915
			WO 2001-US6255	W 20010228

PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FAN 2001:208239				
PI WO 2001019788	A2	20010322	WO 2000-US25196	20000915
WO 2001019788	A3	20010809		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
AU 2000074867	A5	20010417	AU 2000-74867	20000915
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
			WO 2000-US25196	W 20000915
EP 1216228	A2	20020626	EP 2000-963452	20000915

L3 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
BR 2000014076	A	20021015	BR 2000-14076	20000915
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
JP 2003509406	T2	20030311	JP 2001-523368	20000915
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
			WO 2000-US25196	W 20000915
NO 2002001229	A	20020521	NO 2002-1229	20000915
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
			WO 2000-US25196	W 20000915

FAN 2001:208248
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI WO 2001019798 A2 20010322 WO 2000-US25195 20000915
 WO 2001019798 A3 20011025

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2000074866	A5	20010417	AU 2000-74866	20000915
			US 1999-154332P	P 19990917
			WO 2000-US25195	W 20000915

EP 1216231 A2 20020626
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

BR 2000014078	A	20021231	BR 2000-14078	20000915
			US 1999-154332P	P 19990917
			US 2000-US25195	W 20000915
TR 200201413	T2	20030221	TR 2002-200201413	20000915
			US 1999-154332P	P 19990917
JP 2003509412	T2	20030311	JP 2001-523378	20000915
			US 1999-154332P	P 19990917
			WO 2000-US25195	W 20000915
NZ 517828	A	20031031	NZ 2000-517828	20000915
			US 1999-154332P	P 19990917
			WO 2000-US25195	W 20000915
NO 2002001230	A	20020521	NO 2002-1230	20000915
			US 1999-154332P	P 19990917
			WO 2000-US25195	W 20000915

FAN 2001:661391
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI WO 2001064642 A2 20010907 WO 2001-US6247 20010228
 WO 2001064642 A3 20020502

Patel

L3 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2000-185746P P 20000229
 US 2000-663420 A 20000915

FAN 2002:11104
 PATENT NO. KIND DATE APPLICATION NO. DATE

PI US 2002002183 A1 20020103 US 2001-794225 20010228

US 6376515 B2 20020423

US 2000-185746P P 20000229

US 2000-663420 A2 20000915

US 2002-126976 20020422

US 2000-185746P P 20000229

US 2000-663420 A2 20000915

US 2001-794225 A1 20010228

US 2003-687134 20031015

US 2000-185746P P 20000229

US 2000-663420 A2 20000915

US 2001-794225 A1 20010228

US 2002-126976 A1 20020422

FAN 2002:522631
 PATENT NO. KIND DATE APPLICATION NO. DATE

PI US 2002091116 A1 20020711 US 2001-794214 20010228

US 6632815 B2 20031014

US 1999-154332P P 19990917

US 2000-662807 A2 20000915

US 2000-662807 20000915

US 1999-154332P P 19990917

US 2003-387927 20031012

US 1999-154332P P 19990917

US 2000-662807 A3 20000915

US 2003-600695 20030620

US 1999-154332P P 19990917

US 2000-662807 A2 20000915

US 2001-794214 A1 20010228

OS MARPAT 135:226888

IT 358659-62-8P 358659-63-9P 358659-64-0P 358659-65-1P 358659-74-2P 358659-75-3P 358659-76-4P 358659-77-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridyl benzamides and related compds. as Factor Xa



inhibitors)

RN 358659-62-8 CAPLUS



CN Benzamide, 2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)

<8/14/2004>

L3 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-63-9 CAPLUS
 CN Benzamide,
 N-(5-chloro-2-pyridinyl)-2-[[4-{imino(methylamino)methyl}phenyl
 methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-64-0 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[4-{imino-1-
 pyrrolidinylmethyl}phenylmethyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-65-1 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[4-{imino-4-
 morpholinylmethyl}phenylmethyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-74-2 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[4-{imino-4-
 thiomorpholinylmethyl}phenylmethyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-75-3 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[4-{imino-1-
 piperazinylmethyl}phenylmethyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-76-4 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[4-{imino(4-methyl-1-
 piperazinyl)methyl}phenylmethyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-77-5 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[4-[[hexahydro-1H-azepin-1-
 yl]iminomethyl}phenylmethyl]amino]- (9CI) (CA INDEX NAME)



AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R2C(NR3), (substituted) Ph,
 naphthyl, heterocyclyl, etc.; R1-R3 = H, OR5, NR5R6, alkyl, alkenyl,
 etc.;
 R1R2 or R2R3 = atoms to form (substituted) cycloalkyl, heterocyclyl; R5,
 R6 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted) alkylphenyl,
 alkylphenyl; R5R6 = atoms to form a 3-8 membered (substituted) ring; Q =
 bond, CH2, CO, O, S, SO, SO2, NR7, SO2NR7, etc.; R7 = H, alkyl, alkenyl,
 alkynyl, cycloalkyl, alkylcycloalkyl, (substituted) alkylphenyl,
 alkylphenyl; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic
 heterocyclyl; E = bond, alkyl, O, S, SO, SO2, alkylcarbonyl, etc.; G =
 (substituted) alkenyl, cycloalkenyl, phenylene, 3-8 membered (fused)

Patel

L3 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

(arom.) heterocyclyl; J = bond, NR9CO, O, S, SO, SO2, CH2, NR9SO2, etc.;
 X
 = (substituted) Ph, naphthyl, (fused) heteroaryl, were prep'd. as
 antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl)-2-
 aminophenylcarboxamide (prepn. given), 4-cyanobenzoyl chloride, and
 pyridine were stirred overnight in CH2Cl2 to give 70% N-(5-bromo-2-
 pyridinyl)-[2-(4-cyanophenylcarbonyl)amino]phenylcarboxamide. The latter
 in MeOH at 0° was sat'd. with HCl and stirred overnight followed by
 solvent evapn. The residue was refluxed 2 h with NH4OAc in MeOH to give
 70%
 N-(5-bromo-2-pyridinyl)-[2-(4-aminophenylcarbonyl)amino]phenylcarbox-
 amide.

<8/14/2004>

L3 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 AN 2001:661391 CAPLUS
 DN 135:210946
 TI Preparation of pyridylamides as Factor Xa inhibitors.
 IN Zhu, Bing-yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Erick; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
 PA Cor Therapeutics, Inc., USA
 SO PCT Int. Appl., 306 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001064642	A2	20010907	WO 2001-US6247	20010228
WO 2001064642	A3	20020502		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
		US 2000-185746P	P	20000229
		US 2000-663420	A	20000915

PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FAN 2001:208239				
PI WO 2001019788	A2	20010322	WO 2000-US25196	20000915
WO 2001019788	A3	20010809		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
		US 1999-154332P	P	19990917
		US 2000-185746P	P	20000229
		US 2000-663420	A	20000915
AU 2000074867	A5	20010417	AU 2000-74867	20000915
		US 1999-154332P	P	19990917
		US 2000-185746P	P	20000229
		US 2000-663420	A	20000915
EP 1216228	A2	20020626	EP 2000-963452	20000915
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
		US 1999-154332P	P	19990917
		US 2000-185746P	P	20000229
		US 2000-663420	A	20000915
BR 2000014076	A	20021015	BR 2000-14076	20000915
		US 1999-154332P	P	19990917

L3 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1259485 A2 20021127
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 2000-185746P P 20000229
 US 2000-663420 A 20000915
 EP 2001-918257 20010228
 WO 2001-US6255 W 20000915
 FAN 2002:11104
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI US 2002002183 A1 20020103 US 2001-794225 20010228
 US 6376515 B2 20020423
 US 2000-185746P P 20000229
 US 2000-663420 A 20000915
 US 2002-126976 20020422
 US 2000-185746P P 20000229
 US 2000-663420 A 20000915
 US 2001-794225 A1 20010228
 US 2003-687334 20031015
 US 2000-185746P P 20000229
 US 2000-663420 A 20000915
 US 2001-794225 A1 20010228
 US 2002-126976 A1 20020422
 FAN 2002:522631
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI US 2002091116 A1 20020711 US 2001-794214 20010228
 US 6632815 B2 20031014
 US 1999-154332P P 19990917
 US 2000-662807 A 20000915
 US 2000-662807 20000422
 US 2000-185746P P 20000229
 US 2000-663420 A 20000915
 US 2001-794225 A1 20010228
 US 2003-687334 20031015
 US 2000-185746P P 20000229
 US 2000-662807 A 20000915
 US 2001-794225 A1 20010228
 US 2002-126976 A1 20020422
 US 1999-154332P P 19990917
 US 2000-662807 A 20000915
 US 2000-662807 20000422
 US 2000-185746P P 20000229
 US 2000-663420 A 20000915
 US 2001-794225 A1 20010228
 US 2003-687334 20031015
 US 2000-185746P P 20000229
 US 2000-662807 A 20000915
 US 2001-794225 A1 20010228
 US 2002-126976 A1 20020422
 OS MARPAT 135:210946
 IT 358659-62-8P 358659-63-9P 358659-64-0P
 358659-65-1P 358659-74-2P 358659-75-3P
 358659-76-4P 358659-77-5P
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyridylamides as Factor Xa inhibitors)
 RN 358659-62-8 CAPLUS
 CN Benzamide, 2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 JP 2003509406 T2 20030311
 WO 2002001229 A 20020521
 US 2000-185746P P 20000229
 WO 2000-US25196 W 20000915
 JP 2001-523368 20000915
 US 1999-154332P P 19990917
 US 2000-185746P P 20000229
 WO 2000-US25196 W 20000915
 NO 2002-1229 20020312
 US 1999-154332P P 19990917
 US 2000-185746P P 20000229
 WO 2000-US25196 W 20000915

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FAN 2001:208248				
PI WO 2001019798	A2	20010322	WO 2000-US25195	20000915
WO 2001019798	A3	20011025		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
		US 1999-154332P	P	19990917
		US 2000-185746P	P	20000229
		US 2000-663420	A	20000915



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1216231	A2	20020626	EP 2000-963451	20000915
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
		US 1999-154332P	P	19990917
		US 2000-US25195	W	20000915
BR 2000014078	A	20021231	BR 2000-14078	20000915
		US 1999-154332P	P	19990917
		US 2000-US25195	W	20000915
TR 200201413	T2	20030221	TR 2002-200201413	20000915
		US 1999-154332P	P	19990917
JP 2003509412	T2	20030311	JP 2001-523378	20000915
		US 1999-154332P	P	19990917
		US 2000-US25195	W	20000915
NZ 517828	A	20031031	NZ 2000-517828	20000915
		US 1999-154332P	P	19990917
		US 2000-US25195	W	20000915
NO 2002001230	A	20020521	NO 2002-1230	20020312
		US 1999-154332P	P	19990917
		US 2000-US25195	W	20000915

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FAN 2001:661392				
PI WO 2001064643	A2	20010907	WO 2001-US6255	20010228
WO 2001064643	A3	20020404		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

L3 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-63-9 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino(methylamino)methyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-64-0 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-65-1 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-morpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-74-2 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-thiomorpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-75-3 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperazinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 alkenyl, cycloalkenyl, phenylene, heterocyclyl, fused cyclic system; J = bond, NR9CO, O, S, SO, SO2, SO2NR9, CH2, NR9, etc.; R9 = H, alkyl, (alkyl)aryl, etc.; X = (substituted) Ph, naphthyl, heteroaryl, fused bicycyl, were prepd. as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl)-2-aminophenylcarboxamide (prepn. given), 4-[(2-tert-butylaminosulfonyl)phenyl]benzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 85% N-(5-bromo-2-pyridinyl)-[2-4-[(2-aminosulfonyl)phenyl]phenyl]carbonylamino]phenylcarboxamide.


L3 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-76-4 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-methyl-1-piperazinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-77-5 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-methyl-1-piperazinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R1C(NR3), (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl, etc.; R1-R3 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (alkyl)aryl, (alkyl)heteroaryl, etc.; R1R2 or R2R3 = atoms to form a 3-8 membered (substituted) (heterocyclic) ring; Q = bond, CH2, CO, O, NR7, etc.; R7 = H, alkyl, (alkyl)aryl, (alkyl)heteroaryl, etc.; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, S, SO, SO2, alkoxy, etc.; G = (substituted)

L3 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:565010 CAPLUS
 DN 135:137407
 TI Preparation of 2-aminonicotinamides as VEGF receptor tyrosine kinase inhibitors
 IN Manley, Paul William; Bold, Guido
 PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
 SO PCT Int. Appl., 66 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001055114	A1	20010802	WO 2001-EP835	20010125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001028499	A5	20010807	AU 2001-28499	20010125
AU 771626	B2	20040401		
BR 2001007805	A	20021022	GB 2000-1930	A 20000127
			WO 2001-EP835	W 20010125
			BR 2001-7805	20010125
			GB 2000-1930	A 20000127
			WO 2001-EP835	W 20010125
EP 1259487	A1	20021127	EP 2001-94684	20010125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			GB 2000-1930	A 20000127
			WO 2001-EP835	W 20010125
JP 2003520853	T2	20030708	JP 2001-555056	20010125
			GB 2000-1930	A 20000127
			WO 2001-EP835	W 20010125
NZ 520005	A	20040227	NZ 2001-520005	20010125
			GB 2000-1930	A 20000127
			WO 2001-EP835	W 20010125
NO 2002003218	A	20020916	NO 2002-3218	20020702
			GB 2000-1930	A 20000127
			WO 2001-EP835	W 20010125
US 2003032656	A1	20030213	US 2002-181005	20020711
US 6624174	B2	20030923		
			GB 2000-1930	A 20000127
			WO 2001-EP835	W 20010125
ZA 2002005988	A	20030728	ZA 2002-5988	20020726
			GB 2000-1930	A 20000127

OS MARPAT 135:137407
 IT 62636-33-3P 352227-86-2P 352227-92-0P
 352228-00-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

Patel


<8/14/2004>

L3 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 (prepn. of 2-aminonicotinamides as VEGF-receptor tyrosine Kinase
 inhibitors)
 RN 62636-33-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




• HCl

RN 352227-86-2 CAPLUS
 CN 3-Pyridinecarboxamide,
 2-[[[3-[(methylamino)carbonyl]phenyl]methyl]amino]-
 N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 352227-92-0 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-(4-hydroxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 352228-00-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-(4-hydroxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; n = 1-6; W = O, S; R1, R3 = H, alkyl, acyl; R2 = (un)substituted cycloalkyl, aryl, mono- or bicyclic heteroaryl comprising

L3 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 one or more ring N atoms and 0-2 heteroatoms selected from O and S; R, R' = H, alkyl; X = (un)substituted aryl, mono- or bicyclic heteroaryl comprising one or more ring N atoms and 0-2 heteroatoms selected from O and S] and their pharmaceutically acceptable salts, useful for therapy of a disease which responds to an inhibition of the VEGF-receptor tyrosine kinase activity (such as neoplastic disease), were prepd. and formulated. Thus, amidation of 3-aminobenzotrifluoride with 2-chloronicotinoyl chloride followed by reacting 4 pyridineethanamine with the resulting carboxamide afforded I [n = 2; R, R' = H; X = 4-pyridyl; W = O; R1, R3 = H; R2 = 3-(F3C)C6H4].

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1999:409260 CAPLUS


DI 131:73440
 TI Preparation of aromatic amide derivatives as ACC inhibitor
 IN Igawa, Hiroshi; Nishimura, Masato; Okada, Keiji; Nakamura, Takashi
 PA Fujirebio, Inc., Japan
 SO Jpn. Kokai Tokkyo Koho, 72 pp.
 CODEN: JKXXAF

DT Patent
 LA Japanese


FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11171848	A2	19990629	JP 1998-270721	19980925
JP 1997-277942			JP 1997-277942	19970926

OS MARPAT 131:73440
 IT 228580-60-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of aromatic amide deriva. as ACC inhibitor)
 RN 228580-60-7 CAPLUS
 CN Benzoic acid, 2-[[2-[(phenylmethyl)amino]benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




IT 228580-61-8P 228580-84-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of aromatic amide deriva. as ACC inhibitor)
 RN 228580-61-8 CAPLUS
 CN Benzoic acid, 2-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)




RN 228580-84-5 CAPLUS
 CN Benzoic acid, 2-[[2-[[3-(phenylpropyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



AB Title compds. [I; R = 3-CF₃C₆H₄, C₆H₅(CH₂)₂, C₆H₅, CH₃(CH₂)₅, CH₃(CH₂)₃, CH₃(CH₂)₂, CH₃CH₂, CH₃, C₆H₅(CH₂)₃, etc.; R₁ = H, CH₃(CH₂)₄, 5-CH₃(CH₂)₅CC, 5-CH₃CH₂CC, 5-(CH₃)₃CC, 4-C₆H₅CH₂, 4-C₆H₅CC, 3-C₆H₅CC, 3-C₆H₅CC, 3-(4-NO₂C₆H₄)CC, 3-(4-NCC₆H₄)CC, 3-(4-HOC₆H₄)CC, etc.; R₂ = 5-OH, 5-Cl, 5-OMe, 5-Me, 5-Br, etc.; R₃ = H, CH₃, etc.; R₄ = CO₂H, AcNH₂, CH₃(CH₂)₄CONH₂, 4-CF₃C₆H₄CONH₂, PhCONH₂, (CH₃)₃CONH₂, CH₃(CH₂)₂NHCONH₂, etc.; X = CH, N, dotted bond = single, double bond are prepared and tested as ACC (acetyl-CoA carboxylase) inhibitors in treatment of lipids oxidation related diseases, such as myocardial infarction, cerebral infarction, and diabetes. The title compound I (R = 3-CF₃C₆H₄; R₁ = H; R₂ = N; R₃ = H; X = CH; dotted bonds were double bonds) was prepared with 72% yield from 3-ETOC₆H₄NH₂ and 3-(2-HOCC₆H₄NH)C₆H₄CF₃.

L3 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

IL 116917 A1 20000831 IL 1996-116917 A 19960126
US 1995-391901 A 19950221
US 1995-472067 A 19950606
TW 486469 B 20020511 TW 1996-85100978 A 19960126
US 1995-391901 A 19950221
US 1995-472067 A 19950606
CA 2213466 AA 19960829 CA 1996-2213466 A 19960201
US 1995-391901 A 19950221
US 1995-472067 A 19950606
WO 9626205 A1 19960829 WO 1996-US824 A 19960201
W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
AU 9647631 A1 19960911 AU 1996-47631 A 19960201
AU 699865 B2 19981217 US 1995-391901 A 19950221
US 1995-472067 A 19950606
WO 1996-US824 W 19960201
CN 1176640 A 19980318 CN 1996-192015 A 19960201
CN 1108301 B 20030514 US 1995-391901 A 19950221
US 1995-472067 A 19950606
EP 886637 A1 19981230 EP 1996-903604 A 19960201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE
US 1995-391901 A 19950221
US 1995-472067 A 19950606
WO 1996-US824 W 19960201
JP 11500442 T2 19990112 JP 1996-525679 A 19960201
US 1995-391901 A 19950221
US 1995-472067 A 19950606
WO 1996-US824 W 19960201
NZ 302055 A 20000228 NZ 1996-302055 A 19960201
US 1995-391901 A 19950221
US 1995-472067 A 19950606
WO 1996-US824 W 19960201
PL 185443 B1 20030530 PL 1996-322003 A 19960201
US 1995-391901 A 19950221
US 1995-472067 A 19950606
WO 1996-US824 W 19960201
ZA 9601340 A 19970911 ZA 1996-1340 A 19960220
US 1995-391901 A 19950221
US 1997-896872 A 19970721
US 1993-117362 A2 19930903
US 1994-284808 B2 19940805
US 1995-391901 B2 19950221
US 1995-472067 A3 19950606
US 1997-898304 A 19970721
US 1993-117362 A2 19930903
US 1994-284808 B2 19940805
US 1995-391901 B2 19950221
US 1995-472067 A1 19950606
US 6066650 A 20000523 US 1997-898303 A 19970721
US 1993-117362 A2 19930903
US 1994-284808 B2 19940805
US 1995-391901 B2 19950221
US 1995-472067 A1 19950606

L3 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1998:236274 CAPLUS

DN 128:282780

TI Preparation of heterocyclic inhibitors of microsomal triglyceride transfer

protein

IN Biller, Scott A.; Dickson, John K.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Sulsky, Richard B.; Tino, Joseph A.

PA Bristol-Myers Squibb Co., USA

SO U.S., 185 pp., Cont. in part of U.S. Ser. No. 391,901, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN: CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5739135	A	19980414	US 1995-472067	A 19950606
			US 1993-117362	A2 19930903
			US 1994-284808	B2 19940805
			US 1995-391901	B2 19950221
CA 2091102	AA	19930907	CA 1993-2091102	A 19930305
			US 1992-847503	A 19920306
HU 67962	A2	19950529	HU 1993-627	19930305
HU 218419	B	20000828		
JP 06038761	A2	19940215	US 1992-847503	A 19920306
			JP 1993-46499	19930308
			US 1992-847503	A 19920306
EP 584446	A2	19940302	EP 1993-103697	19930308
EP 584446	A3	19950426		
EP 584446	B1	20020619		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 219514	E	20020715	US 1992-847503	A 19920306
			AT 1993-103697	19930308
			US 1992-847503	A 19920306
PT 584446	T	20020930	PT 1993-103697	19930308
			US 1992-847503	A 19920306
ES 2178640	T3	20030101	ES 1993-103697	19930308
AU 670930	B2	19960808	US 1992-847503	A 19920306
AU 9334064	A1	19930909	AU 1993-34064	19930309
US 5595872	A	19970121	US 1992-847503	A 19920306
			US 1993-117362	19930903
			US 1992-847503	B2 19920306
			US 1993-15449	B2 19930222
US 5789197	A	19980804	US 1995-486924	19950607
			US 1992-847503	B2 19920306
			US 1993-15449	B2 19930222
			US 1993-117362	A3 19930903
US 6492365	B1	20021210	US 1995-486924	B2 19920306
			US 1992-847503	B2 19920306
			US 1993-15449	B2 19930222
			US 1993-117362	A3 19930903
US 5712279	A	19980127	US 1996-548811	19960111
			US 1995-391901	B2 19950221
			US 1995-472067	A2 19950606

L3 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

FI 9703416 A 19970820 FI 1997-3416 A 19970820
US 1995-391901 A 19950221
US 1995-472067 A 19950606
WO 1996-US824 W 19960201
NO 9703821 A 19970820 NO 1997-3821 A 19970820
US 1995-391901 A 19950221
US 1995-472067 A 19950606
WO 1996-US824 W 19960201
LT 4367 B 19980825 LT 1997-152 A 19970919
LV 11951 B 19981120 LV 1997-171 A 19970919
US 2003166590 A1 20030904 US 1995-391901 A 19950221
US 1995-472067 A 19950606
US 2001-933593 A 20010821
US 1992-847503 B2 19920306
US 1993-15449 B2 19930222
US 1993-117362 A3 19930903
US 1995-486924 A3 19950607

PATENT FAMILY INFORMATION:

FAN 1995:568500

PATENT NO.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 643057	A1	19950315	EP 1994-113800	19940902
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2091102	AA	19930907	US 1993-117362	A 19930903
			CA 1993-2091102	A 19930305
ZA 9301601	A	19931005	US 1992-847503	A 19920306
			ZA 1993-1601	19930305
HU 67962	A2	19950529	US 1993-117362	A 19930903
HU 218419	B	20000828	HU 1993-627	19930305
JP 06038761	A2	19940215	US 1992-847503	A 19920306
			JP 1993-46499	19930308
			US 1992-847503	A 19920306
EP 584446	A2	19940302	EP 1993-103697	19930308
EP 584446	A3	19950426		
EP 584446	B1	20020619		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 219514	E	20020715	AT 1993-103697	A 19930308
			US 1992-847503	A 19920306
PT 584446	T	20020930	PT 1993-103697	19930308
			US 1992-847503	A 19920306
ES 2178640	T3	20030101	ES 1993-103697	19930308
AU 670930	B2	19960808	US 1992-847503	A 19920306
AU 9334064	A1	19930909	AU 1993-34064	19930309
US 5595872	A	19970121	US 1992-847503	A 19920306
			US 1993-117362	19930903
			US 1992-847503	B2 19920306
			US 1993-15449	B2 19930222
CA 2131430	AA	19950304	CA 1994-2131430	19940902
			US 1993-117362	A 19930903
FI 9404048	A	19950304	FI 1994-4048	19940902
			US 1993-117362	A 19930903
NO 9403260	A	19950306	NO 1994-3260	19940902
			US 1993-117362	A 19930903

L3 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1996:641305 CAPLUS
 DN 125:275663
 TI Preparation of 9-(piperidinoalkyl)fluorene-9-carboxamides and analogs as
 microsome triglyceride transfer protein inhibitors
 IN Wetterau, John R. II; Sharp, Daru Young; Gregg, Richard E.; Biller, Scott
 A.; Dickson, John A.; Lawrence, R. Michael; Magnin, David R.; Poss,
 Michael A.; Robl, Jeffrey A.; et al.
 PA Bristol-Myers Squibb Company, USA
 SO PCT Int. Appl., 427 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 PAN CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9626205	A1	19960829	WO 1996-US824	19960201
W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA				
RN: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2091102	AA	19930907	US 1995-391901	A 19950221
HU 67962	A2	19950529	US 1995-472067	A 19950606
HU 218419	B	20000828	CA 1992-2091102	A 19930305
JP 06038761	A2	19940215	US 1992-847503	A 19920306
EP 584446	A2	19940302	HU 1993-627	19930305
EP 584446	A3	19950426	US 1992-847503	A 19920306
EP 584446	B1	20020619	JP 1993-46499	A 19930308
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			US 1992-847503	A 19920306
AT 219514	E	20020715	US 1993-103697	A 19930308
PT 584446	T	20020930	US 1992-847503	A 19920306
ES 2178640	T3	20030101	PT 1993-103697	A 19930308
AU 670930	B2	19960808	US 1992-847503	A 19920306
AU 9334064	A1	19930909	AU 1993-34064	19930309
US 5739135	A	19980414	US 1992-847503	A 19920306
AU 9647631	A1	19960911	US 1995-472067	A 19950606
AU 699865	B2	19981217	US 1993-117362	A2 19930903
EP 886637	A1	19981230	US 1994-284808	B2 19940805
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, SE			US 1995-391901	B2 19950221
US 1995-391901	A	19950221	AU 1996-47631	19960201
US 1995-472067	A	19950606	US 1995-391901	A 19950221
WO 1996-US824	W	19960201	US 1995-472067	A 19950606
EP 1996-903604	EP	19960201	WO 1996-US824	W 19960201

L3 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5712279	A	19980127	US 1996-548811	19960111
CA 2091102	AA	19930907	US 1995-391901	B2 19950221
HU 67962	A2	19950529	US 1995-472067	A2 19950606
HU 218419	B	20000828	CA 1992-2091102	A 19930305
JP 06038761	A2	19940215	US 1992-847503	A 19920306
EP 584446	A2	19940302	HU 1993-627	19930305
EP 584446	A3	19950426	US 1992-847503	A 19920306
EP 584446	B1	20020619	JP 1993-46499	A 19930308
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			US 1992-847503	A 19920306
AT 219514	E	20020715	US 1993-103697	A 19930308
PT 584446	T	20020930	US 1992-847503	A 19920306
ES 2178640	T3	20030101	PT 1993-103697	A 19930308
AU 670930	B2	19960808	US 1992-847503	A 19920306
AU 9334064	A1	19930909	AU 1993-34064	19930309
US 5595872	A	19970121	US 1992-847503	A 19920306
CA 2131430	AA	19950304	US 1993-117362	A 19930903
FI 9404048	A	19950304	US 1992-847503	B2 19920306
NO 9403260	A	19950306	US 1993-15449	B2 19930222
AU 9471642	A1	19950316	CA 1994-2131430	19940902
AU 690125	B2	19980423	US 1993-117362	A 19930903
ZA 9406772	A	19950403	FI 1994-4048	A 19940902
JP 07165712	A2	19950627	US 1993-117362	A 19930903
CN 1106003	A	19950802	NO 1994-3260	A 19940902
HU 70613	A2	19951030	US 1993-117362	A 19930903
US 5789197	A	19980804	AU 1994-71642	19940902
US 6492365	B1	20021210	US 1993-117362	A 19930903
US 2003166590	A1	20030904	US 1995-486924	19950607
FAN 1998:115356			US 1992-847503	B2 19920306
PATENT NO.			US 1993-15449	B2 19930222
PI US 5712279	A	19980127	US 1993-117362	A3 19930903
CA 2091102	AA	19930907	US 1995-486929	19950607
HU 67962	A2	19950529	US 1992-847503	B2 19920306
HU 218419	B	20000828	US 1993-15449	B2 19930222
JP 06038761	A2	19940215	US 1993-117362	A3 19930903
EP 584446	A2	19940302	US 2001-933593	20010821
EP 584446	A3	19950426	US 1992-847503	B2 19920306
EP 584446	B1	20020619	US 1993-15449	B2 19930222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			US 1993-117362	A3 19930903
AT 219514	E	20020715	US 1995-486929	A3 19950607
PT 584446	T	20020930	US 1992-847503	B2 19920306
ES 2178640	T3	20030101	US 1993-103697	A 19930308
AU 670930	B2	19960808	US 1992-847503	A 19920306
AU 9334064	A1	19930909	US 1995-391901	A 19950221
US 5595872	A	19970121	US 1995-472067	A 19950606
US 5789197	A	19980804	US 1993-117362	A2 19930903
US 6492365	B1	20021210	US 1994-284808	B2 19940805
US 5712279	A	19980127	US 1995-391901	B2 19950221
IL 116917	A1	20000831	CA 1993-2091102	A 19930305

Patel

L3 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 643057	A1	19950315	EP 1994-113800	19940902
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			US 1993-117362	A 19930903
CA 2091102	AA	19930907	CA 1993-2091102	A 19930305
ZA 9301601	A	19931005	US 1992-847503	A 19920306
HU 67962	A2	19950529	ZA 1993-1601	A 19930305
HU 218419	B	20000828	US 1993-117362	A 19930903
JP 06038761	A2	19940215	HU 1993-627	19930305
EP 584446	A2	19940302	US 1992-847503	A 19920306
EP 584446	A3	19950426	JP 1993-46499	19930308
EP 584446	B1	20020619	US 1992-847503	A 19920306
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			EP 1993-103697	19930308
AT 219514	E	20020715	AT 1993-103697	19930308
PT 584446	T	20020930	US 1992-847503	A 19920306
ES 2178640	T3	20030101	PT 1993-103697	A 19930308
ES 1993-103697			US 1992-847503	A 19920306
US 1992-847503	A	19920306	ES 1993-103697	19930308
US 1995-472067	A	19950606	US 1992-847503	A 19920306
WO 1996-US824	W	19960201	US 1992-847503	A 19920306
EP 1996-903604	EP	19960201	US 1992-847503	A 19920306
US 1992-847503	A	19920306	US 1992-847503	A 19920306
US 1993-103697	A	19930308	US 1992-847503	A 19920306
US 1992-847503	A	19920306	US 1992-847503	A 19920306
US 1995-391901	A	19950221	US 1992-847503	A 19920306
US 1995-472067	A	19950606	US 1992-847503	A 19920306
WO 1996-US824	W	19960201	US 1992-847503	A 19920306
EP 1996-903604	EP	19960201	US 1992-847503	A 19920306
US 1992-847503	A	19920306	US 1992-847503	A 19920306
US 1993-103697	A	19930308	US 1992-847503	A 19920306
US 1992-847503	A	19920306	US 1992-847503	A 19920306
US 1995-391901	A	19950221	US 1992-847503	A 19920306
US 1995-472067	A	19950606	US 1992-847503	A 19920306
WO 1996-US824	W	19960201	US 1992-847503	A 19920306
EP 1996-903604	EP	19960201	US 1992-847503	A 19920306
US 1992-847503	A	19920306	US 1992-847503	A 19920306
US 1993-103697	A	19930308	US 1992-847503	A 19920306
US 1992-847503	A	19920306	US 1992-847503	A 19920306
US 1995-391901	A	19950221	US 1992-847503	A 19920306
US 1995-472067	A	19950606	US 1992-847503	A 19920306
WO 1996-US824	W	19960201	US 1992-847503	A 19920306
EP 1996-903604	EP	19960201	US 1992-847503	A 19920306
US 1992-847503	A	19920306	US 1992-847503	A 19920306
US 1993-103697	A	19930308	US 1992-847503	A 19920306
US 1992-847503	A	19920306	US 1992-847503	A 19920306
US 1995-391901	A	19950221	US 1992-847503	A 19920306
US 1995-472067	A	19950606	US 1992-847503	A 19920306
WO 1996-US824	W	19960201	US 1992-847503	A 19920306
EP 1996-903604	EP	19960201	US 1992-847503	A 19920306
US 1992-847503	A	19920306	US 1992-847503	A 19920306
US 1993-103697	A	19930308	US 1992-847503	A 19920306
US 1992-847503	A	19920306	US 1992-847503	A 19920306
US 1995-391901	A	19950221	US 1992-847503	A 19920306
US 1995-472067	A	19950606	US 1992-847503	A 19920306
WO 1996-US824	W	19960201	US 1992-847503	A 19920306
EP 1996-903604	EP	19960201	US 1992-847503	A 19920306
US 1992-847503	A	19920306	US 1992-847503	A 19920306
US 1993-103697	A	19930308	US 1992-847503	A 19920306
US 1992-847503	A	19920306	US 1992-847503	A 19920306
US 1995-391901	A	19950221	US 1992-847503	A 19920306
US 1995-472067	A	19950606	US 1992-847503	A 19920306
WO 1996-US824	W	19960201	US 1992-847503	A 19920306
EP 1996-903604	EP	19960201	US 1992-847503	A 19920306
US 1992-847503	A	19920306	US 1992-847503	A 19920306
US 1993-103697	A	19930308	US 1992-847503	A 19920306
US 1992-847503	A	19920306	US 1992-847503	A 19920306
US 1995-391901	A	19950221	US 1992-847503	A 19920306
US 1995-472067	A	19950606	US 1992-847503	A 19920306
WO 1996-US824	W	19960201	US 1992-847503	A 19920306
EP 1996-903604	EP	19960201	US 1992-847503	A 19920306
US 1992-847503	A	19920306	US 1992-847503	A 19920306
US 1993-103697	A	19930308	US 1992-847503	A 19920306
US 1992-847503	A	19920306	US 1992-847503	A 19920306
US 1995-391901	A	19950221	US 1992-847503	A 19920306
US 1995-472067	A	19950606	US 1992-847503	A 19920306
WO 1996-US824	W	19960201	US 1992-847503	A 19920306
EP 1996-903604	EP	19960201	US 1992-847503	A 19920306
US 1992-847503	A	19920306	US 1992-847503	A 19920306
US 1993-103697	A	19930308	US 1992-847503	A 19920306
US 1992-847503				

L3	ANSWER 22 OF 32	CAPLUS	COPYRIGHT 2004 ACS on STN	(Continued)
TW 486469	B	20020511	US 1995-472067	A 19950606
			TW 1996-85100978	A 19960126
			US 1995-391901	A 19950221
CA 2213466	AA	19960829	US 1995-472067	A 19950606
			CA 1996-2213466	A 19960201
			US 1995-391901	A 19950221
WO 9626205	A1	19960829	US 1995-472067	A 19950606
W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA			WO 1996-US824	19960201
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
AU 9647631	A1	19960911	US 1995-472067	A 19960201
AU 699865	B2	19981217	US 1995-391901	A 19950221
			US 1995-472067	A 19950606
CN 1176640	A	19980318	WO 1996-US824	W 19960201
CN 1108301	B	20030514	CN 1996-192015	19960201
			US 1995-391901	A 19950221
EP 886637	A1	19981230	US 1995-472067	A 19950606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			EP 1996-903604	19960201
IE			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
JP 11500442	T2	19990112	JP 1996-525679	19960201
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
NZ 302055	A	20000228	WO 1996-US824	W 19960201
			NZ 1996-302055	19960201
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
PL 185443	B1	20030530	WO 1996-US824	W 19960201
			PL 1996-322003	19960201
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
ZA 9601340	A	19970911	WO 1996-US824	W 19960201
			ZA 1996-1340	19960220
US 5883099	A	19990316	US 1995-391901	A 19950221
			US 1997-896872	19970721
			US 1993-117362	A2 19930903
			US 1994-284808	B2 19940805
			US 1995-391901	B2 19950221
US 6034098	A	20000307	US 1995-472067	A3 19950606
			US 1997-898304	19970721
			US 1993-117362	A2 19930903
			US 1994-284808	B2 19940805
			US 1995-391901	B2 19950221
US 6066650	A	20000523	US 1995-472067	A3 19950606
			US 1997-898303	19970721
			US 1993-117362	A2 19930903
			US 1994-284808	B2 19940805


L3	ANSWER 22 OF 32	CAPLUS	COPYRIGHT 2004 ACS on STN	(Continued)
			US 1995-391901	B2 19950221
FI 9703416	A	19970820	US 1995-472067	A1 19950606
			FI 1997-3416	19970820
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
NO 9703821	A	19970820	WO 1996-US824	W 19960201
			NO 1997-3821	19970820
			US 1995-391901	A 19950221
LT 4367	B	19980825	US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
LV 11951	B	19981120	LT 1997-152	19970919
			US 1995-391901	A 19950221
			LV 1997-171	19970919
			US 1995-391901	A 19950221
US 2003166590	A1	20030904	US 1995-472067	A 19950606
			US 2001-933593	20010821
			US 1992-847503	B2 19940306
			US 1993-15449	B2 19930222
			US 1993-117362	A3 19930903
			US 1995-486929	A3 19950607
OS	MARPAT 125:275663			
IT	182429-79-4P 182433-96-1P			
	RL: BAC (Biological activity or effector, except adverse); BSU			
(Biological				
	study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);			
	BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(preparation of 9-(piperidinoalkyl)fluorene-9-carboxamides and			
	analogues as			
	microsomal triglyceride transfer protein inhibitors)			
RN	182429-79-4 CAPLUS			
CN	9H-Fluorene-9-carboxamide,			
	9-[4-[[2-[(phenylmethyl)amino]benzoyl]amino]-			
	1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)			

L3 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 182433-96-1 CAPLUS
 CN 9H-Fluorene-9-carboxamide, 9-[4-[[2-[(phenylmethyl)amino]benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




GI

L3 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)





AB R5Z3NRR6 [R = piperidyl group Q1; R5 = alkyl, alkoxy, (hetero)aryl, etc.; R6 = H, alk(enyl), R5R6 = atoms to form a benzannellated ring; Z3 = CO or SO2; 1 of Z4,Z5 = NR1 and the other = CH2; R1 = e.g., (un)substituted aryl group Q2; R12 = H, (halo)alkyl, heteroaryl, etc.; Z = bond, O, S, alkylimino, etc.; Z1,Z2 = bond, O, SOO-2, CO, etc.; Z11 = bond, alkylene, arylene, etc.] were prepared as microsomal triglyceride transfer protein inhibitors (no data). Thus, N-propyl 9-fluorene-carboxamide (preparation given) was alkylated by 1(CH2)4OSiMe2CMe3 (preparation given) and the deprotected and iodinated product aminated by 2-(4-piperidinyl)-2,3-dihydro-1H-isoindol-1-one (preparation given) to give title compound I.

L3 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1992:571361 CAPLUS
 DN 117:171361
 TI Synthesis of biologically active 4(3H)-quinazolinonim perchlorates
 AU Chernobrovina, N. I.; Kozhevnikov, Yu. V.; Morozova, G. E.; Chernobrovina, T. A.
 CS Perm. Pharm. Inst., Perm, Russia
 SO Khimiko-Farmatsevticheskii Zhurnal (1992), 26(3), 48-51
 CODEN: KHFZAN; ISSN: 0023-1134
 DT Journal
 LA Russian
 IT 139602-64-5P 139602-66-7P 139602-67-8P
 139602-68-9P 139602-69-0P 139602-71-4P
 139602-72-5P 139602-73-6P 143424-22-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and acetylation of)
 RN 139602-64-5 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-phenyl]- (9CI) (CA INDEX NAME)




RN 139602-66-7 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)]- (9CI) (CA INDEX NAME)




RN 139602-67-8 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)]- (9CI) (CA INDEX NAME)


L3 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 139602-68-9 CAPLUS
 CN Benzamide, N-(4-chlorophenyl)-2-[[[(2,4-dimethoxyphenyl)methyl]amino]]- (9CI) (CA INDEX NAME)



RN 139602-69-0 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-phenyl]- (9CI) (CA INDEX NAME)




RN 139602-71-4 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)]- (9CI) (CA INDEX NAME)




L3 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 139602-72-5 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)]- (9CI) (CA INDEX NAME)



RN 139602-73-6 CAPLUS
 CN Benzamide, N-(4-chlorophenyl)-2-[[[(3,4-dimethoxyphenyl)methyl]amino]]- (9CI) (CA INDEX NAME)




RN 143424-22-0 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




AB Title salts I (R = H, 3-Me, 4-Me, 4-MeO, 4-Cl; R1 = OMe, R2 = H; R1 = H, R2 = OMe) were prepared by condensation of anthranililides with dimethoxybenzaldehydes, followed by borohydride reduction of the imine group, N-acetylation, and acid cyclization. The acute toxicity and anticonvulsant, analgesic, and antimicrobial activities of some I were tested.


L3 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1992:128388 CAPLUS
 DN 116:128388
 TI Arylamides of N-(p-2',4'- or -3',4'-dimethoxybenzyl)anthranilic acid
 IN Chernobrov, N. I.; Kozhevnikov, Yu. V.; Zalesov, V. S.; Semenova, Z. N.
 PA Perm Pharmaceutical Institute, USSR
 SO U.S.S.R.
 From: Otkrytiya, Izobret. 1991, (28), 258.
 CODEN: URXXAF
 DT Patent
 LA Russian
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI SU 1156362	A1	19910730	SU 1983-3573020	19830217
IT 139602-64-5			SU 1983-3573020	19830217
139602-65-6				
139602-66-7				
139602-67-8				
139602-68-9				
139602-69-0				
139602-70-3				
139602-71-4				
139602-72-5				
139602-73-6				

RL: RCT (Reactant); RACT (Reactant or reagent)
 (intermediate for quinazolinonium perchlorate deriva.)
 RN 139602-64-5 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)





RN 139602-65-6 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 139602-66-7 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139602-67-8 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 139602-68-9 CAPLUS
 CN Benzamide, N-(4-chlorophenyl)-2-[[[(2,4-dimethoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 139602-69-0 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)


L3 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139602-70-3 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 139602-71-4 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 139602-72-5 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139602-73-6 CAPLUS
CN Benzamide, N-(4-chlorophenyl)-2-[[[(3,4-dimethoxyphenyl)methyl]amino]-
(9CI) (CA INDEX NAME)



GI



AB The title compds. (I; R = H, Me, p-Cl; R1 o-OMe, m-OMe) are intermediates for biol. active 1-(2',4'- or -3',4'-dimethoxybenzyl)-2-methyl-3-aryl-4-(3H)-quinazolinium perchlorates.

L3 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1991:514559 CAPLUS
DN 115:114559
TI Preparation of 5,11-dihydro-6H-dipyrido [3,2-b:2',3'-e] (1,4) diazepines and their use in the prevention or treatment of HIV infection
IN Hargrave, Karl D.; Schmidt, Guenther; Engel, Wolfhard; Trummelitz, Guenther; Eberlein, Wolfgang
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Thomae, Dr. Karl, G.m.b.H.
SO Eur. Pat. Appl., 42 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 429987	A2	19910605	EP 1990-121954	19901116
EP 429987	A3	19920122		
EP 429987	B1	19990317		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2030056	AA	19910518	US 1989-438923	A 19891117
CA 2030056	C	19951017	US 1990-579001	A 19900906
			US 1990-600390	A 19901019
			CA 1990-2030056	19901115
FI 9005674	A	19910518	US 1989-438923	A 19891117
FI 94529	B	19950615	US 1990-579001	A 19900906
FI 94529	C	19950925	FI 1990-5674	19901116
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
NO 9004986	A	19910521	NO 1990-4986	19901116
NO 175478	B	19940711		
NO 175478	C	19941019		
HU 56103	A2	19910729	US 1989-438923	A 19891117
HU 208139	B	19930830	US 1990-579001	A 19900906
			US 1990-600390	A 19901019
JP 04178386	A2	19920625	HU 1990-7186	19901116
JP 2912007	B2	19990628	US 1989-438923	A 19891117
IL 96367	A1	19970218	JP 1990-311230	19901116
			US 1989-438923	A 19891117
			IL 1990-96267	19901116
			US 1989-438923	A 19891117
			IL 1990-94883	A0 19900627
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
AT 177744	E	19990415	AT 1990-121954	19901116
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
ES 2130114	T3	19990701	ES 1990-121954	19901116
			US 1989-438923	A 19891117

L3 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

AU 9066732	A1	19910523	US 1990-579001	A 19900906
AU 630251	B2	19921022	US 1990-600390	A 19901019
			AU 1990-66732	19901119
ZA 9009246	A	19920729	US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
JP 04257584	A2	19920911	ZA 1990-9246	19901119
JP 2539116	B2	19961002	US 1989-438923	A 19891117
			JP 1991-211068	19910822
HU 59407	A2	19920528	US 1990-579001	A 19900906
HU 214595	B	19980428	US 1990-600390	A 19901019
			HU 1991-2865	19910904
RU 2040527	C1	19950725	US 1990-579001	A 19900906
			US 1990-600390	A 19901019
			US 1989-438923	A 19900906
US 5366972	A	19941122	US 1990-579001	A 19901019
			US 1991-91418	19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1991-740828	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1991-91418	A3 19930713
US 5620974	A	19970415	US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1991-91418	A3 19930713
HK 1011025	A1	20000420	US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1991-91418	A3 19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1991-91418	A3 19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1991-91418	A3 19930713

PATENT FAMILY INFORMATION:

FAN 1991:102069				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 393529	A1	19901024	EP 1990-107098	19900412
EP 393529	B1	19930630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 91128	E	19930715	US 1989-340970	A 19890420
			AT 1990-107098	19900412
			US 1989-340970	A 19890420
			EP 1990-107098	A 19900412
ES 2058656	T3	19941101	ES 1990-107098	19900412
			US 1989-340970	A 19890420
CA 2014771	AA	19901020	CA 1990-2014771	19900418
CA 2014771	C	20000801		
JP 03063276	A2	19910319	US 1989-340970	A 19890420
JP 2851913	B2	19990127	JP 1990-104379	19900419
			US 1989-340970	A 19890420

L3 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

US 5366972	A	19941122	US 1993-91418	19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1991-740828	B2 19890420
			US 1989-340970	B2 19890628
			US 1989-372974	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1991-91418	A3 19930713
FAN 1991:449732				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 410148	A1	19910130	EP 1990-112072	19900626
EP 410148	B1	19940406		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2019812	AA	19901228	US 1989-372974	A 19890628
CA 2019812	C	20001123	CA 1990-2019812	19900626
DD 295849	A5	19911114	US 1989-372974	A 19890628
			DD 1990-342100	19900626
			US 1989-372974	A 19890628
AT 103918	E	19940415	AT 1990-112072	19900626
			US 1989-372974	A 19890628
			EP 1990-112072	A 19900626
			ES 1990-112072	19900626
			US 1989-372974	A 19890628
NO 9002851	A	19910102	NO 1990-2851	19900627
NO 174668	B	19940131		
NO 174668	C	19940518		
HU 55017	A2	19910429	US 1989-372974	A 19890628
HU 206504	B	19921130	HU 1990-4021	19900627
JP 03115283	A2	19910516	US 1989-372974	A 19890628
JP 2911967	B2	19990628	JP 1990-169663	19900627
ZA 9004991	A	19920325	US 1989-372974	A 19890628
			ZA 1990-4991	19900627
FI 92828	B	19940930	US 1989-372974	A 19890628
FI 92828	C	19950110	FI 1990-3225	19900627
IL 94883	A1	19941007	US 1989-372974	A 19890628
			IL 1990-94883	19900627
AU 9057921	A1	19910103	US 1989-372974	A 19890628
AU 620724	B2	19920220	AU 1990-57921	19900628
RU 2024522	C1	19941215	US 1989-372974	A 19890628
			RU 1992-5011432	19920427
US 5366972	A	19941122	US 1989-372974	A 19890628
			US 1993-91418	19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906

Patel

<8/14/2004>

L3 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

US 5620974 A 19970415

US 1990-600390 B2 19901019
US 1991-740828 B1 19910805
US 1994-279464 B1 19940722
US 1989-340970 B2 19890420
US 1989-372974 B2 19890628
US 1989-438923 B2 19891117
US 1990-579001 B2 19900906
US 1990-600390 B2 19901019
US 1991-740828 B1 19910805
US 1993-91418 A3 19930713

CS MARPAT 115:114559



IT 132312-45-9P 132362-76-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of antiviral dihydrodipyrroliodiazepines)


RN 132312-45-9 CAPLUS

CN 3 Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 132362-76-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1991:449732 CAPLUS

DN 115:49732

TI Preparation of

5,11-dihydro-6H-dipyrro[3,2-b:2',3' e][1,4]diazepin-6-one and thionones and their use in the prevention or treatment of AIDS

IN Schmidt, Guenther; Engel, Wolfhard; Trummlitz, Guenter; Eberlein, Wolfgang; Hargrave, Karl D.

PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Thomae, Dr. Karl, G.m.b.H.

SO Eur. Pat. Appl., 20 pp.

CODEN: EPXXDW

DT Patent


LA English

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 410148	A1	19910130	EP 1990-112072	19900626
EP 410148	B1	19940406		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2019812	AA	19901228	US 1989-372974	A 19890628
CA 2019812	C	20001121	CA 1990-2019812	19900626
DD 295849	A5	19911114	US 1989-372974	A 19890628
			DD 1990-342100	19900626
AT 103918	E	19940415	US 1989-372974	A 19890628
			AT 1990-112072	19900626
			US 1989-372974	A 19890628
			EP 1990-112072	A 19900626
ES 2063202	T3	19950101	ES 1990-112072	19900626
			US 1989-372974	A 19890628
			NO 1990-2851	19900627
NO 9002851	A	19910102	US 1989-372974	A 19890628
NO 174468	B	19940131	HU 1990-4021	19900627
NO 174468	C	19940518		
HU 55017	A2	19910429	US 1989-372974	A 19890628
HU 206504	B	19921130	HU 1990-4021	19900627
JP 03115283	A2	19910516	US 1989-372974	A 19890628
JP 2911967	B2	19900628	JP 1990-169663	19900627
ZA 9004991	A	19920325	US 1989-372974	A 19890628
			ZA 1990-4991	19900627
FI 92828	B	19940930	US 1989-372974	A 19890628
FI 92828	C	19950110	FI 1990-3225	19900627
IL 94883	A1	19941007	US 1989-372974	A 19890628
			IL 1990-94883	19900627
AU 9057921	A1	19910103	US 1989-372974	A 19890628
AU 620724	B2	19920220	AU 1990-57921	19900628
RU 2024522	C1	19941215	US 1989-372974	A 19890628
			RU 1992-5011432	19920427
			US 1989-372974	A 19890628
			US 1993-91418	A 19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
US 5366972	A	19941122	US 1993-91418	A3 19930713

Patel

L3 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB Title compds. I (Z = O, S, :NCN, :NOR; R1-R8 = various subsets of groups selected from H, alkyl, cycloalkyl, fluoroalkyl, aryl, tetrahydrofuryl, alkanoyl, trihalomethyl, alkoxy-carbonyl, halo, amino, and many more; R9 = Cl-3 alkyl; numerous provisions and exceptions) were prepared for prevention and treatment of HIV-1 infection. For example, 2-hydroxy-4-methyl-3-nitropyridine was converted by chlorination with POCl3 and reduction to 3-amino-2-chloro-4-methylpyridine, which underwent amidation with 2-chloronicotinoyl chloride and condensation with EtNH2 to give (chloromethylpyridinyl)(ethylamino)pyridinecarboxamide II. Cyclization of II by NaH in DMP at reflux temperature gave I (Z = O, R1 = R3 = R4 = R6-R8 = H, R2 = Et, R5 = Me) (III). At 3 µg/mL, III gave 100% inhibition of HIV-1 replication in a human T-cell culture assay. III also gave 100% inhibition of HIV-1 reverse transcriptase at 10 µg/mL in vitro; no activity was seen for I against 2 related enzymes, indicating high specificity. Three formulations, 77 synthetic examples, and addnl. test results including cytotoxicity are given.

L3 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

US 5620974 A 19970415

US 1994-279464 B2 19940722
US 1989-340970 B2 19890420
US 1989-372974 B2 19890628
US 1989-438923 B2 19891117
US 1990-579001 B2 19900906
US 1990-600390 B2 19901019
US 1991-740828 B1 19910805
US 1993-91418 A3 19930713

PATENT FAMILY INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 393529	A1	19901024	EP 1990-107098	19900412
EP 393529	B1	19930630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 91128	E	19930715	AT 1990-107098	A 19900412
			US 1989-340970	A 19890420
ES 2058656	T3	19941101	EP 1990-107098	A 19900412
			ES 1990-107098	A 19900412
CA 2014771	AA	19901020	US 1989-340970	A 19890420
CA 2014771	C	20000801	CA 1990-2014771	19900418
JP 03063276	A2	19910319	US 1989-340970	A 19890420
JP 2851913	B2	19990127	JP 1990-104379	19900419
US 5366972	A	19941122	US 1989-340970	A 19890420
			US 1993-91418	19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1993-91418	A3 19930713
US 5620974	A	19970415	US 1994-279464	B2 19940722
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1993-91418	A3 19930713
1991:514559				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 429987	A2	19910605	EP 1990-121954	19901116
EP 429987	A3	19920122		
EP 429987	B1	19990317		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2030056	AA	19910518	US 1989-438923	A 19891117
CA 2030056	C	19951017	US 1990-579001	A 19900906
			US 1990-600390	A 19901019
			CA 1990-2030056	19901115
FI 9005674	A	19910518	US 1989-438923	A 19891117
FI 94529	B	19950615	US 1990-579001	A 19900906
FI 94529	C	19950925	FI 1990-5674	19901116

<8/14/2004>


L3	ANSWER 26 OF 32	CAPLUS	COPYRIGHT	2004	ACS on STN	(Continued)
						US 1989-438923 A 19891117
						US 1990-579001 A 19900906
						US 1990-600390 A 19901019
						NO 1990-4986 19901116
NO 9004986	A	19910521				
NO 175478	B	19940711				
NO 175478	C	19941019				
						US 1989-438923 A 19891117
						US 1990-579001 A 19900906
						US 1990-600390 A 19901019
						HU 1990-7186 19901116
HU 56103	A2	19910729				
HU 208139	B	19930830				
JP 04178386	A2	19920625				
JP 2912007	B2	19990628				
IL 96367	A1	19970218				
						US 1989-438923 A 19891117
						IL 1990-96367 19901116
						US 1989-438923 A 19891117
						IL 1990-94883 A0 19900627
						US 1990-579001 A 19900906
						US 1990-600390 A 19901019
AT 177744	E	19990415				19901116
						US 1989-438923 A 19891117
						US 1990-579001 A 19900906
						US 1990-600390 A 19901019
						ES 1990-121954 19901116
ES 2130114	T3	19990701				
						US 1989-438923 A 19891117
						US 1990-579001 A 19900906
						US 1990-600390 A 19901019
AU 9066732	A1	19910523				
AU 630251	B2	19921022				
						US 1989-438923 A 19891117
						US 1990-579001 A 19900906
						US 1990-600390 A 19901019
ZA 9009246	A	19920729				
						ZA 1990-9246 19901119
JP 04257584	A2	19920911				
JP 2539116	B2	19961002				
						US 1989-438923 A 19891117
						JP 1991-211068 19910822
						US 1990-579001 A 19900906
						US 1990-600390 A 19901019
HU 59407	A2	19920528				
HU 214595	B	19980428				
						HU 1991-2865 19910904
						US 1990-579001 A 19900906
						US 1990-600390 A 19901019
RU 2040527	C1	19950725				
						RU 1992-5011559 19920506
						US 1989-438923 A 19891117
						US 1990-579001 A 19900906
						US 1990-600390 A 19901019
US 5366972	A	19941122				
						US 1993-91418 B2 19890420
						US 1989-340970 B2 19890628
						US 1989-372974 B2 19891117
						US 1989-438923 B2 19891117
						US 1990-579001 B2 19900906
						US 1990-600390 B2 19901019
						US 1991-740828 B1 19910805
US 5620974	A	19970415				
						US 1994-279464 19940722

L3 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 etc.; R2 = H, (substituted) alkyl, alkenyl, etc.; R3-R8 = H, or 1 of
 R3-R8
 is alkyl, alkoxy, alkylthio, etc., and the remaining 5 of R3-R8 are each
 H, or R3 R5 are H, alkyl with the proviso that at least one is H or 1 of
 R3 R5 is Bu with the remaining 2 being H; and R6-R8 are H, alkyl with the
 proviso that at least 1 is H, or 1 of R6-R8 is Bu with the remaining 2
 being H; with the proviso that when R1 and R2 are H, alkyl and R3-R8 are
 all H then Z is S] were prepd. A mixt. of
 5,11-dihydro-11 ethyl-5-methyl
 6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one and Lawesson's reagent in
 toluene was refluxed for 2.5 h to give I (R1 = Me; Z = S; R2 = Et; R3 =
 R4
 = R5 = R6 = R7 = R8 = H), which at 10 µg/mL gave 100% in vitro
 inhibition of reverse transcriptase.

L3	ANSWER 26 OF 32	CAPLUS	COPYRIGHT	2004	ACS on STN	(Continued)
						US 1989-340970 B2 19890420
						US 1989-372974 B2 19890628
						US 1989-438923 B2 19891117
						US 1990-579001 B2 19900906
						US 1990-600390 B2 19901019
						US 1991-740828 B1 19910805
						US 1993-91418 A3 19930713
						HK 1998-112090 19981117
						US 1989-438923 A 19900906
						US 1990-579001 A 19901019
						US 1990-600390 A 19901019
HK 1011025	A1	20000420				
OS	MARPAT	115:49732				
IT	132312-45-9P					
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT					
	(Reactant or reagent)					
	(preparation and reaction of, in preparation of drug for treatment of					
AIDS)						
RN	132312-45-9	CAPLUS				
CN	3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[[4-methoxyphenyl]methyl]amino]- (9CI) (CA INDEX NAME)					





GI




AB The title compds. I [Z = O, S; R1 = H, (substituted) alkyl, arylmethyl,

L3	ANSWER 27 OF 32	CAPLUS	COPYRIGHT	2004	ACS on STN	(Continued)
AN	1991:449642	CAPLUS				
DN	115:49642					
TI	Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1.					
	Tricyclic pyridobenz- and dipyridodiazepinones					
AU	Hargrave, Karl D.; Proudfoot, John R.; Grozinger, Karl G.; Cullen,					
Ernest;						
	Kapadia, Suresh R.; Patel, Usha R.; Fuchs, Victor U.; Mauldin, Scott C.;					
	Vitouse, Jana; et al.					
CS	Boehringer Ingelheim Pharm., Inc., Ridgefield, CT, 06877, USA					
SO	Journal of Medicinal Chemistry (1991), 34(7), 2231-41					
	CODEN: JMCMAR; ISSN: 0022 2623					
DT	Journal					
LA	English					
OS	CASREACT 115:49642					
IT	132312-45-9P					
	RL: SPN (Synthetic preparation); PREP (Preparation)					
	(preparation and reductive intramol. cyclocondensation of,					
	dipyridodiazepinone from)					
RN	132312-45-9	CAPLUS				
CN	3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[[4-methoxyphenyl]methyl]amino]- (9CI) (CA INDEX NAME)					



GI



AB Novel pyrido[2,3-b][1,4]benzodiazepinones, pyrido[2,3-b][1,5]benzodiazepinones, and dipyrido[3,2-b:2',3'-e][1,4]diazepinones
 e.g., I (X = N, X1 = CH; X = CH; X1 = N) and II inhibited human
 immunodeficiency virus type 1 reverse transcriptase in vitro at concns.

<8/14/2004>

L3 ANSWER 27 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 low as 35 nM. In all three series, small substituents (e.g., Me, Et, Ac) are preferred at the lactam nitrogen, whereas slightly larger alkyl moieties (e.g., Et, cyclopropyl) are favored at the other (N-11) diazepinone nitrogen. In general, lipophilic substituents are preferred on the A ring, whereas substitution on the C ring generally reduces potency relative to the corresponding compds. with no substituents on the arom. ring. Max. potency is achieved with Me substitution at the position ortho to the lactam nitrogen atom; however, in this case an unsubstituted lactam nitrogen is preferred. Addnl. substituents on the A ring can be readily tolerated. II (Br-RG-587) is a potent (IC50 = 84 nM) and selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, and has been chosen for preclin. development. II is noncytotoxic except at high doses and effective against all clin. isolates of HIV-1, including those which are AZT-resistant. It is specific for HIV-1, ineffective against HIV-2, inactive against simian and feline reverse transcriptase, and does not inhibit DNA polymerase.

L3 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 AN 1991:102069 CAPLUS
 DN 114:102069
 TI Preparation of
 S,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-ones as drugs for prevention or treatment of AIDS
 IN Schmidt, Guenther; Engel, Wolfhard; Trummelitz, Guenter; Eberlein, Wolfgang; Hargrave, Karl D.
 PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Thomae, Dr. Karl, G.m.b.H.
 SO Eur. Pat. Appl., 21 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 393529	A1	19901024	EP 1990-107098	19900412
EP 393529	B1	19930630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 91128	E	19930715	US 1989-340970	A 19890420
			AT 1990-107098	19900412
			US 1989-340970	A 19890420
			EP 1990-107098	A 19900412
ES 2058656	T3	19941101	ES 1990-107098	19900412
			US 1989-340970	A 19890420
CA 2014771	AA	19901020	CA 1990-2014771	19900418
CA 2014771	C	20000801		
JP 03063276	A2	19910319	US 1989-340970	A 19890420
JP 2851913	B2	19990127	JP 1990-104379	19900419
			US 1989-340970	A 19890420
US 5366972	A	19941122	US 1993-91418	19930713
			US 1989-340970	B2 19890628
			US 1989-372974	B2 19891117
			US 1989-438923	B2 19900906
			US 1990-579001	B2 19901019
			US 1990-600390	B1 19910805
			US 1991-740828	19940722
US 5620974	A	19970415	US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1993-91418	A3 19930713

PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 410148	A1	19910130	EP 1990-112072	19900626
EP 410148	B1	19940406		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2019812	AA	19901228	CA 1990-2019812	19900626

L3 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CA 2019812 C 20001121

DD 295849	A5	19911114	US 1989-372974	A 19890628
			DD 1990-342100	19900626
AT 103918	E	19940415	US 1989-372974	A 19890628
			AT 1990-112072	19900626
			US 1989-372974	A 19890628
ES 2063202	T3	19950101	EP 1990-112072	A 19900626
			ES 1990-112072	19900626
NO 9002851	A	19910102	US 1989-372974	A 19890628
NO 174468	B	19940131	NO 1990-2851	19900627
NO 174468	C	19940518		
HU 55017	A2	19910429	US 1989-372974	A 19890628
HU 206504	B	19921130	HU 1990-4021	19900627
JP 03115283	A2	19910516	US 1989-372974	A 19890628
JP 2911967	B2	19990628	JP 1990-169663	19900627
ZA 9004991	A	19920325	US 1989-372974	A 19890628
			ZA 1990-4991	19900627
FI 92828	B	19940930	US 1989-372974	A 19890628
FI 92828	C	19950110	FI 1990-3225	19900627
IL 94883	A1	19941007	US 1989-372974	A 19890628
			IL 1990-94883	19900627
AU 9057921	A1	19910103	US 1989-372974	A 19890628
AU 620724	B2	19920220	AU 1990-57921	19900628
RU 2024522	C1	19941215	US 1989-372974	A 19890628
			RU 1992-5011432	19920427
US 5366972	A	19941122	US 1989-372974	A 19890628
			US 1993-91418	19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1994-279464	19940722
US 5620974	A	19970415	US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1993-91418	A3 19930713

FAN 1991:514559
 PATENT NO. KIND DATE APPLICATION NO. DATE

PI EP 429987 A2 19910605 EP 1990-121954 19901116

EP 429987 A3 19920122

EP 429987 B1 19990317

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE

CA 2030056 AA 19910518

CA 2030056 C 19951017

US 1989-438923 A 19891117

US 1990-579001 A 19900906

US 1990-600390 A 19901019

CA 1990-2030056 19901115

L3 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



FI 9005674	A	19910518	US 1990-579001	A 19900906
FI 94529	B	19950615	FI 1990-5674	19901116
FI 94529	C	19950925		
NO 9004986	A	19910521	US 1989-438923	A 19891117
NO 175478	B	19940711	US 1990-579001	A 19900906
NO 175478	C	19941019	US 1990-600390	A 19901019
			NO 1990-4986	19901116
HU 56103	A2	19910729	US 1989-438923	A 19891117
HU 208139	B	19930830	US 1990-579001	A 19900906
JP 04178386	A2	19920625	US 1990-600390	A 19901019
JP 2912007	B2	19990628	HU 1990-7186	19901116
IL 96367	A1	19970218	US 1989-438923	A 19891117
			IL 1990-96367	19901116
			US 1989-438923	A 19891117
			IL 1990-94883	A0 19900627
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
AT 177744	E	19990415	AT 1990-121954	19901116
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
ES 2130114	T3	19990701	ES 1990-121954	19901116
			US 1989-438923	A 19891117
AU 9066732	A1	19910523	US 1990-579001	A 19900906
AU 630251	B2	19921022	US 1990-600390	A 19901019
			AU 1990-66732	19901119
ZA 9009246	A	19920729	US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
JP 04257584	A2	19920911	ZA 1990-9246	19901119
JP 2539116	B2	19961002	US 1989-438923	A 19891117
			JP 1991-211068	19910822
HU 59407	A2	19920528	US 1990-579001	A 19900906
HU 214595	B	19980428	US 1990-600390	A 19901019
			HU 1991-2865	19910904
RU 2040527	C1	19950725	US 1990-579001	A 19900906
			US 1990-600390	A 19901019
			RU 1992-5011559	19920506
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
US 5366972	A	19941122	US 1993-91418	19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1994-279464	19940722

US 5620974 A 19970415


<8/14/2004>

L3 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 US 1989-340970 B2 19890420
 US 1989-372974 B2 19890628
 US 1989-438923 B2 19891117
 US 1990-579001 B2 19900906
 US 1990-600390 B2 19901019
 US 1991-740828 B1 19910805
 US 1993-91418 A3 19930713
 HK 1011025 A1 20000420 HK 1998-112090 19981117
 US 1989-438923 A 19891117
 US 1990-579001 A 19900906
 US 1990-600390 A 19901019

OS MARPAT 114:102069
 IT 132312-45-9P 132362-76-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as intermediate for dipyridodiazepinone reverse
 transcriptase inhibitor)
 RN 132312-45-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[4-(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 132362-76-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[phenylmethyl]amino]- (9CI) (CA INDEX NAME)




GI

L3 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1984:611088 CAPLUS
 DN 101:211088
 TI Studies of 4[3H]-quinazolinone. XII. Synthesis and biological activity of 1-benzyl 4'-nitrobenzyl-2-methyl-3-alkyl(aryl)-4(3H)-quinazolinone perchlorates
 AU Chernobrovina, N. I.; Kozhevnikov, Yu. V.; Zalesov, V. S.; Gradel, I. I.
 CS Perm. Pharm. Inst., Perm, USSR
 SO Khimiko-Farmatsevticheskii Zhurnal (1984), 18(7), 830-3
 CODEN: KHFZAN; ISSN: 0023-1134
 DT Journal
 LA Russian
 IT 92944-76-8P 92944-77-9P 92944-78-0P
 92944-79-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and acetylation of)
 RN 92944-76-8 CAPLUS
 CN Benzamide, N-(2,4-dimethylphenyl)-2-[[phenylmethyl]amino]- (9CI) (CA INDEX NAME)




RN 92944-77-9 CAPLUS
 CN Benzamide, N-(4-methoxyphenyl)-2-[[phenylmethyl]amino]- (9CI) (CA INDEX NAME)




RN 92944-78-0 CAPLUS
 CN Benzamide, N-(4-methoxyphenyl)-2-[[4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




AB The title compds. (I; R1, R2 = H, C1-5 alkyl), were prepared. Thus, N-(2-chloro-3-pyridinyl)-2-[[4-(4-methoxyphenyl)methyl]amino]-3-pyridinecarboxamide (preparation given) was refluxed 8 h with NaH in DMF to give 50% 5,11-dihydro-11-[[4-(4-methoxyphenyl)methyl]-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, which was converted to title compound II in 3 steps. II at 10 µg/mL gave 100% inhibition of HIV-I reverse transcriptase. Dosage formulations were prepared containing I (R1 = H, R2 = Pr).


L3 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 92944-79-1 CAPLUS
 CN Benzamide, N-(4-ethoxyphenyl)-2-[[4-nitrophenyl)methyl]amino]- (9CI)
 (CA INDEX NAME)



GI




L3 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
PhCH₂NH, 4-methyl-1-piperazinyl, 4-(2-hydroxyethyl)-1-piperazinyl,
piperidino], useful as sedatives and muscle relaxants, were obtained in
56-98% yields by amination of chloronicotinamides with R₂NH.

L3 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1971:76431 CAPLUS
DN 74:76431
TI 3-Substituted picolinyl penicillins and cephalosporins, useful as animal
feed supplements and in germicidal preparations employed as surface
disinfectants
IN Schwarz, J. S. Paul; Sheehan, John T.
PA E. R. Squibb and Sons, Inc.
SO U.S., 11 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3553203	A	19710105	US 1969-834157	19690617
	BR 6915314	A0	19730419	BR 1969-215314	19691219
	CA 963003	A1	19750218	CA 1970-85025	19700609
	DE 2028830	A	19710107	DE 1970-2028830	19700611
	CH 517116	A	19711231	CH 1970-517116	19700616
	FR 2052982	A1	19710416	FR 1970-22345	19700617
	FR 2052982	A5	19710416	US 1969-834157	19690617

IT 30861-03-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 30861-03-1 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[3-
(benzylamino)picolinamido]-3,3-dimethyl-7-oxo-, monosodium salt (BCI)
(CA INDEX NAME)

Absolute stereochemistry.



● Na

AB The title compds. were prepared Thus, ClCO₂Et was added to an ice-cold
solution of 3-benzoyloxy-2-picolinic acid-HCl sesquihydrate in CHCl₃
containing

L3 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Et₃N; after 30 min, ice-cold 6-aminopenicillanic acid and Et₃N in CHCl₃
was added and the soln. kept 12 hr to give, after alk. addn., Na
6-(3-benzoyloxy-2-picolinamido)penicillanate. Prepd. similarly were: Na
7-(3-benzoyloxy-2-picolinamido)cephalosporanate, Na 6-(3-hydroxy-2-
picolinamido)penicillanate, and Na 7-(3-hydroxy-2-picolinamido)-
cephalosporanate.

=> log y

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

253.01

408.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

ENTRY

TOTAL

SESSION

CA SUBSCRIBER PRICE

-23.52

-23.52

STN INTERNATIONAL LOGOFF AT 10:17:57 ON 14 AUG 2004

Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	May 12	EXTEND option available in structure searching
NEWS	4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in Cplus
NEWS	6	May 27	Cplus super roles and document types searchable in REGISTRY
NEWS	7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12	AUG 02	Cplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS EXPRESS	JULY 30		CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:10:15 ON 14 AUG 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:10:31 ON 14 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 AUG 2004 HIGHEST RN 726125-61-7

DICTIONARY FILE UPDATES: 12 AUG 2004 HIGHEST RN 726125-61-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>


Uploading c:\program files\stnexp\queries\10823809.4

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 Cb,Hy

G2 N,CH

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full

FULL SEARCH INITIATED 10:10:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 525425 TO ITERATE

76.1% PROCESSED 400000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.07

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 525425 TO 525425
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS FUL L1

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

155.42

155.63

STN INTERNATIONAL LOGOFF AT 10:11:06 ON 14 AUG 2004

Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3 May 12	EXTEND option available in structure searching
NEWS	4 May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5 May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAlus
NEWS	6 May 27	CAlus super roles and document types searchable in REGISTRY
NEWS	7 Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8 Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9 Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10 Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11 AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12 AUG 02	CAlus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13 AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14 AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15 AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS EXPRESS	JULY 30	CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:01:02 ON 14 AUG 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:01:13 ON 14 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 AUG 2004 HIGHEST RN 726125-61-7

DICTIONARY FILE UPDATES: 12 AUG 2004 HIGHEST RN 726125-61-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>


Uploading c:\program files\stnexp\queries\10823809.2

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 Cb,Hy

G2 N,CH

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full

FULL SEARCH INITIATED 10:01:34 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 40288 TO ITERATE

100.0% PROCESSED 40288 ITERATIONS
SEARCH TIME: 00.00.01

239 ANSWERS

L2 239 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

155.42

155.63

FILE 'CAPLUS' ENTERED AT 10:01:41 ON 14 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Aug 2004 VOL 141 ISS 8

FILE LAST UPDATED: 13 Aug 2004 (20040813/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2

L3 49 L2

=> d l3 fbib hitstr abs total

L3 ANSWER 1 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:589247 CAPLUS
 TI Preparation of heterocyclic compounds as selective phosphodiesterase V
 inhibitors
 IN Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji; Kikkawa, Kohei
 PA Japan
 SO U.S. Pat. Appl. Publ., 116 pp., Cont.-in-part of U.S. Ser. No. 258,545.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004142930	A1	20040722	US 2003-699804	20031104
			JP 2000-130371	A 20000428
			JP 2000-277652	A 20000913
			WO 2001-JP2034	W 20010315
JP 2002012587	A2	20020115	US 2002-258545	A2 20021025
			JP 2000-277652	20000913
			JP 1999-261852	A 19990916
			JP 2000-130371	A 20000428
WO 2001083460	A1	20011108	WO 2001-JP2034	20010315
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NG, SN, TD, TG				
US 2003229089	A1	20031211	JP 2000-130371	A 20000428
			US 2002-258545	20021025
			JP 2000-130371	A 20000428
			WO 2001-JP2034	W 20010315


PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001019802	A1	20010322	WO 2000-JP6258	20000913
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NG, SN, TD, TG				
AU 2000073118	A5	20010417	AU 2000-73118	20000913
AU 767558	B2	20031113	JP 1999-261852	A 19990916
			JP 2000-130371	A 20000428
			WO 2000-JP6258	W 20000913

L3 ANSWER 1 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 NZ 522217 A 20040430
 US 2003229089 A1 20031211
 US 2004142930 A1 20040722
 IT 372115-86-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 [preparation of heterocyclic compds. as selective phosphodiesterase V inhibitors for treating various diseases due to functional disorders]

on cGMP-signaling)
 RN 372115-86-1 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3-chloro-4-methoxyphenyl)methylamino]-N-(trans-4-hydroxycyclohexyl)-6-[[[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-9C1] (CA INDEX NAME)

Absolute stereochemistry.




G:

L3 ANSWER 1 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 BR 2000014526 A 20020618 BR 2000-14526 20000913
 JP 1999-261852 A 19990916
 JP 2000-130371 A 20000428
 WO 2000-JP6258 W 20000918
 TR 200200701 T2 20020621 TR 2002-200200701 20000913
 JP 1999-261852 A 19990916
 JP 2000-130371 A 20000428
 EP 1219609 A1 20020703 EP 2000-960979 20000913
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL
 RU 2233273 C2 20040727 RU 2002-109792 20000913
 JP 1999-261852 A 19990916
 WO 2000-JP6258 W 20000918
 US 2003032647 A1 20030213 US 2001-925892 20010810
 US 6656935 B2 20031202
 JP 1999-261852 A 19990916
 JP 2000-130371 A 20000428
 WO 2000-JP6258 W 20000913
 ZA 2002001499 A 20020902 ZA 2002-1499 20020222
 JP 1999-261852 A 19990916
 NO 2002001308 A 20020424 NO 2002-1308 20020315
 JP 1999-261852 A 19990916
 JP 2000-130371 A 20000428
 WO 2000-JP6258 W 20000913
 BG 106566 A 20030228 BG 2002-106566 20020402
 JP 1999-261852 A 19990916
 JP 2000-130371 A 20000428
 WO 2000-JP6258 W 20000913
 US 2003229095 A1 20031211 US 2003-426884 20030501
 JP 1999-261852 A 19990916
 JP 2000-130371 A 20000428
 WO 2000-JP6258 W 20000913
 US 2001-925892 A3 20010810

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FAN 2001:816647				
PI WO 2001083460	A1	20011108	WO 2001-JP2034	20010315
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NG, SN, TD, TG				
AU 2001041142	A5	20011112	AU 2001-41142	20010315
			JP 2000-130371	A 20000428
			WO 2001-JP2034	W 20010315
EP 1277741	A1	20030122	EP 2001-912373	20010315

L3 ANSWER 1 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The title compds. (I) [X = CH, N; Y = NH, NR, S, O, CH:N, N:CH, N:N, CH:CHC(R5)N, CH:C(R5), N:C(R7); R1 = each (un)substituted lower alkoxy, amino, heterocyclyl containing N atom(s), HO, or heterocyclyloxy containing N atom(s), cyano; R2 = lower alkylamino or lower alkoxy each optionally substituted by an (un)substituted aryl, lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), lower alkylamino group substituted by a (un)substituted heterocyclic ring, (un)substituted arylamino; R3 = each (un)substituted aryl, heterocyclyl containing N atom(s), lower alkyl, lower alkoxy, lower cycloalkoxy, heterocyclyloxy containing N atom(s), or NH2; R4-R7 = each (un)substituted aryl, heterocyclyl containing N atom(s), lower alkoxy, or NH2; R4, R5, R6 or R7 may combine with R3 to form a lactone ring Q or Q1; when X = N, Y = CH:N, or N:CH, R2 = an amino group monosubstituted by an (un)substituted arylmethyl, and R3 = (un)substituted lower alkyl, amino monosubstituted by an (un)substituted heterocyclyl-lower alkyl containing N atom(s) in the ring, heterocyclylamino containing N atom(s) in the ring, or (un)substituted lower cycloalkylamino, R1 = each (un)substituted lower alkoxy, amino, heterocyclyloxy containing N atom(s) in the ring, or cyano group] or pharmacol. acceptable salts thereof are prepared. These compds. have excellent selective PDE V inhibitory activity and therefore, are useful as therapeutic or prophylactic drugs for treating various diseases due to functional disorders on cGMP-signaling, such as erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis. Thus,
 2-(hydroxymethyl)pyridine
 was treated with NaH in THF and etherified with 2-chloro-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine to give
 2-(2-pyridylmethoxy)-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine.

L3 ANSWER 2 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:41461 CAPLUS
 DN 140:93789
 TI Preparation of substituted anthranilic amide derivatives as VEGF
 modulators and methods of use against cancer and other disorders
 IN Huang, Qi; Chen, Guoqing; Li, Aiwen; Rishi, Babak; Tasker, Andrew; Yang,
 Kevin; Yuan, Chester Chenguang
 PA Amgen Inc., USA
 SO PCT Int. Appl., 204 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN, CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005279	A2	20040115	WO 2003-US21601	20030709
WO 2004005279	A3	20040311		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
 NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, ML, MR, NE, SN, TD, TG

US 2004087568 A1 20040506 US 2002-395144P P 20020709
 US 2003-615809 A 20030708
 US 2003-615809 P 20030708
 US 2002-395144P P 20020709


OS MARPAT 140:93789
 IT 645418-48-0P, N-(1-Acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-
 2-(4-fluorobenzylamino)benzamide 645418-50-4P,
 2-(4-Fluorobenzylamino)-N-[(4-{1-methyl-1-(1-methylpiperidin-4-
 yl)ethyl}phenyl)benzamide 645418-56-0P, N-[3,3-Dimethyl-1-[(4-
 methylpiperazin-1-yl)carbonyl]-2,3-dihydro-1H-indol-6-yl]-2-(4-
 fluorobenzylamino)benzamide 645418-64-0P, N-(4,4-Dimethyl-
 1,2,3,4-tetrahydroisoquinolin-7-yl)-2-(4-fluorobenzylamino)benzamide
 645418-68-4P, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-
 3-fluoro-6-(4-fluorobenzylamino)benzamide 645418-69-5P,
 N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-fluoro-6-(4-
 fluorobenzylamino)benzamide 645418-70-8P, N-(4,4-Dimethyl-
 1,2,3,4-tetrahydroisoquinolin-7-yl)-3,4-difluoro-6-(4-
 fluorobenzylamino)benzamide 645418-98-0P, 4,4-Dimethyl-7-[[2-
 [[(quinoxalin-5-yl)methyl]amino]benzoyl]amino]-3,4-dihydro-1H-isoquinoline-
 2-carboxylic acid tert-butyl ester 645418-99-1P,
 N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-[[[quinoxalin-5-
 yl)methyl]amino]benzamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (drug candidate; preparation of substituted anthranilic amide deriva.

aa


L3 ANSWER 2 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 645418-64-0 CAPLUS
 CN Benzamide, 2-[[[4-(fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-
 dimethyl-7-isoquinolinyl)]-(9CI) (CA INDEX NAME)




RN 645418-68-4 CAPLUS
 CN Benzamide, 5-fluoro-2-[[[4-(fluorophenyl)methyl]amino]-N-(1,2,3,4-
 tetrahydro-4,4-dimethyl-7-isoquinolinyl)]-(9CI) (CA INDEX NAME)




RN 645418-69-5 CAPLUS
 CN Benzamide, 4-fluoro-2-[[[4-(fluorophenyl)methyl]amino]-N-(1,2,3,4-
 tetrahydro-4,4-dimethyl-7-isoquinolinyl)]-(9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 VEGF modulators and methods of use against cancer and other disorders
 RN 645418-48-0 CAPLUS
 CN Benzamide, N-(1-acetyl-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[[[4-
 fluorophenyl)methyl]amino]-(9CI) (CA INDEX NAME)




RN 645418-50-4 CAPLUS
 CN Benzamide,
 2-[[[4-(fluorophenyl)methyl]amino]-N-(4-{1-methyl-1-(1-methyl-4-
 piperidinyl)ethyl}phenyl)]-(9CI) (CA INDEX NAME)




RN 645418-56-0 CAPLUS
 CN Benzamide, N-[2,3-dihydro-3,3-dimethyl-1-[(4-methyl-1-
 piperazinyl)carbonyl]-1H-indol-6-yl]-2-[[[4-(fluorophenyl)methyl]amino]-
 (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 645418-70-8 CAPLUS
 CN Benzamide, 4,5-difluoro-2-[[[4-(fluorophenyl)methyl]amino]-N-(1,2,3,4-
 tetrahydro-4,4-dimethyl-7-isoquinolinyl)]-(9CI) (CA INDEX NAME)




RN 645418-98-0 CAPLUS
 CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-4,4-dimethyl-7-[[2-[[[5-
 quinoxaliny]methyl]amino]benzoyl]amino]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)




RN 645418-99-1 CAPLUS
 CN Benzamide, 2-[[[5-(quinoxaliny]methyl)amino]-N-(1,2,3,4-tetrahydro-4,4-
 dimethyl-7-isoquinolinyl)]-(9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT 645418-65-1P, 7-[[2-[(4-Fluorobenzylamino)benzoyl]amino]-4,4-dimethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of substituted anthranilic amide derivs. as VEGF modulators and methods of use against cancer and other disorders)
 RN 645418-65-1 CAPLUS
 CN 2 (1H)-Isoquinolinecarboxylic acid, 7-[[2-[[[4-(fluorophenyl)methyl]amino]benzoyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



GI

L3 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:950836 CAPLUS

DN 140:16722

TI Preparation of 1,1-disubstituted cycloalkyl derivatives as factor Xa inhibitors for treating a thromboembolic disorder

IN Qiao, Jennifer X.; Pinto, Donald J.; Orwat, Michael J.; Han, Wei; Friedrich, Sarah R.

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 686 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN: CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003/099276	A1	20031204	WO 2003-US13893	20030505
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

US 2002 379357P P 20020510
 US 2002 415367P P 20021002

OS MARPAT 140:16722

IT 630385-55-6P 630385-58-9P 630385-59-0P

630388-70-4P 630388-71-5P 630388-72-6P

630388-73-7P 630388-74-8P 630388-75-9P

630388-76-0P 630388-77-1P 630388-84-0P

630388-85-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of 1,1-disubstituted cycloalkyl derivs.

factor Xa inhibitors for treating thromboembolic disorder)

RN 630385-55-6 CAPLUS

CN Benzeneacetic acid,
 4-[[[2-[[[5-chloro-2-pyridinyl]amino]carbonyl]phenyl]amino]methyl]-α,α-dimethyl-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



II

AB Selected substituted anthranilic amide derivs. (shown as I; variables defined below; e.g. II) are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving cancer and the like. Although the methods of preparation are not



claimed, .apprx.139 example preps. of I and .apprx.80 of intermediates are included. For example, II was prepared in 3 steps starting from 2-nitrobenzoic acid and [4-[1-Methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]amine and involving intermediates

2-nitro-N-[4-[1-methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]benzamide and 2-amino-N-[4-[1-methyl-



1-(1-methylpiperidin-4-yl)ethyl]phenyl]benzamide. Compds. I showed inhibition of KDR at doses <50 μM. Some of the exemplified I inhibit VEGF-stimulated HUVEC proliferation at 1 μM. Compds. I are active at doses <150 mpk in a tumor model. For I: R = (un)substituted 9- or 10-membered fused heterocyclyl, -(CH2)1-2-R3; R1 = (un)substituted 5-6 membered saturated or partially saturated heterocyclyl, 9-10 membered bicyclic and

13-14 membered tricyclic saturated or partially saturated heterocyclyl, and phenyl; R2 is 21 substituents = H, halo, hydroxy, amino, C1-6-alkyl, C1-6-haloalkyl, C1-6-alkoxy, C1-2-alkylamino, aminosulfonyl, C3-6-cycloalkyl, cyano, C1-2-hydroxyalkyl, nitro, C2-3-alkenyl, C2-3-alkynyl, C1-6-haloalkoxy, C1-6-carboxyalkyl, 4-6-membered heterocyclyl, C1-6-alkylamino, (un)substituted Ph and (un)substituted 4-6 membered heterocyclyl; Ra = H, C1-2-alkyl; addnl. details are given in the claims.



L3 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 630385-58-9 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(2-hydroxy-1,1-dimethylethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 630385-59-0 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(2-dimethylamino)-1,1-dimethylethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 630388-70-4 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[[2-oxo-1-

<8/14/2004>

L3 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
pyrrolidinyl)methyl)cyclopropyl]phenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 630388-71-5 CAPLUS
CN Benzamide,
2-[[[4-[1-[(acetyl)methylamino)methyl]cyclopropyl]phenyl]methyl]
amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 630388-72-6 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-
[[methyl[(methylamino)carbonyl]amino)methyl]cyclopropyl]phenyl]methyl]amin
o]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 630388-73-7 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-
[[methyl(methylsulfonyl)amino)methyl]cyclopropyl]phenyl]methyl]amino]-
(9CI) (CA INDEX NAME)




RN 630388-74-8 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-
[(methylsulfonyl)amino]cyclopropyl]phenyl]methyl]amino]- (9CI) (CA INDEX
NAME)


L3 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 630388-75-9 CAPLUS
CN Benzamide, 2-[[[4-[1-(acetylamino)cyclopropyl]phenyl]methyl]amino]-5-
chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 630388-76-0 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[[[2-
hydroxyethyl]amino)methyl]cyclopropyl]phenyl]methyl]amino]- (9CI) (CA
INDEX NAME)




RN 630388-77-1 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[[[2-
hydroxyethyl]methylamino)methyl]cyclopropyl]phenyl]methyl]amino]- (9CI)
(CA INDEX NAME)


L3 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 630388-84-0 CAPLUS
CN Benzamide,
5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[2-(dimethylamino)-
2-oxoethyl]cyclopropyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 630388-85-1 CAPLUS
CN Benzamide,
2-[[[4-[1-[2-(2-amino-2-oxoethyl)cyclopropyl]phenyl]methyl]amino]-
5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



GI

<8/14/2004>

L3 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



AB The present application describes 1,1-disubstituted cycloalkyl compds.
and
derivs. thereof (P4-P M-M4; variables defined below; most of the examples
contain 1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, e.g. the
trifluoroacetate of I), or pharmaceutically acceptable salt forms
thereof,
which are useful as inhibitors of factor Xa for treatment of a
thromboembolic disorder. Although the methods of preparation are not
claimed,
approx. 240 example preps. are included. A number of I exhibit K_i 's of
<10
 μ M towards factor Xa; also some I are direct acting inhibitors (K_i < 10
 μ M) of the serine protease thrombin as indicated by their ability to
inhibit the cleavage of small mol. substrates by thrombin in a purified
system; the specific compds. are not stated. For I: M is a 3-10 membered
carbocycle or a 4-10 membered heterocycle, consisting of: C atoms and 1-3
heteroatoms = O, S(O)p, N, and NZ2; ring M is substituted with 0-3 R1a
and
0-2 carbonyl groups, and there are 0-3 ring double bonds; P is fused onto
ring M and is a 5, 6, or 7 membered carbocycle or a 5, 6, or 7 membered
heterocycle, consisting of: C atoms and 1-3 heteroatoms = O, S(O)p, and
N;
ring P is substituted with 0-3 R1a and 0-2 carbonyl groups, and there are
0-3 ring double bonds; alternatively, ring P is absent and P4 is directly
attached to ring M, provided that when ring P is absent, P4 and M4 are
attached to the 1,2, 1,3, or 1,4 positions of ring M. One of P4 and M4
is
Z A-B and the other -G1-G, provided that P4 and M4 are attached to
different rings when ring P is present; G consists of 2 fused rings D
and E (ring D, including the two atoms of Ring E to which it is attached,
is a 5-6 membered ring consisting of carbon atoms and 0-2 heteroatoms
selected from the group consisting of N, O, and S(O)p; E is selected from
(un)substituted Ph, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl;
alternatively, ring D is absent and ring E is selected from
(un)substituted Ph, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrrolyl,

L3 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, thienyl, and
thiazolyl; G1 is absent or = (CR3R3a)1-5, etc. A = (un)substituted
C1-10
carbocycle and 5-12 membered heterocycle consisting of: C atoms and 1-4
heteroatoms N, O, and S(O)p; B is Y-R4a or X-Y-R4a, provided that Z and B
are attached to different atoms on A and A and R4a or X and R4a are
attached to the same atom on Y; Z = a bond, -(CR3R3e)1-4, etc. Addnl.
details including provisos are given in the claims.
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS ON STN
AN 2003:950057 CAPLUS
DN 140:16647
TI Preparation of 2-aminopyridine-3-carboxamides as remedies for
angiogenesis
mediated diseases
IN Askew, Benny; Adams, Jeffrey; Booker, Shon; Chen, Guoqing; Dipietro,
Lucian V.; Elbaum, Daniel; Germain, Julie; Geuns-Meyer, Stephanie D.;
Hagood, Gregory J.; Handley, Michael; Huang, Qi; Kim, Tae-seong; Li,
Aiwon; Nishimura, Nobuko; Nomak, Rana; Patel, Vinod P.; Riahi, Babak;
Kim,
Joseph L.; Xi, Ning; Yang, Kevin; Yuan, Chester Chenguang
PA Amgen Inc., USA
SO U.S. Pat. Appl. Publ., 252 pp., Cont.-in-part of U.S. Ser. No. 46,681.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2
PATENT NO. KIND DATE APPLICATION NO. DATE
PI US 2003225106 A1 20031204 US 2002-197974 20020717
US 2001-261339P P 20010112
US 2001-323764P P 20010919
US 2002-46681 A2 20020110
US 2002-46681 20020110
US 2001-261339P P 20010112
US 2001-323764P P 20010919
WO 2004007458 A1 20040122 WO 2003-US22417 20030715
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GM, ML, MR, NE, SN, TD, TG
US 2002-197974 A 20020717
PATENT FAMILY INFORMATION:
FAN 2002:658116
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2002066470 A1 20020829 WO 2002-US743 20020111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, EE, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GM, ML, MR, NE, SN, TD, TG
US 2001-261339P P 20010112
US 2001-323764P P 20010919
US 2002-46681 A 20020110
US 2002-46681 20020110
US 2001-261339P P 20010112
US 2001-323764P P 20010919
US 2003125339 A1 20030703

Patel


L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
BR 2002006435 A 20030923 BR 2002-6435 20020111
US 2001-261339P P 20010112
US 2001-323764P P 20010919
US 2002-46681 A 20020110
WO 2002-US743 W 20020111
EP 1358184 A1 20031105 EP 2002-717325 20020111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2001-261339P P 20010112
US 2001-323764P P 20010919
US 2002-46681 A 20020110
WO 2002-US743 W 20020111
EE 200300324 A 20031215 EE 2003-324 20020111
US 2001-261339P P 20010112
US 2001-323764P P 20010919
US 2002-46681 A 20020110
WO 2002-US743 W 20020111
NO 2003003181 A 20030911 NO 2003-3181 20030711
US 2001-261339P P 20010112
US 2001-323764P P 20010919
US 2002-46681 A 20020110
WO 2002-US743 W 20020111
OS MARPAT 140:16647
IT 453561-07-4P 453561-08-5P 453561-23-4P
453561-01-4P, 2-[(2,3-Dihydrobenzofuran-5-ylmethyl)amino]-N-[3,3-
dimethyl-1-(piperidin-4-ylmethyl)-2,3-dihydro-1H-indol-6-yl]nicotinamide
453561-25-2P 453561-26-3P 453561-27-4P
453561-28-5P 453561-33-2P 453561-34-3P
453561-35-4P 453561-26-5P 453561-04-3P
453561-40-4P 453561-41-5P 453561-42-6P
629650-58-4P 629650-64-2P 629650-65-3P
629650-69-7P 629650-71-1P 629650-72-2P
629650-73-3P 629650-74-4P 629651-29-2P
629652-03-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of 2-aminopyridine-3-carboxamides for treating
angiogenesis
mediated diseases)
RN 453561-07-4 CAPLUS
CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[(6-quinolinylmethyl)amino]-
(9CI) (CA INDEX NAME)

<8/14/2004>

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 453561-08-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(3,4-dichlorophenyl)-2-[(6-quinolinylmethyl)amino]-] (9CI) (CA INDEX NAME)




RN 453561-23-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(4-chlorophenyl)-2-[(6-quinolinylmethyl)amino]-] (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 453561-81-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinylmethyl)-1H-indol-6-yl]-] (9CI) (CA INDEX NAME)




RN 453563-25-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-[(1,1-dimethylethyl)phenyl]-2-[(6-quinolinylmethyl)amino]-] (9CI) (CA INDEX NAME)


L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453563-26-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]-] (9CI) (CA INDEX NAME)




RN 453563-27-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-[(1,1-dimethylethyl)phenyl]-2-[(6-quinolinylmethyl)amino]-] (9CI) (CA INDEX NAME)




Patel

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 453563-28-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]-] (9CI) (CA INDEX NAME)




RN 453563-33-2 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-(1-methyl-1-(1-methyl-4-piperidinyl)ethyl)phenyl]-] (9CI) (CA INDEX NAME)




RN 453563-34-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(1-acetyl-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-] (9CI) (CA INDEX NAME)

<8/14/2004>

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 453563-35-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[6-[[2-[[2,3-dihydro-5-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 453563-36-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[2,3-dihydro-3,3-dimethyl-1-[(1-methyl-4-piperidinyl)methyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 453563-84-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[2-[[2,3-dihydro-6-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 453564-40-4 CAPLUS
CN 2-(1H)-Isoquinolinecarboxylic acid, 7-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 453564-41-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolyl)- (9CI) (CA INDEX NAME)



RN 453564-42-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-(4-(pentafluoroethyl)-3-[(2S)-2-pyrrolidinylmethoxy]phenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 629650-58-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-(4-(1-methyl-1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl)phenyl)- (9CI) (CA INDEX NAME)


Patel

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 629650-64-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[[[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-4-(trifluoromethyl)phenyl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 629650-65-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[[[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-5-(trifluoromethyl)phenyl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

<8/14/2004>


L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 629650-69-7 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[(6-quinolinylmethyl)amino]-N-[(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)] (9CI) (CA INDEX NAME)




RN 629650-71-1 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[(6-quinolinylmethyl)amino]-N-[(3-[(trifluoromethyl)oxy]-5-(trifluoromethyl)phenyl)] (9CI) (CA INDEX NAME)




RN 629650-72-2 CAPLUS

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 629651-29-2 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[(5-benzoxazolylmethyl)amino]-N-[(4-(1-methylethyl)phenyl)] (9CI) (CA INDEX NAME)




RN 629652-03-5 CAPLUS
 CN 1-Azetidinecarboxylic acid, 3-[(3-[(2,3-dihydro-5-benzofuranyl)methyl]amino)-3-pyridinyl]carbonylamino)-5-(trifluoromethyl)phenoxy)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




G1

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 3-Pyridinecarboxamide, N-[(3-[(dimethylamino)acetyl]amino)-4-(1,1-dimethylethyl)phenyl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 629650-73-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[(6-quinolinylmethyl)amino]-N-[(3-[(3R)-tetrahydro-3-furanyl]oxy)-5-(trifluoromethyl)phenyl)] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 629650-74-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2,3-dihydro-2-oxo-3,3-bis(trifluoromethyl)-1H-indol-6-yl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The title compds. [I; R = (un)substituted 4-pyridyl, 2-pyridyl, 4-pyrimidinyl, 4-quinolyl, etc.; R1 = (un)substituted aryl, cycloalkyl, 5-6 membered heteroaryl, 9-10 membered bicyclic and 11-14 membered tricyclic heterocyclyl], which are effective for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like, were prepared. Thus, the title compound II was prepared from 2-aminonicotinic acid, 4-chloroaniline, and 4-pyridinecarboxaldehyde. The compds. I showed inhibition of KDR kinase at < 50 μ M. Many compds. I inhibited VEGF-stimulated HUVEC proliferation at a level below 50 nM. Pharmaceutical composition comprising the compound I is claimed.

L3 ANSWER 5 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:913147 CAPLUS
DN 139:381477
TI Preparation of 4,5-dihydro-1H-benzo[g]indazole-3-carboxamides as IKK2
inhibitors for the treatment of cancer and inflammation
IN Lennon, Patrick; Bonafoux, Dominique; Oburn, David S.; Wolfson, Serge G.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 312 pp.
CODEN: PIXKXD
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003095430	A1	20031120	WO 2003-US8917	20030319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, RW, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003024935	A2	20030327	US 2002-379090P	P 20020509
WO 2003024935	A3	20030821	WO 2002-US29774	A 20020919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, RW, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2001-323423P	P	20010919		
US 2002-379090P	P	20020509		


PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003024935	A2	20030327	WO 2002-US29774	20020919
WO 2003024935	A3	20030821		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, RW, TJ, TM				


L3 ANSWER 5 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2001-323423P P 20010919
US 2002-379090P P 20020509
US 2002-247096 20020919
US 2001-323423P P 20010919
US 2002-379090P P 20020509
EP 1444207 A2 20040811 EP 2002-775879 20020919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
US 2001-323423P P 20010919
US 2002-379090P P 20020509
WO 2002-US29774 W 20020919
WO 2003095430 A1 20031120 WO 2003-US8917 20030319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, RW, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2002-379090P P 20020509
WO 2002-US29774 A 20020919

OS MARPAT 139:381477
IT 503555-09-7P, 1-((1,3-Benzodioxol-5-yl)-8-[[2-[[4-(4-methoxybenzyl)amino]pyridin-3-yl]carbonyl]amino]-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
[drug candidate; preparation of 4,5-dihydro-1H-benzo[g]indazole-3-carboxamides as IKK2 inhibitors for treatment of cancer and inflammation]
RN 503555-09-7 CAPLUS
CN 1H-Benz[g]indazole-3-carboxamide, 1-((1,3-benzodioxol-5-yl)-4,5-dihydro-8-[[2-[[4-(4-methoxyphenyl)methyl]amino]-3-pyridinyl]carbonyl]amino)- (9CI) (CA INDEX NAME)


L3 ANSWER 5 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I



II

AB The present invention relates to substituted pyrazolyl derivs., compns. comprising such, intermediates, methods of making substituted pyrazolyl derivs., and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis, 4,5-Dihydro-1H-

Patel


L3 ANSWER 5 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
benzo[g]indazole-3-carboxamides (shown as I; variables defined below;

e.g. II) were prepd. via conventional and solid phase synthetic methods as 1x8 protein kinase β (IKK β or IKK2) inhibitors. Although the methods of prepn. are not claimed, 480 example preps. and/or characterization data are included. For example, reaction of 7-nitro-1-tetralone with Et acetate in the presence of Li⁺ bis(trimethylsilyl)amide in ether gave the 1,3-diketone (87%), which was cyclized with 4-sulfonamidophenylhydrazine-HCl with HCl in MeOH to give the Et 1H-dihydrobenzo[g]indazole-3-carboxylate (69%). Amidation with NH₄OH in MeOH provided II. In IKK β resin enzyme assays, I exhibited IKK β activity with IC₅₀ values ranging from $\leq 1 \mu\text{M}$ to $> 100 \mu\text{M}$. Thus, I are useful for treating cancer, inflammation, and inflammation-assocd. disorders, such as arthritis (no data). For I: B is a 5 or 6 membered heteroaryl, aryl, (un)satd. heterocyclic (un)substituted with R1, R2, and R12; W is a 5 or 6 membered heteroaryl, aryl, (un)satd. heterocyclic. R1 = hydrido, halo, alkyl, heteroaryl, alkenyl, alkynyl, haloalkyl, CN, NO₂, ORS, OCOORS, CO₂R7, CON(R6)R7, COR6, SR6, SOR6, SO₂R6, NR6R7, NR6COR7, NR6CONHR7, NR6SO₂R7, NR6SO₂NHR7, and SO₂N(R6)R7; R2 = halo, hydrido, hydroxyalkyl, alkyl, OR6, CN, NO₂, SR6, NHR6, CON(R6)R7, NHCONHR6, CO₂H, and haloalkyl; R1 and R2 may be taken together to form a 5 to 7 membered (un)satd. carbocyclic ring optionally contg. 0 to 3 heteroatoms N, O, or S, and wherein said ring is (un)substituted with R1. R12 = hydrido, halo, alkyl, and alkoxy; R15 = alkylsulfonamide, sulfamyl, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, halo, acyloxy, oxy, formyl, haloalkyl, cyano, haloalkoxy, acyl, carboxy, hydroxy, hydroxyalkoxy, phenoxy, nitro, azido, benzyloxy, dialkylaminoacyl, thioalkyl, aminoacyloxy, thiocyanate, isothiocyanate, alkylidioxo, hydroxyalkyl, alkylamino, alkylalkoxy, alkoxyalkyl, alkenylamino, alkynylamino, alkenyl, alkynyl, dialkylaminoalkoxy, and heterocyclic; addnl. details are given in the claims.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

<8/14/2004>

L3 ANSWER 6 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:665525 CAPLUS
 DN 139:345320
 TI Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching
 AU Puret, Pascal; Bold, Guido; Hofmann, Francesco; Manley, Paul; Meyer, Thomas; Altmann, Karl-Heinz
 CS Oncology Research, Novartis Pharma AG, Basel, CH-4002, Switz.
 SO Bioorganic & Medicinal Chemistry Letters (2003), 13(18), 2967-2971
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science B.V.
 DT Journal
 LA English
 OS CASREACT 139:345320
 IT 610359-41-4
 RL PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (identification, synthesis and structure-activity relationship studies on a new chemical class of potent angiogenesis inhibitors (anthranilamides)-based on conformational considerations and database searching)
 RN 610359-41-4 CAPLUS
 CN Benzamide, N-(2-fluorophenyl)-2-[[4-(fluorophenyl)methylamino]- (9CI) (CA INDEX NAME)




AB The vascular endothelial growth factor (VEGF) tyrosine kinase receptors KDR and Flt-1 are targets of current interest in anticancer drug research.
 PTK787/ZK222584 is a potent inhibitor of these enzymes in clin. evaluation
 as an antiangiogenic agent. The development of a hypothesis concerning the bioactive conformation of this compound has led to the discovery of a new class of potent inhibitors of KDR and Flt-1, the anthranilamides. This could be achieved with a limited exptl. effort, which only involved the testing of one archive compound and the synthesis and testing of one appropriate analog.
 RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:551370 CAPLUS
 DN 139:111679
 TI Combination of microsomal triglyceride transfer protein (MTP) inhibitors or apoB secretion inhibitors with fibrates for use as drugs
 IN Thomas, Leo; Mark, Michael
 PA Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
 SO PCT Int. Appl., 220 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057205	A2	20030717	WO 2003-EP57	20030107
WO 2003057205	A3	20040401		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10200633	A1	20030724	DE 2002-1020633	A 20020110
DE 10256184	A1	20040609	DE 2002-10256184	A 20021202
US 2003162788	A1	20030828	US 2003-339088	P 20030109
			DE 2002-1020633	A 20020110
			US 2002-353397P	P 20020201
			DE 2002-10256184	A 20021202
			US 2002-435386P	P 20021220

OS MARPAT 139:111679
 IT 486436-62-8P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)
 RN 486436-62-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 1-methyl N-[[4'-methyl[1,1'-biphenyl]-4-yl)methyl]-4-[[2'[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The invention discloses the use of fibrates for reducing the hepatic toxicity of MTP inhibitors, as well as pharmaceutical compns. that contain an MTP inhibitor and a fibrate. Compound preparation is included.

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:551381 CAPLUS
 DN 139:117319
 TI Preparation of substituted arylamine derivatives as antitumor agents
 IN Elbaum, Daniel; Aekew, Benny; Booker, Shon; Germain, Julie; Hagood, Gregory; Handley, Michael; Kim, Tae-Seong; Li, Aiven; Nishimura, Nobuko; Patel, Vinod P.; Yuan, Chester Chenguang; Kim, Joseph L.
 PA Amgen Inc., USA
 SO U.S. Pat. Appl. Publ., 106 pp., Cont.-in-part of U.S. Ser. No. 46,526.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003134836	A1	20030717	US 2002-197960	20020717
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
US 2002147198	A1	20021010	US 2002-46526	A2 20020110
			US 2002-46526	20020110
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
WO 2004007457	A2	20040122	WO 2003-US22276	20030715
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
			US 2002-197960	A 20020717

PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002:539663				
FI 2002055501	A2	20020718	WO 2002-US742	20020111
WO 2002055501	A3	20021219		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
US 2002147198	A1	20021010	US 2002-46526	A 20020110
			US 2002-46526	20020110
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
EP 1358161	A2	20031105	EP 2002-717324	20020111
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
			US 2001-261360P	P 20010112

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 US 2001-323686P P 20010919
 US 2002-46526 A 20020110
 WO 2002-US742 W 20020111

OS MARPAT 139.117339


IT 561297-65-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of substituted aminopyridines as antitumor agents)

RN 561297-65-2 CAPLUS

CN 1-Azetidinecarboxylic acid, 3-[[2-chloro-5-[[[2-[[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 561297-60-7P 561297-61-8P 561297-62-9P

561297-63-0P 561297-64-1P 561297-66-3P

561297-70-9P 561297-71-0P 561297-72-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted aminopyridines as antitumor agents)

RN 561297-60-7 CAPLUS


CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl 1-(methylsulfonyl)-1H-indol-6-yl]-2-[[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 561297-63-0 CAPLUS


CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-[3-((methylsulfonyl)amino)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 561297-64-1 CAPLUS


CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-[4-[[1-methyl-1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 561297-61-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[[[dimethylamino]acetyl]amino]-4-(1,1-dimethylethyl)phenyl]-2-[[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 561297-62-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-[3-[[[2R]-1-methyl-2-pyrrolidinyl]methoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 561297-66-3 CAPLUS


CN 3-Pyridinecarboxamide, N-[3-((3-azetidinylmethoxy)-4-chlorophenyl)-2-[[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 561297-70-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-((3-azetidinylmethoxy)-5-(trifluoromethyl)phenyl)-2-[[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 561297-71-0 CAPLUS
CN 3-Pyridinecarboxamide,
2-[[(4-hydroxy-3-nitrophenyl)methyl]amino]-N-[4-(1-
methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 561297-72-1 CAPLUS
CN 3-Pyridinecarboxamide,
2-[[[3-amino-4-hydroxyphenyl)methyl]amino]-N-[4-(1-
methylethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 442845-74-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-(3-fluoro-4-methylphenyl)-2-[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-77-4 CAPIUS
CN 3-Pyridinecarboxamide, 2-[[{3-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 442846-13-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid,
2-[[5-[[[2-[[[4-fluorophenyl)methyl]amino]-3-
pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-,
1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



```


IT 442847-21-4
RL: RCT (Reactant); RACT (Reactant or reagent)
    (preparation of substituted aminopyridines as antitumor agents)
RN 442847-21-4 CAPLUS
CN 3-Pyridinecarboxamide,
N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinylmethyl)-
1H-indol-6-yl]-2-[[[4-(fluorophenyl)methyl]amino]-
(9CI) (CA INDEX NAME)

```




IT 442845-74-1P 442845-77-4P 442846-13-1P
442846-17-5P 442846-22-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOI (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compound; preparation of substituted aminopyridines as antitumor

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-17-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[6-[[[2-[[[4-fluorophenyl]methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-22-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-acetyl-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-6-yl)-2-[[{(4-fluorophenyl)methyl}amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT 442845-71-8P 442845-72-9P 442845-73-0P
 442845-75-2P 442845-76-3P 442845-78-5P
 442845-79-6P 442845-80-9P 442845-81-0P
 442845-82-1P 442845-83-2P 442845-84-3P
 442845-85-4P 442845-86-5P 442845-87-6P
 442845-88-7P 442845-89-8P 442845-90-1P
 442845-91-2P 442845-92-3P 442845-93-4P
 442845-94-5P 442845-95-6P 442845-96-7P
 442845-97-8P 442845-99-0P 442846-00-6P
 442846-01-7P 442846-02-8P 442846-03-9P
 442846-04-0P 442846-05-1P 442846-06-2P
 442846-07-3P 442846-08-4P 442846-09-5P
 442846-10-8P 442846-11-9P 442846-12-0P
 442846-14-2P 442846-15-3P 442846-16-4P
 442846-18-6P 442846-19-7P 442846-20-0P
 442846-21-1P 442846-23-3P 442846-24-4P
 442846-25-5P 442846-26-6P 442846-27-7P
 442846-28-8P 442846-29-9P 442846-30-2P
 442846-31-3P 442846-32-4P 442846-33-5P
 442846-34-6P 442846-35-7P 442846-36-8P
 442846-38-0P 442846-39-1P 442846-40-4P
 442846-42-6P 442846-44-8P 442847-23-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(target compound; preparation of substituted aminopyridines as antitumor agents)

RN 442845-71-8 CAPLUS

CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-((phenylmethyl)amino)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 442845-75-2 CAPLUS
 CN 3-Pyridinecarboxamide, 6-chloro-N-(3-fluoro-4-methylphenyl)-2-[[[4-methoxyphenyl)methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 442845-76-3 CAPLUS


CN 3-Pyridinecarboxamide, 6-chloro-N-(4-chlorophenyl)-2-[[[4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-78-5 CAPLUS


CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[3-(trifluoromethyl)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442845-72-9 CAPLUS

CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[[[4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-73-0 CAPLUS

CN 2-Pyridinecarboxamide, N-(3-fluoro-4-methylphenyl)-3-[[[4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)




L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442845-79-6 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[4-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 442845-80-9 CAPLUS


CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[3-(trifluoromethyl)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-81-0 CAPLUS

<8/14/2004>

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 3-Pyridinecarboxamide, 2-[[[(2-bromophenyl)methyl]amino]-N-(4-phenoxyphenyl)]- (9CI) (CA INDEX NAME)




RN 442845-82-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[4-(trifluoromethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-83-2 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,3-difluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442845-84-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[[[(4-cyanophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-85-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[[[(2-cyanophenyl)methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-86-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-(4-(2-methylpropyl)phenyl)]- (9CI) (CA INDEX NAME)




RN 442845-87-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-(1,1-dimethylethyl)phenyl)-2-[[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-88-7 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3-methoxyphenyl)methyl]amino]-N-(4-(1-

Patel


L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-89-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3-aminophenyl)methyl]amino]-N-(4-(1-methylethyl)phenyl)]- (9CI) (CA INDEX NAME)




RN 442845-90-1 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-(4-(1-methylethyl)phenyl)]- (9CI) (CA INDEX NAME)




<8/14/2004>


L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 442845-91-2 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-92-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3,4-dimethoxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-93-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[phenylmethyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-97-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[2,4-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-99-0 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[2,4-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




Patel

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 442845-94-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-95-6 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-96-7 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 442846-00-6 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[2,3-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-01-7 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[2-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-02-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[2,6-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-03-9 CAPLUS
 <8/14/2004>

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 3-Pyridinecarboxamide, 2-[[[3-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-04-0 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-fluorophenyl)methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-05-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-[3-[3-(dimethylamino)propyl]-5-(trifluoromethyl)phenyl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-06-2 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl)methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-07-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl)methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-08-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-bromo-2-fluorophenyl]-2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-09-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-10-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-fluoro-3-[3-(4-morpholinyl)-1-propynyl]phenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-11-9 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[1,3-benzodioxol-5-yl)methyl]amino]-N-[4-phenoxyphenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-12-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-[3-[2-(1-pyrrolidinyl)ethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-14-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[2-[(1,1-dimethylethyl)-5-[[[2-[[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-15-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(1-methyl-4-piperidinyl)-1H-indol-6-yl]-2-[[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-16-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-[[[dimethylamino]acetyl]-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl]-2-[[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-18-6 CAPLUS
CN Carbamic acid, [2-[6-[[[2-[[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 442846-19-7 CAPLUS
CN 2(1H) Isoquinolinecarboxylic acid, 7-[[[2-[[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-20-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[2-[[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 442846-21-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[2-[(1,1-dimethylethyl)-5-[[[2-[[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-23-3 CAPLUS
 CN 1-Piperidinecarboxylic acid,
 4-[[[3-[[[2-[[[4-fluorophenyl)methyl]amino]-3-
 pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-24-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-fluorophenyl)methyl]amino]-N-[4-(
 pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-25-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-fluorophenyl)methyl]amino]-N-[3-[(2R)-2-
 pyrrolidinylmethoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 442846-26-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-
 piperidinylmethoxy)phenyl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA
 INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-27-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(2R)-2-
 pyrrolidinylmethoxy]phenyl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 442846-28-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-fluorophenyl)methyl]amino]-N-[1,2,3,4-
 tetrahydro-4,4-dimethyl-7-isoquinolinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-29-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[1-(aminoacetyl)-2,3-dihydro-3,3-dimethyl-1H-
 indol-6-yl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-30-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1H-indol-6-yl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-31-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-[3-(4-piperidinylmethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-32-4 CAPLUS
 CN 3-Pyridinecarboxamide,
 N-[2,3-dihydro 2,2-dimethyl-1H-1,4-benzoxazin-6-yl]-
 2-[[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-35-7 CAPLUS
 CN 3-Pyridinecarboxamide,
 2-[[[(4-fluorophenyl)methyl]amino]-N-[4-(1-methyl-1-(1-methyl-4-piperidinyl)ethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-36-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-2-oxo-7-quinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-33-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-[3-[[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 442846-34-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2,3-dihydro 3,3-dimethyl-1-[(1-methyl-4-piperidinyl)methyl]-1H-indol-6-yl]-2-[[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-38-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-5-benzofuranyl-2-[[[3-(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-39-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-2-[[[3-(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-40-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3,4-difluorophenyl)methyl]amino]-N-[4-(1,1-

<8/14/2004>

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 442846-42-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 442846-44-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]-2-[[4-(fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




GI



AB The title comds. I (R2 = (un)substituted Ph, 9-10 membered bicyclic and 11-14 membered tricyclic (un)saturated heterocyclyl; R8 = halo, NH2, NO2, etc.), and their pharmaceutically acceptable derivs., are prepared and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. E.g., a multi-step synthesis of II, starting from 1-dimethylamino-2-propyne and 3-bromo-5-trifluoromethylaniline, was given. Selected comds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below

50 nm. The invention encompasses novel comds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical comds. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.


L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442847-23-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(3-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 442845-77-4
CMF C25 H20 F N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L3 ANSWER 9 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:454323 CAPLUS

DN 139:22501

TI Preparation of glycineamide heterocyclic derivatives as factor Xa inhibitors

IN Pinto, Donald J. P.; Han, Wei; Hu, Zilun

PA Bristol-Myers Squibb Company, USA; Qiao, Jennifer

SO PCT Int. Appl., 451 pp.

CODEN: PIXXD2

DT Patent

LA English

PAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003048158	A1	20030612	WO 2002-US38239	20021127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003232804	A1	20031218	US 2001-336994P	P 20011204
				US 2002-304070	20021125
				US 2001-336994P	P 20011204

PATENT FAMILY INFORMATION:

PAN 2003:454257

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003048081	A2	20030612	WO 2002-US37212	20021118
	WO 2003048081	A3	20030912		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003232804	A1	20031218	US 2001-336994P	P 20011204
				US 2002-304070	20021125
				US 2001-336994P	P 20011204

OS MARPAT 139:22501

IT 536759-09-8P 536759-10-1P 536759-11-3P

536759-12-3P 536759-13-4P 536759-14-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of glycineamide heterocyclic derivs. as factor Xa inhibitors)


RN 536759-09-8 CAPLUS

CN 1-Pyrrolidineacetamide, N-[4-[[[4-chloro-2-[[[5-chloro-2-pyridinyl]amino]carbonyl]phenyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA

<8/14/2004>

L3 ANSWER 9 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 536759-10-1 CAPLUS
CN Benzamide, 5-chloro-N-[(5-chloro-2-pyridinyl)-2-[[[4-
[[dimethylamino)acetyl]methylamino]phenyl]methyl]amino]- (9CI) (CA
INDEX NAME)

L3 ANSWER 9 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 536759-11-2 CAPLUS
CN Benzamide, 2-[[[4-(acetyl[methylamino]phenyl)methyl]amino]-5-chloro-N-(5-
chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 536759-12-3 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[dimethylamino)acetyl]methyla-
mino]phenyl]methyl]amino]-5-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 536759-13-4 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[dimethylamino)acetyl]methyla-
mino]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 536759-14-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[dimethylamino)acetyl]methyla-
mino]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



G1

L3 ANSWER 9 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB Comps. P4-P.M.M4 [M is a 3-10 membered carbocycle or a 4-10 membered
heterocycle; P is null or a 5-7 membered carbocycle or heterocycle fused
to ring M; one of P4 and M4 is -Z-A-B and the other is G1-G, where G is
(un)substituted (fused) (hetero)aryl or (hetero)cyclyl; G1 is null or
(un)substituted optionally-functionalized alk(en)(yn)yl; Z is a bond or
(hetero)alkylene; A is (substituted) 3-10 membered carbocyclyl or 5-12
membered heterocyclyl; B is a functionalized amino group (with provisos)]
or their pharmaceutically-acceptable salts were prepared for use as
inhibitors of factor Xa. Thus, 1H-pyrazolo(3,4-c)pyridine derivative

I.TFA was prepared by reactions of 3-aminobenzamide,
3 hydroxy-1-(4-iodophenyl)-4-
(trifluoroacetyl)-5,6 dihydro-2(1H)-pyridinone, chloroacetyl chloride,
and dimethylamine.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:454257 CAPLUS

DN 139:7167

TI Preparation of glycineamide heterocyclic derivatives as factor Xa inhibitors

IN Pinto, Donald J. P.; Han, Wei; Hu, Zilun

PA Bristol-Myers Squibb Company, USA; Qiao, Jennifer

SO PCT Int. Appl., 448 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048081	A2	20030612	WO 2002-US37212	20021118
WO 2003048081	A3	20030912		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003232804	A1	20031218	US 2001-336994P	P 20011204
			US 2002-304070	20021125
			US 2001-336994P	P 20011204

PATENT FAMILY INFORMATION:

FAN 2003:454323

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048158	A1	20030612	WO 2002-US38239	20021127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003232804	A1	20031218	US 2001-336994P	P 20011204
			US 2002-304070	20021125
			US 2001-336994P	P 20011204

OS MARPAT 139:7167


IT 536759-09-8P 536759-10-1P 536759-11-2P

536759-12-3P 536759-13-4P 536759-14-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of glycineamide heterocyclic derivs. as factor Xa inhibitors)

L3 ANSWER 10 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 536759-11-2 CAPLUS

CN Benzamide, 2-[[[4-(acetyl(methylamino)phenyl)methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)]- (9CI) (CA INDEX NAME)



RN 536759-12-3 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[[dimethylamino]acetyl]methylamino]phenyl]methyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 536759-13-4 CAPLUS

CN Benzamide,


Patel

L3 ANSWER 10 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 536759-09-8 CAPLUS

CN 1-Pyrrolidineacetamide, N-[4-[[[4-chloro-2-[[[5-chloro-2-pyridinyl]amino]carbonyl]phenyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 536759-10-1 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[[[dimethylamino]acetyl]methylamino]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 10 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

minolphenyl)methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 536759-14-5 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[[dimethylamino]acetyl]methylamino]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



G1



I

AB Comps. P4-P-M-M4 [M is a 3-10 membered carbocycle or a 4-10 membered heterocycle; P is null or a 5-7 membered carbocycle or heterocycle fused to ring M; one of P4 and M4 is -Z-A-B and the other is -G1-G, where G is (un)substituted (fused) (hetero)aryl or (hetero)cyclyl; G1 is null or (un)substituted optionally-functionalized alk(en)(yn)yl; Z is a bond or (hetero)alkylene; A is (substituted) 3-10 membered carbocyclyl or 5-12 membered heterocyclyl; B is a functionalized amino group (with proviso)] or their pharmaceutically-acceptable salts were prepared for use as inhibitors of factor Xa. Thus, 1H-pyrazolo[3,4-c]pyridine derivative


<8/14/2004>

L3 ANSWER 10 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 was prepd. by reactions of 3-aminobenzamide,
 3-hydroxy-1-(4-iodophenyl)-4-
 (trifluoroacetyl)-5,6-dihydro-2(1H)-pyridinone, chloroacetyl chloride,
 and dimethylamine.

L3 ANSWER 11 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:376824 CAPLUS
 DN 138:368777
 TI Preparation of pyridyl-substituted anthranilic acid amides for treating
 neoplastic disease
 IN Bold, Guido, Furet, Pascal; Manley, Paul William
 PA Novartis AG, Switz.; Novartis Pharma GmbH
 SO PCT Int. Appl., 33 PP.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003040101	A1	20030515	WO 2002-EP12445	20021107
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, ME, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW, AM, AZ, BY, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR		GB 2001-26901 GB 2002-12917	A 20011108 A 20020605

OS MARPAT 138:368777
 IT 524729-00-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyridyl-substituted anthranilic acid amides for treating neoplastic disease)
 RN 524729-00-8 CAPLUS
 CN Benzamide, 2-[[[3-[(methylamino)carbonyl]phenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 11 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The title compds. [I; Ar = II (wherein R_a = H, alkyl, and R₁ = H, perfluoroalkyl, R₂ = H, halo, alkyl, alkenyl, alkynyl); or Ar = 4-pyridyl and R₁ = perfluoroalkyl; R₂ = Br, I, alkyl, alkenyl, alkynyl; or R₁ = H, and R₂ = F, Br, I, Et, alkyl, alkenyl or alkynyl and their N-oxides and salts, useful for the treatment especially of a neoplastic disease, such as a

tumor disease, of retinopathy or age-related macular degeneration in the human or animal body, were prepared and formulated. Thus, reductive amination of 4 pyridinecarboxaldehyde with 2-amino-N-(4-bromo-3-trifluoromethylphenyl)benzamide (preparation given) in the presence of NaBH₃CN afforded I (Ar = 4-pyridyl; R₁ = CF₃; R₂ = Br). The IC₅₀-values that can be found for the compds. I are in range of 0.001 to 1 μM in test for activity against VEGF-receptor tyrosine kinase.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:242305 CAPLUS
 DN 138:271675
 TI Preparation of 4,5-dihydro-1H-benzo[g]indazole-3-carboxamides for the treatment of inflammation
 IN Bergmanis, Arijia A.; Bonafoux, Dominique; Clare, Michael; Crich, Joyce Z.; Fletcher, Theresa R.; Geng, Lifeng; Hagen, Timothy J.; Hamper, Bruce C.; Hanson, Gunnar J.; Houdek, Stephen C.; Huang, He; Iula, Donna M.; Kozsyk, Francis J.; Lennon, Patrick J.; Liao, Shuyuan; Liao, Subo; Metz, Suzanne; Mohler, Scott B.; Nguyen, Maria; Oburn, David S.; Owen, Thomas J.; Partis, Richard A.; Scates, Angela M.; Stealey, Michael A.; Tollefson, Michael B.; Vazquez, Michael L.; Weier, Richard M.; Wolfson, Serge G.; Xu, Xiangdong
 PA Pharmacia Corporation, USA
 SO PCT Int. Appl., 331 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003024935	A2	20030327	WO 2002-US29774	20020919
WO 2003024935	A3	20030821		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MN, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		US 2001-323423P US 2002-379090P US 2002-247096 US 2001-323423P US 2002-379090P EP 2002-775879	P 20010919 P 20020509 20020919 P 20010919 P 20020509 20020919
EP 1444207	A2	20040811		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK		US 2001-323423P US 2002-379090P WO 2002-US29774	P 20010919 P 20020509 W 20020919
WO 2003095430	A1	20031120	WO 2003-US8917	20030319
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MN, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		US 2002-379090P	P 20020509

L3 ANSWER 12 OF 49 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
WO 2002-US29774 A 20020919

PATENT FAMILY INFORMATION:

FAN 2003-913147


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003095430	A1	20031120	WO 2003-US8917	20030319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003024935	A2	20030327	US 2002-379090P	P 20020509
WO 2003024935	A3	20030821	WO 2002-US29774	A 20020919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-323423P	P 20010919
			US 2002-379090P	P 20020509

OS MARPAT 138:271675


IT 503555-09-7P, 1-((1,3-Benzodioxol-5-yl)-8-[[[2-[[4-methoxybenzyl]amino]pyridin-3-yl]carbonyl]amino]-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (IKK2 inhibitor; preparation of benzo[g]carboxamides as IKK2 inhibitors for treatment of cancer, inflammation, and inflammation-associated disorders)
 RN 503555-09-7 CAPLUS
 CN 1H-Benz[g]indazole-3-carboxamide, 1-((1,3-benzodioxol-5-yl)-4,5-dihydro-8-[[[2-[[4-methoxybenzyl]amino]pyridin-3-yl]carbonyl]amino]-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide)-3-pyridinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 12 OF 49 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 R, or (un)substituted (aryl)alkyl, (hetero)aryl, heterocyclylalkyl, or heteroarylalkyl; R11 = H, halo, (halo)alkyl, CN, alkoxy, carbonyl, alkenyl, alkynyl, alkoxy, carbamoyl, etc.; R12 = H, halo, alkyl, or alkoxy; with proviso: and isomers, tautomers, carriers, esters, prodrugs, and pharmaceutically acceptable salts thereof] were prepd. via conventional and solid phase synthetic methods as IκB protein kinase β (IKKβ or IKK2) inhibitors. For example, reaction of 7-nitro-1-tetralone with Et acetate in the presence of Li bis(trimethylsilyl)amide in ether gave the 1,3-diketone (87%), which was cyclized with 4-sulfonamidophenylhydrazine·HCl with HCl in MeOH to give the Et 1H-dihydrobenzo[g]indazole-3-carboxylate (69%). Amidation with NH3OH in MeOH provided II. In IKKβ resin enzyme assays, I exhibited IKKβ activity with IC50 values ranging from ≤ 1 μM to > 100 μM. Thus, I are useful for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis (no data).

L3 ANSWER 12 OF 49 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



GI



AB The present invention relates to substituted pyrazolyl derivs., compns. comprising such, intermediates, methods of making substituted pyrazolyl derivs., and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis. Title compds. I (wherein A = (un)substituted (CH2)m; m = 0-3; B = (un)substituted (hetero)aryl; X = N or C; Y and Z = independently N, C, CH, CR3, S, or O; R1 = H, halo, (halo)alkyl, (hetero)aryl, alkenyl, alkynyl, CN, NO2, alkoxy, carbonyl, carbamoyl, acyl, alkylthio, sulfamoyl, ureido, etc.; R2 = H, halo, (halo)alkyl, hydroxyalkyl, alkoxy, CN, NO2, alkylthio, amino, carbamoyl, ureido, CO2H, etc.; R3 = (un)substituted amidine, alkylamino, aminoalkyl, carbamoyl, NH2, or acylamino(methyl); R4 = H, halo, alkylsulfonfyl, alkylsulfonfyl, CN, alkoxy, carbonyl, (halo)alkyl, hydroxyalkyl, haloalkoxy, heterocyclyl, NO2, acylamino, (hetero)aryl, alkenyl, alkoxy, alkylthio, sulfamoyl, acyl, ureido, carbamoyl, etc.; R5 =

L3 ANSWER 13 OF 49 CAPLUS COPYRIGHT 2004 ACS ON STN
 AN 2003-42101 CAPLUS
 DN 138:106502

TI Preparation of biphenylcarboxylic acid amides as inhibitors of microsomal triglyceride transfer protein (MTP)
 IN Priepke, Henning; Haeufel, Norbert; Dahmann, Georg; Thomas, Leo; Mark, Michael

PA Boehringer Ingelheim Pharma K.-G., Germany

SO PCT Int. Appl., 193 pp.

CODEN: PIXXD2

DT Patent

IA German

FAN: CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003004020	A1	20030116	WO 2002-EP7215	20020629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10132686	A1	20030116	DE 2001-10132686	A 20010705
US 2003073836	A1	20030417	US 2002-187860	20020702
			DE 2001-10132686	A 20010705
			US 2001-304584P	P 20010711

OS MARPAT 138:106502

IT 486436-62-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of biphenylcarboxylic acid amides as microsomal triglyceride transfer protein (MTP) inhibitors)


RN 486436-62-8 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 1-methyl-N-((4'-methyl[1,1'-biphenyl]-4-yl)methyl)-4-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 13 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI




I


AB Title compds. I [X1 = CR1; X2 = CR2; X3 = CR3; X4 = CR4; with 1-2 of the groups being a N atom; R1, R2, R3, R4 = H, halo, alkyl, etc.; A = O, S, NH, etc.; R8 = (un)substituted Ph, 1-naphthyl, 2-naphthyl, etc.; R5 = H, (un)substituted alkyl; R6 = H, alkyl; R7 = (un)substituted alkyl; Y = 1-2 carbon atom(s) bound to (un)substituted 5-membered heteroaryl] and their pharmaceutically acceptable salts were prepared. For example, coupling of acid II, e.g., prepared from 4-hydrazinobenzonitrile in 5-steps, and 4-phenylbenzylamine afforded biphenylcarboxylic acid amide III in 86% yield. In triglyceride transfer protein inhibition studies, compds. I exhibited IC50 values ≤ 100μM. Compds. I are claimed useful as inhibitors of microsomal triglyceride transfer protein (MTP) for the treatment of atherosclerosis.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I

AB A method of treating cardiovascular disease comprises administration of title compds. [I, R1, R3 = CF3, halo, cyano, alkyl, alkenyl, alkynyl, (substituted) cycloalkyl, heterocyclyl, etc.; R2 = H, halo, Me, L = NHCO, NHCS, NH, NHCH2, NHCOCO, etc.; R4 = (substituted) alkyl, alkoxy, alkylthio, alkylamino, alkoxyalkyl, alkylthioalkyl, carbocyclyl, heterocyclyl, etc.; R8 = H, NH2] (no data). Thus, 2-chloronicotinic acid in MeCN was treated with EDC and then with 1-(4-aminophenyl)-3-(3-pyridyl)-5-trifluoromethylpyrazole under ice cooling followed by stirring for 1 h to give 1 (R1 = 3-pyridyl; R2, R8 = H; R3 = CF3; L = NHCO; R4 = 2-chloropyridin-3-yl).

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:22869 CAPLUS

DN 138:89806

TI Preparation of arylpyrazoles as soluble epoxide hydrolase inhibitors for treatment of cardiovascular disease.

IN Inghram, Richard H.; Proudfoot, John R.

PA Boehringer Ingelheim Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003002555	A1	20030109	WO 2002-US18752	20020614
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
TM RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003022929	A1	20030130	US 2002 172457	20020614
EP 1406892	A1	20040414	EP 2002-739870	20020614
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2004092567	A1	20040513	US 2001-302066P	P 20010629
			US 2002-US18752	W 20020614
			US 2003-670668	20030925
			US 2001-302066P	P 20010629
			US 2002-172457	A1 20020614

OS MARPAT 138:89806

IT 483342-21-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylpyrazoles as soluble epoxide hydrolase inhibitors for treatment of cardiovascular disease)

RN 483342-21-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[4-[(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:900736 CAPLUS

DN 138:4612

TI Preparation of 2-heterocyclyl-4-aminopyrimidine-5-carboxamide and 5-heterocyclyl-3-aminopyrazine-2-carboxamide derivatives as selective inhibitors of phosphodiesterase IV

IN Yamada, Koichiro; Matsumoto, Kenji; Omori, Kenji; Yoshikawa, Kohei

PA Tanabe Seiyaku Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 53 pp.

CODEN: JKXXAP

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2002338466	A2	20021127	JP 2002-61580	20020307
			JP 2001-73385	A 20010315

OS MARPAT 138:4612

IT 330785-09-6P 330785-10-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclylaminopyrimidinecarboxamide and heterocyclylaminopyrazinecarboxamide derivs. as selective inhibitors of phosphodiesterase IV for prevention and/or treatment of diseases)


RN 330785-09-6 CAPLUS

CN Pyrazinecarboxamide,

3-[[[3-chloro-4-methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)-5-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.




PN 330785-10-9 CAPLUS

CN Pyrazinecarboxamide, 3-[[[3-chloro-4-methoxyphenyl)methyl]amino]-5-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-N-(trans-4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Relative stereochemistry.



GI



AB Disclosed is a pharmaceutical composition containing the title compound [I]; the ring
A = (un)substituted N-containing heterocyclyl; R1 = (un)substituted lower alkyl, NH-Q-R3, NH-R4; wherein R3 = (un)substituted N-containing heterocyclyl;
Q = a single bond, lower alkylene; R4 = (un)substituted cycloalkyl; R2 = (un)substituted aryl; one of Y and Z is CH and the other is N] or pharmacol. acceptable salt thereof as the active ingredient for the prevention and/or treatment of impotence, pulmonary hypertension, or diabetic stomach failure or paralysis. Thus, a solution of 2.057 g 2-methylthio-4-(3-chloro-4-methoxybenzylamino)-5-formylpyrimidine was treated with 1.468 g m-chloroperbenzoic acid (80%) at 0° for 30 min, followed by successively adding 0.901 g L-prolinol and 1.33 mL Et3N, and the resulting mixture was allowed to react at 0° for 1 h to give 2.00 g (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-formylpyrimidine (II). A solution of 91.0 mg II in 20

L3 ANSWER 15 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
mL THF was reacted with 1.1 mL 1.10 M MeLi/Et2O at -78° for 10 min to give, after treatment with aq. NaHCO3 and extn. with EtOAc, an EtOAc soln. of crude (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-(1-hydroxyethyl)pyrimidine which was stirred with 0.5 g MnO2 at room temp. overnight and then at refluxing temp. for 5 h to give (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-acetylpyrimidine (III). III and inhibitors N-(2-pyridylmethyl) 2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine-5-carboxamide showed IC50 of 5.18 and 0.0859
μM, resp., against PDE IV isolated from a dog lung. III in vitro exhibited the relaxant activity on rabbit corpus cavernosum with ED50 of 1 nM.

L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:658116 CAPLUS
DN 137:201332
TI Preparation of heterocyclylalkylamine derivatives as remedies for angiogenesis mediated diseases
IN Chen, Duqing; Adams, Jeffrey; Bemis, Jean; Booker, Shon; Cai, Guolin; Croghan, Michael; DiPietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Geuns-meyer, Stephanie; Handley, Michael; Huang, Qi; Kim, Joseph L.; Kim, Tae-seong; Kiselyov, Alexander; Ouyang, Xiaohu; Patel, Vinod F.; Smith, Leon M.; Stec, Markian; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang
PA Angen Inc., USA
SO PCT Int. Appl., 502 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN: CNT 2
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2002066470 A1 20020829 WO 2002-US743 20020111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO
US 2001-261339P P 20010112
US 2001-323764P P 20010919
US 2002-46681 A 20020110
US 2002-46681 A 20020110
US 2001-261339P P 20010112
US 2001-323764P P 20010919
BR 2002006435 A 20030923 BR 2002-6435 20020111
US 2001-261339P P 20010112
US 2001-323764P P 20010919
US 2002-46681 A 20020110
WO 2002-US743 W 20020111
EP 1358184 A1 20031105 EP 2002-717325 20020111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2001-261339P P 20010112
US 2001-323764P P 20010919
US 2002-46681 A 20020110
WO 2002-US743 W 20020111
EE 200300324 A 20031215 EE 2003-324 20020111
US 2001-261339P P 20010112
US 2001-323764P P 20010919
US 2002-46681 A 20020110
WO 2002-US743 W 20020111
NO 2003003181 A 20030911 NO 2003-3181 20020111
US 2001-261339P P 20010112
US 2001-323764P P 20010919
US 2002-46681 A 20020110
WO 2002-US743 W 20020111


PATENT FAMILY INFORMATION:

FAN 2003:950057

PATENT NO. KIND DATE APPLICATION NO. DATE

Patel


L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
PI US 2003225106 A1 20031204 US 2002-197974 20020717
US 2001-261339P P 20010112
US 2001-323764P P 20010919
US 2002-46681 A 20020110
US 2002-46681 A 20020110
US 2001-261339P P 20010112
US 2001-323764P P 20010919
WO 2004007458 A1 20040122 WO 2003-US22417 20030715
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2002-197974 A 20020717
OS MARPAT 137:201332
IT 453561-07-4P 453561-08-5P 453561-23-4P
453561-81-4P, 2-[(2,3-Dihydrobenzofuran-5-ylmethyl)amino]-N-[3,3-dimethyl-1-(piperidin-4-ylmethyl)-2,3-dihydro-1H-indol-6-yl]nicotinamide
453563-25-2P 453563-26-3P 453563-27-4P
453563-28-5P 453563-31-2P 453563-34-3P
453563-35-4P 453563-36-3P 453563-84-3P
453564-40-4P 453564-41-5P 453564-42-5P
453564-46-0P 453564-69-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclylalkylamine deriva. as remedies for angiogenesis mediated diseases)
RN 453561-07-4 CAPLUS
CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 453561-08-5 CAPLUS

<8/14/2004>

L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 3-Pyridinecarboxamide, N-[(3,4-dichlorophenyl)-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 453561-23-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 453561-81-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinylmethyl)-1H-indol-6-yl]- (9CI) (CA INDEX NAME)


L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 453563-27-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453563-28-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 453563-25-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 453563-26-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[(6-quinolinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 453563-33-2 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453563-34-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-(1-acetyl-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 453563-35-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[6-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 453563-36-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[2,3-dihydro-5-benzofuranyl)methyl]amino]-N-
[2,3-dihydro-3,3-dimethyl-1-[(1-methyl-4-piperidinyl)methyl]-1H-indol-6-
yl]-9H-1) (CA INDEX NAME)




RN 453563-84-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[[2,3-dihydro-6-

L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 453564-42-6 CAPLUS
CN 3-Pyridinecarboxamide,
2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-
(pentafluoroethyl)-3-[(2S)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA
INDEX
NAME)

Absolute stereochemistry.




RN 453564-46-0 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[(5-quinolinylmethyl)amino]-
(9CI) (CA INDEX NAME)




RN 453564-69-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(7-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
benzofuranyl)methylamino]-3-pyridinyl]carbonylamino]-2-
(pentafluoroethyl)phenoxy)methyl] , 1,1-dimethylethyl ester (9CI) (CA
INDEX NAME)




RN 453564-40-4 CAPLUS
 CN 2(1H)-Isoquinolinecarboxylic acid, 7-[[[2-[[[2,3-dihydro-5-benzofuranyl)methyl]amino] 3-pyridinyl]carbonyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 453564-41-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[2,3-dihydro-5-benzofuranyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



AB Title compds. [I; A1, A2 independently = C, N; A = 5-, or 6-membered partially saturated heterocyclyl, 5-, or 6-membered heterocyclyl, 9-, or 10-membered fused partially saturated heterocyclyl, 9-, 10-, or 11-membered fused heteroaryl, naphthyl, 4-, 5-, or 6-membered cycloalkenyl; X = C2NR3, C2NR3(R4); Z = O, S; Y = N:CH, NR5(CR6R7), R6N(R5)(CR6R7), NR5(CR6R7)R8; R = 5-, or 6-membered (un)substituted heterocyclyl, 9-, 10-, 11-membered heterocyclyl; R1 = 6-10-membered (un)substituted aryl, 5-, or 6-membered (un)substituted heterocyclyl, 9-11-membered (un)substituted fused heterocyclyl, cycloalkyl, cycloalkenyl; R2 = H, halo, oxo, SH, COOH, CHO; R3 = H, alkyl, 5-, or 6-membered heterocyclyl; R4 = alkylenyl, alkylenyl, alkyl, alkyl, R5 = H, alkyl, aryl, C6H5, R6 = H, alkyl, alkyl, independently = H, halo, CN, alkyl; R6R7 = cycloalkyl; R8 = alkylenyl; etc.] are prepared and are effective for prophylaxis and treatment of


<8/14/2004>

L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 diseases, such as angiogenesis mediated diseases. The invention
 encompasses novel compds., analogs, prodrugs and pharmaceutically
 acceptable derivs. thereof, pharmaceutical compns. and methods for
 prophylaxis and treatment of diseases and other maladies or conditions
 involving, cancer and the like. The subject invention also relates to
 processes for making such compds. as well as to intermediates useful in
 such processes. Thus, the title compd. II was prepd. from Me
 3-amino-2-thiophenecarboxylate, 4-chloroaniline, and 4-pyridine
 carboxaldehyde via coupling reaction.
 RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



L3 ANSWER 17 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:637637 CAPLUS
 DN 137:185325
 TI Preparation of acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenylamines as
 stimulators of endothelial NO synthase transcription
 IN Strobel, Hartmut; Wohlfart, Paulus
 PA Aventis Pharma Deutschland GmbH, Germany
 SO PCT Int. Appl., 101 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064546	A2	20020822	WO 2002-EP1449	20020212
WO 2002064546	A3	20021107		
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EE 200300370	A	20031015	EP 2001-102853	A 20010213
			EE 2003-370	20020212
			EP 2001-102853	A 20010213
			WO 2002-EP1449	W 20020212
EP 1362027	A2	20031119	EP 2002-722069	20020212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, NC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			EP 2001-102853	A 20010213
JP 2004518720	T2	20040624	WO 2002-EP1449	W 20020212
			JP 2002-564479	20020212
			EP 2001-102853	A 20010213
			WO 2002-EP1449	W 20020212
BR 2002007197	A	20040706	BR 2002-7197	20020212
			EP 2001-102853	A 20010213
			WO 2002-EP1449	W 20020212
US 2003008915	A1	20030109	US 2002-73203	20020212
US 6759412	B2	20040706		
			EP 2001-102853	A 20010213
NO 2003003566	A	20031013	NO 2003-3566	20030812
			EP 2001-102853	A 20010213
			WO 2002-EP1449	W 20020212
OS MARPAT 137:185325				
IT 450368-07-7P				
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (eNOS transcription stimulator; preparation of acylated tetrahydrobenzocycloheptenylamines as stimulators of endothelial NO-synthase transcription)				
RN 450368-07-7 CAPLUS				

L3 ANSWER 17 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 2-pyridinecarboxamide, 6-chloro-3-[(phenylmethyl)amino]-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl) (9CI) (CA INDEX NAME)




GI



AB Title compds. I [wherein R1 and R4 = independently H, (pseudo)halo, CF3, NO2, or (un)substituted alkyl, alkenyl, alkynyl, Ph, heteroaryl, amino, alkoxy, sulfamoyl, etc.; R2 and R3 = independently H, (pseudo)halo, OH, Ph, alkoxy, CF3, CN, NO2, or (un)substituted alkyl, amino, acylamino, etc.; A = CH2, CHOH, or CH(alkyl); B, C, and D = independently CH2 or CH(alkyl); R5 = (un)substituted (hetero)aryl; and stereoisomers, mixts., or pharmaceutically acceptable salts thereof] were prepared as stimulators of endothelial NO-synthase (eNOS) transcription, which has a vasodilating effect and inhibits the aggregation of platelets, the adhesion of leukocytes to the endothelium, and the proliferation of intimal smooth muscle cells. For example, amidation of 4-fluorobenzoic acid chloride with 6,7,8,9-tetrahydro-5H-benzocyclohepten-6-ylamine in the presence of TEA in dioxane afforded II. The latter activated eNOS transcription in primary human umbilical vein cord endothelial cells (HUEVC) with EC50 of 0.02 µM. I are useful for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchial, chronic renal failure, cirrhosis of the liver, osteoporosis, or restricted memory performance or for a restricted ability to learn, or the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives (no data).

L3 ANSWER 18 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:603273 CAPLUS
 DN 138:122629
 TI Synthesis of 1,4-benzodiazepine-2,5-dione derivatives
 AU Ho, Tong-Ing; Chen, Wen-Shiong; Hsu, Chi-Wei; Tsai, Yeun-Min; Fang, Jim-Min
 CS Dep. of Chem., National Taiwan Univ., Taipei, Taiwan
 SO Heterocycles (2002), 57(8), 1501-1506
 CODEN: HETCYM; ISSN: 0365-5414
 PB Japan Institute of Heterocyclic Chemistry
 DT Journal
 LA English
 OS CASREACT 138:122629
 IT 489446-50-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent).
 RN 489446-50-6 CAPLUS
 CN Benzamide, N-(4-methoxyphenyl)-2-[[[3-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



AB A synthesis of a series of 1,4-benzodiazepine-2,5-dione derivs. with a carboxy group at the 3-position is realized in good yields by using Me malonylchloride as a key reagent and intramol. nucleophilic substitution as ring closure reaction. The synthesis of 4-(4-methoxyphenyl)-1-[[[3-methoxyphenyl)methyl]-2,5-dioxo-1H-1,4-benzodiazepine-3-carboxylic acid ester was described.
 RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:539663 CAPLUS
 DN 137:109210
 TI Preparation of substituted arylamine derivatives and methods of use as antitumor agents
 IN Chen, Guoqing; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Huang, Qi; Kim, Joseph L.; Kim, Tae-Seong; Patel, Vinod F.; Smith, Leon M.; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang
 PA Amgen Inc., USA
 SO PCT Int. Appl., 253 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055501	A2	20020718	WO 2002-US742	20020111
WO 2002055501	A3	20021219		
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002147198	A1	20021010	US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
			US 2002-46526	A 20020110
			US 2002-46526	A 20020110
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
EP 1358161	A2	20031105	EP 2002-717324	20020111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
			US 2002-46526	A 20020110
			WO 2002-US742	W 20020111


PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003134836	A1	20030717	US 2002-197960	20020717
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
			US 2002-46526	A2 20020110
US 2002147198	A1	20021010	US 2002-46526	20020110
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
WO 2004007457	A2	20040122	WO 2003-US22276	20030715
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BJ, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-77-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)-(9CI) (CA INDEX NAME)




RN 442846-13-1 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[5-[[[2-[[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester, (2R) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LJ, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2002-197960 A 20020717

OS MARPAT 137:109210
 IT 442847-21-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of substituted aminopyridines as antitumor agents)
 RN 442847-21-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinylmethyl)-1H-indol-6-yl] 2-[[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




IT 442845-74-1P 442845-77-4P 442846-13-1P
 442846-17-5P 442846-22-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (target compound; preparation of substituted aminopyridines as antitumor agents)
 RN 442845-74-1 CAPLUS
 CN 3-Pyridinecarboxamide, 6-chloro-N-[3-fluoro-4-methylphenyl]-2-[[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-17-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[6-[[[2-[[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-22-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-acetyl-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-6-yl)-2-[[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT 442845-71-8P 442845-72-9P 442845-73-0P
 442845-75-2P 442845-76-3P 442845-78-5P
 442845-79-6P 442845-80-9P 442845-81-0P
 442845-82-1P 442845-83-2P 442845-84-3P
 442845-85-4P 442845-86-5P 442845-87-6P
 442845-88-7P 442845-89-8P 442845-90-1P
 442845-91-2P 442845-92-3P 442845-93-4P
 442845-94-5P 442845-95-6P 442845-96-7P
 442845-97-8P 442845-99-0P 442846-00-6P
 442846-01-7P 442846-02-8P 442846-03-9P
 442846-04-0P 442846-05-1P 442846-06-2P
 442846-07-3P 442846-08-4P 442846-09-5P
 442846-10-6P 442846-11-7P 442846-12-0P
 442846-14-2P 442846-15-3P 442846-16-4P
 442846-18-6P 442846-19-7P 442846-20-0P
 442846-21-1P 442846-23-3P 442846-24-4P
 442846-25-5P 442846-26-6P 442846-27-7P
 442846-28-8P 442846-29-9P 442846-30-2P
 442846-31-3P 442846-32-4P 442846-33-5P
 442846-34-6P 442846-35-7P 442846-36-8P
 442846-38-0P 442846-39-1P 442846-40-4P
 442846-42-6P 442846-44-8P 442846-46-0P
 442846-48-2P 442846-50-6P 442846-52-8P
 442846-53-9P 442847-23-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(Target compound; preparation of substituted aminopyridines as antitumor agents)

RN 442845-71-8 CAPLUS

CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 442845-75-2 CAPLUS
 CN 3-Pyridinecarboxamide, 6-chloro-N-(3-fluoro-4-methylphenyl)-2-[[4-methoxyphenyl]methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 442845-76-3 CAPLUS


CN 3-Pyridinecarboxamide, 6-chloro-N-(4-chlorophenyl)-2-[[4-methoxyphenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-78-5 CAPLUS


CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[3-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442845-72-9 CAPLUS

CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-73-0 CAPLUS

CN 2-Pyridinecarboxamide, N-(3-fluoro-4-methylphenyl)-3-[[4-methoxyphenyl]methyl]amino]- (9CI) (CA INDEX NAME)




L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442845-79-6 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[4-(trifluoromethyl)phenyl]methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 442845-80-9 CAPLUS


CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-81-0 CAPLUS

<8/14/2004>

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 3-Pyridinecarboxamide, 2-[[[2-bromophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 442845-82-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[4-(trifluoromethoxy)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-83-2 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[2,3-difluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442845-84-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[[[4-cyanophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-85-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[[[4-cyanophenyl)methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-86-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-fluorophenyl)methyl]amino]-N-(4-(2-methylpropyl)phenyl)- (9CI) (CA INDEX NAME)




RN 442845-87-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-(1,1-dimethylethyl)phenyl)-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-88-7 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-methoxyphenyl)methyl]amino]-N-(4-(1-

patel


L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-89-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-aminophenyl)methyl]amino]-N-(4-(1-methylethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 442845-90-1 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-fluorophenyl)methyl]amino]-N-(4-(1-methylethyl)phenyl)- (9CI) (CA INDEX NAME)




<8/14/2004>


L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 442845-91-2 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-92-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-93-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(phenylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-97-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,4-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-99-0 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,6-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




Patel

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 442845-94-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3-chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-95-6 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(4-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-96-7 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(4-chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 442846-00-6 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,3-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-01-7 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-02-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,6-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-03-9 CAPLUS

<8/14/2004>

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 3-Pyridinecarboxamide, 2-[[[3-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-04-0 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-fluorophenyl)methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-05-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-[3-[3-(dimethylamino)propyl]-5-(trifluoromethyl)phenyl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-08-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-bromo-2-fluorophenyl]-2-[[[3-(dimethylamino)propyl]-4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-09-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-06-2 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-(dimethylamino)propyl]-4-fluorophenyl)methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-07-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-(dimethylamino)propyl]-4-fluorophenyl)methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-10-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-fluoro-3-[3-(4-morpholinyl)-1-propynyl]phenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-11-9 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[1,3-benzodioxol-5-yl)methyl]amino]-N-[4-phenoxyphenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-12-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-[3-[2-(1-pyrrolidinyl)ethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-14-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[2-[(1,1-dimethylethyl)-5-[[2-[[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-15-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(1-methyl-4-piperidinyl)-1H-indol-6-yl]-2-[[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-16-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-[(dimethylamino)acetyl]-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl]-2-[[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-18-6 CAPLUS
CN Carbamic acid, [2-[6-[[2-[[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 442846-19-7 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 7-[[2-[[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-20-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[3-[[2-[[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 442846-21-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[3-[[2-[[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-23-3 CAPLUS
 CN 1-Piperidinecarboxylic acid,
 4-[[3-[[[2-[[[4-fluorophenyl)methyl]amino]-3-
 pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-,
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-24-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-fluorophenyl)methyl]amino]-N-[4-(
 pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-25-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-fluorophenyl)methyl]amino]-N-[3-[(2R)-2-
 pyrrolidinylmethoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 442846-26-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-
 piperidinylmethoxy)phenyl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA
 INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-27-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(2R)-2-
 pyrrolidinylmethoxy]phenyl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 442846-28-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-fluorophenyl)methyl]amino]-N-(1,2,3,4-
 tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-29-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[1-(aminoacetyl)-2,3-dihydro-3,3-dimethyl-1H-
 indol-6-yl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-30-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinyl)-1H-
 indol-6-yl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-31-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-[3-(4-piperidinylmethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)]




RN 442846-32-4 CAPLUS
CN 3-Pyridinecarboxamide,
N-(3,4-dihydro-2,2-dimethyl-1,4-benzoxazin-6-yl)-
2-[[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)]

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-35-7 CAPLUS
CN 3-Pyridinecarboxamide,
2-[[[4-(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)]




RN 442846-36-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-2-oxo-7-quinoliny)- (9CI) (CA INDEX NAME)]

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-33-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-[3-[[[(2S)-1-methyl-2-pyrrolidinyl)methoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 442846-34-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-[[[1-methyl-4-piperidinyl)methyl]-1H-indol-6-yl]-2-[[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)]


L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-38-0 CAPLUS
CN 3-Pyridinecarboxamide, N-5-benzofuranyl-2-[[[3-(hydroxymethyl)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)]




RN 442846-39-1 CAPLUS
CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-2-[[[3-(hydroxymethyl)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)]




RN 442846-40-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3,4-difluorophenyl)methyl]amino]-N-[4-(1,1,1-trifluoro-2-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-2-yl)- (9CI) (CA INDEX NAME)]

<8/14/2004>

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
dimethylethyl]-3-[[2-(1-piperidinylethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 442846-42-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-((1,1-dimethylethyl)-3-[[2-(1-piperidinylethyl)amino]phenyl]-2-((phenylmethyl)amino))- (9CI) (CA INDEX NAME)




RN 442846-44-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-((1,1-dimethylethyl)-3-[[2-(1-piperidinylethyl)amino]phenyl]-2-((phenylmethyl)amino))- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-46-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 442846-48-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-(2-pyrrolidinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-50-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-[3-(2-pyrrolidinylmethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-52-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-((1,1-dimethylethyl)-3-[[2-(1-piperidinylethyl)amino]phenyl]-2-((phenylmethyl)amino))- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-53-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-[3-(1-methyl-2-pyrrolidinylmethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442847-23-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3-(4-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 442845-77-4
CMF C25 H20 F N3 O2

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 76-05-1

CMF C2 H F3 O2



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 and R2 independently equal C or N, wherein R1R2 form part of 5-6 membered heteroaryl ring A; R1 = one or more substituents selected from H, halo, oxo, (un)substituted cycloalkyl, phenylalkyl, etc.;

R2 = (un)substituted cycloalkyl, cycloalkenyl, 6-10 membered aryl or 5-6 membered heterocyclyl, etc.; R3 = (un)substituted aryl; R4 = H, alkyl, (un)substituted Ph or aralkyl; X1 = bond, alkylenyl, alkenylenyl and alkynylenyl, where one of the CH2 groups may be substituted with O or NH, wherein X1 is optionally substituted with OH; X2 = (un)substituted N containing linker, e.g., -NHCH2-, and there pharmaceutically acceptable deriva., are prepared and disclosed as agents effective for prophylaxis

and

treatment of diseases, such as angiogenesis mediated diseases. Thus, II was prepared via arylation of 1-dimethylamino-2-propyne with 3-bromo-5-trifluoromethylbenzylamine, hydrogenation, amidation with 2-chloropyridine-3-carbonyl chloride and chloro-substitution with 4-fluorobenzylamine. Selected compds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below 50 nM. The

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable deriva. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

L3 ANSWER 20 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:171853 CAPLUS

DN 136:232201

TI Preparation of cyclic amine derivatives as CCR3 antagonists

IN Morihira, Koichiro; Inami, Hiroshi; Kubota, Hirokazu; Yokoyama, Kazuhiro; Morokata, Tatsuki; Takeuchi, Makoto; Takahashi, Toshiya; Kaneko, Masayuki; Imaoka, Takayuki; Torii, Yuichi; Iura, Yosuke

PA Yamanouchi Pharmaceutical Co., Ltd., Japan; Toray Industries, Inc.
SO PCT Int. Appl., 92 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

PAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002018335	A1	20020307	WO 2001-JP7321	20010827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GM, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001080187	A5	20020313	JP 2000-257451	A 20000828
			AU 2001-80187	20010827
			JP 2000-257451	A 20000828
			WO 2001-JP7321	W 20010827

OS MARPAT 136:232201


IT 403477-79-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyclic amine deriva. as CCR3 antagonists)


RN 403477-79-2 CAPLUS

CN Benzamide, 2-[[[(2-chlorophenyl)methylamino]-N-[8-[(6-fluoro-2-naphthalenyl)methyl]-8-azabicyclo[3.2.1]oct-3-yl)]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 20 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)





AB The title compds. I [ring A = (un)substituted heterocyclic ring, etc.; X =

bond, O, CO, etc.; ring B = Q1, etc.; ring V3 = hydrocarbon ring, etc.; W = CH, N; Y = CO, etc.; R21, R22 = H, halo, etc.; T1 = (CH2)n; n = 0-2; ring D = (un)substituted aryl, etc.] are prepared in an in vitro test


(for CCR3 antagonism) using cells, compds. of this invention showed IC50 values of 0.001 μM to 0.45 μM.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-64-0 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-65-1 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-morpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-69-5 CAPLUS
 CN Benzamide, 5-chloro N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-74-2 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-thiomorpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-75-3 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperazinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-76-4 CAPLUS

Patel


L3 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-66-2 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-67-3 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-68-4 CAPLUS
 CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino(4-methyl-1-piperazinyl)methyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-77-5 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(hexahydro-1H-azepin-1-yl)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-78-6 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)




RN 358659-79-7 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)

<8/14/2004>


L3 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-80-0 CAPLUS
 CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 358659-81-1 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-82-2 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-87-7 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-88-8 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-83-3 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-84-4 CAPLUS
 CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-85-5 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R2C(NR3), (substituted) Ph, naphthyl, heterocyclyl, etc.; R1-R3 = H, OR5, NR5R6, alkyl, alkenyl, etc.; R1R2 or R2R3 = atoms to form (substituted) cycloalkyl, heterocyclyl; R5, R6 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted) alkylphenyl, alkylphenyl; R5R6 = atoms to form a 3-8 membered (substituted) ring; Q = bond, CH2, CO, O, S, SO, SO2, NR7, SO2NR7, etc.; R7 = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, (substituted) alkylphenyl, alkylphenyl; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, O, S, SO, SO2, alkylcarbonyl, etc.; G = (substituted) alkenyl, cycloalkenyl, phenylene, 3-8 membered (fused) (aromatic) heterocyclyl; J = bond, NR9CO, O, S, SO, SO2, CH2, NR9SO2, etc.; X = (substituted) Ph, naphthyl, (fused) heteroaryl, were prepared as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl)-2-aminophenylcarboxamide (preparation given), 4-cyanobenzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 70% N-(5-bromo-2-pyridinyl)-2-(4-cyanophenylcarbonyl)aminophenylcarboxamide. The latter in MeOH at 0° was saturated with HCl and stirred overnight followed by solvent evaporation. The residue was refluxed 2 h with NH4OAc in MeOH to give 70% N-(5-bromo-2-pyridinyl)-2-(4-amidinophenylcarbonyl)aminophenylcarboxamide.

LN ANSWER 22 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:816647 CAPLUS
DI 135:357948
TN Preparation of heterocyclic compounds as phosphodiesterase V (PDE V)
inhibitors
IN Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji; Kikkawa, Kohsei
PA Tanabe Seiyaku Co., Ltd., Japan
SO PCT Int. Appl., 207 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
EAN.CNT.3

PATENT NO.		KIND		DATE		APPLICATION NO.		DATE	
PI	WO 2001083460	A1		20011108		WO 2001-JP2034		20010315	
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, IL, IN, JP, KE, KG, KR, KZ, LC, LU, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OL, OM, OS, PA, PE, PG, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM							
	RW:	GH, GM, KE, LS, MM, MZ, SD, SE, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG							
	AU 2001041142	A5		20011112		JP 2000-130371		A 20000428	
					AU 2001-41142		A 20010315		
					JP 2000-130371		A 20000428		
					WO 2001-JP2034		W 20010315		
	EP 1277741	A1		20030122		EP 2001-912373		20010315	
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR							
					JP 2000-130371		A 20000428		
NZ	522217	A		20040430		WO 2001-JP2034		W 20010315	
					NZ 2001-522217		A 20000428		
US	2003229089	A1		20031211		US 2002-258545		20021025	
					JP 2000-130371		A 20000428		
US	2004142930	A1		20040722		WO 2001-JP2034		W 20010315	
					US 2002-258545		A2 20021025		

FAN 2001:208252

PAN	2001:208252 PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019802	A1	20010322	WO 2000-JP6258	20000913
N:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DO, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HN, HU, IL, IN, IS, IT, JP, KE, KG, KP, KR, KZ, LA, LK, LR, LS, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AE, AY, BG, KZ, MD, RU, TJ, TM	RW:	GH, GM, KE, LS, MW, MS, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,		

L3	ANSWER 22 OF 49	CAPLUS	COPYRIGHT 2004 ACS on STN	(Continued)
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,			
	CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
			JP 1999-261852	A 19990916
			JP 2000-130378	A 20000428
AU 2000073118	A5	20010417	AU 2000-73118	20000913
AU 767558	B2	20031113		


BR 2000014526	A	20020618	JP 1999-261852 JP 2000-130371 WO 2000-JP6258 BR 2000-14526 JP 1999-261852 JP 2000-130371 JP 2000-JP6258	A A W A A A W	19990916 20000428 20000913 20000913 19990916 20000428 20000918
TR 200200701	T2	20020621	TR 2002-200200701 JP 1999-261852 JP 2000-130371	A A A	20000913 19990916 20000428
EP 1219609 R: AT, BE, CH, DE, DK, ES, FR, GB, IE, SI, LT, LV, FI, RO, MK, CY, AL	A1	20020703	EP 2000-960979 JP 1999-261852 JP 2000-130371 RU 2002-109792 JP 1999-261852 JP 2000-130371 WO 2000-JP6258	A A A W A A W	20000913 19990916 20000428 20000913 19990916 20000428 20000918
RU 2233273	C2	20040727	US 2001-925892	A	20010810
US 2003032647 US 6656935	A1 B2	20030213 20021202			

				JP 1999-261852	A	19990916
				JP 2000-130371	A	20000428
				WO 2000-JP6258	A1	20000913
ZA	2002001499	A	20020902	ZA 2002-1499		20020222
				JP 1999-261852	A	19990916
NO	2002001308	A	20020424	NO 2002-1308		20020215
				JP 1999-261852	A	19990916
				JP 2000-130371	A	20000428
				WO 2000-JP6258	W	20000913
BG	106566	A	20030228	BG 2002-106566		20020402
				JP 1999-261852	A	19990916
				JP 2000-130371	A	20000428
				WO 2000-JP6258	W	20000913
US	2003229095	A1	20031211	US 2003-426884		20030501
				JP 1999-261852	A	19990916
				JP 2000-130371	A	20000428
				WO 2000-JP6258	A1	20000913
				US 2001-925892	A3	20010810


PAN	2004:589247			US 2003-699804	A3	20031104
	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2004142930	A1	20040722	US 2003-699804		20031104
				JP 2000-130371	A	20000428
				JP 2000-277652	A	20000913
				WO 2001 JP2034	W	20010315
				US 2002-258545	A2	20021025
JP	2002012587	A2	20020115	JP 2000-277652		20000913

L3	ANSWER 22 OF 49	CAPLUS	COPYRIGHT 2004 ACS ON STN	(Continued)	
			JP 1999-261852	A 19990916	
			JP 2000-130371	A 20000428	
WO	2001083460	A1	20011108	WO 2001-JP2034	20010315
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BI, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, ES, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IT, IW, IS, KE, KG, KR, KZ, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, SZ, SZ, TZ, UZ, UZ, WZ, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, IJ, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US	2003229089	A1	20031211	US 2002-259545	A 20000428
				JP 2000-130371	A 20000428
				WO 2001-JP2034	W 20010315
OS	MARPAT 135:357948				
IT	372115-86-1P				
		RU: BAC	(Biological activity or effector, except adverse); BSU		
		(Biological			
		study, (unclassified); SPN (Synthetic preparation); THU (Therapeutic use);			
		BIOL (Biological study); PREP (Preparation); USES (Uses)			
		(preparation of heterocyclic compds. as phosphodiesterase V inhibitors			
		preventive or therapeutic agents for various diseases due to			
		dysfunction of signal transduction through cAMP)			
RN	372115-86-1	CAPLUS			
CN	3-Pyridinecarboxamide, 2-[[[3-chloro 4-methoxyphenyl]amino]-N-(trans-4-hydroxycyclohexyl)-6-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-				
	(-9CI) (CA INDEX NAME)				

.....



(continued)



AB Compsds. of the general formula (I) or pharmacol. acceptable salts thereof
[wherein X is :CH or N; Y is NH, NR4, S, O, CH=N, N=CH, N=N, CH=CH, or
the like; R1 is lower alkoxy, amino, a nitrogenous heterocyclic group, or a
hydroxyl group substituted with a heterocyclic group (wherein each group
may be substituted); R2 is either a lower alkylamino or lower alkoxy
group which may be substituted with aryl, or a lower alkoxy group substituted
with a nitrogenous aromatic heterocyclic group; and R3 is aryl, a
nitrogenous heterocyclic group, lower alkyl, lower alkoxy, lower cycloalkoxy, a
hydroxyl group substituted with a nitrogenous heterocyclic group, or
amino (wherein each group may be substituted), or alternatively, R3 and the
substituent of Y may be united to form a lactone ring] or pharmacol.
acceptable salts thereof are prepared. These compsds. exhibit excellent
PDE V inhibitory activity and are useful as preventive or therapeutic agents
for various diseases due to dysfunction of the signal transduction through
cGMP, in particular impotence, pulmonary hypertension and diabetic renal
failure paralysis (no data). Thus, 2-(hydroxymethyl)pyridine was treated
with NaH in THF at room temperature for 30 min and then condensed with
2-chloro-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-
methoxybenzylamino)pyrimidine (preparation given) in THF at room
temperature for 1 hr
to give 2-(2-pyridylmethoxy)-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-
chloro-4-methoxybenzylamino)pyrimidine.

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
AN 2001:661392 CAPLUS
DN 135:226888
TI Preparation of pyridyl benzamides and related compounds as Factor Xa inhibitors
IN Zhu, Bing-yan; Zhang, Pengli; Wang, Lingyan; Huang, Wenrong; Goldman, Erick; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
PA Cor Therapeutics, Inc., USA
SO PCT Int. Appl., 322 pp.
CODEN: P1XXD2
DT Patent
LA English
FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001064643	A2	20010907	WO 2001-US6255	20010228
WO 2001064643	A3	20020404		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2000-185746P	P	20000229		
US 2000-663420	A	20000915		
EP 2001 918257	P	20010228		
US 2000-185746P	P	20000229		
US 2000-663420	A	20000915		
WO 2001-US6255	W	20010228		

PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FAN 2001:208239				
PI WO 2001019788	A2	20010322	WO 2000-US25196	20000915
WO 2001019788	A3	20010809		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 1999-154332P	P	19990917		
US 2000-185746P	P	20000229		
AU 2000074867	A5	20010417	AU 2000-74867	20000915
US 1999-154332P	P	19990917		
US 2000-185746P	P	20000229		
WO 2000-US25196	W	20000915		
EP 1216228	A2	20020626	EP 2000-963452	20000915

L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL
US 1999-154332P P 19990917
US 2000-185746P P 20000229
BR 2000014076 A 20021015 WO 2000-US25196 W 20000915
BR 2000-14076 W 20000915
US 1999-154332P P 19990917
US 2000-185746P P 20000229
JP 2003509406 T2 20030311 US 2000-US25196 W 20000915
JP 2001-523368 P 20000915
US 1999-154332P P 19990917
US 2000-185746P P 20000229
NO 2002001229 A 20020521 WO 2000-US25196 W 20000915
NO 2002-1229 W 20000915
US 1999-154332P P 19990917
US 2000-185746P P 20000229
WO 2000-US25196 W 20000915

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FAN 2001:208248				
PI WO 2001019798	A2	20010322	WO 2000-US25195	20000915
WO 2001019798	A3	20011025		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 1999-154332P	P	19990917		
AU 2000074866	A5	20010417	AU 2000-74866	20000915
US 1999-154332P	P	19990917		
WO 2000-US25195	W	20000915		
EP 1216231	A2	20020626	EP 2000-963451	20000915
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 1999-154332P	P	19990917		
BR 2000014078	A	20021231	BR 2000-14078	20000915
US 1999-154332P	P	19990917		
WO 2000-US25195	W	20000915		
TR 200201413	T2	20030221	TR 2002-200201413	20000915
US 1999-154332P	P	19990917		
JP 2003509412	T2	20030311	JP 2001-523378	20000915
US 1999-154332P	P	19990917		
NZ 517828	A	20031031	NZ 2000-517828	20000915
US 1999-154332P	P	19990917		
NO 2002001230	A	20020521	NO 2000-US25195	20000915
NO 2002-1230	W	20020312		
US 1999-154332P	P	19990917		
WO 2000-US25195	W	20000915		

FAN 2001:661391

L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001064642	A2	20010907	WO 2001-US6247	20010228
WO 2001064642	A3	20020502		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2000-185746P	P	20000229		
US 2000-663420	A	20000915		

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FAN 2002:11104				
PI US 2002002183	A1	20020103	US 2001-794225	20010228
US 6376515	B2	20020423		
US 2003162690	A1	20030828	US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
			US 2002-126976	P 20020422
			US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
US 2004097561	A1	20040520	US 2001-794225	A1 20010228
			US 2003-687334	P 20031015
			US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
			US 2001-794225	A1 20010228
			US 2002-126976	A1 20020422


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FAN 2002:522631				
PI US 2002091116	A1	20020711	US 2001-794214	20010228
US 6632815	B2	20031014		
US 6720317	B1	20040413	US 1999-154332P	P 19990917
			US 2000-662807	A2 20000915
			US 2000-662807	P 20000915
US 6686368	B1	20040203	US 1999-154332P	P 19990917
			US 2003-387927	P 20031012
			US 1999-154332P	P 19990917
			US 2000-662807	A2 20000915
US 2004116399	A1	20040617	US 2003-600695	P 20030620
			US 1999-154332P	P 19990917
			US 2000-662807	A2 20000915
			US 2001-794214	A1 20010228

OS MARPAT 135:226888
IT 350659-61-7P 350659-62-8P 350659-63-9P
350659-64-0P 350659-65-1P 350659-66-2P
350659-67-3P 350659-68-4P 350659-69-5P
350659-70-6P 350659-71-7P 350659-72-8P
350659-73-9P 350659-74-0P 350659-75-1P
350659-76-2P 350659-77-3P 350659-78-4P
350659-79-5P 350659-80-6P 350659-81-7P
350659-82-8P 350659-83-9P 350659-84-0P
350659-85-1P 350659-86-2P 350659-87-3P
350659-88-4P 350659-89-5P
350659-90-6P 350659-91-7P 350659-92-8P
350659-93-9P 350659-94-0P 350659-95-1P
350659-96-2P 350659-97-3P 350659-98-4P
350659-99-5P 350659-100-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);


Patel

L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyridyl benzamides and related compds. as Factor Xa inhibitors)
RN 358659-61-7 CAPLUS
CN Benzamide, 5-chloro-N-[(4-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-62-8 CAPLUS
CN Benzamide, 2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 358659-63-9 CAPLUS
CN Benzamide, 2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)

<8/14/2004>

L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-64-0 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-65-1 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-morpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-69-5 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-74-2 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-thiomorpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-75-3 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperazinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-76-4 CAPLUS

Patel


L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-66-2 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(dimethylamino)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-67-3 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-68-4 CAPLUS
 CN Benzamide, 2-[[[4-(1-azetidinylinomethyl)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino(4-methyl-1-piperazinyl)methyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-77-5 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(hexahydro-1H-azepin-1-yl)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-78-6 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[dimethylamino]iminomethyl]phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)




RN 358659-79-7 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)

<8/14/2004>


L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-80-0 CAPLUS
 CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 358659-81-1 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-82-2 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-87-7 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-88-8 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-83-3 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-84-4 CAPLUS
 CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-85-5 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB AQDEGUX [A = alkyl, cycloalkyl, NR1R2, NR1R2C(NR3), (substituted) Ph, naphthyl, heterocyclyl, etc.; R1-R3 = H, OR5, NR5R6, alkyl, alkenyl, etc.;

R1R2 or R2R3 = atoms to form (substituted) cycloalkyl, heterocyclyl; R5, R6 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted) alkylphenyl, alkylphenyl; R5R6 = atoms to form a 3-8 membered (substituted) ring; Q =

= bond, CH2, CO, O, S, SO, SO2, NR7, SO2NR7, etc.; R7 = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, (substituted) alkylphenyl, alkylphenyl; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, O, S, SO, SO2, alkylcarbonyl, etc.; G = (substituted) alkenyl, cycloalkenyl, phenylene, 3-8 membered (fused) (aromatic) heterocyclyl; J = bond, NR9CO, O, S, SO, SO2, CH2, NR9SO2, etc.; X =

= (substituted) Ph, naphthyl, (fused) heteroaryl, were prepared as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl)-2-aminophenylcarboxamide (preparation given), 4-cyanobenzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 70% N-(5-bromo-2-pyridinyl)-2-(4-cyanophenylcarbonyl)aminophenylcarboxamide. The latter in MeOH at 0° was saturated with HCl and stirred overnight followed by solvent evaporation. The residue was refluxed 2 h with NH4OAc in MeOH to give

70%
 N-(5-bromo-2-pyridinyl)-2-(4-aminophenylcarbonyl)aminophenylcarboxamide.

L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 AN 2001:661391 CAPLUS
 DN 135:210946
 TI Preparation of pyridylamides as Factor Xa inhibitors.
 IN Zhu, Bing-yan; Zhang, Pengli; Wang, Liqiang; Huang, Wenrong; Goldman, Erick; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
 PA Cor Therapeutics, Inc., USA
 SO PCT Int. Appl., 306 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001064642	A2	20010907	WO 2001-US6247	20010228
WO 2001064642	A3	20020502		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 2000-185746P	P 20000229
			US 2000-663420	A 20000915



PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001019788	A2	20010322	WO 2000-US25196	20000915
WO 2001019788	A3	20010809		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
			AU 2000-74867	20000915
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
			WO 2000-US25196	W 20000915
			EP 2000-963452	20000915
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
			WO 2000-US25196	W 20000915
			BR 2000-14076	20000915
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
			US 2000-663420	A 20000915
			WO 2001-US6255	W 20010228


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002002183	A1	20020103	US 2001-794225	20010228
US 6376515	B2	20020423		
			US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
			US 2002-126976	20020422
			US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
			US 2001-794225	A1 20010228
			US 2003-687334	20031015
			US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
			US 2001-794225	A1 20010228
			US 2002-126976	A1 20020422
			US 1999-154332P	P 19990917
			US 2000-662807	A2 20000915
			US 2000-662807	20000915
			US 1999-154332P	P 19990917
			US 2003-387927	20030312
			US 1999-154332P	P 19990917
			US 2000-662807	A3 20000915
			US 2003-600695	20030620
			US 1999-154332P	P 19990917
			US 2000-662807	A2 20000915
			US 2001-794214	A1 20010228

OS MARPAT 135:210946
 IT 358659-61-7P 358659-62-8P 358659-63-9P
 358659-64-0P 358659-65-1P 358659-66-2P
 358659-67-3P 358659-68-4P 358659-69-5P
 358659-70-6P 358659-71-7P 358659-72-8P
 358659-73-9P 358659-74-0P 358659-75-1P
 358659-76-2P 358659-77-3P 358659-78-4P
 358659-79-5P 358659-80-6P 358659-81-7P
 358659-82-8P 358659-83-9P 358659-84-0P
 358659-85-1P 358659-86-2P 358659-87-3P
 358659-88-4P 358659-89-5P 358659-90-6P
 358659-91-7P 358659-92-8P 358659-93-9P
 358659-94-0P 358659-95-1P 358659-96-2P
 358659-97-3P 358659-98-4P 358659-99-5P
 358659-100-6P 358659-101-7P 358659-102-8P
 358659-103-9P 358659-104-0P 358659-105-1P
 358659-106-2P 358659-107-3P 358659-108-4P
 358659-109-5P 358659-110-6P 358659-111-7P
 358659-112-8P 358659-113-9P 358659-114-0P
 358659-115-1P 358659-116-2P 358659-117-3P
 358659-118-4P 358659-119-5P 358659-120-6P
 358659-121-7P 358659-122-8P 358659-123-9P
 358659-124-0P 358659-125-1P 358659-126-2P
 358659-127-3P 358659-128-4P 358659-129-5P
 358659-130-6P 358659-131-7P 358659-132-8P
 358659-133-9P 358659-134-0P 358659-135-1P
 358659-136-2P 358659-137-3P 358659-138-4P
 358659-139-5P 358659-140-6P 358659-141-7P
 358659-142-8P 358659-143-9P 358659-144-0P
 358659-145-1P 358659-146-2P 358659-147-3P
 358659-148-4P 358659-149-5P 358659-150-6P
 358659-151-7P 358659-152-8P 358659-153-9P
 358659-154-0P 358659-155-1P 358659-156-2P
 358659-157-3P 358659-158-4P 358659-159-5P
 358659-160-6P 358659-161-7P 358659-162-8P
 358659-163-9P 358659-164-0P 358659-165-1P
 358659-166-2P 358659-167-3P 358659-168-4P
 358659-169-5P 358659-170-6P 358659-171-7P
 358659-172-8P 358659-173-9P 358659-174-0P
 358659-175-1P 358659-176-2P 358659-177-3P
 358659-178-4P 358659-179-5P 358659-180-6P
 358659-181-7P 358659-182-8P 358659-183-9P
 358659-184-0P 358659-185-1P 358659-186-2P
 358659-187-3P 358659-188-4P 358659-189-5P
 358659-190-6P 358659-191-7P 358659-192-8P
 358659-193-9P 358659-194-0P 358659-195-1P
 358659-196-2P 358659-197-3P 358659-198-4P
 358659-199-5P 358659-200-6P 358659-201-7P
 358659-202-8P 358659-203-9P 358659-204-0P
 358659-205-1P 358659-206-2P 358659-207-3P
 358659-208-4P 358659-209-5P 358659-210-6P
 358659-211-7P 358659-212-8P 358659-213-9P
 358659-214-0P 358659-215-1P 358659-216-2P
 358659-217-3P 358659-218-4P 358659-219-5P
 358659-220-6P 358659-221-7P 358659-222-8P
 358659-223-9P 358659-224-0P 358659-225-1P
 358659-226-2P 358659-227-3P 358659-228-4P
 358659-229-5P 358659-230-6P 358659-231-7P
 358659-232-8P 358659-233-9P 358659-234-0P
 358659-235-1P 358659-236-2P 358659-237-3P
 358659-238-4P 358659-239-5P 358659-240-6P
 358659-241-7P 358659-242-8P 358659-243-9P
 358659-244-0P 358659-245-1P 358659-246-2P
 358659-247-3P 358659-248-4P 358659-249-5P
 358659-250-6P 358659-251-7P 358659-252-8P
 358659-253-9P 358659-254-0P 358659-255-1P
 358659-256-2P 358659-257-3P 358659-258-4P
 358659-259-5P 358659-260-6P 358659-261-7P
 358659-262-8P 358659-263-9P 358659-264-0P
 358659-265-1P 358659-266-2P 358659-267-3P
 358659-268-4P 358659-269-5P 358659-270-6P
 358659-271-7P 358659-272-8P 358659-273-9P
 358659-274-0P 358659-275-1P 358659-276-2P
 358659-277-3P 358659-278-4P 358659-279-5P
 358659-280-6P 358659-281-7P 358659-282-8P
 358659-283-9P 358659-284-0P 358659-285-1P
 358659-286-2P 358659-287-3P 358659-288-4P
 358659-289-5P 358659-290-6P 358659-291-7P
 358659-292-8P 358659-293-9P 358659-294-0P
 358659-295-1P 358659-296-2P 358659-297-3P
 358659-298-4P 358659-299-5P 358659-300-6P
 358659-301-7P 358659-302-8P 358659-303-9P
 358659-304-0P 358659-305-1P 358659-306-2P
 358659-307-3P 358659-308-4P 358659-309-5P
 358659-310-6P 358659-311-7P 358659-312-8P
 358659-313-9P 358659-314-0P 358659-315-1P
 358659-316-2P 358659-317-3P 358659-318-4P
 358659-319-5P 358659-320-6P 358659-321-7P
 358659-322-8P 358659-323-9P 358659-324-0P
 358659-325-1P 358659-326-2P 358659-327-3P
 358659-328-4P 358659-329-5P 358659-330-6P
 358659-331-7P 358659-332-8P 358659-333-9P
 358659-334-0P 358659-335-1P 358659-336-2P
 358659-337-3P 358659-338-4P 358659-339-5P
 358659-340-6P 358659-341-7P 358659-342-8P
 358659-343-9P 358659-344-0P 358659-345-1P
 358659-346-2P 358659-347-3P 358659-348-4P
 358659-349-5P 358659-350-6P 358659-351-7P
 358659-352-8P 358659-353-9P 358659-354-0P
 358659-355-1P 358659-356-2P 358659-357-3P
 358659-358-4P 358659-359-5P 358659-360-6P
 358659-361-7P 358659-362-8P 358659-363-9P
 358659-364-0P 358659-365-1P 358659-366-2P
 358659-367-3P 358659-368-4P 358659-369-5P
 358659-370-6P 358659-371-7P 358659-372-8P
 358659-373-9P 358659-374-0P 358659-375-1P
 358659-376-2P 358659-377-3P 358659-378-4P
 358659-379-5P 358659-380-6P 358659-381-7P
 358659-382-8P 358659-383-9P 358659-384-0P
 358659-385-1P 358659-386-2P 358659-387-3P
 358659-388-4P 358659-389-5P 358659-390-6P
 358659-391-7P 358659-392-8P 358659-393-9P
 358659-394-0P 358659-395-1P 358659-396-2P
 358659-397-3P 358659-398-4P 358659-399-5P
 358659-400-6P 358659-401-7P 358659-402-8P
 358659-403-9P 358659-404-0P 358659-405-1P
 358659-406-2P 358659-407-3P 358659-408-4P
 358659-409-5P 358659-410-6P 358659-411-7P
 358659-412-8P 358659-413-9P 358659-414-0P
 358659-415-1P 358659-416-2P 358659-417-3P
 358659-418-4P 358659-419-5P 358659-420-6P
 358659-421-7P 358659-422-8P 358659-423-9P
 358659-424-0P 358659-425-1P 358659-426-2P
 358659-427-3P 358659-428-4P 358659-429-5P
 358659-430-6P 358659-431-7P 358659-432-8P
 358659-433-9P 358659-434-0P 358659-435-1P
 358659-436-2P 358659-437-3P 358659-438-4P
 358659-439-5P 358659-440-6P 358659-441-7P
 358659-442-8P 358659-443-9P 358659-444-0P
 358659-445-1P 358659-446-2P 358659-447-3P
 358659-448-4P 358659-449-5P 358659-450-6P
 358659-451-7P 358659-452-8P 358659-453-9P
 358659-454-0P 358659-455-1P 358659-456-2P
 358659-457-3P 358659-458-4P 358659-459-5P
 358659-460-6P 358659-461-7P 358659-462-8P
 358659-463-9P 358659-464-0P 358659-465-1P
 358659-466-2P 358659-467-3P 358659-468-4P
 358659-469-5P 358659-470-6P 358659-471-7P
 358659-472-8P 358659-473-9P 358659-474-0P
 358659-475-1P 358659-476-2P 358659-477-3P
 358659-478-4P 358659-479-5P 358659-480-6P
 358659-481-7P 358659-482-8P 358659-483-9P
 358659-484-0P 358659-485-1P 358659-486-2P
 358659-487-3P 358659-488-4P 358659-489-5P
 358659-490-6P 358659-491-7P 358659-492-8P
 358659-493-9P 358659-494-0P 358659-495-1P
 358659-496-2P 358659-497-3P 358659-498-4P
 358659-499-5P 358659-500-6P 358659-501-7P
 358659-502-8P 358659-503-9P 358659-504-0P
 358659-505-1P 358659-506-2P 358659-507-3P
 358659-508-4P 358659-509-5P 358659-510-6P
 358659-511-7P 358659-512-8P 358659-513-9P
 358659-514-0P 358659-515-1P 358659-516-2P
 358659-517-3P 358659-518-4P 358659-519-5P
 358659-520-6P 358659-521-7P 358659-522-8P
 358659-523-9P 358659-524-0P 358659-525-1P
 358659-526-2P 358659-527-3P 358659-528-4P
 358659-529-5P 358659-530-6P 358659-531-7P
 358659-532-8P 358659-533-9P 358659-534-0P
 358659-535-1P 358659-536-2P 358659-537-3P
 358659-538-4P 358659-539-5P 358659-540-6P
 358659-541-7P 358659-542-8P 358659-543-9P
 358659-544-0P 358659-545-1P 358659-546-2P
 358659-547-3P 358659-548-4P 358659-549-5P
 358659-550-6P 358659-551-7P 358659-552-8P
 358659-553-9P 358659-554-0P 358659-555-1P
 358659-556-2P 358659-557-3P 358659-558-4P
 358659-559-5P 358659-560-6P 358659-561-7P
 358659-562-8P 358659-563-9P 358659-564-0P
 358659-565-1P 358659-566-2P 358659-567-3P
 358659-568-4P 358659-569-5P 358659-570-6P
 358659-571-7P 358659-572-8P 358659-573-9P
 358659-574-0P 358659-575-1P 358659-576-2P
 358659-577-3P 358659-578-4P 358659-579-5P
 358659-580-6P 358659-581-7P 358659-582-8P
 358659-583-9P 358659-584-0P 358659-585-1P
 358659-586-2P 358659-587-3P 358659-588-4P
 358659-589-5P 358659-590-6P 358659-591-7P
 358659-592-8P 358659-593-9P 358659-594-0P
 358659-595-1P 358659-596-2P 358659-597-3P
 358659-598-4P 358659-599-5P 358659-600-6P
 358659-601-7P 358659-602-8P 358659-603-9P
 358659-604-0P 358659-605-1P 358659-606-2P
 358659-607-

L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-64-0 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-65-1 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-morpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-69-5 CAPLUS
 CN Benzamide, 5-chloro N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-74-2 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-thiomorpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-75-3 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperazinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-76-4 CAPLUS

Patel


L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-66-2 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(dimethylamino)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-67-3 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-68-4 CAPLUS
 CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino(4-methyl-1-piperazinyl)methyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-77-5 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(hexahydro-1H-azepin-1-yl)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-78-6 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)




RN 358659-79-7 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)

<8/14/2004>


L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-80-0 CAPLUS
 CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 358659-81-1 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-82-2 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-5-methoxy-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-87-7 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-5-methoxy-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-88-8 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-83-3 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-84-4 CAPLUS
 CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-85-5 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




AB AQDEGUX [A = alkyl, cycloalkyl, NR1R2, NR1R1C(:NR3), (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl, etc.; R1-R3 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (alkyl)aryl, (alkyl)heteroaryl, etc.; R1R2 or R2R3 = atoms to form a 3-8 membered (substituted) (heterocyclic) ring; Q = bond, CH2, CO, O, NR7, etc.; R7 = H, alkyl, (alkyl)aryl, (alkyl)heteroaryl, etc.; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, S, SO, SO2, alkoxy, etc.; G = (substituted) alkenyl, cycloalkenyl, phenylene, heterocyclyl, fused cyclic system; J = bond, NR9CO, O, S, SO, SO2, SO2NR9, CH2, NR9, etc.; R9 = H, alkyl, (alkyl)aryl, etc.; X = (substituted) Ph, naphthyl, heteroaryl, fused bicycyl, were prepared as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl) 2-aminophenylcarboxamide (preparation given), 4-[(2-tert-butylaminosulfonyl)phenyl]benzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 85% N-(5-bromo-2-pyridinyl)-[2-4-[(2-aminosulfonyl)phenyl]phenyl]carbonylamino]phenylcarboxamide.

L3 ANSWER 25 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:565010 CAPLUS
 DN 135:137407
 TI Preparation of 2-aminonicotinamides as VEGF-receptor tyrosine kinase inhibitors
 IN Manley, Paul William; Bold, Guido
 PA Novartis A.-G., Switz.; Novartis Erfindungen Verwaltungsgesellschaft m.b.H.
 SO PCT Int. Appl., 66 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001055114	A1	20010802	WO 2001-EP835	20010125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001028499	A5	20010807	AU 2001-28499	20010125
AU 771626	B2	20040401		
BR 2001007805	A	20021022		
EP 1259487	A1	20021127	EP 2001-946854	20010125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003520853	T2	20030708		
NZ 520005	A	20040227		
NO 2002003218	A	20020916		
US 2003032656	A1	20030213		
US 6624174	B2	20030923		
ZA 2002005988	A	20030728		
OS MARPAT 135:137407				
IT 62636-33-3P 352227-86-2P 352227-92-0P 352228-00-3P				

L3 ANSWER 25 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BLOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of 2-aminonicotinamides as VEGF-receptor tyrosine kinase inhibitors)
 RN 62636-33-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 352227-86-2 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-[(methylamino)carbonyl]phenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 352227-92-0 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-(4-hydroxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 25 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 352228-00-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-(4-hydroxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; n = 1-6; W = O, S; R1, R3 = H, alkyl, acyl; R2 = (un)substituted cycloalkyl, aryl, mono- or bicyclic heteroaryl comprising one or more ring N atoms and 0-2 heteroatoms selected from O and S; R, R' = H, alkyl; X = (un)substituted aryl, mono- or bicyclic heteroaryl comprising one or more ring N atoms and 0-2 heteroatoms selected from O and S] and their pharmaceutically acceptable salts, useful for therapy of

Patel

L3 ANSWER 25 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 a disease which responds to an inhibition of the VEGF-receptor tyrosine kinase activity (such as neoplastic disease), were prepd. and formulated. Thus, amidation of 3-aminobenzotrifluoride with 2-chloronicotinoyl chloride followed by reacting 4-pyridineethanamine with the resulting carboxamide afforded I [n = 2; R, R' = H; X = 4-pyridyl; W = O; R1, R3 = H; R2 = 3-(F3C)C6H4].
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

<8/14/2004>

L3 ANSWER 26 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

AN 2001:208252 CAPLUS

DN 134:252363

TI Preparation and effect of nitrogen-containing six-membered aromatic compounds as PDE V activity inhibitors

IN Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji; Kikkawa, Kohei

PA Tanabe Seiyaku Co., Ltd., Japan

SO PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001019802	A1	20010322	WO 2000-JP6258	20000913
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000073118	A5	20010417	AU 2000-73118	20000913
AU 767558	B2	20031113		
BR 2000014526	A	20020618		
TR 200200701	T2	20020621		
EP 1219609	A1	20020703		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
RU 2231273	C2	20040727		
US 2003032647	A1	20030213		
US 6656935	B2	20031202		
ZA 2002001499	A	20020902		
NO 2002001308	A	20020424		

L3 ANSWER 26 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

BG 106566

A 20030228

US 2003229095

A1 20031211

JP 1999-261852

A 19990916

JP 2000-130371

A 20000428

WO 2000-JP6258

W 20000913

BQ 2002-106566

20020402

JP 1999-261852

A 19990916

JP 2000-130371

A 20000428

WO 2000-JP6258

W 20000913

US 2003-426884

20030501

JP 1999-261852

A 19990916

JP 2000-130371

A 20000428

WO 2000-JP6258

A1 20000913

US 2001-925892

A3 20010810

PATENT FAMILY INFORMATION:

FAN 2001:816647

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001083460	A1	20011108	WO 2001-JP2034	20010315
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001041142	A5	20011112	AU 2001-41142	20010315
EP 1277741	A1	20030122	EP 2001-912373	20010315
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 522217	A	20040430	NZ 2001-522217	20010315
US 2003229089	A1	20031211	US 2002-258545	20021025
US 2004142930	A1	20040722	US 2003-699804	20031104
FAN 2004-589247			JP 2000-130371	A 20000428
PATENT NO.	KIND <th>DATE</th> <th>APPLICATION NO.</th> <th>DATE</th>	DATE	APPLICATION NO.	DATE
PI US 2004142930	A1	20040722	US 2003-699804	20031104
JP 2000-130371	A	20000428	JP 2000-277652	A 20000913
WO 2001-JP2034	W	20010315	US 2002-258545	A2 20021025
JP 2000-277652	W	20000913	JP 2000-277652	20000913

L3 ANSWER 26 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

WO 2001083460

A1 20011108

JP 1999-261852

A 19990916

JP 2000-130371

A 20000428

WO 2001-JP2034

20010315

OS MARPAT 134:252363

IT 330785-09-6P 330785-10-9P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and effect of heteroarom. compds. as PDE V activity inhibitors)

RN 330785-09-6 CAPLUS

CN Pyrazinecarboxamide, 3-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)-5-[[[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 330785-10-9 CAPLUS

CN Pyrazinecarboxamide, 3-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-N-(trans-4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.

Patel

L3 ANSWER 26 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



AB Title compds. [I; A is an optionally substituted nitrogenous heterocyclic group; R1 is optionally substituted lower alkyl, NHQR3 (wherein R3 is an optionally substituted nitrogenous heterocyclic group; and Q is lower alkylene or a single bond), or NHRA (wherein R4 is optionally substituted cycloalkyl); R2 is optionally substituted aryl, and either of Y and Z is CH and the other is N], pharmacol. acceptable salts are prepared and are exhibiting an excellent selective inhibitory activity against PDE V and being useful as preventive or therapeutic drugs for erectile dysfunction (no data). Thus, the title compound II was prepared

<8/14/2004>


L3 ANSWER 26 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 27 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:457059 CAPLUS
DN 133:89437
TI Preparation of heteroaryl-substituted aromatic amides as factor Xa inhibitors
IN Beight, Douglas Wade; Craft, Trella Joyce; Denny, Carl Penman; Francisovich, Jeffrey Bernard; Goodson, Theodore, Jr.; Hall, Steven Edward; Herron, David Kent; Joseph, Sajjan Pariyadan; Klinkowski, Valentine
Joseph; Masters, John Joseph; Mendel, David; Milot, Guy; Pineiro-Nunez, Marta Maria; Sawyer, Jason Scott; Shuman, Robert Theodore; Smith, Gerald Floyd; Tebbe, Anne Louise; Tinsley, Jennifer Marie; Weir, Leonard Crayton;
Wikel, James Howard; Wiley, Michael Robert; Yee, Ying Kwong
PA Eli Lilly and Co., USA; Kyle, Jeffrey, Alan; et al.
SO PCT Int. Appl., 403 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000039118	A1	20000706	WO 1999-US29946	19991215
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RM: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2361149	AA	20000706	CA 1999-2361149	19991215
EP 1140903	A1	20011010	US 1998-113556P	19981223
EP 1140903	B1	20040804	CA 1999-2361149	19991215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			US 1998-113556P	19981223
JP 200253454	T2	20021008	JP 2000-591029	19991215
US 6635657	B1	20031021	US 1998-113556P	19981223
US 2004029874	A1	20040212	WO 1999-US29946	19991215
US 6759414	B2	20040706	EP 1999-964279	19991215
			US 1998-113556P	19981223
			WO 1999-US29946	19991215
			US 2001-857751	20010608
			US 1998-113556P	19981223
			WO 1999-US29946	19991215
			US 2003-629760	20030729
			US 1998-113556P	19981223
			WO 1999-US29946	19991215
			US 2001-857751	A3 20010608

OS MARPAT 133:89437
IT 280769-65-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological)

L3 ANSWER 27 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroaryl-substituted arom. amides as factor Xa inhibitors)
RN 280769 65 5 CAPLUS
CN Benzamide,
2-[[[4-(acetylamino)phenyl]methyl]amino] 5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; A3-A6, together with the two carbons to which they are attached, complete a substituted benzene in which A3 = CR3, A4 = CR4, A5 = CR5, and A6 = CR6 (wherein R1 = H, Me, MeO, etc.; one of R4 and R5 = H, alkyl, halo, etc.; the other of R4 and R5 = H; R6 = H, Me, F, etc.);

L1 = CONH; Q1 = 2-pyridinyl (un)substituted at the 5-position, 3-pyridinyl (un)substituted at the 6-position, 2-pyrimidinyl (un)substituted at the 5-position, etc.; R2 = L2Q2 (L2 = NHCO, NHCH2, OCH2, etc.; Q2 = (un)substituted piperidinyl, piperazinyl, Ph, etc.) and their pharmaceutically acceptable salts, useful as inhibitors of factor Xa (no data), were prepared and formulated. E.g., a multi-step synthesis of

II.HCl was given. In general, compds. I are effective at 0.01-1000 mg/kg/day.
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 28 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:335388 CAPLUS
DN 132:347491
TI Preparation of N acyl(thio)anthranilic acid amides as VEGF receptor tyrosine kinase inhibitors
IN Altmann, Karl-Heinz; Bold, Guido; Furet, Pascal; Manley, Paul William; Wood, Jeanette Marjorie; Ferrari, Stefano; Hofmann, Francesco; Mestian, Jurgen; Huth, Andreas; Kruger, Martin; Seidelmann, Dieter; Menrad, Andreas; Haberey, Martin; Thierauch, Karl-Heinz
PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Schering Aktiengesellschaft
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000027820	A1	20000518	WO 1999-EP8545	19991108
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RM: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2346898	AA	20000518	GB 1998-24579	A 19981110
BR 9915210	A	20010724	CA 1999-2346898	19991108
TR 200101237	T2	20010821	GB 1998-24579	A 19981110
EP 1129075	A1	20010905	BR 1999-15210	19991108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			GB 1998-24579	A 19981110
			WO 1999-EP8545	19991108
			JP 2000-581000	19991108
			GB 1998-24579	A 19981110
			WO 1999-EP8545	19991108
			AU 2000-13811	19991108
			GB 1998-24579	A 19981110
			WO 1999-EP8545	19991108
			NZ 1999-511339	19991108
			GB 1998-24579	A 19981110
			WO 1999-EP8545	19991108
			NO 2001-1894	20010417
			GB 1998-24579	A 19981110
			WO 1999-EP8545	19991108
			ZA 2001-3290	20010423
			GB 1998-24579	A 19981110
			US 2001-850434	20010507
			GB 1998-24579	A 19981110
			WO 1999-EP8545	19991108

Patel

<8/14/2004>

L3 ANSWER 28 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 ZA 2001004673 A 20020909 ZA 2001-4673 20010607
 GB 1998-24579 A 19981110
 US 2002-180289 20020626
 GB 1998-24579 A 19981110
 WO 1999-EP8478 W 19991109
 US 2001-850434 A3 20010507

PATENT FAMILY INFORMATION:

FAN 2000:335387

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000027819	A2	20000518	WO 1999-EP8478	19991109
WO 2000027819	A3	20000817		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RM: GH, GM, KE, LS, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19910396	A1	20000907	DE 1999-19910396	19990303
DE 19910396	C2	20011213	DE 1999-19910396	19990303
BR 9915553	A	20010814	BR 1999-15553	19991109
			GB 1998-24579	19981110
			DE 1999-19910396	19990303
			WO 1999-EP8478	19991109
EP 1129074	A2	20010905	EP 1999-953967	19991109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101307	T2	20020521	TR 2001 200101307	19991109
			GB 1998-24579	19981110
			DE 1999-19910396	19990303
JP 2002529452	T2	20020910	JP 2000-580999	19991109
			GB 1998-24579	19981110
			DE 1999-19910396	19990303
EE 200100258	A	20021216	EE 2001-258	19991109
			GB 1998 24579	19981110
			DE 1999-19910396	19990303
NZ 511413	A	20040130	WO 1999-EP8478	19991109
			NZ 1999-511413	19991109
			GB 1998-24579	19981110
			DE 1999-19910396	19990303
AU 771180	B2	20040318	WO 1999-EP8478	19991109
			AU 2000-10454	19991109
			GB 1998-24579	19981110
			DE 1999-19910396	19990303
NO 2001002245	A	20010710	WO 1999-EP8478	19991109
			NO 2001-2245	20010507

L3 ANSWER 28 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 prepn. of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity is claimed. Thus, a mixt. of 4 pyridinecarboxaldehyde and
 2-amino-N-(4-(trifluoromethyl)phenyl)benzamide (prepn. given) in MeOH contg.
 HOAc was treated with NaBH3CN followed by 16 h stirring to give
 2-[(4-pyridyl)methyl]amino-N-[(4-(trifluoromethyl)phenyl)benzamide].
 Tested
 1 inhibited Flt-1 VEGF receptor tyrosine kinase with IC50 = 0.18-0.56 μ M.
 RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 28 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 GB 1998-24579 A 19981110
 DE 1999-19910396 A 19990303
 WO 1999-EP8478 W 19991109
 BG 105588 A 20020430
 BG 2001-105588 20010611
 GB 1998-24579 A 19981110
 DE 1999-19910396 A 19990303
 WO 1999-EP8478 W 19991109

OS MARPAT 132:347491


IT 269390-99-0P

RL: BAC (Biological activity or effector, except adverse); BSU


(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of N-aryl(thio)anthranilic acid amides as VEGF receptor tyrosine kinase inhibitors)

RN 269390-99-0 CAPLUS

CN Benzamide, 2-[(5-quinolinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)



GI



AB Use of title compds. I; W = O, S; X = NR8; Y = CHR10(CH2)n, SO2; R9, R10 = H, alkyl; n = 0-3; R1 = aryl; R2 = mono- or bicyclic heteroaryl with the exception that R2 cannot = 2-phthalimidyl, and when Y = SO2 cannot represent 2,1,3-benzothiadiazol-4-yl; R3-R6 = H, substituent; R7, R8 = H, alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof, for the

L3 ANSWER 29 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1999:409260 CAPLUS
 DN 131:73440
 TI Preparation of aromatic amide derivatives as ACC inhibitor
 IN Igawa, Hiroshi; Nishimura, Masato; Okada, Keiji; Nakamura, Takashi
 PA Fujirebio, Inc., Japan
 SO Jpn. Kokai Tokkyo Koho, 72 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 11171848	A2	19990629	JP 1998-270721	19980925
			JP 1997-277942	19970926

OS MARPAT 131:73440


IT 228580-72-1P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation of aromatic amide derivs. as ACC inhibitor)

RN 228580-72-1 CAPLUS

CN Benzoic acid, 2-[[4-(phenylethynyl)-2-[(phenylmethyl)aminobenzoyl]amino]- (9CI) (CA INDEX NAME)




IT 228580-60-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of aromatic amide derivs. as ACC inhibitor)

RN 228580-60-7 CAPLUS

CN Benzoic acid, 2-[[2-[(phenylmethyl)aminobenzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




IT 228580-61-8P


RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of aromatic amide derivs. as ACC inhibitor)

<8/14/2004>

L3 ANSWER 29 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 228580-61-8 CAPLUS
 CN Benzoic acid, 2-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)



GI



AB Title compds. [I; R = 3-CP3C6H4, C6H5(CH2)2, C6H5, CH3(CH2)5, CH3(CH2)3, CH3(CH2)2, CH3CH2, CH3, C6H5(CH2)3, etc.; R1 = H, CH3(CH2)4, 5-CH3(CH2)5CC, 5-CH3CH2CC, 5-(CH3)3CCC, 4-C6H5CH2O, 4-C6H5CC, 3-C6H5CC, 3-C6H5CC, 3 (4-NO2C6H4)CC, 3-(4-MCC6H4)CC, 3-(4-HOC6H4)CC, etc.; R2 = 5-OH, 5-Cl, 5-OMe, 5-Me, 5-Br, etc.; R3 = H, CH3, etc.; R4 = CO2H, AcNHCO2, CH3(CH2)4CONHCO2, 4-CP3C6H4CONHCO2, PhCONHCO2, (CH3)3CONHCO2, CH3(CH2)2NHCONHCO2, etc.; X = CH, N; dotted bond = single, double] are prepared and tested as ACC (acetyl-CoA carboxylase) inhibitors in treatment of lipids oxidation related diseases, such as myocardial infarction, cerebral infarction, and diabetes. The title compound I (R = 3-CP3C6H4; R1 = H; R2 = H; R3 = H; X = CH; dotted bonds were double bonds) was prepared with 72% yield from 3-EtO2CC6H4NH2 and 3-(2-HO2CC6H4NH)C6H4CF3.

L3 ANSWER 30 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 IL 116917 A1 20000831 IL 1996-116917 A 19960126
 US 1995-391901 A 19950221
 US 1995-472067 A 19950606
 TW 486469 B 20020511 TW 1996-85100978 A 19960126
 US 1995-391901 A 19950221
 US 1995-472067 A 19950606
 CA 2213466 AA 19960829 CA 1996-2213466 A 19960201
 US 1995-391901 A 19950221
 US 1995-472067 A 19950606
 WO 9626205 A1 19960829 WO 1996-US824 A 19960201
 W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA
 RM: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 AU 9647631 A1 19960911 AU 1996-47631 A 19960201
 AU 699865 B2 19981217 US 1995-391901 A 19950221
 US 1995-472067 A 19950606
 WO 1996-US824 W 19960201
 CN 1176640 A 19980318 CN 1996-192015 A 19960201
 CN 1108301 B 20030514 US 1995-391901 A 19950221
 US 1995-472067 A 19950606
 EP 886637 A1 19981230 EP 1996-903604 A 19960201
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, NL, SE, MC, PT, IE
 US 1995-391901 A 19950221
 US 1995-472067 A 19950606
 WO 1996-US824 W 19960201
 JP 11500442 T2 19990112 JP 1996-525679 A 19960201
 US 1995-391901 A 19950221
 US 1995-472067 A 19950606
 WO 1996-US824 W 19960201
 NZ 302055 A 20000228 NZ 1996-302055 A 19960201
 US 1995-391901 A 19950221
 US 1995-472067 A 19950606
 WO 1996-US824 W 19960201
 PL 185443 B1 20030530 PL 1996-122003 A 19960201
 US 1995-391901 A 19950221
 US 1995-472067 A 19950606
 WO 1996-US824 W 19960201
 ZA 9601340 A 19970911 ZA 1996-1340 A 19960220
 US 1995-391901 A 19950221
 US 1997-896872 A 19970721
 US 1993-117362 A2 19930903
 US 1994-284808 B2 19940805
 US 1995-391901 B2 19950221
 US 1995-472067 A3 19950606
 US 1997-898304 A 19970721
 US 1993-117362 A2 19930903
 US 1994-284808 B2 19940805
 US 1995-391901 B2 19950221
 US 1995-472067 A1 19950606
 US 6066650 A 20000523 US 1997-898303 A 19970721
 US 1993-117362 A2 19930903
 US 1994-284808 B2 19940805
 US 1995-391901 B2 19950221
 US 1995-472067 A1 19950606

L3 ANSWER 30 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 AN 1998:236274 CAPLUS
 DN 128:282780
 TI Preparation of heterocyclic inhibitors of microsomal triglyceride transfer protein
 IN Biller, Scott A.; Dickson, John K.; Lawrence, R. Michael; Magnin, David R.; Posa, Michael A.; Suleky, Richard B.; Tino, Joseph A.
 PA Bristol Myers Squibb Co., USA
 SO U.S., 185 pp., Cont.-in-part of U.S. Ser. No. 391,901, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5739135	A	19980414	US 1995-472067	A 19950606
			US 1993-117362	A2 19930903
			US 1994-284808	B2 19940805
			US 1995-391901	B2 19950221
CA 2091102	AA	19930907	CA 1993-2091102	A 19930305
HU 67962	A2	19950529	US 1992-847503	A 19920306
HU 218419	B	20000828	HU 1993-627	19930305
JP 06038761	A2	19940215	US 1992-847503	A 19920306
			JP 1993-46499	19930308
EP 584446	A2	19940302	US 1992-847503	A 19920306
EP 584446	A3	19950426	EP 1993-103697	19930308
EP 584446	B1	20020619		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 219514	E	20020715	US 1992-847503	A 19920306
			AT 1993-103697	19930308
			US 1992-847503	A 19920306
PT 584446	T	20020930	PT 1993-103697	19930308
			US 1992-847503	A 19920306
ES 2178640	T3	20030101	ES 1993-103697	19930308
			US 1992-847503	A 19920306
AU 670930	B2	19960808	AU 1993-34064	19930309
AU 9334064	A1	19930909		
US 5595872	A	19970121	US 1992-847503	A 19920306
			US 1993-117362	19930903
			US 1992-847503	B2 19920306
			US 1993-15449	B2 19930222
US 5789197	A	19980804	US 1995-486924	19950607
			US 1992-847503	B2 19920306
			US 1993-15449	B2 19930222
			US 1993-117362	A3 19930903
US 6492365	B1	20021210	US 1995-486929	19950607
			US 1992-847503	B2 19920306
			US 1993-15449	B2 19930222
			US 1993-117362	A3 19930903
US 5712279	A	19980127	US 1996-548811	19960111
			US 1995-391901	B2 19950221
			US 1995-472067	A2 19950606


PATENT FAMILY INFORMATION:
 FAN 1995:568500
 PATENT NO.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 643057	A1	19950315	EP 1994-113800	19940902
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2091102	AA	19930907	US 1993-117362	A 19930903
			CA 1993-2091102	A 19930305
ZA 9301601	A	19931005	US 1992-847503	A 19920306
			ZA 1993-1601	A 19930305
HU 67962	A2	19950529	US 1993-117362	A 19930903
HU 218419	B	20000828	HU 1993-627	19930305
JP 06038761	A2	19940215	US 1992-847503	A 19920306
			JP 1993-46499	19930308
EP 584446	A2	19940302	US 1992-847503	A 19920306
EP 584446	A3	19950426	EP 1993-103697	19930308
EP 584446	B1	20020619		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 219514	E	20020715	US 1992-847503	A 19920306
			AT 1993-103697	19930308
PT 584446	T	20020930	PT 1993-103697	19930308
			US 1992-847503	A 19920306
ES 2178640	T3	20030101	ES 1993-103697	19930308
			US 1992-847503	A 19920306
AU 670930	B2	19960808	AU 1993-34064	19930309
AU 9334064	A1	19930909		
US 5595872	A	19970121	US 1992-847503	A 19920306
			US 1993-117362	19930903
			US 1992-847503	B2 19920306
			US 1993-15449	B2 19930222
CA 2131430	AA	19950304	CA 1994-2131430	19940902
			US 1993-117362	A 19930903
FI 9404048	A	19950304	FI 1994-4048	19940902
			US 1993-117362	A 19930903
NO 9403260	A	19950306	NO 1994-3260	19940902
			US 1993-117362	A 19930903

L3 ANSWER 30 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

ANSWER	30 OF 49	CAPLUS	COPYRIGHT 2004	ACS on STN	(Continued)
AU 9471642	A1	19950316	AU 1994-71642	19940902	
AU 690125	B2	19980423			
ZA 9406772	A	19950403	US 1993-117362	A 19930903	
JP 07165712	A2	19950627	JP 1994-210057	19940902	
CN 1106003	A	19950802	CN 1994-115640	19940902	
HU 70613	A2	19951030	HU 1994-2542	19940902	
US 5789197	A	19980804	US 1993-117362	A 19930903	
			US 1995-486924	19950607	
			US 1992-847503	B2 19920306	
			US 1993-15449	B2 19930222	
			US 1993-117362	A3 19930903	
			US 1995-486929	19950607	
			US 1992-847503	B2 19920306	
			US 1993-15449	B2 19930222	
			US 1993-117362	A3 19930903	
			US 2001-933593	20010821	
			US 1992-847503	B2 19920306	
			US 1993-15449	B2 19930222	
			US 1993-117362	A3 19930903	
			US 1995-486929	A3 19950607	
FAN 1996:641305					
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI WO 9626205	A1	19960829	WO 1996-US824	19960201	
W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
CA 2091102	AA	19930907	US 1995-391901	A 19950221	
HU 67962	A2	19950529	US 1995-472067	A 19950606	
HU 218419	B	20000828	CA 1993-2091102	19930305	
JP 06038761	A2	19940215	US 1992-847503	A 19920306	
EP 584446	A2	19940302	HU 1993-627	19930305	
EP 584446	A3	19950426	US 1992-847503	A 19920306	
EP 584446	B1	20020619	EP 1993-103697	19930308	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
AT 219514	E	20020715	US 1992-847503	A 19920306	
PT 584446	T	20020930	AT 1993-103697	A 19930308	
ES 2178640	T3	20030101	US 1992-847503	A 19920306	
AU 670930	B2	19960808	PT 1993-103697	19930308	
AU 9334064	A1	19930909	US 1992-847503	A 19920306	
US 5739135	A	19980414	ES 1993-103697	19930308	
ZA 9601340	A	19970911	US 1992-847503	A 19920306	
LT 4367	B	19980825	AU 1993-34064	19930309	
OS MARPAT 128:282780			US 1992-847503	A 19920306	
IT 182429-79-4P					
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of heterocyclic inhibitors of microsomal triglyceride transfer protein)					
RN 182429-79-4 CAPLUS					
CN 9H Fluorene-9-carboxamide, 9-[4-{4-[(2-[(phenylmethyl)amino]benzoyl)amino]-1-piperidinyl]butyl}-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)]					


PAGE 1-A



L3 ANSWER 30 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

ANSWER	30 OF 49	CAPLUS	COPYRIGHT 2004	ACS on STN	(Continued)
US 5739135	A	19980414	US 1995-472067	19950606	
			US 1993-117362	A2 19930903	
			US 1994-284808	B2 19940805	
			US 1995-391901	B2 19950221	
AU 9647631	A1	19960911	AU 1996-47631	19960201	
AU 699865	B2	19981217			
EP 886637	A1	19981230	EP 1996-903604	19960201	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
JP 11500442	T2	19990112	US 1995-391901	A 19950221	
			US 1995-472067	A 19950606	
			WO 1996-US824	W 19960201	
			JP 1996-525679	19960201	
			US 1995-391901	A 19950221	
			US 1995-472067	A 19950606	
			WO 1996-US824	W 19960201	
NZ 302055	A	20000228	NZ 1996-302055	19960201	
			US 1995-391901	A 19950221	
			US 1995-472067	A 19950606	
			WO 1996-US824	W 19960201	
PL 185443	B1	20030530	PL 1996-322003	19960201	
			US 1995-391901	A 19950221	
			US 1995-472067	A 19950606	
			WO 1996-US824	W 19960201	
ZA 9601340	A	19970911	ZA 1996-1340	19960201	
FI 9703416	A	19970820	US 1995-391901	A 19950221	
			FI 1997-3416	19970820	
			US 1995-391901	A 19950221	
			US 1995-472067	A 19950606	
			WO 1996-US824	W 19960201	
			NO 1997-3821	19970820	
			US 1995-391901	A 19950221	
			US 1995-472067	A 19950606	
			WO 1996-US824	W 19960201	
LT 4367	B	19980825	LT 1997-152	19970919	
			US 1995-391901	A 19950221	
FAN 1998:115356					
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI US 5712279	A	19980127	US 1996-548811	19960111	
			US 1995-391901	B2 19950221	
			US 1995-472067	A2 19950606	
			CA 1993-2091102	19930305	
			US 1992-847503	A 19920306	
CA 2091102	AA	19930907	HU 1993-627	19930305	
HU 67962	A2	19950529	US 1992-847503	A 19920306	
HU 218419	B	20000828	EP 1993-103697	19930308	
JP 06038761	A2	19940215	US 1992-847503	A 19920306	
EP 584446	A2	19940302	EP 1993-103697	19930308	
EP 584446	A3	19950426			
EP 584446	B1	20020619			

PAGE 2-A



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I-V; Q = C(O), S(O)2; X = CHR8, C(O), CHR9CHR10, CR9:CR10 (wherein R8-R10 = H, alkyl, alkenyl, etc.); Y = (CH2)m, C(O) (m = 2-3); R1 = alkyl, alkenyl, alkynyl, etc.; R2-R4 = H, halo, alkyl, etc.; R5 = alkyl, alkenyl, alkynyl, etc.; R6 = H, Cl-4 alkyl, Cl-4 alkenyl] which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases such as hyperglycemia and obesity, were prepared. Thus, reaction of 1-(3,3-diphenylpropyl)-4-piperidinamine.HCl (preparation described) with benzoyl chloride in the presence of Et3N in CH2Cl2 afforded 84% the title compound III.HCl [Q = C(O); R1 = 3,3-diphenylpropyl; R5 = Ph; R6 = H]. Compds. I-V are effective at 5-500 mg/day.

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1996:641305 CAPLUS
 DN 125:275663
 TI Preparation of 9-(piperidinoalkyl)fluorene-9-carboxamides and analogs as
 microtubule triglyceride transfer protein inhibitors
 IN Wettstein, John R. II; Sharp, Daru Youns; Gregg, Richard E.; Biller, Scott
 A.; Dickson, John A.; Lawrence, R. Michael; Magnin, David R.; Poss,
 Michael A.; Robl, Jeffrey A.; et al.
 PA Bristol-Myers Squibb Company, USA
 SO PCT Int. Appl., 427 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9626205	A1	19960829	WO 1996-US824	19960201
W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2091102	AA	19930907	CA 1993-2091102	19930305
HU 67962	A2	19950529	HU 1993-627	19930305
HU 218419	B	20000828		
JP 06038761	A2	19940215	JP 1993-46499	19930308
EP 584446	A2	19940302	EP 1993-103697	19930308
EP 584446	A3	19950426		
EP 584446	B1	20020619		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 219514	E	20020715	AT 1993-103697	19930308
PT 584446	T	20020930	PT 1993-103697	19930308
ES 2178640	T3	20030101	ES 1993-103697	19930308
AU 670930	B2	19960808	AU 1993-34064	19930309
AU 9334064	A1	19930909		
US 5739135	A	19980414	US 1992-847503	19920306
			US 1995-472067	19950606
			US 1993-117362	19930308
			US 1994-284808	19940805
			US 1995-391901	19950221
			AU 1996-47631	19960201
AU 9647631	A1	19960911		
AU 699865	B2	19981217		
EP 886637	A1	19981230	EP 1996-903604	19960201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				

L3 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 US 1995-391901 A 19950221
 US 1995-472067 A 19950606
 WO 1996-US824 W 19960201
 JP 1996-525679 A 19960201
 US 1995-391901 A 19950221
 US 1995-472067 A 19950606
 WO 1996-US824 W 19960201
 NZ 1996-302055 A 19950221
 US 1995-391901 A 19950606
 US 1995-472067 W 19960201
 WO 1996-US824 A 19950221
 PL 185443 B1 20030530 PL 1996-322003 19960201
 US 1995-391901 A 19950221
 US 1995-472067 A 19950606
 WO 1996-US824 W 19960201
 ZA 9601340 A 19970911 ZA 1996-1340 19960220
 FI 9703416 A 19970820 FI 1997-3416 19970820
 US 1995-391901 A 19950221
 US 1995-472067 A 19950606
 WO 1996-US824 W 19960201
 NO 1997-3821 A 19970820
 US 1995-391901 A 19950221
 US 1995-472067 A 19950606
 WO 1996-US824 W 19960201
 LT 4367 B 19980825 LT 1997-152 19970919
 US 1995-391901 A 19950221

PATENT FAMILY INFORMATION:
 FAN 1995:568500

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 643057	A1	19950315	EP 1994-113800	19940902
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2091102	AA	19930907	CA 1993-2091102	19930305
ZA 9301601	A	19931005	ZA 1993-1601	19930305
HU 67962	A2	19950529	HU 1993-627	19930305
HU 218419	B	20000828		
JP 06038761	A2	19940215	JP 1993-46499	19930308
EP 584446	A2	19940302	EP 1993-103697	19930308
EP 584446	A3	19950426		
EP 584446	B1	20020619		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 219514	E	20020715	AT 1993-103697	19930308
PT 584446	T	20020930	PT 1993-103697	19930308
ES 2178640	T3	20030101	ES 1993-103697	19930308

L3 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 AU 670930 B2 19960808 US 1992-847503 A 19920306
 AU 9334064 A1 19930909 US 1993-34064 19930309
 US 5595872 A 19970121 US 1992-847503 A 19920306
 US 1993-117362 19930903
 US 1992-847503 B2 19920306
 US 1993-15449 B2 19920306
 CA 2131430 AA 19950304 CA 1994-2131430 19940902
 FI 9404048 A 19950304 FI 1994-4048 19940902
 NO 9403260 A 19950306 US 1993-117362 A 19930903
 NO 1994-3260 19940902
 AU 9471642 A1 19950316 US 1993-117362 A 19930903
 AU 690125 B2 19980423 AU 1994-71642 19940902
 ZA 9406772 A 19950403 ZA 1994-6772 19940902
 JP 07165712 A2 19950627 JP 1994-210057 19940902
 CN 1106003 A 19950802 CN 1994-115640 19940902
 HU 70613 A2 19951030 US 1993-117362 A 19930903
 HU 1994-2542 19940902
 US 5789197 A 19980804 US 1993-117362 A 19930903
 US 1995-486924 19950607
 US 1992-847503 B2 19920306
 US 1993-15449 B2 19920306
 US 1993-117362 A3 19930903
 US 1995-486929 19950607
 US 1992-847503 B2 19920306
 US 1993-15449 B2 19920306
 US 1993-117362 A3 19930903
 US 2001-933593 20010821
 US 1992-847503 B2 19920306
 US 1993-117362 B2 19920306
 US 1993-117362 A3 19930903
 US 1995-486929 A3 19950607

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5712279	A	19980127	US 1996-548811	19960111
			US 1995-391901 B2 19950221	
			US 1995-472067 A2 19950606	
CA 2091102	AA	19930907	CA 1993-2091102	19930305
HU 67962	A2	19950529	HU 1993-627	19930305
HU 218419	B	20000828		
JP 06038761	A2	19940215	JP 1993-46499	19930308
EP 584446	A2	19940302	EP 1993-103697	19930308
EP 584446	A3	19950426		
EP 584446	B1	20020619		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 219514	E	20020715	AT 1993-103697	19930308
PT 584446	T	20020930	PT 1993-103697	19930308

L3 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 ES 2178640 T3 20030101 US 1992-847503 A 19920306
 ES 1993-103697 19930308
 AU 670930 B2 19960808 US 1992-847503 A 19920306
 AU 9334064 A1 19930909 AU 1993-34064 19930309
 US 5739135 A 19980414 US 1992-847503 A 19920306
 US 1995-472067 19950606
 US 1993-117362 A2 19930903
 US 1994-284808 B2 19940805
 US 1995-391901 B2 19950221
 ZA 9601340 A 19970911 ZA 1996-1340 19960220
 LT 4367 B 19980825 LT 1997-152 19970919
 US 1995-391901 A 19950221

FAN 1998:236274

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5739135	A	19980414	US 1995-472067	19950606
			US 1993-117362 A2 19930903	
			US 1994-284808 B2 19940805	
			US 1995-391901 B2 19950221	
CA 2091102	AA	19930907	CA 1993-2091102	19930305
HU 67962	A2	19950529	HU 1993-627	19930305
HU 218419	B	20000828		
JP 06038761	A2	19940215	JP 1993-46499	19930308
EP 584446	A2	19940302	EP 1992-847503	19920306
EP 584446	A3	19950426		
EP 584446	B1	20020619		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 219514	E	20020715	AT 1992-847503	19920306
PT 584446	T	20020930	AT 1993-103697	19930308
ES 2178640	T3	20030101	US 1992-847503	19920306
AU 670930	B2	19960808	AU 1993-34064	19930309
AU 9334064	A1	19930909		
US 5595872	A	19970121	US 1992-847503	19920306
			US 1993-117362 19930903	
			US 1992-847503 B2 19920306	
			US 1993-15449 B2 19930222	
US 5789197	A	19980804	US 1995-486924	19950607
			US 1992-847503 B2 19920306	
			US 1993-15449 B2 19930222	
			US 1993-117362 A3 19930903	
US 6492365	B1	20021210	US 1995-486929	19950607
			US 1992-847503 B2 19920306	
			US 1993-15449 B2 19930222	
			US 1993-117362 A3 19930903	
US 5712279	A	19980127	US 1996-548811	19960111
			US 1995-391901 B2 19950221	
			US 1995-472067 A2 19950606	
IL 116917	A1	20000831	IL 1995-116917	19950606
			US 1995-391901 A 19950221	

L3 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

TW 486469 B 20020511 US 1995-472067 A 19950606
TW 1996-85100978 19960126
US 1995-391901 A 19950221
US 1995-472067 A 19950606
CA 2213466 AA 19960829 CA 1996-2213466 19960201
US 1995-391901 A 19950221
US 1995-472067 A 19950606
WO 9626205 A1 19960829 WO 1996-US824 19960201
W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ,
PL, RO, RU, SG, SK, UA
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
US 1995-391901 A 19950221
US 1995-472067 A 19950606
AU 9647631 A1 19960911 AU 1996-47631 19960201
AU 699865 B2 19981217
US 1995-391901 A 19950221
US 1995-472067 A 19950606
WO 1996-US824 W 19960201
CN 1176640 A 19980318 CN 1996-192015 19960201
CN 1108301 B 20030514
US 1995-391901 A 19950221
US 1995-472067 A 19950606
EP 886637 A1 19981230 EP 1996-903604 19960201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE

US 1995-391901 A 19950221
US 1995-472067 A 19950606
WO 1996-US824 W 19960201
JP 11500442 T2 19990112 JP 1996-525679 19960201
US 1995-391901 A 19950221
US 1995-472067 A 19950606
WO 1996-US824 W 19960201
NZ 302055 A 20000228 NZ 1996-302055 19960201
US 1995-391901 A 19950221
US 1995-472067 A 19950606
WO 1996-US824 W 19960201
PL 185443 B1 20030530 PL 1996-322003 19960201
US 1995-391901 A 19950221
US 1995-472067 A 19950606
WO 1996-US824 W 19960201
ZA 9601340 A 19970911 ZA 1996-1340 19960220
US 1995-391901 A 19950221
US 1997-896872 19970721
US 1993-117362 A2 19930903
US 1994-284808 B2 19940805
US 1995-391901 B2 19950221
US 1995-472067 A3 19950606
US 1997-898303 19970721
US 1993-117362 A2 19930903
US 1994-284808 B2 19940805


L3 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

US 1995-391901 B2 19950221
US 1995-472067 A1 19950606
FI 9703416 A 19970820 FI 1997-3416 19970820
US 1995-391901 A 19950221
US 1995-472067 A 19950606
WO 1996-US824 W 19960201
NO 9703821 A 19970820 NO 1997-3821 19970820
US 1995-391901 A 19950221
US 1995-472067 A 19950606
WO 1996-US824 W 19960201
LT 4367 B 19980825 LT 1997-152 19970919
US 1995-391901 A 19950221
LV 11951 B 19981120 LV 1997-171 19970919
US 1995-391901 A 19950221
US 1995-472067 A 19950606
US 2001-933593 20010821
US 1992-847503 B2 19920306
US 1993-15449 B2 19930222
US 1993-117362 A3 19930903
US 1995-486929 A3 19950607


OS MARPAT 125:275663
IT 182429-79-4P 182433-96-1P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 9 (piperidinoalkyl)fluorene-9-carboxamides and
analogues as microsomal triglyceride transfer protein inhibitors)
RN 182429-79-4 CAPLUS
CN 9H-Fluorene-9-carboxamide,
9-[4-[[2-[(phenylmethyl)amino]benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 182433-96-1 CAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[[1-oxido-4-[[2-[(phenylmethyl)amino]benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




GI

L3 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)





AB RSZ3NRR6 [R = piperidyl group Q1; RS = alkyl, alkoxy, (hetero)aryl, etc.; R6 = H, alk(enyl), R5R6 = atoms to form a benzannellated ring; Z3 = CO or SO2; 1 of Z4,Z5 = NR1 and the other = CH2; R1 = e.g., (un)substituted aryl group Q2; R12 = H, (halo)alkyl, heteroaryl, etc.; Z = bond, O, S, alkylimino, etc.; Z1,Z2 = bond, O, SOO-2, CO, etc.; Z11 = bond, alkylene, arylene, etc.] were prepared as microsomal triglyceride transfer protein inhibitors (no data). Thus, N-propyl-9-fluorene-carboxamide (preparation given) was alkylated by I(CH2)4OSiMe2CMe3 (preparation given) and the deprotected and iodinated product aminated by 2-(4-piperidinyl)-2,3-dihydro-1H-isoindol-1-one (preparation given) to give title compound I.

L3 ANSWER 32 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1992:571361 CAPLUS
 DN 117:171361
 TI Synthesis of biologically active 4(3H)-quinazolinonium perchlorates
 AU Chernobrovina, N. I.; Kozhevnikov, Yu. V.; Morozova, G. E.; Chernobrovina, T. A.
 CS Perm. Pharm. Inst., Perm, Russia
 SO Khimiko-Farmatsevticheskii Zhurnal (1992), 26(3), 48-51
 CODEN: KHFZAN; ISSN: 0023-1134
 DT Journal
 LA Russian
 IT 139602-64-5P 139602-66-7P 139602-67-8P
 139602-68-9P 139602-69-0P 139602-71-4P
 139602-72-5P 139602-73-6P 143424-22-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and acetylation of)
 RN 139602-64-5 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-phenyl]- (9CI) (CA INDEX NAME)




RN 139602-66-7 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 139602-67-8 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 32 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 139602-68-9 CAPLUS
 CN Benzamide, N-(4-chlorophenyl)-2-[[[(2,4-dimethoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 139602-69-0 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-phenyl]- (9CI) (CA INDEX NAME)




RN 139602-71-4 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




L3 ANSWER 32 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 139602-72-5 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 139602-73-6 CAPLUS
 CN Benzamide, N-(4-chlorophenyl)-2-[[[(3,4-dimethoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 143424-22-0 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 32 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




AB Title salts I (R = H, 3-Me, 4-Me, 4-MeO, 4-Cl; R1 = OMe, R2 = H; R1 = H, R2 = OMe) were prepared by condensation of anthranililides with dimethoxybenzaldehydes, followed by borohydride reduction of the imine group, N-acetylation, and acid cyclization. The acute toxicity and anticonvulsant, analgesic, and antimicrobial activities of some I were tested.

L3 ANSWER 33 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN


AN 1992:128388 CAPLUS
 DN 116:128388
 TI Arylamides of N-(p-2',4'- or -3',4'-dimethoxybenzyl)anthranilic acid
 IN Chernobrovin, N. I.; Kozhevnikov, Yu. V.; Zalesov, V. S.; Semenova, Z. N.
 PA Perm Pharmaceutical Institute, USSR
 SO U.S.S.R.
 From: Otkrytiya, Izobret. 1991, (28), 258.
 CODEN: URXXAF
 DT Patent
 LA Russian
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI SU 1156362	A1	19910730	SU 1983-3573020	19830217
IT 139602-64-5			SU 1983-3573020	19830217
139602-65-6				
139602-66-7				
139602-67-8				
139602-68-9				
139602-69-0				
139602-70-3				
139602-71-4				
139602-72-5				
139602-73-6				

RL: RCT (Reactant); RACT (Reactant or reagent)
 (intermediate for quinazolinonium perchlorate derivs.)
 RN 139602-64-5 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 139602-65-6 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 139602-66-7 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 33 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139602-67-8 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 139602-68-9 CAPLUS
 CN Benzamide, N-(4-chlorophenyl)-2-[[[(2,4-dimethoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 139602-69-0 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)


L3 ANSWER 33 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139602-70-3 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)





RN 139602-71-4 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 139602-72-5 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 34 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 US 5620974 A 19970415 US 1990-600390 B2 19901019
 US 1991-740828 B1 19910805
 US 1994-279464 19940722
 US 1989-340970 B2 19890420
 US 1989-372974 B2 19890628
 US 1989-438923 B2 19891117
 US 1990-579001 B2 19900906
 US 1990-600390 B2 19901019
 US 1991-740828 B1 19910805
 US 1993-91418 A3 19930713

OS MARPAT 115:114559
 IT 132312-45-99 132362-76-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction of, in preparation of antiviral
 dihydrodipyrrodozepines)
 RN 132312-45-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[4-(
 methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 132362-76-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[phenylmethyl]amino]-
 (9CI) (CA INDEX NAME)




GI

L3 ANSWER 35 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1991-449732 CAPLUS
 DN 115:49732
 TI Preparation of
 5,11-dihydro-6H-dipyrrodo[3,2-b:2',3'-e][1,4]diazepin-6-ones
 and thionas and their use in the prevention or treatment of AIDS
 IN Schmidt, Guenther; Engel, Wolfhard; Trummlitz, Guenter; Eberlein,
 Wolfgang; Hargrave, Karl D.
 PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Thomae, Dr. Karl,
 G.m.b.H.
 SO Eur. Pat. Appl., 20 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 410148	A1	19910130	EP 1990-112072	19900626
EP 410148	B1	19940406		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2019812	AA	19901228	CA 1990-2019812	19900626
CA 2019812	C	20001121		
DD 295849	A5	19911114	US 1989-372974	A 19890628
AT 103918	E	19940415	US 1989-372974	A 19890628
ES 2063202	T3	19950101	DD 1990-342100	19900626
NO 9002851	A	19910102	US 1989-372974	A 19890628
NO 174468	B	19940131	AT 1990-112072	19900626
NO 174468	C	19940518	EP 1990-112072	A 19900626
HU 55017	A2	19910429	ES 1990-112072	19900626
HU 206504	B	19921130	US 1989-372974	A 19890628
JP 03115283	A2	19910516	NO 1990-2851	19900627
JP 2911967	B2	19990628	US 1989-372974	A 19890628
ZA 9004991	A	19920325	HU 1990-4021	19900627
FI 92828	B	19940930	US 1989-372974	A 19890628
FI 92828	C	19950110	JP 1990-169663	19900627
IL 94883	A1	19941007	US 1989-372974	A 19890628
AU 9057921	A1	19910103	ZA 1990-4991	A 19890628
AU 620724	B2	19920220	US 1989-372974	A 19890628
RU 2024522	C1	19941215	FI 1990-1225	19900627
US 5366972	A	19941122	US 1989-372974	A 19890628
			RU 1992-5011432	19920427
			US 1989-372974	A 19890628
			US 1991-91418	19930713
			US 1989-340970	B2 19890420
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1993-91418	A3 19930713

Patel

L3 ANSWER 34 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB Title compds. I (Z = O, S, :NCN, :NOR9; R1-R8 = various subsets of groups
 selected from H, alkyl, cycloalkyl, fluoroalkyl, aryl, tetrahydrofuryl,
 alkanoyl, trihalomethyl, alkoxycarbonyl, halo, amino, and many more; R9 =
 Cl-3 alkyl; numerous provisions and exceptions) were prepared for
 prevention
 and treatment of HIV-1 infection. For example, 2-hydroxy-4-methyl-3-
 nitropyridine was converted by chlorination with POCl3 and reduction to
 3-amino-2-chloro-4-methylpyridine, which underwent amidation with
 2-chloronicotinoyl chloride and condensation with EtNH2 to give
 (chloromethylpyridinyl)(ethylamino)pyridinecarboxamide II. Cyclization
 of
 II by NaH in DMF at reflux temperature gave I (Z = O, R1 = R3 = R4 =
 R6-R8 = H.
 R2 = Et, R5 = Me) (III). At 3 µg/mL, III gave 100% inhibition of HIV-1
 replication in a human T-cell culture assay. III also gave 100%
 inhibition of HIV-1 reverse transcriptase at 10 µg/mL in vitro; no
 activity was seen for I against 2 related enzymes, indicating high
 specificity. Three formulations, 77 synthetic examples, and addnl. test
 results including cytotoxicity are given.

L3 ANSWER 35 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

US 5620974 A 19970415 US 1994-279464 19940722
 US 1989-340970 B2 19890420
 US 1989-372974 B2 19890628
 US 1989-438923 B2 19891117
 US 1990-579001 B2 19900906
 US 1990-600390 B2 19901019
 US 1991-740828 B1 19910805
 US 1993-91418 A3 19930713

PATENT FAMILY INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 393529	A1	19901024	EP 1990-107098	19900412
EP 393529	B1	19930630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 91128	E	19930715	US 1989-340970	A 19890420
ES 2058656	T3	19941101	AT 1990-107098	A 19900412
CA 2014771	AA	19901020	US 1989-340970	A 19890420
CA 2014771	C	20000801	EP 1990-107098	A 19900412
JP 03063276	A2	19910319	ES 1990-107098	A 19900412
JP 2851913	B2	19990127	US 1989-340970	A 19890420
US 5366972	A	19941122	CA 1990-2014771	19900418
			US 1989-340970	A 19890420
			US 1993-91418	19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1993-91418	A3 19930713
US 5620974	A	19970415	US 1994-279464	19940722
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1993-91418	A3 19930713
FAN 1991-514559				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 429987	A2	19910605	EP 1990-121954	19901116
EP 429987	A3	19920122		
EP 429987	B1	19990317		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2030056	AA	19910518	US 1989-438923	A 19891117
CA 2030056	C	19951017	US 1990-579001	A 19900906
			US 1990-600390	A 19901019
			CA 1990-2030056	19901115
FI 9005674	A	19910518	US 1989-438923	A 19891117
FI 94529	B	19950615	US 1990-579001	A 19900906
FI 94529	C	19950925	FI 1990-5674	19901116

<8/14/2004>


L3	ANSWER 35 OF 49	CAPLUS	COPYRIGHT 2004 ACS on STN	(Continued)
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
			NO 1990-4986	19901116
NO 9004986	A	19910521		
NO 175478	B	19940711		
NO 175478	C	19941019		
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
			HU 1990-7186	19901116
HU 56103	A2	19910729		
HU 208139	B	19930830		
			US 1989-438923	A 19891117
JP 04178386	A2	19920625		
JP 2912007	B2	19930628		
			US 1989-438923	A 19891117
IL 96367	A1	19970218		
			IL 1990-96367	19901116
			US 1989-438923	A 19891117
			IL 1990-94883	A0 19900627
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
AT 177744	E	19990415		
			AT 1990-121954	19901116
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
ES 2130114	T3	19990701		
			ES 1990-121954	19901116
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
AU 9066732	A1	19910523		
AU 630251	B2	19921022		
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
ZA 9009246	A	19920729		
			ZA 1990-9246	19901119
JP 04257584	A2	19920911		
JP 2539116	B2	19961002		
			US 1989-438923	A 19891117
			JP 1991-211068	19910822
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
HU 59407	A2	19920528		
HU 214595	B	19980428		
			HU 1991-2865	19910904
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
RU 2040527	C1	19950725		
			RU 1992-5011559	19920506
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
US 5366972	A	19941122		
			US 1993-91418	19930713
			US 1989-140970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
US 5620974	A	19970415		
			US 1991-740828	B1 19910805
			US 1994-279464	19940722

L3 ANSWER 35 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 etc.; R2 = H, (substituted) alkyl, alkenyl, etc.; R3-R8 = H, or 1 of
 R3-R8
 is alkyl, alkoxy, alkylthio, etc., and the remaining 5 of R3-R8 are each
 H, or R3-R5 are H, alkyl with the proviso that at least one is H or 1 of
 R3-R5 is Bu with the remaining 2 being H; and R6-R8 are H, alkyl with the
 proviso that at least 1 is H, or 1 of R6-R8 is Bu with the remaining 2
 being H; with the proviso that when R1 and R2 are H, alkyl and R3-R8 are
 all H then Z is S] were prep'd. A mixt. of
 5,11-dihydro-11-ethyl-5-methyl-
 6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one and Lawesson's reagent in
 toluene was refluxed for 2.5 h to give I (R1 = Me; Z = S; R2 = Et; R3 =
 R4 = R5 = R6 = R7 = R8 = H), which at 10 µg/mL gave 100% in vitro
 inhibition of reverse transcriptase.

L3 ANSWER 35 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 US 1989-340970 B2 19890420
 US 1989-172974 B2 19890628
 US 1989-438923 B2 19891117
 US 1990-579001 B2 19900906
 US 1990-600390 B2 19901019
 US 1991-740828 B1 19910805
 US 1993-91418 A3 19930713
 HK 1011025 A1 20000420 HK 1998-112090 19981117
 US 1989-438923 A 19891117
 US 1990-579001 A 19900906
 US 1990-600390 A 19901019
 OS MARPAT 115:49732
 IT 132312-45-99
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction of, in preparation of drug for treatment of
 AIDS)
 RN 132312-45-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[[4-
 methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)





GI




I

AB The title compds. I [Z = O, S; R1 = H, (substituted) alkyl, arylmethyl,

L3 ANSWER 36 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1991:449642 CAPLUS
 DN 115:49642
 TI Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1.
 Tricyclic pyridobenzo- and dipyridodiazepinones
 AU Hargrave, Karl D.; Proudfoot, John R.; Grozinger, Karl G.; Cullen,
 Ernest;
 Kapadia, Suresh R.; Patel, Usha R.; Fuchs, Victor U.; Mauldin, Scott C.;
 Vitous, Jana; et al.
 CS Boehringer Ingelheim Pharm., Inc., Ridgefield, CT, 06877, USA
 SO Journal of Medicinal Chemistry (1991), 34(7), 2231-41
 CODEN: JMCMAR; ISSN: 0022-2623
 DT Journal
 LA English
 OS CASREACT 115:49642
 IT 132312-45-99
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and reductive intramol. cyclocondensation of,
 dipyridodiazepinone from)
 RN 132312-45-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[[4-
 methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



GI



AB Novel pyrido[2,3-b][1,4]benzodiazepinones, pyrido[2,3-
 b][1,5]benzodiazepinones, and dipyrido[3,2-b:2',3'-e][1,4]diazepinones
 e.g., I (X = N, X1 = CH; X = CH; X1 = N) and II inhibited human
 immunodeficiency virus type 1 reverse transcriptase in vitro at concns.

<8/14/2004>

L3 ANSWER 36 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
low as 35 nM. In all three series, small substituents (e.g., Me, Et, Ac) are preferred at the lactam nitrogen, whereas slightly larger alkyl moieties (e.g., Et, cyclopropyl) are favored at the other (N-11) diazepinone nitrogen. In general, lipophilic substituents are preferred on the A ring, whereas substitution on the C ring generally reduces potency relative to the corresponding compds. with no substituents on the arom. ring. Max. potency is achieved with Me substitution at the position ortho to the lactam nitrogen atom; however, in this case an unsubstituted lactam nitrogen is preferred. Addnl. substituents on the A ring can be readily tolerated. II (BI-RG-587) is a potent (IC50 = 84 nM) and selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, and has been chosen for preclin. development. II is noncytotoxic except at high doses and effective against all clin. isolates of HIV-1, including those which are AZT resistant. It is specific for HIV-1, ineffective against HIV-2, inactive against simian and feline reverse transcriptase, and does not inhibit DNA polymerases.

L3 ANSWER 37 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1991:102069 CAPLUS
DN 114:102069
TI Preparation of
5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
as drugs for prevention or treatment of AIDS
IN Schmidt, Guenther; Engel, Wolfrard; Trummlitz, Guenter; Eberlein, Wolfgang; Hargrave, Karl D.
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Thomas, Dr. Karl, G.m.b.H.
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 393529	A1	19901024	EP 1990 107098	19900412
EP 393529	B1	19930630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 91128	E	19930715	US 1989-340970	A 19890420
			AT 1990-107098	19900412
			US 1989-340970	A 19890420
			EP 1990-107098	A 19900412
ES 2058656	T3	19941101	ES 1990-107098	19900412
			US 1989-340970	A 19890420
CA 2014771	AA	19901020	CA 1990-2014771	19900418
CA 2014771	C	20000801		
			US 1989-340970	A 19890420
JP 03063276	A2	19910319	JP 1990-104379	19900419
JP 2851913	B2	19990127		
			US 1989-340970	A 19890420
US 5366972	A	19941122	US 1993-91418	19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
US 5620974	A	19970415	US 1994-279464	19940722
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1993-91418	A3 19930713

PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 410148	A1	19910130	EP 1990-112072	19900626
EP 410148	B1	19940406		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2019812	AA	19901228	CA 1990-2019812	19900626

L3 ANSWER 37 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CA 2019812	C	20001121	US 1989-372974	A 19890628
DD 295849	A5	19911114	DD 1990-342100	19900626
AT 103918	E	19940415	US 1989-372974	A 19890628
			AT 1990-112072	19900626
			US 1989-372974	A 19890628
ES 2063202	T3	19950101	EP 1990-112072	A 19900626
			ES 1990-112072	19900626
NO 9002851	A	19910102	US 1989-372974	A 19890628
NO 174468	B	19940131	NO 1990-2851	19900627
NO 174468	C	19940518		
			US 1989-372974	A 19890628
HU 55017	A2	19910429	HU 1990-4021	19900627
HU 206504	B	19921130		
			US 1989-372974	A 19890628
JP 03115283	A2	19910516	JP 1990-169663	19900627
JP 2911967	B2	19990628		
			US 1989-372974	A 19890628
ZA 9004991	A	19920325	ZA 1990-4991	19900627
FI 92828	B	19940930	FI 1990-3225	19900627
FI 92828	C	19950110		
			US 1989-372974	A 19890628
IL 94883	A1	19941007	IL 1990-94883	19900627
			US 1989-372974	A 19890628
AU 9057921	A1	19910103	AU 1990-57921	19900628
AU 620724	B2	19920220		
			US 1989-372974	A 19890628
RU 2024522	C1	19941215	RU 1992-5011432	19920427
			US 1989-372974	A 19890628
US 5366972	A	19941122	US 1993-91418	19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1994-279464	19940722
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1993-91418	A3 19930713

FAN 1991:514559
PATENT NO. KIND DATE APPLICATION NO. DATE

PI EP 429987 A2 19910605 EP 1990-121954 19901116

EP 429987 A3 19920122

EP 429987 B1 19990317

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE

US 1989-438923 A 19891117

US 1990-579001 A 19900906

US 1990-600390 A 19901019

CA 2030056 AA 19910518 CA 1990-2030056 19901115

CA 2030056 C 19951017

US 1989-438923 A 19891117

L3 ANSWER 37 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

FI 9005674	A	19910518	US 1990-579001	A 19900906
FI 94529	B	19950615	FI 1990-5674	19901116
FI 94529	C	19950925		
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
NO 9004986	A	19910521	NO 1990-4986	19901116
NO 175478	B	19940711		
NO 175478	C	19941019		
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
HU 56103	A2	19910729	HU 1990-7186	19901116
HU 208139	B	19930830		
			US 1989-438923	A 19891117
JP 04178386	A2	19920625	JP 1990-311230	19901116
JP 2912007	B2	19990628		
			US 1989-438923	A 19891117
IL 96367	A1	19970218	IL 1990-96367	19901116
			US 1989-438923	A 19891117
			IL 1990-94883	A0 19900627
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
AT 177744	E	19990415	AT 1990-121954	19901116
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
ES 2130114	T3	19990701	ES 1990-121954	19901116
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
AU 9066732	A1	19910523	AU 1990-66732	19901119
AU 630251	B2	19921022		
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
ZA 9009246	A	19920729	ZA 1990-9246	19901119
			US 1989-438923	A 19891117
JP 04257584	A2	19920911	JP 1991-211068	19910822
JP 2539116	B2	19961002		
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
HU 59407	A2	19920528	HU 1991-2865	19910904
HU 214595	B	19980428		
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
RU 2040527	C1	19950725	RU 1992-5011559	19920506
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
US 5366972	A	19941122	US 1993-91418	19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1994-279464	19940722

L3 ANSWER 37 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

US 1989-340970	B2 19890420
US 1989-372974	B2 19890628
US 1989-438923	B2 19891117
US 1990-579001	B2 19900906
US 1990-600390	B2 19901019
US 1991-740828	B1 19910805
US 1993-91418	A3 19930713
HK 1998-112090	19981117
US 1989-438923	A 19891117
US 1990-579001	A 19900906
US 1990-600390	A 19901019

HK 1011025 A1 20000420



OS MARPAT 114:102069

IT 132312-45-9P 132362-76-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for dipyriddiazepinone reverse transcriptase inhibitor)


RN 132312-45-9 CAPLUS

CN 3 Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 132362-76-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 38 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1984:611088 CAPLUS

DN 101:211088

TI Studies of 4[3H]-quinazolinone. XII. Synthesis and biological activity of 1-benzyl(4'-nitrobenzyl)-2-methyl-3-alkyl(aryl)-4[3H]-quinazolinone perchlorates

AU Chernobrovina, N. I.; Kozhevnikov, Yu. V.; Zalesov, V. S.; Gradel, I. I.

CS Perm. Farm. Inst., Perm, USSR

SO Khimiko-Farmatsevticheski Zhurnal (1984), 18(7), 830-3

CODEN: KHPZAN; ISSN: 0023-1134

DT Journal

LA Russian

IT 92944-76-8P 92944-77-9P 92944-78-0P


92944-79-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and acetylation of)


RN 92944-76-8 CAPLUS

CN Benzamide, N-(2,4-dimethylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 92944-77-9 CAPLUS


CN Benzamide, N-(4-methoxyphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 92944-78-0 CAPLUS


CN Benzamide, N-(4-nitrophenyl)-2-[(4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 37 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




AB The title compds. (I; R1, R2 = H, C1-5 alkyl), were prepared Thus, N-(2-chloro-3-pyridinyl)-2-[(4-methoxyphenyl)methyl]amino]-3-pyridinecarboxamide (preparation given) was refluxed 8 h with NaH in DMF to give 50% 5,11-dihydro-11-[(4-methoxyphenyl)methyl]-6H-dipyrdo[3,2-b:2',3'-e][1,4]diazepin-6-one, which was converted to title compound II in 3 steps. II at 10 µg/mL gave 100% inhibition of HIV-I reverse transcriptase. Dosage formulations were prepared containing I (R1 = H, R2 = Pr).

L3 ANSWER 38 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 92944-79-1 CAPLUS

CN Benzamide, N-(4-ethoxyphenyl)-2-[(4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




GI




L3 ANSWER 38 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 AB The title compds. I (R = 2,4-xylyl, 4-MeOC6H4, Bu, hexyl, R1 = H; R = 4-MeOC6H4, 4-ETOC6H4, R1 = NO2) were prepared in 58.6-83.4% yields by acetylation of o-RNHCOC6H4NR2CH2C6H4R1 p (II, R2 = H) to give 61.3-98.1% II (R2 = Ac) which were cyclized by refluxing in MeOH containing 57% HClO4. I (R = 4-MeOC6H4, R1 = NO2) was an effective antispasmodic for white mice at 150 mg/kg dosage.

L3 ANSWER 39 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1984:34516 CAPLUS
 DN 100:34516
 TI New synthesis of 11-acyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones and related studies
 AU Kovacs, T.; Oklobdzija, M.; Comisso, G.; Decorte, E.; Fajdiga, T.; Moimas, F.; Angeli, C.; Zonno, F.; Toso, R.; Sunjic, V.
 CS Chem. Res. Co., San Giovanni, Italy
 SO Journal of Heterocyclic Chemistry (1983), 20(5), 1339-49
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 OS CASREACT 100:34516
 IT 88369-73-7P 88369-74-8P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 88369-73-7 CAPLUS
 CN Benzamide, N-(2-chloro-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 88369-74-8 CAPLUS
 CN Benzamide, N-(2-chloro-1-oxido-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 39 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




AB 11-Acyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones I (R = 4-methylpiperazino, imidazo, 2-methylimidazo) were prepared via N-α-chloroacetylation and aminolysis. Other attempts at cyclization to form I are also reported.

L3 ANSWER 40 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1983:558250 CAPLUS
 DN 99:158250
 TI Antihypertensive sulfamoylbenzamides
 PA Mitsui Toatsu Chemicals, Inc., Japan
 SO Jpn. Kokai Tokkyo Koho, 6 pp.
 CODEN: JXXXXF
 DT Patent
 LA Japanese
 FAN CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 58124766	A2	19830725	JP 1982-4979	19820118
JP 02033030	B4	19900725		

OS CASREACT 99:158250
 IT 87445-66-7P 87445-71-4P 87445-72-5P
 87445-73-6P 87445-74-7P 87445-75-8P
 87445-76-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation and antihypertensive activity of)
 RN 87445-66-7 CAPLUS
 CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 87445-71-4 CAPLUS
 CN Benzamide,
 5-(aminosulfonyl)-4-chloro-2-[[[4-chlorophenyl)methyl]amino]-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 40 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 87445-72-5 CAPLUS
 CN Benzamide, 5-(aminosulfonyl)-4-chloro-2-[[[(2-chlorophenyl)methyl]amino]-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)]- (9CI) (CA INDEX NAME)




RN 87445-73-6 CAPLUS
 CN Benzamide, 5-(aminosulfonyl)-4-chloro-2-[[[(2,4-dichlorophenyl)methyl]amino]-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)]- (9CI) (CA INDEX NAME)

L3 ANSWER 40 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 87445-74-7 CAPLUS
 CN Benzamide, 5-(aminosulfonyl)-4-chloro-2-[[[(3,4-dichlorophenyl)methyl]amino]-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)]- (9CI) (CA INDEX NAME)




RN 87445-75-8 CAPLUS
 CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-2-[[[(3-methylphenyl)methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 40 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 87445-76-9 CAPLUS
 CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-2-[[[(2-methylphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



GI




AB I [R₁ = H, (substituted) alkyl; R₂ = substituted Ph, (substituted) benzyl]
 were prepared via condensation of II with HNR₁CH₂R₂. Thus, heating a
 Patel

L3 ANSWER 40 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 of 6 g I (R = Cl) with 25 mL H₂NCH₂Ph at 90° for 45 h gave 5 g I (R₁ = H, R₂ = Ph). At 30 mg/kg/day p.o. I decreased deoxycorticosterone acetate/saline-induced hypertension (182-195 mmHg) in rats by 9-24% in 5 days.


<8/14/2004>

LJ ANSWER 41 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1977:534708 CAPLUS
 DN 87:134708
 TI Substituted anthranilamides and preparation thereof
 IN Shetty, Bolva V.
 PA Pennwalt Corp., USA
 SO Can., 26 pp.
 CODEN: CAXXA4
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 1000736	A1	19761130	CA 1971-103215	19710120
23375-97-5P 28524-75-6P 28524-80-3P			CA 1971-103215	19710120
31933-24-1P				
RL: SPN (Synthetic preparation); PREP (Preparation)				
(preparation of)				
RN 23375-97-5 CAPLUS				
CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)				




RN 28524-75-6 CAPLUS
 CN Benzamide, 4-chloro-5-[(methylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 28524-80-3 CAPLUS
 CN Benzamide, 4-chloro-5-[(dimethylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)

LJ ANSWER 42 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1977:467996 CAPLUS
 DN 87:67996
 TI Substituted anthranilamides
 IN Shetty, Bolva V.
 PA Pennwalt Corp., USA
 SO Can., 26 pp.
 CODEN: CAXXA4
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 1000736		19761130	CA 1971-103215	19710120
23375-97-5P 28524-75-6P 28524-80-3P				
31933-24-1P				
RL: SPN (Synthetic preparation); PREP (Preparation)				
(preparation of)				
RN 23375-97-5 CAPLUS				
CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)				




RN 28524-75-6 CAPLUS
 CN Benzamide, 4-chloro-5-[(methylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 28524-80-3 CAPLUS
 CN Benzamide, 4-chloro-5-[(dimethylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



LJ ANSWER 41 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 31933-24-1 CAPLUS
 CN Benzamide, 5-[(bis(phenylmethyl)amino)sulfonyl]-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




AB Substituted anthranilamides 5,2,4-(RR1NO2S) (R2HN)ClC6H2CONHC6H2R3R4R5 (I: R, R1 = H, alkyl, Ph, PhCH2; R2 = H, alkyl, PhCH2, Ac; R3, R4, R5 = H, alkyl, alkoxy, NH2, etc.), useful in the synthesis of diuretic 1,2,3,4-tetrahydro-7-chloro-3-phenyl-6-sulfamoyl-4-quinazolinone derivs., were prepared by one of several routes. Thus, 2,5-MeC6H3NH2 was converted by sequential acetylation, sulfamoylation, oxidation, and hydrolysis, then treatment with COCl2-AcOH, followed by 2-MeC6H4NH2, into I (R = R1 = R2 = R3 = R4 = H, R5 = 2-Me).

LJ ANSWER 42 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 31933-24-1 CAPLUS
 CN Benzamide, 5-[(bis(phenylmethyl)amino)sulfonyl]-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




GI




AB Sixteen anthranilamides I (R = H, PhCH2, CH2CH2NEt, CH2CH2OH; R1 = R2 = H, Me, PhCH2, or R1 = H, R2 = Me; R3, R4, R5 independently = H, Me, Cl, MeO, SO2NH2, Et, OH), which are useful in the preparation of quinazolinone derivs., were prepared by different routes. Thus, sequential treatment of 5,2,4-(ClO2S)Cl2C6H2CO2H with (PhCH2)2NH, SOCl2, 2-MeC6H4NH2, and PhCH2NH2 gave I (R = R1 = R2 = PhCH2, R3 = 2-Me, R4 = R5 = H).

L3 ANSWER 43 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1977:171214 CAPLUS
 DN 86:171214
 TI Synthesis and pharmacological properties of 2-aminonicotinamide derivatives
 AU Zhmurenko, L. A.; Borisenko, S. A.; Salimov, R. M.; Glozman, O. M.; Zagorevskii, V. A.
 CS Nauchno-Issled. Inst. Farmakol., Moscow, USSR
 SO Fiziologicheski Aktivnye Veshchestva (1976), 8, 89-92
 CODEN: FAVUAI; ISSN: 0533-1153
 DT Journal
 LA Russian
 IT 62636-33-3P 62636-39-9P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and pharmacol. properties of)
 RN 62636-33-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 62636-39-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-(2-methoxyphenyl)-2-[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

GI

L3 ANSWER 44 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1973:537186 CAPLUS
 DN 79:117186
 TI 3-Acyl-6-sulfamoyl-7-halo-1,2,3,4-tetrahydro-4-quinazolinones
 IN Shetty, Bola V.
 PA Pennwalt Corp.
 SO U.S., 15 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3761480	A	19730925	US 1972-235087	19720315
			US 1968-743615	19680710
			US 1970-874960	19701107
US 3567746	A	19710302	US 1968-743615	19680710

PATENT FAMILY INFORMATION:
 FAN 1971:405517

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3567746	A	19710302	US 1968-743615	19680710
US 3761480	A	19730925	US 1972-235087	19720315
			US 1968-743615	19680710
			US 1970-874960	19701107
US 3862949	A	19750128	US 1972-315702	19721215
			US 1968-743615	19680710
			US 1969-874960	19691107
			US 1970-50895	19700629

FAN 1972:85835

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2131622	A	19720105	DE 1971-2131622	19710625
CH 546244	A	19740228	US 1970-50895	19700629
			CH 1971-8509	19710611
NL 7108861	A	19711231	US 1970-50895	19700629
			NL 1971-8861	19710625
FR 2104765	A5	19720421	US 1970-50895	19700629
FR 2104765	B1	19751010	FR 1971-23420	19710628
			US 1970-50895	19700629


IT 23375-97-5 28524-80-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(cyclocondensation of, with aldehydes)

RN 23375-97-5 CAPLUS

CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 28524-80-3 CAPLUS

CN Benzamide, 4-chloro-5-[(dimethylamino)sulfonyl]-N-(2-methylphenyl)-2-


Patel

L3 ANSWER 43 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The title compds. I [R = H, m-F3CC6H4, o-MeOC6H4, NR21 = HOCH2CH2NH, PhCH2NH, 4-methyl-1-piperazinyl, 4-(2-hydroxyethyl)-1-piperazinyl, piperidino], useful as sedatives and muscle relaxants, were obtained in 56-98% yields by amination of chloronicotinamides with R21NH.

L3 ANSWER 44 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 [(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




IT 28524-75-6

RL: RCT (Reactant); RACT (Reactant or reagent)
 (cyclocondensation with aldehydes)

RN 28524-75-6 CAPLUS

CN Benzamide, 4-chloro-5-[(methylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



GI For diagram(s), see printed CA issue.

AB Cyclization of I by condensation with R1CHO or the acetal gave II with diuretic activity. Thus, PhCH2CH(OMe)2 was reacted with I (R = 2-Me, R1 = HOAc containing H2SO4 and stirred overnight to give II (R = 2-Me, R1 = PhCH2).

An addnl. 53 examples are given.

LJ ANSWER 45 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1971:405517 CAPLUS
 DN 75:5517
 TI Diuretic sulfamoyl o-benzotoluidides
 IN Shetty, Bola V.
 PA Pennwalt Corp.
 SO U.S., 7 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN. CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 3567746	A	19710302	US 1968-743615	19680710
US 3761480	A	19730925	US 1972-235087	19720315
			US 1968-743615	19680710
US 3862949	A	19750128	US 1970-874960	19701107
			US 1972-315702	19721215
			US 1968-743615	19680710
			US 1969-874960	19691107
			US 1970-50895	19700629


PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 2131622	A	19720105	DE 1971-2131622	19710625
CH 546244	A	19740228	US 1970-50895	19700629
NL 7108861	A	19711231	CH 1971-8509	19710611
FR 2104765	A5	19720421	US 1970-50895	19700629
FR 2104765	B1	19751010	NL 1971-8861	19710625
			US 1970-50895	19700629
			FR 1971-23420	19710628
			US 1970-50895	19700629

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 3761480	A	19730925	US 1972-235087	19720315
			US 1968-743615	19680710
			US 1970-874960	19701107
US 3567746	A	19710302	US 1968-743615	19680710


IT 23375-97-5P 28524-75-6P 28524-80-3P
 31933-24-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 23375-97-5 CAPLUS
 CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-
 [(phenylmethyl)amino]- (9CI) (CA INDEX NAME)

LJ ANSWER 45 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




AB 5-Chloro-o-toluidine with Ac2O gave 5'-chloro-2'-methylacetanilide, which was heated with ClSO3H and NH4OH to give 5'-chloro 2'-methyl-4'-sulfamoylacetanilide (I). I was oxidized with KMnO4 to give N-acetyl-4-chloro-5-sulfamoylanthranilic acid, which was refluxed in aqueous NaOH to give 4-chloro-5-sulfamoylanthranilic acid (II). II in Ac2O was treated with COCl2 to give 7-chloro-6-sulfamoylisatoic anhydride, which was heated with o-toluidine to give 2-amino-4-chloro-5-sulfamoyl-N-o-tolylbenzamide (III). Nine other benzamides were similarly prepared. III heated with MeCHO and MeO(CH2)2OMe in DMF gave 2-methyl-3-o-tolyl-6-sulfamoyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone (IV). The 2-Ph, 2-Me, and 2-(CH2Cl) analogs of IV were similarly prepared.


LJ ANSWER 45 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 28524-75-6 CAPLUS
 CN Benzamide, 4-chloro-5-[(methylamino)sulfonyl]-N-(2-methylphenyl)-2-
 [(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 28524-80-3 CAPLUS
 CN Benzamide, 4-chloro-5-[(dimethylamino)sulfonyl]-N-(2-methylphenyl)-2-
 [(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 31933-24-1 CAPLUS
 CN Benzamide, 5-[[bis(phenylmethyl)amino]sulfonyl]-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)

LJ ANSWER 46 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN


AN 1971:141846 CAPLUS
 DN 74:141846
 TI N- and N,N-Alkyl-, -acyl, and -arylsulfamyltetrahydroquinazolinones as diuretics
 IN Shetty, Bola V.
 SO U.S., 6 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 3557111	A	19710119	US 1968-717437	19680329
GB 1256969	A	19711215	GB 1969-1256969	19690320
			US 1968-717437	19680329

IT 28524-75-6P 28524-80-3P 31933-24-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 28524-75-6 CAPLUS
 CN Benzamide, 4-chloro-5-[(methylamino)sulfonyl]-N-(2-methylphenyl)-2-
 [(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 28524-80-3 CAPLUS
 CN Benzamide, 4-chloro-5-[(dimethylamino)sulfonyl]-N-(2-methylphenyl)-2-
 [(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 31933-24-1 CAPLUS
 CN Benzamide, 5-[[bis(phenylmethyl)amino]sulfonyl]-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 46 OF 49 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



AB The title tetrahydroquinazolinones which have diuretic and saluretic properties, are prepared 5-Chloro-o-toluidine in H₂O was stirred 4 hr with Ac₂O to give 5-chloro 2-methylacetanilide (I), m. 138-9°. I was cautiously added to ClSO₃H under N, then NaCl added, the mixture heated 3 hr, and treated with NH₄OH to give 5-chloro-2-methyl-4-sulfamoylacetamide (II) m. 248-50°. II was oxidized with KMnO₄ to N-acetyl-4-chloro-5-sulfamoylanthranilic acid (III), m. 264-66°. III refluxed 3 hr with 3N NaOH, then brought to pH 4 with HCl gave 4-chloro-5-sulfamoylanthranilic acid (IV) m. 275-6°. IV in HOAc with COCl₂ gave 7-chloro-6-sulfamoylisatoic acid (V), m. 290-2°. V, under N, heated with 1,2-MeC₆H₄NH₂ gave 2-amino-4-chloro-5-sulfamoyl N-(o-tolyl)benzamide (VI) m. 289-92°. To VI in HOAc was added MeCH(OMe)₂ in H₂SO₄ and the mixture stirred 3.5 hr to give 2-methyl-3-(o-tolyl)-6-sulfamoyl 7-chloro-1,2,3,4-tetrahydro-4-quinazolinone (VII) m. 246-50°. VII in C₅H₅SN, stirred 6 hr with Ac₂O gave 7-chloro-6-acetylsulfamoyl-2-methyl-3-(o-tolyl)-1,2,3,4-quinazolinone m. 243-6°. An addnl. 3 examples are described.

L3 ANSWER 47 OF 49 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 Et₃N; after 30 min, ice-cold 6-aminopenicillanic acid and Et₃N in CHCl₃ was added and the soln. kept 12 hr to give, after alk. addn., Na 6-(3-benzyloxy-2-picolinamido)penicillanate. Prepd. similarly were: Na 7-(3-benzyloxy-2-picolinamido)cephalosporanate, Na 6-(3-hydroxy-2-picolinamido)penicillanate, and Na 7-(3-hydroxy-2-picolinamido)cephalosporanate.

L3 ANSWER 47 OF 49 CAPLUS COPYRIGHT 2004 ACS ON STN

AN 1971:76431 CAPLUS

DN 74:76431

TI 3-Substituted picolinyl penicillins and cephalosporins, useful as animal feed supplements and in germicidal preparations employed as surface disinfectants

IN Schwarz, J. S. Paul; Sheehan, John T.

PA E. R. Squibb and Sons, Inc.

SO U.S., 11 pp.

CODEN: USXXAM

DT Patent

LA English

FAN. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3553203	A	19710105	US 1969-834157	19690617
BR 6915314	A0	19730419	BR 1969-215314	19691219
CA 963003	A1	19750218	US 1969-834157	19690617
DE 2028830	A	19710107	CA 1970-85025	19700609
CH 517116	A	19711231	US 1969-834157	19690617
FR 2052982	A1	19710416	DE 1970-2028830	19700611
FR 2052982	A5	19710416	US 1969-834157	19690617
			FR 1970-22345	19700617
			US 1969-834157	19690617

IT 30861-03-1P

RL: SPN (Synthetic preparation); PREP (Preparation)


(Preparation of)

RN 30861-03-1 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[3-(benzylamino)picolinamido]-3,3-dimethyl-7-oxo-, monosodium salt (SCI)

(CA INDEX NAME)

Absolute stereochemistry.



● Na

AB The title compds. were prepared. Thus, ClCO₂Et was added to an ice-cold solution of 3-benzyloxy 2-picolinic acid-HCl sesquihydrate in CHCl₃ containing

L3 ANSWER 48 OF 49 CAPLUS COPYRIGHT 2004 ACS ON STN

AN 1970:477191 CAPLUS

DN 73:77191

TI Synthesis and activity of some 3-aryl- and

3-alkyl 1,2,3,4-tetrahydro-4-

oxo-6-quinazolinonesulfonamides

AU Shetty, Bola V.; Campanella, Liborio A.; Thomas, Telfer L.; Fedorchuk,

M.;

Davidson, T. A.; Michelson, L.; Volz, H.; Zimmerman, S. E.; Belair, E.

J.;

Truant, A. P.

CS Dep. Chem., Pennwalt Corp., Rochester, NY, USA

SO Journal of Medicinal Chemistry (1970), 13(5), 886-95

CODEN: JMCNAR; ISSN: 0022-2623

DT Journal

LA English

OS CASREACT 73:77191

IT 23375-97-5P 28524-75-6P 28524-80-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(Preparation of)

RN Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

CN

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)


Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

Benzamide, 4-chloro-5-[(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-

[(phenylmethyl)amino]- (SCI) (CA INDEX NAME)

L3 ANSWER 48 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI For diagram(s), see printed CA Issue.

AB A series of 3-aryl- and 3-aryalkyl di- and -tetrahydro-4-oxo-6-quinazolinonesulfonamides were synthesized and tested for pharmacol. activity. Several of the compds. were potent diuretics, especially I (metolazone), a potent, virtually nontoxic diuretic and natriuretic.

L3 ANSWER 49 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1969:470632 CAPLUS

DN 71:70632

TI 1-Benzyl-2-methyl-3-(o-tolyl)-6-sulfamoyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone

IN Shetty, Bola V.

PA Wallace and Tiernan Inc.

SO U.S., 5 pp. Continuation-in-part of U.S. 3360518

CODEN: USXXAM

DT Patent

LA English


FAN. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3452019	A	19690624	US 1967-683450	19671116
23375-97-5P			US 1967-683450	19671116

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 23375-97-5 CAPLUS

CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



AB The title compound I, useful as a diuretic, saluretic, and antihypertensive, was prepared. Thus, 800 g. of 2,4-dichlorobenzoic acid was added to 4 kg. of ClSO₃H at room temperature, the mixture refluxed 90 min., left to cool to 30°, 8 kg. of ice and 5 l. of H₂O added slowly, the mixture cooled to 0°, 8 l. of 28% NH₄OH added, acidified with HCl after 2 hrs., and the precipitate filtered, washed, dried, and clarified with C to give 790 g. 2,4-dichloro-5-sulfamylbenzoic acid, m. 225-8° (H₂O). This compound (270 g.) was added to 500 cc. of PhCH₂NH₂, the temperature quickly raised to 130°, kept 1 hr., cooled to 100°, the mixture poured into 5 l. of ice water, acidified with 400 cc. of HCl, and stirred 4 hrs. and the precipitate filtered to give 192 g. of 4-chloro-5-sulfamyl-N-benzylanthranilic acid, m. 242-6° (decomposition) (95% EtOH). This compound (35.0 g.) and 15 cc. of liquid COCl₂ was added to 400 cc. glacial AcOH, the mixture stirred 24 hrs., and the precipitate filtered, washed with Et₂O and air dried to give 25.2 g. 4-benzyl-6-chloro-7-sulfamylisatoic anhydride. This compound (25 g.) was added to 300 cc. of o-toluidine at room temperature, the mixture quickly

L3 ANSWER 49 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
warmed to 190°, kept 5 min., left to cool (50°), poured into 3 l. of Et₂O, and the ppt. washed and dried to give 2-benzylamino-4-chloro-5-sulfamyl-N-(O-tolyl)benzamide (II). Acetal (3.0 g.) was added to a suspension of 5.3 g. II in AcOH followed by 4 drops of H₂SO₄ dropwise during 5 min., the soln. stirred overnight, the ppt. filtered, washed with Et₂O and dried to give 3.2 g. of I, m. 193-5° (AcOH). Some pharmacol. data are given.

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	391.35	546.98
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-36.02	-36.02

STN INTERNATIONAL LOGOFF AT 10:02:54 ON 14 AUG 2004

Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3 May 12	EXTEND option available in structure searching
NEWS	4 May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5 May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in Cplus
NEWS	6 May 27	Cplus super roles and document types searchable in REGISTRY
NEWS	7 Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8 Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9 Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10 Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11 AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12 AUG 02	Cplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13 AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14 AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15 AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS EXPRESS	JULY 30	CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:05:29 ON 14 AUG 2004

=> file reg

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:05:38 ON 14 AUG 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 AUG 2004 HIGHEST RN 726125-61-7
 DICTIONARY FILE UPDATES: 12 AUG 2004 HIGHEST RN 726125-61-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>


Uploading c:\program files\stnexp\queries\10823809.3

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 Cb,Hy

G2 N,CH

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full

FULL SEARCH INITIATED 10:06:05 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 123026 TO ITERATE

Patel

<8/14/2004>

100.0% PROCESSED 123026 ITERATIONS
SEARCH TIME: 00.00.02

240 ANSWERS

L2 240 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
155.42	155.63

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 10:06:13 ON 14 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Aug 2004 VOL 141 ISS 8
FILE LAST UPDATED: 13 Aug 2004 (20040813/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2

L3 37 L2

=> d l3 fbib hitstr abs total

L3 ANSWER 1 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:41461 CAPLUS
 DN 140:93789
 TI Preparation of substituted anthranilic amide derivatives as VEGF
 modulators and methods of use against cancer and other disorders
 IN Huang, Qi; Chen, Guoqing; Li, Aiwen; Riahi, Babak; Tasker, Andrew; Yang,
 Kevin; Yuan, Chester Chenguang
 PA Amgen Inc., USA
 SO PCT Int. Appl., 204 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005279	A2	20040115	WO 2003-US21601	20030709
WO 2004005279	A3	20040311		

W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


RW: GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004007568	A1	20040506	US 2002-395144P	P	20020709
			US 2003-615809	A	20030708
			US 2002-395144P	P	20020709


OS MARPAT 140:93789
 IT 645418-48-OP, N-(1-Acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-((4-fluorobenzylamino)benzamide 645418-50-4P, 2-((4-fluorobenzylamino)benzamide 645418-56-OP, N-[3,3-Dimethyl-1-((4-methylpiperazin-1-yl)carbonyl)-2,3-dihydro-1H-indol-6-yl]-2-((4-fluorobenzylamino)benzamide 645418-64-OP, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-((4-fluorobenzylamino)benzamide 645418-68-4P, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-fluoro-6-((4-fluorobenzylamino)benzamide 645418-98-OP, 4,4-Dimethyl-7-[[2-[[[quinoxalin-5-yl)methyl]amino]benzoyl]amino]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 645418-99-1P, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-[[[quinoxalin-5-yl)methyl]amino]benzamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of substituted anthranilic amide deriva.

as VEGF modulators and methods of use against cancer and other disorders)
 RN 645418-48-0 CAPLUS
 CN Benzamide, N-(1-acetyl-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 645418-64-0 CAPLUS
 CN Benzamide, 2-[[[4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)




RN 645418-68-4 CAPLUS
 CN Benzamide, 5-fluoro-2-[[[4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)




RN 645418-98-0 CAPLUS
 CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-4,4-dimethyl-7-[[2-[[[quinoxalin-5-yl)methyl]amino]benzoyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 645418-50-4 CAPLUS
 CN Benzamide, 2-[[[4-fluorophenyl)methyl]amino]-N-(4-[[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 645418-56-0 CAPLUS
 CN Benzamide, N-[2,3-dihydro-3,3-dimethyl-1-[[4-methyl-1-piperazinyl]carbonyl]-1H-indol-6-yl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 645418-99-1 CAPLUS
 CN Benzamide, 2-((5-quinoxalinylmethyl)amino)-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)




IT 645418-65-1P, 7-[[2-((4-Fluorobenzylamino)benzoyl)amino]-4,4-dimethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of substituted anthranilic amide deriva. as VEGF modulators and methods of use against cancer and other disorders)
 RN 645418-65-1 CAPLUS
 CN 2(1H)-Isoquinolinecarboxylic acid, 7-[[2-[[[4-fluorophenyl)methyl]amino]benzoyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 37 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



GI



I



II

AB Selected substituted anthranilic amide deriva. (shown as I; variables defined below; e.g. II) are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving cancer and the like. Although the methods of preparation are

not claimed, .apprx.139 example preps. of I and .apprx.80 of intermediates are included. For example, II was prepared in 3 steps starting from 2-nitrobenzoic acid and [4-[1-Methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]amine and involving intermediates 2-nitro-N-[4-[1-methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]benzamide and 2-amino-N-[4-[1-methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]benzamide. Compds. I showed inhibition of KDR at doses <50 μ M. Some of the exemplified I inhibit VEGF stimulated HUVEC proliferation <1 μ M. Compds. I are active at

L3 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2004 ACS ON STN

AN 2003.950836 CAPLUS

DN 140:16722

TI Preparation of 1,1-disubstituted cycloalkyl derivatives as factor Xa inhibitors for treating a thromboembolic disorder

IN Qiao, Jennifer X.; Pinto, Donald J.; Orwat, Michael J.; Han, Wei;

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 686 pp.

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003099276	A1	20031204	WO 2003-US13893	20030505
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2002-379357P	P 20020510
			US 2002-415367P	P 20021002

OS MARPAT 140:16722

IT 630385-55-6P 630385-58-9P 630385-59-0P

630388-70-4P 630388-71-5P 630388-72-6P

630388-73-7P 630388-74-8P 630388-75-9P

630388-76-0P 630388-77-1P 630388-84-0P

630388-85-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 1,1-disubstituted cycloalkyl deriva.

factor Xa inhibitors for treating thromboembolic disorder)

RN 630385-55 6 CAPLUS

CN Benzenesulfonic acid,

4-[[[2-[[[5-chloro-2-pyridinyl]amino]carbonyl]phenyl]amino]methyl] α,α -dimethyl-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 37 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



doses <150 mpk in a tumor model. For I: R = (un)substituted 9- or 10-membered fused heterocyclyl, -(CH₂)₁₋₂-R₃; R₁ = (un)substituted 5-6 membered satd. or partially satd. heterocyclyl, 9-10 membered bicyclic

and



13-14 membered tricyclic satd. or partially satd. heterocyclyl, and phenyl; R₂ is ≥ 1 substituents = H, halo, hydroxy, amino, C1-6-alkyl, C1-6-haloalkyl, C1-6-alkoxy, C1-2-alkylamino, aminosulfonyl, C3-6-cycloalkyl, cyano, C1-2-hydroxyalkyl, nitro, C2-3-alkenyl, C2-3-alkynyl, C1-6-haloalkoxy, C1-6-carboxyalkyl, 4-6-membered heterocyclyl-C1-6-alkylamino, (un)substituted Ph and (un)substituted 4-6 membered heterocyclyl; R₃ = H, C1-2-alkyl; addnl. details are given in

the claims.



L3 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 630385-58-9 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(2-hydroxy-1,1-dimethylethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 630385-59-0 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(2-(dimethylamino)-1,1-dimethylethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 630388-70-4 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[(2-oxo-1-

<8/14/2004>

L3 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
pyrrolidinyl)methyl)cyclopropyl]phenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 630388-71-5 CAPLUS
CN Benzamide,
2-[[[4-[1-[(acetylmethylamino)methyl]cyclopropyl]phenyl)methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 630388-72-6 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[(methyl(methylsulfonyl)amino)methyl]cyclopropyl]phenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 630388-73-7 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[(methyl(methylsulfonyl)amino)methyl]cyclopropyl]phenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 630388-74-8 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[(methylsulfonyl)amino)methyl]cyclopropyl]phenyl)methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 630388-75-9 CAPLUS
CN Benzamide, 2-[[[4-[1-(acetylamino)cyclopropyl]phenyl)methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 630388-76-0 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[(2-hydroxyethyl)amino)methyl]cyclopropyl]phenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 630388-77-1 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[(2-hydroxyethyl)methylamino)methyl]cyclopropyl]phenyl)methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 630388-84-0 CAPLUS
CN Benzamide,
5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-(2-dimethylamino)-2-oxoethyl]cyclopropyl]phenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 630388-85-1 CAPLUS
CN Benzamide,
2-[[[4-[1-(2-amino-2-oxoethyl)cyclopropyl]phenyl)methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



GI

<8/14/2004>

L3 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



AB The present application describes 1,1-disubstituted cycloalkyl compds. and
 derivs. thereof (P4-P-M-M4; variables defined below; most of the examples contain 1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, e.g. the trifluoroacetate of I), or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa for treatment of a thromboembolic disorder. Although the methods of preparation are not claimed, .apprx.240 example preps. are included. A number of I exhibit Ki's of <10 μ M towards factor Xa; also some I are direct acting inhibitors (Ki < 10 μ M) of the serine protease thrombin as indicated by their ability to inhibit the cleavage of small mol. substrates by thrombin in a purified system; the specific compds. are not stated. For I: M is a 3-10 membered carbocycle or a 4-10 membered heterocycle, consisting of: C atoms and 1-3 heteroatoms = O, S(O)p, N, and N22; ring M is substituted with 0-3 R1a and 0-2 carbonyl groups, and there are 0-3 ring double bonds; P is fused onto ring M and is a 5, 6, or 7 membered carbocycle or a 5, 6, or 7 membered heterocycle, consisting of: C atoms and 1-3 heteroatoms = O, S(O)p, and N; ring P is substituted with 0-3 R1a and 0-2 carbonyl groups, and there are 0-3 ring double bonds; alternatively, ring P is absent and P4 is directly attached to ring M, provided that when ring P is absent, P4 and M4 are attached to the 1,2, 1,3, or 1,4 positions of ring M. One of P4 and M4 is Z-A-B and the other -G1-G, provided that P4 and M4 are attached to different rings when ring P is present; G consists of 2 fused rings D and E (ring D, including the two atoms of Ring E to which it is attached, is a 5-6 membered ring consisting of carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O)p; E is selected from (un)substituted Ph, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl; alternatively, ring D is absent and ring E is selected from (un)substituted Ph, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrrolyl,

L3 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, thienyl, and thiazolyl); G1 is absent or = (CR3R3a)1-5, etc. A = (un)substituted carbocycle and 5-12 membered heterocycle consisting of: C atoms and 1-4 heteroatoms N, O, and S(O)p; B is Y-R4a or X-Y-R4a, provided that Z and B are attached to different atoms on A and A and R4a or X and R4a are attached to the same atom on Y; Z = a bond, -(CR3R3e)1-4-, etc. Addnl. details including provisos are given in the claims.
 RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS ON STN
 AN 2003:950057 CAPLUS
 DN 140:16647
 TI Preparation of 2-aminopyridine-3-carboxamides as remedies for angiogenesis mediated diseases
 IN Aekew, Benny; Adams, Jeffrey; Booker, Shon; Chen, Guoqing; Dipietro, Lucian V.; Elbaum, Daniel; Germain, Julie; Geuns-Meyer, Stephanie D.; Habgood, Gregory J.; Handley, Michael; Huang, Qi; Kim, Tae-seong; Li, Aiwen; Nishimura, Nobuko; Nomak, Rana; Patel, Vinod F.; Riahi, Babak; Kim, Joseph L.; Xi, Ning; Yang, Kevin; Yuan, Chester Chenguang
 PA Amgen Inc., USA
 SO U.S. Pat. Appl. Publ., 252 pp., Cont.-in-part of U.S. Ser. No. 46,681.
 CODEN: USXXCO
 DT Patent
 LA English
 PAN.CNT 2
 PATENT NO. KIND DATE APPLICATION NO. DATE
 P1 US 2003225106 A1 20031204 US 2002-197974 20020717
 US 2001-261339P P 20010112
 US 2001-323764P P 20010919
 US 2002-46681 A2 20020110
 US 2002-46681 P 20020110
 US 2001-261339P P 20010112
 US 2001-323764P P 20010919
 WO 2003-052247 20030715
 WO 2004007458 A1 20040122
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PATENT FAMILY INFORMATION:
 FAN 2002:658116
 PATENT NO. KIND DATE APPLICATION NO. DATE
 P1 WO 2002066470 A1 20020829 WO 2002-05743 20020111
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2001-261339P P 20010112
 US 2001-323764P P 20010919
 US 2002-46681 A 20020110
 US 2002-46681 P 20020110
 US 2001-261339P P 20010112
 US 2001-323764P P 20010919
 US 2003125339 A1 20030703


Patel

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 BR 2002006435 A 20030923 BR 2002-6435 20020111
 US 2001-261339P P 20010112
 US 2001-323764P P 20010919
 US 2002-46681 A 20020110
 WO 2002-US743 W 20020111
 EP 1358184 A1 20031105 EP 2002-717325 20020111
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 2001-261339P P 20010112
 US 2001-323764P P 20010919
 US 2002-46681 A 20020110
 WO 2002-US743 W 20020111
 EE 200300324 A 20031215 EE 2003-324 20020111
 US 2001-261339P P 20010112
 US 2001-323764P P 20010919
 WO 2002-US743 W 20020111
 NO 2003003181 A 20030911 NO 2003-3181 20030711
 US 2001-261339P P 20010112
 US 2001-323764P P 20010919
 US 2002-46681 A 20020110
 WO 2002-US743 W 20020111
 OS MARPAT 140:16647
 IT 453561-07-4P 453561-08-5P 453561-23-4P
 453561-01-4P, 2-[(2,3-Dihydrobenzofuran-5-ylmethyl)amino]-N-[3,3-dimethyl-1-(piperidin-4-ylmethyl)-2,3-dihydro-1H-indol-6-yl]nicotinamide
 453563-25-2P 453563-26-3P 453563-27-4P
 453563-28-5P 453563-33-2P 453563-34-3P
 453563-35-4P 453563-36-5P 453563-04-3P
 453564-40-4P 453564-41-5P 453564-42-6P
 629650-58-4P 629650-64-2P 629650-65-3P
 629650-69-7P 629650-71-1P 629650-72-2P
 629650-73-3P 629650-74-4P 629651-29-2P
 629652-03-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 2-aminopyridine-3-carboxamides for treating angiogenesis mediated diseases)
 RN 453561-07-4 CAPLUS
 CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[(6-quinolinylmethyl)amino]-(9CI) (CA INDEX NAME)

<8/14/2004>

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 453561-08-5 CAPLUS
CN 3-Pyridinecarboxamide, N-(3,4-dichlorophenyl)-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 453561-23-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453563-26-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(6-quinolinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453563-27-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(6-quinolinylmethyl)amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




Patel

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 453561-81-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinylmethyl)-1H-indol-6-yl]- (9CI) (CA INDEX NAME)




RN 453563-25-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 453563-28-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453563-33-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-(1-methyl-1-(1-methyl-4-piperidinyl)ethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453563-34-3 CAPLUS
CN 3-Pyridinecarboxamide, N-(1-acetyl-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(2,3-dihydro-5-benzofuranyl)methyl]amino]- (9CI) (CA INDEX NAME)

<8/14/2004>

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 453563-35-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[6-[[[2-[[[2,3-dihydro-5-benzofuranyl)methyl]amino] 3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 453563-36-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[2,3-dihydro-3,3-dimethyl-1-[(1-methyl-4-piperidinyl)methyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 453564-41-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[2,3-dihydro-5-benzofuranyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolyl)- (9CI) (CA INDEX NAME)



RN 453564-42-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-[(2S)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 629650-58-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-[[1-methyl-1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]phenyl]- (9CI) (CA INDEX NAME)

Patel

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 453563-84-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[5-[[[2-[[[2,3-dihydro-6-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 453564-40-4 CAPLUS
CN 2-[(1H)-isoquinolinecarboxylic acid, 7-[[[2-[[[2,3-dihydro-5-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 629650-64-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[[[2R]-1-methyl-2-pyrrolidinyl]methoxy]-4-(trifluoromethyl)phenyl]-2-[[6-quinolinyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 629650-65-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[[[2R]-1-methyl-2-pyrrolidinyl]methoxy]-5-(trifluoromethyl)phenyl]-2-[[6-quinolinyl)methyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

<8/14/2004>


L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 629650 69-7 CAPLUS
CN 3-Pyridinecarboxamide,
2-[(6-quinolinylmethyl)amino]-N-(1,2,3,4-tetrahydro-
4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)




RN 629650-71-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(6-quinolinylmethyl)amino]-N-[3-[(tetrahydro-2-furanyl)methoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 629650-72-2 CAPLUS

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 629651-29-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(5-benzoxazolylmethyl)amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 629652-03-5 CAPLUS
 CN 1-Azetidinecarboxylic acid, 3-[[[3-[[[2-[[2,3-dihydro-5-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



GI


L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 3-Pyridinecarboxamide, N-[3-[[[(dimethylamino)acetyl]amino]-4-(1,1-dimethylethyl)phenyl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 629650-73-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[6-quinolinylmethyl]amino]-N-[3-[[{(3R)-
tetrahydro-3-furanyl]oxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 629650-74-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-2-oxo-3,3-bis(trifluoromethyl)-1H-indol-6-yl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The title compounds, [I; R = (un)substituted 4-pyridyl, 2-pyridyl, 4-pyrimidinyl, 4-quinolyl, etc.; R' = (un)substituted aryl, cycloalkyl, 5-6 membered heteroaryl; 9-10 membered bicyclic and 11-14 membered tricyclic heterocyclyl], which are effective for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like, were prepared. Thus, the title compound II was prepared from 2-aminonicotinic acid, 4-chloroaniline, and 4-pyridinecarboxaldehyde.

The compds. I showed inhibition of KDR kinase at $< 50 \mu\text{M}$. Many compds. I inhibited VEGF-stimulated HUVEC proliferation at a level below 50 nM . Pharmaceutical composition comprising the compound I is claimed.

L3 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003.913147 CAPLUS
 DN 139.381477
 TI Preparation of 4,5-dihydro-1H-benzo[g]indazole-3-carboxamides as IKK2
 inhibitors for the treatment of cancer and inflammation
 IN Lennon, Patrick; Bonafoux, Dominique; Oburn, David S.; Wolfson, Serge G.
 PA Pharmacia Corporation, USA
 SO PCT Int. Appl., 312 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003095430	A1	20031120	WO 2003-US8917	20030319
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			


WO 2003024935	A2	20030327	US 2002-379090P	P 20020509
WO 2003024935	A3	20030821	WO 2002-US29774	A 20020919

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024935	A2	20030327	US 2002-379090P	P 20020509
WO 2003024935	A3	20030821	WO 2002-US29774	20020919
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			


PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024935	A2	20030327	WO 2002-US29774	20020919
WO 2003024935	A3	20030821		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

L3 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I

II

AB The present invention relates to substituted pyrazolyl deriva., compns. comprising such, intermediates, methods of making substituted pyrazolyl deriva., and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis. 4,5-Dihydro-1H-

Patel

L3 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2001-323423P	P 20010919
US 2002-379090P	P 20020509
US 2002-247096	P 20020919
US 2001-323423P	P 20010919
US 2002-379090P	P 20020509

EP 1444207	A2	20040811	EP 2002-775879	20020919
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			

US 2001-323423P	P 20010919
US 2002-379090P	P 20020509
WO 2002-US29774	W 20020919

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003095430	A1	20031120	WO 2003-US8917	20030319
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			


OS MARPAT 139.381477
 IT 503555-09-79, 1-((1,3-Benzodioxol-5-yl)-8-[[[2-((4-methoxybenzyl)amino)pyridin-3-yl]carbonyl]amino]-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide)
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of 4,5-dihydro-1H-benzo[g]indazole-3-carboxamides as IKK2 inhibitors for treatment of cancer and inflammation)
 RN 503555-09-7 CAPLUS
 CN 1H-Benz[glindazole-3-carboxamide, 1-((1,3-benzodioxol-5-yl)-4,5-dihydro-8-[[[2-((4-methoxyphenyl)methyl)amino]-3-pyridinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 benzo[g]indazole-3-carboxamides (shown as I; variables defined below;

e.g.
 I) were prepd. via conventional and solid phase synthetic methods as IkB protein kinase β (IKK β or IKK2) inhibitors. Although the methods of prepn. are not claimed, 480 example preps. and/or characterization data are included. For example, reaction of 7-nitro-1-tetralone with Et acetate in the presence of Li bis(trimethylsilyl)amide in ether gave the 1,3-diketone (87%), which was cyclized with 4-sulfonamidophenylhydrazine-HCl with HCl in MeOH to give the Et 1H-dihydrobenzo[g]indazole-3-carboxylate (69%). Amidation with NH₄OH in MeOH provided II. In IKK β resin enzyme assays, I exhibited IKK β activity with IC₅₀ values ranging from $\leq 1 \mu\text{M}$ to $> 100 \mu\text{M}$. Thus, I are useful for treating cancer, inflammation, and inflammation-assocd. disorders, such as arthritis (no data). For I: B is a 5 or 6 membered heteroaryl, aryl, (un)satd. heterocyclic (un)substituted with R₁, R₂, and R₁₂; W is a 5 or 6 membered heteroaryl, aryl, (un)satd. heterocyclic. R₁ = hydrido, halo, alkyl, aryl, heteroaryl, alkenyl, alkynyl, haloalkyl, CN, NO₂, OR₅, OCOOR₅, CO₂R₇, CON(R₆)R₇, COR₆, SR₆, SO₂R₆, NR₆R₇, NR₆COR₇, NR₆CONHR₇, NR₆SO₂R₇, NR₆SO₂NHR₇, and SO₂N(R₆)R₇; R₂ = halo, hydrido, hydroxyalkyl, alkyl, OR₆, CN, NO₂, SR₆, NHR₆, CON(R₆)R₇, NHCONHR₆, CO₂H, and haloalkyl; R₁ and R₂ may be taken together to form a 5 to 7 membered (un)satd. carbocyclic ring optionally contg. 0 to 3 heteroatoms N, O, or S, and wherein said ring is (un)substituted with R₁. R₁₂ = hydrido, halo, alkyl, and alkoxy; R₁₅ = alkylsulfonamide, sulfamyl, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, halo, acyloxy, oxy, formyl, haloalkyl, cyano, haloalkoxy, acyl, carboxy, halo, hydroxy, hydroxyalkoxy, phenoxy, nitro, azido, benzyloxy, dialkylaminoalkyl, thioalkyl, aminoalkoxy, thiocyanate, isothiocyanate, alkyldioxy, hydroxyalkyl, alkylamino, alkylalkoxy, alkoxyalkyl, alkenylamino, alkynylamino, alkenyl, alkynyl, dialkylaminoalkoxy, and heterocyclic; addnl. details are given in the claims.
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

<8/14/2004>

LJ ANSWER 5 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:665525 CAPLUS
 DN 139:111679
 TI Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching
 AU Furet, Pascal; Bold, Guido; Hofmann, Francesco; Manley, Paul; Meyer, Thomas; Altmann, Karl-Heinz
 CS Oncology Research, Novartis Pharma AG, Basel, CH-4002, Switz.
 SO Bioorganic & Medicinal Chemistry Letters (2003), 13(18), 2967-2971
 CODEN: BMCLES; ISSN: 0960-894X
 PB Elsevier Science B.V.
 DT Journal
 LA English
 OS CASREACT 139:345320
 IT 610359-41-4
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (identification, synthesis and structure-activity relationship studies on a new chemical class of potent angiogenesis inhibitors (anthranilamides)-based on conformational considerations and database searching)
 RN 610359-41-4 CAPLUS
 CN Benzamide, N-(2-fluorophenyl)-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



AB The vascular endothelial growth factor (VEGF) tyrosine kinase receptors KDR and Flt-1 are targets of current interest in anticancer drug research.
 PTK787/ZK222584 is a potent inhibitor of these enzymes in clin. evaluation
 as an antiangiogenic agent. The development of a hypothesis concerning the bioactive conformation of this compound has led to the discovery of a new class of potent inhibitors of KDR and Flt-1, the anthranilamides. This could be achieved with a limited exptl. effort, which only involved the testing of one archive compound and the synthesis and testing of one appropriate analog.
 RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

LJ ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:551370 CAPLUS
 DN 139:111679
 TI Combination of microsomal triglyceride transfer protein (MTP) inhibitors or apoB secretion inhibitors with fibrates for use as drugs
 IN Thomas, Leo; Mark, Michael
 PA Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
 SO PCT Int. Appl., 220 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057205	A2	20030717	WO 2003-EP57	20030107
WO 2003057205	A3	20040401		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM

RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 2002-10200633			DE 2002-10256184	A	20020110
DE 10200633	A1	20030724	DE 2002-10200633	A	20020110
DE 10256184	A1	20040609	DE 2002-10256184	A	20020110
US 2003162788	A1	20030828	US 2003-133988	A	20030109
			DE 2002-10200633	A	20020110
			US 2002-133979	P	20020201
			DE 2002-10256184	A	20020110
			US 2002-435386P	P	20021220

OS MARPAT 139:111679
 IT 486436-62-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)
 RN 486436-62-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 1-methyl-N-[(4'-methyl[1,1'-biphenyl]-4-yl)methyl]-4-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)

LJ ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The invention discloses the use of fibrates for reducing the hepatic toxicity of MTP inhibitors, as well as pharmaceutical compns. that contain an MTP inhibitor and a fibrate. Compound preparation is included.

LJ ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:551181 CAPLUS
 DN 139:111739
 TI Preparation of substituted arylamine derivatives as antitumor agents
 IN Elbaum, Daniel; Askew, Benny; Booker, Shon; Germain, Julie; Hagood, Gregory; Handley, Michael; Kim, Tae-Seong; Li, Aileen; Nishimura, Nobuko; Patel, Vinod F.; Yuan, Chester Chenguang; Kim, Joseph L.
 PA Amgen Inc., USA
 SO U.S. Pat. Appl. Publ., 106 pp., Cont.-in-part of U.S. Ser. No. 46,526.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003134836	A1	20030717	US 2002-197960	20020717
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
US 2002147198	A1	20021010	US 2002-46526	A2 20020110
			US 2002-46526	20020110
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
WO 2004007457	A2	20040122	WO 2003-US22276	20030715

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM

RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002-197960 A 20020717

PATENT FAMILY INFORMATION:
 FAN 2002:539663

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055501	A2	20020718	WO 2002-US742	20020111
WO 2002055501	A3	20021219		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM

RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2001-261360P	P	20010112
US 2001-323686P	P	20010919
US 2002-46526	A	20020110
US 2002-46526	20020110	
US 2001-261360P	P	20010112
US 2001-323686P	P	20010919
EP 2002-717324	P	20020111
R: AT, BE, CH, DE, DK, EE, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
US 2001-261360P	P	20010112

Patel

<8/14/2004>

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 US 2001-323686P P 20010919
 US 2002-46526 A 20020110
 WO 2002-US742 W 20020111


OS MARPAT 139:117339
 IT 561297-65-2P 561297-67-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of substituted aminopyridines as antitumor agents)

RN 561297-65-2 CAPLUS


CN 1-Azetidinecarboxylic acid, 3-[[2-chloro-5-[[[2-[[[4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 561297-67-4 CAPLUS

CN 4-Pyridazinecarboxamide, 6-chloro N-[4-(1,1-dimethylethyl)phenyl]-3-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




IT 561297-60-7P 561297-61-8P 561297-62-9P
 561297-63-0P 561297-64-1P 561297-66-3P
 561297-68-5P 561297-70-9P 561297-71-0P
 561297-72-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted aminopyridines as antitumor agents)

RN 561297-60-7 CAPLUS


CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(methylsulfonyl)-1H-indol-6-yl]-2-[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 561297-61-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[[[dimethylamino]acetyl]amino]-4-(1,1-dimethylethyl)phenyl]-2-[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 561297-62-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]-N-[3-[[[2R]-1-methyl-2-pyrrolidinylmethoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 561297-63-0 CAPLUS


CN 3-Pyridinecarboxamide, 2-[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]-N-[3-[[[methylsulfonyl]amino]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 561297-64-1 CAPLUS


CN 3-Pyridinecarboxamide, 2-[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]-N-[4-[1-methyl-1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 561297-66-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[[[azetidinylmethoxy]-4-chlorophenyl]-2-[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 561297-68-5 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-3-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 561297-70-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-(3-azetidylmethoxy)-5-(trifluoromethyl)phenyl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 561297-71-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1-methylethyl)phenyl]-2-[[[4-hydroxy-3-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 561297-72-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1-methylethyl)phenyl]-2-[[[3-amino-4-hydroxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




IT 442847-21-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted aminopyridines as antitumor agents)
RN 442847-21-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinylmethyl)-1H-indol-6-yl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



IT 442845-77-4P 442846-13-1P 442846-17-5P
442846-22-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compound; preparation of substituted aminopyridines as antitumor agents)
RN 442845-77-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1-methylethyl)phenyl]-2-[[[3-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)


Patel

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-13-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[5-[[[2-[[[4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 442846-17-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[6-[[[2-[[[4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

<8/14/2004>

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-22-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-acetyl-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-6-yl)-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




IT 442845-71-8P 442845-72-9P 442845-73-0P
442845-78-5P 442845-79-6P 442845-80-9P
442845-81-0P 442845-82-1P 442845-83-2P
442845-84-3P 442845-85-4P 442845-86-5P
442845-87-6P 442845-88-7P 442845-89-8P
442845-90-1P 442845-91-2P 442845-92-3P
442845-93-4P 442845-94-5P 442845-95-6P

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 442845-73-0 CAPLUS
CN 2-Pyridinecarboxamide, N-(3-fluoro-4-methylphenyl)-3-[[4-(methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-78-5 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[3-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-79-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[3-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


442845-96-7P 442845-97-8P 442845-99-0P
442846-00-6P 442846-01-7P 442846-02-8P
442846-03-9P 442846-04-0P 442846-05-1P
442846-06-2P 442846-07-3P 442846-08-4P
442846-09-5P 442846-10-6P 442846-11-7P
442846-12-8P 442846-13-9P 442846-14-0P
442846-15-1P 442846-16-2P 442846-17-3P
442846-18-4P 442846-19-5P 442846-20-6P
442846-21-7P 442846-22-8P 442846-23-9P
442846-24-0P 442846-25-1P 442846-26-2P
442846-27-3P 442846-28-4P 442846-29-5P
442846-30-6P 442846-31-7P 442846-32-8P
442846-33-9P 442846-34-0P 442846-35-1P
442846-36-2P 442846-37-3P 442846-38-4P
442846-39-5P 442846-40-6P 442846-41-7P
442846-42-8P 442846-43-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of substituted aminopyridines as antitumor agents)


RN 442845-71-8 CAPLUS

CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[[4-(4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)





RN 442845-72-9 CAPLUS

CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[[4-(4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 442845-80-9 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-81-0 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-82-1 CAPLUS


CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

<8/14/2004>

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(trifluoromethoxy)phenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 442845-83-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(2,3-difluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 442845-84-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(4-cyanophenyl)methyl]amino]-N-(4-chlorophenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442845-85-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(2-cyanophenyl)methyl]amino]-N-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 442845-86-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-(4-(2-methylpropyl)phenyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-87-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-88-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(3-methoxyphenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-89-8 CAPLUS

Patel

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 3-Pyridinecarboxamide, 2-[[[(3-aminophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-90-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-91-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-[3-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

<8/14/2004>


L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-92-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3,4-dimethoxyphenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-93-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[phenylmethyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-94-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-chlorophenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-97-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[2,4-difluorophenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-99-0 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[2,4-difluorophenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




Patel

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442845-95-6 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-bromophenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-96-7 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-chlorophenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 442846-00-6 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[2,3-difluorophenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-01-7 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[2-fluorophenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-02-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[2,6-difluorophenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-03-9 CAPLUS

<8/14/2004>

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 3-Pyridinecarboxamide, 2-[[[3-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-04-0 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-fluorophenyl)methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-05-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-[3-[3-(dimethylamino)propyl]-5-(trifluoromethyl)phenyl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-06-2 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl)methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-07-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl)methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-08-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-bromo-2-fluorophenyl]-2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-09-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-10-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-fluoro-3-[3-(4-morpholinyl)-1-propynyl]phenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-11-9 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[1,3-benzodioxol-5-yl)methyl]amino]-N-[4-phenoxyphenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-12-0 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-[3-[2-(1-pyrrolidinyl)ethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-14-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[2-[(1,1-dimethylethyl)-5-[[[2-[[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-15-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-[(1-methyl-4-piperidinyl)-1H-indol-6-yl]-2-[[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-16-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[1-[(dimethylamino)acetyl]-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl]-2-[[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-18-6 CAPLUS
 CN Carbamic acid, [2-[6-[[[2-[[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 442846-19-7 CAPLUS
 CN 2(1H) Isoquinolinecarboxylic acid, 7-[[[2-[[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-20-0 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[2-[[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 442846-21-1 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[2-[(1,1-dimethylethyl)-5-[[[2-[[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-23-3 CAPLUS
 CN 1-Piperidinecarboxylic acid,
 4-[[3-[[[2-[[[4-fluorophenyl)methyl]amino]-3-
 pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-,
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-24-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-(1,1-dimethylethyl)-3-[(2R)-2-
 pyrrolidinylmethoxy]phenyl]- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-25-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-(1,1-dimethylethyl)-3-[(2R)-2-
 pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 442846-26-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[4-(1,1-dimethylethyl)-3-[(4-
 piperidinylmethoxy]phenyl]-2-[[[4-(1,1-dimethylethyl)-3-[(2R)-2-
 pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-27-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[4-(1,1-dimethylethyl)-3-[(2R)-2-
 pyrrolidinylmethoxy]phenyl]-2-[[[4-(1,1-dimethylethyl)-3-[(2R)-2-
 pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 442846-28-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-(1,1-dimethylethyl)-3-[(2R)-2-
 pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-29-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[4-(1,1-dimethylethyl)-3-[(2R)-2-
 pyrrolidinylmethoxy]phenyl]-2-[[[4-(1,1-dimethylethyl)-3-[(2R)-2-
 pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 442846-30-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[4-(1,1-dimethylethyl)-3-[(2R)-2-
 pyrrolidinylmethoxy]phenyl]-2-[[[4-(1,1-dimethylethyl)-3-[(2R)-2-
 pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-31-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-(3-(4-piperidinylmethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-32-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-6-yl)-2-[[[4-(4-fluorophenyl)methyl]amino] (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-35-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-(4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl)- (9CI) (CA INDEX NAME)




RN 442846-36-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-2-oxo-7-quinoliny)- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-33-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-(3-[[[(2S)-1-methyl-2-pyrrolidinyl]methoxy] 5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 442846-34-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-[[[1-methyl-4-piperidinyl)methyl]-1H-indol-6-yl]-2-[[[4-(4-fluorophenyl)methyl]amino] (9CI) (CA INDEX NAME)


L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-38-0 CAPLUS
CN 3-Pyridinecarboxamide, N-5-benzofuranyl-2-[[[3-(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-39-1 CAPLUS
CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-2-[[[3-(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-40-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3,4-difluorophenyl)methyl]amino]-N-(4-(1,1-difluoro-2-oxo-2-phenylethyl)-1H-benzothiazol-5-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
dimethyl-ethyl-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 442846-42-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinylmethyl)amino]phenyl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-44-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinylmethyl)amino]phenyl]-2-[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442847-23-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3-(4-fluorophenyl)methyl]amino] N-(4-phenoxymethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 442845-77-4
CMF C25 H20 F N3 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



II

AB The title compds. I (R2 = (un)substituted Ph, 9-10 membered bicyclic and 11-14 membered tricyclic (un)saturated heterocyclyl; R8 = halo, NH2, NO2, etc.), and their pharmaceutically acceptable derivs., are prepared and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. E.g., a multi-step synthesis of II, starting from 1-dimethylamino-2-propyne and 3-bromo-5-trifluoromethylaniline, was given. Selected compds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below

50 nM. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

L3 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:454323 CAPLUS
DN 139:22501

TI Preparation of glycinamide heterocyclic derivatives as factor Xa inhibitors

IN Pinto, Donald J. P.; Han, Wei; Hu, Zilun
PA Bristol-Myers Squibb Company, USA; Qiao, Jennifer
SO PCT Int. Appl., 451 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN,CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048158	A1	20030612	WO 2002-US38239	20021127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003232804	A1	20031218	US 2001-336994P	P 20011204
			US 2002-304070	20021125
			US 2001-336994P	P 20011204

PATENT FAMILY INFORMATION:

FAN 2003:454257

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048081	A2	20030612	WO 2002-US37212	20021118
WO 2003048081	A3	20030912		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003232804	A1	20031218	US 2001-336994P	P 20011204
			US 2002-304070	20021125
			US 2001-336994P	P 20011204

OS MARPAT 139:22501

IT 536759-09-8P 536759-10-1P 536759-11-2P
536759-12-3P 536759-13-4P 536759-14-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of glycinamide heterocyclic derivs. as factor Xa inhibitors)


RN 536759-09-8 CAPLUS

CN 1-Pyrrolidineacetamide, N-[4-[[[4-chloro-2-[[[5-chloro-2-pyridinyl]amino]carbonyl]phenyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

<8/14/2004>

L3 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 536759-10 1 CAPLUS
CN Benzamide, 5-chloro-N-((5-chloro-2-pyridinyl)-2-[[4-[[dimethylamino]acetyl]methylamino]phenyl]methylamino)-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)





RN 536759-11-2 CAPLUS
CN Benzamide, 2-[[4-((acetylmethylamino)phenyl)methylamino]-5-chloro-N-((5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)





RN 536759-12-3 CAPLUS
CN Benzamide, N-((5-chloro-2-pyridinyl)-2-[[4-[[dimethylamino]acetyl]methylamino]phenyl]methylamino)-5-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 536759-13-4 CAPLUS
CN Benzamide, N-((5-chloro-2-pyridinyl)-2-[[4-[[dimethylamino]acetyl]methylamino]phenyl]methylamino)-5-methoxy- (9CI) (CA INDEX NAME)




RN 536759-14-5 CAPLUS
CN Benzamide, N-((5-chloro-2-pyridinyl)-2-[[4-[[dimethylamino]acetyl]methylamino]phenyl]methylamino)-5-methyl- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB Comps. P4-P-M-M4 [M is a 3-10 membered carbocycle or a 4-10 membered heterocycle; P is null or a 5-7 membered carbocycle or heterocycle fused to ring M; one of P4 and M4 is -Z-A-B and the other is -G1-G, where G is (un)substituted (fused) (hetero)aryl or (hetero)cyclyl; G1 is null or (un)substituted optionally-functionalized alk(en)(yn)yl; Z is a bond or (hetero)alkylene; A is (substituted) 3-10 membered carbocyclyl or 5-12 membered heterocyclyl; B is a functionalized amino group (with proviso)] or their pharmaceutically-acceptable salts were prepared for use as inhibitors of factor Xa. Thus, 1H-pyrazolo[3,4-c]pyridine derivative

1.TFA was prepared by reactions of 3-aminobenzamide, 3-hydroxy-1-(4-iodophenyl)-4-(trifluoroacetyl)-5,6-dihydro-2(1H)-pyridinone, chloroacetyl chloride, and dimethylamine.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:45257 CAPLUS
 DN 139:7167
 TI Preparation of glycineamide heterocyclic derivatives as factor Xa inhibitors
 IN Pinto, Donald J. P.; Han, Wei; Hu, Zilun
 PA Bristol-Myers Squibb Company, USA; Qiao, Jennifer
 SO PCT Int. Appl., 448 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003048081	A2	20030612	WO 2002-US37212	20021118
WO 2003048081	A3	20030912		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003232804	A1	20031218	US 2001-336994P	P 20011204
			US 2002-304070	20021125
			US 2001-336994P	P 20011204

PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003048158	A1	20030612	WO 2002-US38239	20021127
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003232804	A1	20031218	US 2001-336994P	P 20011204
			US 2002-304070	20021125
			US 2001-336994P	P 20011204

OS MARPAT 139:7167


IT 536759-09-0P 536759-10-1P 536759-11-2P

536759-12-3P 536759-13-4P 536759-14-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of glycineamide heterocyclic deriva. as factor Xa inhibitors)


L3 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 536759-11-2 CAPLUS
 CN Benzamide, 2-[[[4-(acetylaminophenyl)methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)]- (9CI) (CA INDEX NAME)



RN 536759-12-3 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[[dimethylamino]acetyl]methyl]amino]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 536759-13-4 CAPLUS
 CN Benzamide, 2-[[[4-[[[dimethylamino]acetyl]methyl]amino]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

Patel

L3 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 536759-09-8 CAPLUS
 CN 1-Pyrrolidineacetamide, N-[4-[[[4-chloro-2-[[[5-chloro-2-pyridinyl]amino]carbonyl]phenyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 536759-10-1 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[[[dimethylamino]acetyl]methyl]amino]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 536759-14-5 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[[dimethylamino]acetyl]methyl]amino]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



GI



I

AB Compd. P4-P-M-M4 [M is a 3-10 membered carbocycle or a 4-10 membered heterocycle; P is null or a 5-7 membered carbocycle or heterocycle fused to ring M; one of P4 and M4 is -Z-A-B and the other is -G1-G, where G is (un)substituted (fused) (hetero)aryl or (hetero)cyclyl; G1 is null or (un)substituted optionally-functionalized alk(en)(yn)yl; Z is a bond or (hetero)alkylene; A is (substituted) 3-10 membered carbocyclyl or 5-12 membered heterocyclyl; B is a functionalized amino group (with proviso(s)) or their pharmaceutically-acceptable salts were prepared for use as inhibitors of factor Xa. Thus, 1H-pyrazolo[3,4-c]pyridine derivative

<8/14/2004>

L3 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 was prepd. by reactions of 3-aminobenzamide,
 3-hydroxy-1-(4-iodophenyl)-4-
 (trifluoroacetyl)-5,6-dihydro-2(1H)-pyridinone, chloroacetyl chloride,
 and
 dimethylamine.

L3 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2004 ACS ON STN
 AN 2003:376824 CAPLUS
 DN 138:368777
 TI Preparation of pyridyl-substituted anthranilic acid amides for treating
 neoplastic disease
 IN Bold, Guido; Furet, Pascal; Manley, Paul William
 PA Novartis AG, Switz.; Novartis Pharma Gmbh
 SO PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003040101	A1	20030515	WO 2002 EP12445	20021107
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, TJ, TM, TN, TR, TZ, UA, US, UZ, VC, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR			
			GB 2001-26901	A 20011108
			GB 2002-12917	A 20020605

OS MARPAT 138:368777
 IT 324729-00-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridyl-substituted anthranilic acid amides for treating

neoplastic disease)


RN 524729-00-8 CAPLUS

CN Benzamide, 2-[[[3-[(methylamino)carbonyl]phenyl]methylamino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



AB The title compds. [I; Ar = II (wherein R_a = H, alkyl; and R₁ = H, perfluoroalkyl; R₂ = H, halo, alkyl, alkenyl, alkynyl); or Ar = 4-pyridyl and R₁ = perfluoroalkyl; R₂ = Br, I, alkyl, alkenyl, alkynyl; or R₁ = H, and R₂ = F, Br, I, Et, alkyl, alkenyl or alkynyl and their N-oxides and salts, useful for the treatment especially of a neoplastic disease, such as a

tumor disease, of retinopathy or age-related macular degeneration in the human or animal body, were prepared and formulated. Thus, reductive amination of 4-pyridinecarboxaldehyde with 2-amino-N-(4-bromo-3-trifluoromethylphenyl)benzamide (preparation given) in the presence of NaBH₃CN

afforded I [Ar = 4-pyridyl; R₁ = CF₃; R₂ = Br]. The IC₅₀ values that can be found for the compds. I are in range of 0.001 to 1 μM in test for activity against VEGF-receptor tyrosine kinase.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2004 ACS ON STN
 AN 2003:242305 CAPLUS
 DN 138:27175
 TI Preparation of 4,5-dihydro-1H-benzo[g]indazole-3-carboxamides for the treatment of inflammation
 IN Bergmanis, Arija A.; Bonafoux, Dominique; Clare, Michael; Crich, Joyce Z.;

Fletcher, Theresa R.; Geng, Lifeng; Hagen, Timothy J.; Hamper, Bruce C.; Hanson, Gunnar J.; Houdek, Stephen C.; Huang, He; Iula, Donna M.; Koszyk, Francis J.; Lennon, Patrick J.; Liao, Shuyuan; Liao, Subo; Metz, Suzanne; Mohler, Scott B.; Nguyen, Maria; Oburn, David S.; Owen, Thomas J.;

Partis, Richard A.; Scates, Angela M.; Stealey, Michael A.; Tollefson, Michael B.;

Vazquez, Michael L.; Weier, Richard M.; Wolfson, Serge G.; Xu, Xiangdong

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 331 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003024935	A2	20030327	WO 2002-US29774	20020919
WO 2003024935	A3	20030821		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
			US 2001-323423P	P 20010919
			US 2002-379090P	P 20020509
			US 2002-347096	20020919
			US 2001-323423P	P 20010919
			US 2002-379090P	P 20020509
EP 1444207	A2	20040811	EP 2002-775879	20020919
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
			US 2001-323423P	P 20010919
			US 2002-379090P	P 20020509
			WO 2002-US29774	20020919
			WO 2001-US8917	20010319

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003095430	A1	20031120		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
			US 2002-379090P	P 20020509

L3 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
WO 2002-US29774 A 20020919

PATENT FAMILY INFORMATION:

FAN 2003:913147

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003095430	A1	20031120	WO 2003-US8917	20030319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2002-379090P	P 20020509
WO 2003024935				WO 2002-US29774	A 20020919
WO 2003024935				WO 2002-US29774	20020919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2001-323423P	P 20010919
				US 2002-379090P	P 20020509


OS MARPAT 138:271675

IT 503555-09-7P, 1-[(1,3-Benzodioxol-5-yl)-8-[[[2-[(4-methoxybenzyl)amino]pyridin-3-yl]carbonyl]amino]-4,5-dihydro-1H-benzotriazole-3-carboxamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (IKK2 inhibitor; preparation of benzo[g]carboxamides as IKK2 inhibitors for treatment of cancer, inflammation, and inflammation associated disorders)


RN 503555-09-7 CAPLUS
 CN 1H-Benz[glindazole-3-carboxamide, 1-(1,3-benzodioxol-5-yl)-4,5-dihydro-8-[[[2-[(4-methoxyphenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]- (9CI)
 (CA INDEX NAME)

L3 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 H, or (un)substituted (aryl)alkyl, (hetero)aryl, heterocyclylalkyl, or heteroarylalkyl; R11 = H, halo, (halo)alkyl, CN, alkoxy, carbonyl, alkenyl, alkynyl, alkoxy, carbamoyl, etc.; R12 = H, halo, alkyl, or alkoxy; with proviso; and isomers, tautomers, carriers, esters, prodrugs, and pharmaceutically acceptable salts thereof were prep'd. via conventional and solid phase synthetic methods as IKK protein kinase β (IKK β or IKK2) inhibitors. For example, reaction of 7-nitro-1-tetralone with Et acetate in the presence of Li bis(trimethylsilyl)amide in ether gave the 1,3-diketone (87%), which was cyclized with 4-sulfonamidophenylhydrazine-HCl with HCl in MeOH to give the Et 1H-dihydrobenzo[glindazolecarboxylate (69%). Amidation with NH3OH in MeOH provided II. In IKK β resin enzyme assays, I exhibited IKK β activity with IC50 values ranging from $\leq 1 \mu\text{M}$ to $> 100 \mu\text{M}$. Thus, I are useful for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis (no data).

L3 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



G1



AB The present invention relates to substituted pyrazolyl deriva., compns. comprising such, intermediates, methods of making substituted pyrazolyl deriva., and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis. Title compds. I [wherein A = (un)substituted (CH2)m; m = 0-3; B = (un)substituted (hetero)aryl; X = N or C; Y and Z = independently N, C, CH, CR3, S, or O; R1 = H, halo, (halo)alkyl, (hetero)aryl, alkenyl, alkynyl, CN, NO2, alkoxy(carbonyl), carbamoyl, acyl, alkylthio, sulfamoyl, ureido, etc.; R2 = H, halo, (halo)alkyl, hydroxyalkyl, alkoxy, CN, NO2, alkylthio, amino, carbamoyl, ureido, CO2H, etc.; R3 = (un)substituted amidine, alkylamino, aminoalkyl, carbamoyl, NH2, or acylamino(methyl); R4 = H, halo, alkylsulfonfyl, alkylsulfonfyl, CN, alkoxy, carbonyl, (halo)alkyl, hydroxyalkyl, haloalkoxy, heterocyclyl, NO2, acylamino, (hetero)aryl, alkenyl, alkoxy, alkylthio, sulfamoyl, acyl, ureido, carbamoyl, etc.; R5

L3 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 2003:42101 CAPLUS
 DN 138:106502
 TI Preparation of biphenylcarboxylic acid amides as inhibitors of microsomal triglyceride transfer protein (MTP)
 IN Priepke, Henning; Haeu, Norbert; Dahmann, Georg; Thomas, Leo; Mark, Michael
 PA Boehringer Ingelheim Pharma K.-G., Germany
 SO PCT Int. Appl., 193 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN: CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003004020	A1	20030116	WO 2002-EP7215	20020629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10132686		A1	20030116	DE 2001-10132686 A 20010705
US 2003073836		A1	20030417	US 2002-187860 20020702
				DE 2001-10132686 A 20010705
				US 2001-304584P P 20010711

OS MARPAT 138:106502

IT 486436-62-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of biphenylcarboxylic acid amides as microsomal triglyceride transfer protein (MTP) inhibitors)


RN 486436-62-8 CAPLUS

CN 1H-Pyrole-2-carboxamide, 1-methyl-N-[(4'-methyl[1,1'-biphenyl]-4-yl)methyl]-4-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I

AB Title compds. I [X1 = CR1; X2 = CR2; X3 = CR3; X4 = CR4; with 1-2 of the groups being a N-atom; R1, R2, R3, R4 = H, halo, alkyl, etc.; A = O, S, NH, etc.; R5 = (un)substituted Ph, 1-naphthyl, 2-naphthyl, etc.; R6 = H, (un)substituted alkyl; R7 = (un)substituted alkyl; Y = 1-2 carbon atom(s) bound to (un)substituted 5-membered heteroaryl and their pharmaceutically acceptable salts were prepared. For example, coupling of acid II, e.g., prepared from 4-hydrazinobenzonitrile in 5-steps, and 4-phenylbenzylamine afforded biphenylcarboxylic acid amide III in 86% yield. In triglyceride transfer protein inhibition studies, compds. I exhibited IC50 values $\leq 100\mu\text{M}$. Compds. I are claimed useful as inhibitors of microsomal triglyceride transfer protein (MTP) for the treatment of atherosclerosis.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:22869 CAPLUS

DN 138:89806

TI Preparation of arylpyrazoles as soluble epoxide hydrolase inhibitors for treatment of cardiovascular disease.

IN Ingraham, Richard H.; Proudfoot, John R.

PA Boehringer Ingelheim Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003002555	A1	20030109	WO 2002-US18752	20020614
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003022929	A1	20030130	US 2002-172457	20020614
EP 1406892	A1	20040414	EP 2002-739870	20020614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004092567	A1	20040513	US 2001-302066P	20010629
US 2002-172457 W 20020614				
US 2003-670668 P 20030925				
US 2001-302066P P 20010629				
US 2002-172457 A1 20020614				

OS MARPAT 138:89806

IT 483342-21-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

for [Preparation of arylpyrazoles as soluble epoxide hydrolase inhibitors for treatment of cardiovascular disease]


RN 483342-21-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[4-{3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl}phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I

AB A method of treating cardiovascular disease comprises administration of title compds. I [R1, R3 = CF3, halo, cyano, alkyl, alkenyl, alkynyl, (substituted) cycloalkyl, heterocyclyl, etc.; R2 = H, halo, Me; L = NHCO, NHCS, NH, NHCH2, NHCOCO, etc.; R4 = (substituted) alkyl, alkoxy, alkylthio, alkylamino, alkoxyalkyl, alkylthioalkyl, carbocyclyl, heterocyclyl, etc.; R8 = H, NH2] (no data). Thus, 2-chloronicotinic acid in MeCN was treated with EDC and then with 1-(4-aminophenyl)-3-(3-pyridyl)-5-trifluoromethylpyrazole under ice cooling followed by stirring for 1 h to give I (R1 = 3-pyridyl; R2, R8 = H; R3 = CF3; L = NHCO; R4 = 2-chloropyridin-3-yl).

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:658116 CAPLUS

DN 137:201332

TI Preparation of heterocyclylalkylamine derivatives as remedies for angiogenesis mediated diseases

IN Chen, Guoqing; Adams, Jeffrey; Bemis, Jean; Booker, Shon; Cai, Guolin; Croghan, Michael; DiPietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Geuns-meyer, Stephanie; Handley, Michael; Huang, Qi; Kim, Joseph L.; Kim, Tae-seong; Kiselyov, Alexander; Ouyang, Xiaohu; Patel, Vinod P.; Smith, Leon M.; Stec, Markian; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang

PA Amgen Inc., USA

SO PCT Int. Appl., 502 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002066470	A1	20020829	WO 2002-US743	20020111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003125339	A1	20030703	US 2001-261339P	20010919
US 2001-323764P P 20010919				
US 2002-46681 A 20020110				
US 2002-46681 P 20020110				
US 2001-261339P P 20010112				
US 2001-323764P P 20010919				
BR 2002 6435 P 20020111				
US 2001-261339P P 20010112				
US 2001-323764P P 20010919				
US 2002-46681 A 20020110				
WO 2002-US743 W 20020111				
EP 2002-717325 W 20020111				
EP 1358184	A1	20031105	EP 2002-717325	20020111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2001-261339P P 20010112				
US 2001-323764P P 20010919				
US 2002-46681 A 20020110				
WO 2002-US743 W 20020111				
EE 200300324 A 20031215				
US 2001-261339P P 20010112				
US 2001-323764P P 20010919				
US 2002-46681 A 20020110				
NO 2003003181 A 20030911				
WO 2002-US743 W 20020111				
NO 2003-3181 P 20030711				
US 2001 261339P P 20010112				
US 2001-323764P P 20010919				
US 2002-46681 A 20020110				
WO 2002-US743 W 20020111				

PATENT FAMILY INFORMATION:

FAN 2003:950057

PATENT NO. KIND DATE APPLICATION NO. DATE

<8/14/2004>

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PI US 2003225106 A1 20031204 US 2002-197974 P 20020717
 US 2001-261339P P 20010112
 US 2001-323764P P 20010919
 US 2002-46681 A2 20020310
 US 2002-46681 20020110
 US 2001-261339P P 20010112
 US 2001-323764P P 20010919
 WO 2004007458 A1 20040122 WO 2003-US22417 20030715

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LJ, MC, NL, PT, RO, SE, SI, SK, TW, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002-197974 A 20020717

OS MARPAT 137:201332

IT 453561-07-4P 453561-08-5P 453561-23-4P
 453561-81-4P, 2-[(2,3-dihydrobenzofuran-5-ylmethyl)amino]-N-[3,3-dimethyl-1-(piperidin-4-ylmethyl)-2,3-dihydro-1H-indol-6-yl]nicotinamide
 453563-25-2P 453563-26-3P 453563-27-4P
 453563-28-5P 453563-33-2P 453563-34-3P
 453563-35-4P 453563-36-5P 453563-84-3P
 453564-40-4P 453564-41-5P 453564-42-6P
 453564-46-0P 453564-69-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclylalkylamine deriva. as remedies for angiogenesis mediated diseases)

RN 453561-07-4 CAPLUS


CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453561-08-5 CAPLUS


CN 3-Pyridinecarboxamide, N-(3,4-dichlorophenyl)-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453561-23-4 CAPLUS


CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453561-81-4 CAPLUS


CN 3-Pyridinecarboxamide, 2-[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinylmethyl)-1H-indol-6-yl]- (9CI) (CA INDEX NAME)



RN 453563-25-2 CAPLUS


CN 3-Pyridinecarboxamide, N-(4-(1,1-dimethylethyl)phenyl)-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 453563-26-3 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(6-quinolinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453563-27-4 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 453563-28-5 CAPLUS
 CN 3-Pyridinecarboxamide,
 2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-(3-
 (trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 453563-33-2 CAPLUS
 CN 3-Pyridinecarboxamide,
 2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-(4-
 [1-methyl-1-(1-methyl-4-piperidiny)ethyl]phenyl)- (9CI) (CA INDEX NAME)




RN 453563-34-3 CAPLUS
 CN 3-Pyridinecarboxamide,
 N (1-acetyl-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 453563-35-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[6-[[[2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 453563-36-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[2,3-dihydro-3,3-dimethyl-1-[[[1-methyl-4-piperidiny)methyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 453563-84-3 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[5-[[[2-[[[(2,3-dihydro-6-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 453564-40-4 CAPLUS
 CN 2(1H)-Isoquinolinecarboxylic acid, 7-[[[2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 453564-41-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinoliny)]- (9CI) (CA INDEX NAME)




RN 453564-42-6 CAPLUS
 CN 3-Pyridinecarboxamide,
 2-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-(4-(pentafluoroethyl)-3-[(2S)-2-pyrrolidinylmethoxy]phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 453564-46-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[[[(5-quinoliny)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)





RN 453564-69-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(7-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB Title compds. [I; A1, A2 independently = C, N; A = 5-, or 6-membered partially saturated heterocyclyl, 5-, or 6-membered heterocyclyl, 9-, or 10-membered fused partially saturated heterocyclyl, 9-, 10-, or 11-membered fused heteroaryl, naphthyl, 4-, 5-, or 6-membered cycloalkenyl; X = C:ZNR3, C:ZN(R3)R4; Z = O, S; Y = N:CH, NR5(CR6R7), R8N(R5)(CR6R7), NR5(CR6R7)R8; R = 5-, or 6 membered (un)substituted heterocyclyl, 9-, 10-, 11-membered heterocyclyl; R1 = 6-10 membered (un)substituted aryl, 5-, or 6-membered (un)substituted heterocyclyl, 9-11 membered (un)substituted fused heterocyclyl, cycloalkyl, cycloalkenyl; R2 = H, halo, oxo, SH, COOH, CHO; R3 = H, alkyl, 5-, or 6-membered heterocyclyl; R4 = alkynyl, alkenyl, alkynyl, alkynyl; R5 = H, alkyl, aralkyl, C6H5; R6, R7 independently = H, halo, CN, alkyl; R6R7 = cycloalkyl; R8 = alkynyl; etc.) are prepared and are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compds. as well as to intermediates useful in such processes. Thus, the title compound II was prepared from Me 3-amino-2-thiophenecarboxylate, 4-chloroaniline, and 4-pyridine carboxaldehyde via coupling reaction.

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:637637 CAPLUS
 DN 137:185325
 TI Preparation of acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenylamines as stimulators of endothelial NO-synthase transcription
 IN Strobel, Hartmut; Wohlfart, Paulus
 PA Aventis Pharma Deutschland GmbH, Germany
 SO ICT Int. Appl., 101 pp.
 CODEM: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064546	A2	20020822	WO 2002-EPI449	20020212
WO 2002064546	A3	20021107		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RN: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GG, GM, ML, MR, NE, SN, TD, TG				

EP 2001-102853 A 20010213
 EP 2001-102853 A 20010213
 WO 2002-EPI449 W 20020212
 EP 2002-722069 20020212
 EP 2001-102853 A 20010213
 WO 2002-EPI449 W 20020212
 US 2002-73203 20020213


EP 2001-102853 A 20010213
 WO 2002-EPI449 W 20020212
 JP 2004518720 T2 20040624
 BR 2002007197 A 20040706
 US 2003008915 A1 20030109
 US 6759412 B2 20040706
 NO 2003003566 A 20031013

OS MARPAT 137:185325
 IT 450368-07-79
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (eNOS transcription stimulator; preparation of acylated tetrahydrobenzocycloheptenylamines as stimulators of endothelial NO synthase transcription)
 RN 450368-07-7 CAPLUS
 CN 2-Pyridinecarboxamide, 6-chloro-3-[(phenylmethyl)amino]-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




GI



AB Title compds. I (wherein R1 and R4 = independently H, (pseudo)halo, CF3, NO2, or (un)substituted alkyl, alkenyl, alkynyl, Ph, heteroaryl, amino, alkoxy, sulfamoyl, etc.; R2 and R3 = independently H, (pseudo)halo, OH, PhO, alkoxy, CF3, CN, NO2, or (un)substituted alkyl, amino, acylamino, etc.; A = CH2, CHOH, or CH(alkyl); B, C, and D = independently CH2 or CH(alkyl); R5 = (un)substituted (hetero)aryl; and stereoisomers, mixts., or pharmaceutically acceptable salts thereof) were prepared as stimulators of endothelial NO-synthase (eNOS) transcription, which has a vasodilating effect and inhibits the aggregation of platelets, the adhesion of leukocytes to the endothelium, and the proliferation of intimal smooth muscle cells. For example, amidation of 4-fluorobenzoic acid chloride with 6,7,8,9-tetrahydro-5H-benzocyclohepten-6-ylamine in the presence of TEA in dioxane afforded II. The latter activated eNOS transcription in primary human umbilical vein cord endothelial cells (HUVEC) with EC50 of 0.02 μM. I are useful for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchial, chronic renal failure, cirrhosis of the liver, osteoporosis, or restricted memory performance or for a restricted ability to learn, or the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives (no data).

L3 ANSWER 16 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:603273 CAPLUS
 DN 138:122629
 TI Synthesis of 1,4-benzodiazepine-2,5-dione derivatives
 AU Ho, Tong-Ing; Chen, Wen-Shiong; Hsu, Chi-Wei; Tsai, Yeun-Min; Fang, Jim-Min
 CS Dep. of Chem., National Taiwan Univ., Taipei, Taiwan
 SO Heterocycles (2002), 57(8), 1501-1506
 CODEN: HETCYM; ISSN: 0385-5414
 PB Japan Institute of Heterocyclic Chemistry
 DT Journal
 LA English
 OS CASREACT 138:122629
 IT 489446-50-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 2,5-dioxo-1H-1,4-benzodiazepine-3-carboxylate deriv.)
 RN 489446-50-6 CAPLUS
 CN Benzamide, N-(4-methoxyphenyl)-2-[[[(3-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



AB A synthesis of a series of 1,4-benzodiazepine-2,5-dione derivs. with a carboxy group at the 3-position is realized in good yields by using Me malonylchloride as a key reagent and intramol. nucleophilic substitution as ring closure reaction. The synthesis of 4-(4-Methoxyphenyl)-1-[(3-methoxyphenyl)methyl]-2,5-dioxo-1H-1,4-benzodiazepine-3-carboxylic acid ester was described.
 RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:539663 CAPLUS
 DN 137:109210
 TI Preparation of substituted arylamine derivatives and methods of use as antitumor agents
 IN Chen, Guoqing; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celis; Elbaum, Daniel; Germain, Julie; Huang, Qi; Kim, Joseph L.; Kim, Tae-Seong; Patel, Vinod F.; Smith, Leon M.; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang
 PA Amgen Inc., USA
 SO PCT Int. Appl., 253 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN CNT 2


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055501	A2	20020718	WO 2002-US742	20020111
WO 2002055501	A3	20021219		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002147198	A1	20021010	US 2002-46526	A 20020110
EP 1358161	A2	20031105	EP 2002-717324	20020111
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
			US 2002-46526	A 20020110
			US 2001-323686P	P 20010919
			US 2001-323686P	P 20010919
			US 2002-46526	A 20020110
			US 2002-46526	A 20020110
			WO 2002 US742	W 20020111

PATENT FAMILY INFORMATION:
 FAN 2003:551181

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003134836	A1	20030717	US 2002-197960	20020717
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
			US 2002-46526	A 20020110
US 2002147198	A1	20021010	US 2002-46526	20020110
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
WO 2004007457	A2	20040122	WO 2003-US22276	20030715
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,			


L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2002-197960 A 20020717

OS MARPAT 137:109210
 IT 442847-21-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of substituted aminopyridines as antitumor agents)
 RN 442847-21-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinylmethyl)-1H-indol-6-yl]-2-[[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




IT 442845-77-4P 442846-13-1P 442846-17-5P
 442846-22-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (target compound; preparation of substituted aminopyridines as antitumor agents)
 RN 442845-77-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-13-1 CAPLUS
 CN 1-Pyrrrolidinecarboxylic acid, 2-[[[5-[[[2-[[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 442846-17-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[6-[[[2-[[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-22-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-acetyl-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-6-yl)-2-[[[4-fluorophenyl]methyl]amino]- (9CI) (CA INDEX NAME)




IT 442845-71-8P 442845-72-9P 442845-73-0P
 442845-78-5P 442845-79-6P 442845-80-9P
 442845-81-0P 442845-82-1P 442845-83-2P
 442845-84-3P 442845-85-4P 442845-86-5P
 442845-87-6P 442845-88-7P 442845-89-8P
 442845-90-1P 442845-91-2P 442845-92-3P
 442845-93-4P 442845-94-5P 442845-95-6P

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-73-0 CAPLUS
 CN 2-Pyridinecarboxamide, N-(3-fluoro-4-methylphenyl)-3-[[[4-methoxyphenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-78-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[3-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

442845-96-7P 442845-97-8P 442845-99-0P
 442846-00-6P 442846-01-7P 442846-02-8P
 442846-03-9P 442846-04-0P 442846-05-1P
 442846-06-2P 442846-07-3P 442846-08-4P
 442846-09-5P 442846-10-6P 442846-11-7P
 442846-12-8P 442846-14-2P 442846-15-3P
 442846-16-4P 442846-18-6P 442846-19-7P
 442846-20-0P 442846-21-1P 442846-23-3P
 442846-24-4P 442846-25-5P 442846-26-6P
 442846-27-7P 442846-28-8P 442846-29-9P
 442846-30-2P 442846-31-3P 442846-32-4P
 442846-33-5P 442846-34-6P 442846-35-7P
 442846-36-8P 442846-38-0P 442846-39-1P
 442846-40-4P 442846-42-6P 442846-44-8P
 442846-46-0P 442846-48-2P 442846-50-6P
 442846-52-8P 442846-53-9P 442847-23-6P

RL: PAC (Pharmacological activity); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(target compd.; prepn. of substituted aminopyridines as antitumor agents)

RN 442845-71-8 CAPLUS
 CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[[[phenylmethyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-72-9 CAPLUS
 CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[[[4-nitrophenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-79-6 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-fluorophenyl]methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 442845-80-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[3-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-81-0 CAPLUS
 <8/14/2004>

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 3-Pyridinecarboxamide, 2-[[[(2-bromophenyl)methyl]amino]-N-(4-phenoxyphenyl)]- (9CI) (CA INDEX NAME)




RN 442845-82-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[4-(trifluoromethoxy)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-83-2 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,3-difluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442845-84-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[[[4-cyanophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-85-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[[[(2-cyanophenyl)methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-86-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-(4-(2-methylpropyl)phenyl)]- (9CI) (CA INDEX NAME)




RN 442845-87-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-(1,1-dimethylethyl)phenyl)-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442845-88-7 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3-methoxyphenyl)methyl]amino]-N-(4-(1-


L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 methylethyl)phenyl)]- (9CI) (CA INDEX NAME)




RN 442845-89-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3-aminophenyl)methyl]amino]-N-(4-(1-methylethyl)phenyl)]- (9CI) (CA INDEX NAME)




RN 442845-90-1 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-(4-(1-methylethyl)phenyl)]- (9CI) (CA INDEX NAME)




L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 442845-91-2 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-92-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-93-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(phenylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-97-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,4-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-99-0 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3,4-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




Patel


L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 442845-94-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(3-chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-95-6 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(4-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442845-96-7 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(4-chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 442846-00-6 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,3-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-01-7 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-02-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[(2,6-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-03-9 CAPLUS

<8/14/2004>

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 3-Pyridinecarboxamide, 2-[[[3-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-04-0 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-fluorophenyl)methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-05-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-[3-[3-(dimethylamino)propyl]-5-(trifluoromethyl)phenyl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-06-2 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl)methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-07-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl)methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-08-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-bromo-2-fluorophenyl)-2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-09-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-(4-(1,1-dimethylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl)-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-10-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-fluoro-3-[3-(4-morpholinyl)-1-propynyl]phenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-11-9 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[1,3-benzodioxol-5-yl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-12-0 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-[3-{2-(1-pyrrolidinyl)ethoxy}-4-(trifluoromethyl)phenyl]-9CI] (CA INDEX NAME)




RN 442846-14-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[2-[[2-[[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-15-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(1-methyl-4-piperidinyl)-1H-indol-6-yl]-2-[[[4-(4-fluorophenyl)methyl]amino]-9CI] (CA INDEX NAME)




RN 442846-16-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[1-[(dimethylamino)acetyl]-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl]-2-[[[4-(4-fluorophenyl)methyl]amino]-9CI] (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-18-6 CAPLUS
 CN Carbamic acid, [2-[6-[[[2-[[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 442846-19-7 CAPLUS
 CN 2(1H)-Isoquinolinecarboxylic acid, 7-[[[2-[[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-3,4-dihydro-4,4-dimethyl-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-20-0 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[2-[[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 442846-21-1 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[2-[[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-23-3 CAPLUS
 CN 1 Piperidinecarboxylic acid,
 4 [[3-[[[2-[[[4-(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-24-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-25-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-[3-[(2R)-2-pyrrolidinylmethoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 442846-26-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-piperidinylmethoxy)phenyl]-2-[[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-27-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]-2-[[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 442846-28-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[4-(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-29-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[1-(aminoacetyl)-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl]-2-[[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-30-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinyl)-1H-indol-6-yl]-2-[[[4-(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-31-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-[3-(4-piperidinylmethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-32-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-[[1-methyl-4-piperidinyl)methyl]-1H-indol-6-yl]-2-[[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-35-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-[4-[[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 442846-36-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-2-oxo-7-quinoliny)- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-33-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino]-N-[3-[[[(2S)-1-methyl-2-pyrrolidinyl)methoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 442846-34-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-[[1-methyl-4-piperidinyl)methyl]-1H-indol-6-yl]-2-[[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-38-0 CAPLUS
CN 3-Pyridinecarboxamide, N-5-benzofuranyl-2-[[[3-(hydroxymethyl)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-39-1 CAPLUS
CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-2-[[[3-(hydroxymethyl)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 442846-40-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(3,4-difluorophenyl)methyl]amino]-N-(4-(1,1-dimethyl-2-oxo-7-quinoliny)- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
dimethylethyl]-3-[[2-(1-piperidinylethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 442846-42-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinylethyl)amino]phenyl]-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 442846-44-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinylethyl)amino]phenyl]-2-[[4-(fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-46-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[[4-(fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 442846-48-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-(fluorophenyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-(2-pyrrolidinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 442846-50-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-(fluorophenyl)methyl]amino]-N-[3-(2-pyrrolidinylmethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442846-52-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(2-pyrrolidinylmethoxy)phenyl]-2-[[[4-(fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-53-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-(fluorophenyl)methyl]amino]-N-[3-[(1-methyl-2-pyrrolidinyl)methoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 442847-23-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3-(fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 442845 77-4
CMF C25 H20 F N3 O2

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 76 05-1
CMF C2 H F3 O2

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I (B1 and B2 independently equal C or N, wherein B1B2 form part of 5-6 membered heteroaryl ring A; R1 = one or more substituents selected from H, halo, oxo, (un)substituted cycloalkyl, phenylalkyl, etc.; R2 = (un)substituted cycloalkyl, cycloalkenyl, 6-10 membered aryl or 5-6 membered heterocyclyl, etc.; R3 = (un)substituted aryl; R4 = H, alkyl, (un)substituted Ph or aralkyl; X1 = bond, alkynyl, alkenyl and alkynyl, where one of the CH2 groups may be substituted with O or NH, wherein X1 is optionally substituted with OH; X2 = (un)substituted N containing linker, e.g., -NHCH2-, and there pharmaceutically acceptable derivs., are prepared and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. Thus, II was prepared via arylation of 1-dimethylamino-2-propyne with 3-bromo-5-trifluoromethylbenzylamine, hydrogenation, amidation with 2-chloropyridine-3-carbonyl chloride and chloro-substitution with 4-fluorobenzylamine. Selected compds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below 50 nM. The

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable deriva. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

L3 ANSWER 18 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:171853 CAPLUS

DN 136:232201

TI Preparation of cyclic amine derivatives as CCR3 antagonists

IN Morihira, Koichiro; Inami, Hiroshi; Kubota, Hirokazu; Yokoyama, Kazuhiro; Morokata, Tatsuki; Takeuchi, Makoto; Takahashi, Toshiya; Kaneko, Masayuki; Inaoka, Takayuki; Torii, Yuichi; Iura, Yosuke

PA Yamanouchi Pharmaceutical Co., Ltd., Japan; Toray Industries, Inc.

SO PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002018335	A1	20020307	WO 2001-JP7321	20010827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001080187	A5	20020313	JP 2000-257451	A 20000828
			AU 2001-20187	20010827
			JP 2000-257451	A 20000828
			WO 2001-JP7321	W 20010827

OS MARPAT 136:232201


IT 403477-79-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyclic amine deriva. as CCR3 antagonists)


RN 403477-79-2 CAPLUS

CN Benzamide, 2-[[[(2-chlorophenyl)methyl]amino]-N-[8-[(6-fluoro-2-naphthalenyl)methyl] 8-azabicyclo[3.2.1]oct-3-yl]]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 18 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The title compds. I [ring A = (un)substituted heterocyclic ring, etc.; X = bond, O, CO, etc.; ring B = Q1, etc.; ring V3 = hydrocarbon ring, etc.; Y = CH, N; Y = CO, etc.; R21, R22 = H, halo, etc.; T1 = (CH2)n; n = 0 - 2; ring D = (un)substituted aryl, etc.] are prepared in an in vitro test (for CCR3 antagonism) using cells, compds. of this invention showed IC50 values of 0.001 μM to 0.45 μM.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS ON STN
 AN 200211104 CAPLUS
 DN 136:69743
 TI Preparation of pyridyl benzamides and related compounds as Factor Xa inhibitors.
 IN Zhu, Bing-Yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Erick A.; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
 PA USA
 SO U.S. Pat. Appl. Publ., 259 pp., Cont.-in-part of U.S. Ser. No. 663,420.
 CODEN: USXMOO
 DT Patent
 LA English
 FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002002183	A1	20020103	US 2001-794225	20010228
US 6376515	B2	20020423		
US 2003162690	A1	20030828	US 2000-185746P	P 200000229
			US 2000-663420	A2 20000915
			US 2002-126976	P 20000229
			US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
			US 2001-794225	A1 20010228
US 2004097561	A1	20040520	US 2003-687334	20031015
			US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
			US 2001-794225	A1 20010228
			US 2002-126976	A1 20020422

PATENT FAMILY INFORMATION:

FAN 2001:208239

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001019788	A2	20010322	WO 2000-US25196	20000915
WO 2001019788	A3	20010809		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000074867	A5	20010417	US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
			US 2000-74867	20000915
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
			WO 2000-US25196	W 20000915
EP 1216228	A2	20020626	EP 2000-963452	20000915
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
			US 2000-US25196	W 20000915

L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 BR 2000014076 A 20021015 BR 2000-14076 20000915
 US 1999-154332P P 19990917
 US 2000-185746P P 20000229
 WO 2000-US25196 W 20000915
 JP 2001-523368 20000915
 US 1999-154332P P 19990917
 US 2000-185746P P 20000229
 WO 2000-US25196 W 20000915
 NO 2002001229 A 20020521 NO 2002-1229 20020312
 US 1999-154332P P 19990917
 US 2000-185746P P 20000229
 WO 2000-US25196 W 20000915

FAN 2001:208248

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001019798	A2	20010322	WO 2000-US25195	20000915
WO 2001019798	A3	20011025		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000074866	A5	20010417	US 1999-154332P	P 19990917
			US 1999-154332P	P 19990917
			WO 2000-US25195	W 20000915
EP 1216231	A2	20020626	EP 2000-963451	20000915
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
			US 1999-154332P	P 19990917
			WO 2000-US25195	W 20000915
BR 2000014078	A	20021231	BR 2000-14078	20000915
			US 1999-154332P	P 19990917
TR 200201413	T2	20030221	WO 2000-US25195	W 20000915
			TR 2002-200201413	20000915
JP 2003509412	T2	20030311	US 1999-154332P	P 19990917
			JP 2001-523378	20000915
			US 1999-154332P	P 19990917
			WO 2000-US25195	W 20000915
NZ 517828	A	20031031	NZ 2000-517828	20000915
			US 1999-154332P	P 19990917
NO 2002001230	A	20020521	WO 2000-US25195	W 20000915
			NO 2002-1230	20020312
			US 1999-154332P	P 19990917
			WO 2000-US25195	W 20000915

FAN 2001:661391

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001064642	A2	20010907	WO 2001-US6247	20010228
WO 2001064642	A3	20020502		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 2000-185746P P 200000229
 US 2000-663420 A 20000915

FAN 2001:661392

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001064643	A2	20010907	WO 2001-US6255	20010228
WO 2001064643	A3	20020404		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1259485	A2	20021127	EP 2001-918257	20010228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2000-185746P	P 20000229
			US 2000-663420	A 20000915
			WO 2001-US6255	W 20010228

FAN 2002:522631

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002091116	A1	20020711	US 2001-794214	20010228
US 6632815	B2	20031014		
US 6720317	B1	20040413	US 1999-154332P	P 19990917
			US 2000-662807	A2 20000915
US 6686368	B1	20040203	US 2000-662807	P 20000915
			US 1999-154332P	P 19990917
			US 2003-387927	20030112
			US 1999-154332P	P 19990917
			US 2000-662807	A3 20000915
US 2004116399	A1	20040617	US 2003-600695	20030620
			US 1999-154332P	P 19990917
			US 2000-662807	A2 20000915
			US 2001-794214	A1 20010228

OS MARPAT 136:69743

IT 358659-61-7P 358659-62-8P 358659-63-9P

358659-64-0P 358659-65-1P 358659-66-2P

358659-67-3P 358659-68-4P 358659-69-5P

358659-70-6P 358659-71-7P 358659-72-8P

358659-73-9P 358659-74-0P 358659-75-1P

358659-76-2P 358659-77-3P 358659-78-4P

358659-79-5P 358659-80-6P 358659-81-7P

358659-82-8P 358659-83-9P 358659-84-0P

358659-85-1P 358659-86-2P 358659-87-3P

358659-88-4P 358659-89-5P 358659-90-6P

358659-91-7P 358659-92-8P 358659-93-9P

358659-94-0P 358659-95-1P 358659-96-2P

358659-97-3P 358659-98-4P 358659-99-5P

358659-100-6P 358659-101-7P 358659-102-8P

358659-103-9P 358659-104-0P 358659-105-1P

358659-106-2P 358659-107-3P 358659-108-4P

358659-109-5P 358659-110-6P 358659-111-7P

358659-112-8P 358659-113-9P 358659-114-0P

358659-115-1P 358659-116-2P 358659-117-3P

358659-118-4P 358659-119-5P 358659-120-6P

358659-121-7P 358659-122-8P 358659-123-9P

358659-124-0P 358659-125-1P 358659-126-2P

358659-127-3P 358659-128-4P 358659-129-5P

358659-130-6P 358659-131-7P 358659-132-8P

358659-133-9P 358659-134-0P 358659-135-1P

358659-136-2P 358659-137-3P 358659-138-4P

358659-139-5P 358659-140-6P 358659-141-7P

358659-142-8P 358659-143-9P 358659-144-0P

358659-145-1P 358659-146-2P 358659-147-3P

358659-148-4P 358659-149-5P 358659-150-6P

358659-151-7P 358659-152-8P 358659-153-9P

358659-154-0P 358659-155-1P 358659-156-2P

358659-157-3P 358659-158-4P 358659-159-5P

358659-160-6P 358659-161-7P 358659-162-8P

358659-163-9P 358659-164-0P 358659-165-1P

358659-166-2P 358659-167-3P 358659-168-4P

358659-169-5P 358659-170-6P 358659-171-7P

358659-172-8P 358659-173-9P 358659-174-0P

358659-175-1P 358659-176-2P 358659-177-3P

358659-178-4P 358659-179-5P 358659-180-6P

358659-181-7P 358659-182-8P 358659-183-9P

358659-184-0P 358659-185-1P 358659-186-2P

358659-187-3P 358659-188-4P 358659-189-5P

358659-190-6P 358659-191-7P 358659-192-8P

358659-193-9P 358659-194-0P 358659-195-1P

358659-196-2P 358659-197-3P 358659-198-4P

358659-199-5P 358659-200-6P 358659-201-7P

358659-202-8P 358659-203-9P 358659-204-0P

358659-205-1P 358659-206-2P 358659-207-3P

358659-208-4P 358659-209-5P 358659-210-6P

358659-211-7P 358659-212-8P 358659-213-9P

358659-214-0P 358659-215-1P 358659-216-2P

358659-217-3P 358659-218-4P 358659-219-5P

358659-220-6P 358659-221-7P 358659-222-8P

358659-223-9P 358659-224-0P 358659-225-1P

358659-226-2P 358659-227-3P 358659-228-4P

358659-229-5P 358659-230-6P 358659-231-7P

358659-232-8P 358659-233-9P 358659-234-0P

358659-235-1P 358659-236-2P 358659-237-3P

358659-238-4P 358659-239-5P 358659-240-6P

358659-241-7P 358659-242-8P 358659-243-9P



358659-244-0P 358659-245-1P 358659-246-2P

358659-247-3P 358659-248-4P 358659-249-5P


358659-250-6P 358659-251-7P 358659-252-8P

358659-253-9P 358659-254-0P 358659-255-1P

L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-64-0 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-65-1 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-morpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-69-5 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-74-2 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-thiomorpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-75-3 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperazinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-76-4 CAPLUS

Patel


L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-66-2 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[[[4-(dimethylamino)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-67-3 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-68-4 CAPLUS
 CN Benzamide, 2-[[[4-(1-azetidinylinomethyl)phenyl]methyl]amino]-5-chloro N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino(4-methyl-1-piperazinyl)methyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-77-5 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[[hexahydro-1H-azepin-1-yl]iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-78-6 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[[4-(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)




RN 358659-79-7 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)

<8/14/2004>


L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-80-0 CAPLUS
 CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 358659-81-1 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-piperidinymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-82-2 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-87-7 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinymethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-88-8 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-pyrrolidinymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-83-3 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-84-4 CAPLUS
 CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-85-5 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinymethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R2C(NR3), (substituted) Ph, naphthyl, heterocyclyl, etc.; R1-R3 = H, OR5, NR5R6, alkyl, alkenyl, etc.;

R1R2 or R2R3 = atoms to form (substituted) cycloalkyl, heterocyclyl; R5, R6 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted) alkylphenyl, alkylphenyl; R5R6 = atoms to form a 3-8 membered (substituted) ring; Q =

bond, CH2, CO, O, S, SO, SO2, NR7, SO2NR7, etc.; R7 = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, (substituted) alkylphenyl, alkylphenyl; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, O, S, SO, SO2, alkylcarbonyl, etc.; G = (substituted) alkyl, cycloalkyl, phenylene, 3-8 membered (fused) (aromatic) heterocyclyl; J = bond, NR9CO, O, S, SO, SO2, CH2, NR9SO2, etc.; X =

(substituted) Ph, naphthyl, (fused) heteroaryl, were prepared as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl)-2-aminophenylcarboxamide (preparation given), 4-cyanobenzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 70% N-(5-bromo-2-pyridinyl)-2-(4-cyanophenylcarbonyl)aminophenylcarboxamide. The latter in MeOH at 0° was saturated with HCl and stirred overnight followed by solvent evaporation. The residue was refluxed 2 h with NH4OAc in MeOH to give 70% N-(5-bromo-2-pyridinyl)-[2-(4-aminophenylcarbonyl)amino]phenylcarboxamide.

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:661392 CAPLUS
 DN 135:226888
 TI Preparation of pyridyl benzamides and related compounds as Factor Xa inhibitors.
 IN Zhu, Bing-yan; Zhang, Pengjie; Wang, Lingyan; Huang, Wenrong; Goldman, Erick; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
 PA Cor Therapeutics, Inc., USA
 SO PCT Int. Appl., 322 pp.
 DT Patent
 LA English
 FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064643	A2	20010907	WO 2001-US6255	20010228
WO 2001064643	A3	20020404		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1259485	A2	20021127	EP 2001-918257	
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2000-185746P	P	20000229		
US 2000-663420	A	20000915		
US 2000-185746P	P	20000229		
US 2000-663420	A	20000915		
WO 2001-US6255	W	20010228		

PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019788	A2	20010322	WO 2000-US25196	20000915
WO 2001019788	A3	20010809		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2000074867	A5	20010417	AU 2000-74867	20000915
US 1999-154332P	P	19990917		
US 2000-185746P	P	20000229		
US 1999-154332P	P	19990917		
US 2000-185746P	P	20000229		
WO 2000-US25196	W	20000915		
EP 2000-963452	EP	20000915		

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI WO 2001064642 A2 20010907 WO 2001-US6247 20010228
 WO 2001064642 A3 20020502

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

FAN 2002:11104
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI US 2002002183 A1 20020103 US 2001-794225 20010228
 US 6376515 B2 20020423

US 2000-185746P P 20000229
 US 2000-663420 A2 20000915
 US 2002-126976 20020422
 US 2000-185746P P 20000229
 US 2000-663420 A2 20000915
 US 2001-794225 A1 20010228
 US 2003-687334 20031015
 US 2000-185746P P 20000229
 US 2000-663420 A2 20000915
 US 2001-794225 A1 20010228
 US 2002-126976 A1 20020422

FAN 2002:522631
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI US 2002091116 A1 20020711 US 2001-794214 20010228
 US 6632815 B2 20031014

US 1999-154332P P 19990917
 US 2000-662807 A2 20000915
 US 2000-662807 20000915
 US 1999-154332P P 19990917
 US 2003-387947 20030312
 US 1999-154332P P 19990917
 US 2000-662807 A3 20000915
 US 2003-600695 20030620
 US 1999-154332P P 19990917
 US 2000-662807 A2 20000915
 US 2001-794214 A1 20010228

OS MARPAT 135:226888
 IT 358659-61-7P 358659-62-8P 358659-63-9P
 358659-64-0P 358659-65-1P 358659-66-2P
 358659-67-3P 358659-68-4P 358659-69-5P
 358659-74-2P 358659-75-3P 358659-76-4P
 358659-77-5P 358659-78-6P 358659-79-7P
 358659-80-0P 358659-81-1P 358659-82-2P
 358659-83-3P 358659-84-4P 358659-85-5P
 358659-87-7P 358659-88-8P

RU: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

Patel

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

US 1999-154332P P 19990917
 US 2000-185746P P 20000229
 WO 2000-US25196 W 20000915
 BR 2000-14076 P 19990917
 US 1999-154332P P 19990917
 US 2000-185746P P 20000229
 WO 2000-US25196 W 20000915
 JP 2001-523368 20000915
 US 1999-154332P P 19990917
 US 2000-185746P P 20000229
 WO 2000-US25196 W 20000915
 NO 2002-1229 20000915
 US 1999-154332P P 19990917
 US 2000-185746P P 20000229
 WO 2000-US25196 W 20000915

FAN 2001:208248
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI WO 2001019798 A2 20010322 WO 2000-US25196 20000915
 WO 2001019798 A3 20011025

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 1999-154332P P 19990917
 AU 2000074866 A5 20010417 AU 2000-74866 20000915
 US 1999-154332P P 19990917
 WO 2000-US25196 W 20000915
 EP 2000-963451 20000915

EP 1216231 A2 20020626
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

BR 2000014078 A 20021231
 BR 2000-14078 20000915
 US 1999-154332P P 19990917
 WO 2000-US25196 W 20000915
 TR 2002-200201413 20000915


US 1999-154332P P 19990917
 JP 2001-523378 20000915
 US 1999-154332P P 19990917
 WO 2000-US25196 W 20000915
 NZ 2000-517828 20000915

US 1999-154332P P 19990917
 NZ 517828 A 20031031 NZ 2000-517828 20000915
 WO 2000-US25196 W 20000915
 NO 2002-1230 20020312
 US 1999-154332P P 19990917
 WO 2000-US25196 W 20000915



FAN 2001:661391

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of pyridyl benzamides and related compounds as Factor Xa inhibitors)

RN 358659-61-7 CAPLUS
 CN Benzamide, 5-chloro-N-[(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]-9CI] (CA INDEX NAME)





RN 358659-62-8 CAPLUS
 CN Benzamide, 2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-9CI] (CA INDEX NAME)




RN 358659-63-9 CAPLUS
 CN Benzamide, N-[(5-chloro-2-pyridinyl)-2-[[[4-(imino(methylamino)methyl)phenyl]methyl]amino]-9CI] (CA INDEX NAME)

<8/14/2004>

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-64-0 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-65-1 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-morpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-69-5 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-74-2 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-thiomorpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-75-3 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperazinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-76-4 CAPLUS

Patel


L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-66-2 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(dimethylamino)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-67-3 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-68-4 CAPLUS
 CN Benzamide, 2-[[[4-(1-azetidinylinomethyl)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino(4-methyl-1-piperazinyl)methyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-77-5 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-((hexahydro-1H-azepin-1-yl)iminomethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-78-6 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-((dimethylamino)iminomethyl)phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)




RN 358659-79-7 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)

<8/14/2004>


L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-80-0 CAPLUS
 CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 358659-81-1 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-82-2 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-87-7 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-88-8 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-83-3 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-84-4 CAPLUS
 CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-85-5 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R2C(NR3), (substituted) Ph, naphthyl, heterocyclyl, etc.; R1-R3 = H, OR5, NR5R6, alkyl, alkenyl, etc.;

R1R2 or R2R3 = atoms to form (substituted) cycloalkyl, heterocyclyl; R5, R6 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted) alkylphenyl, alkylphenyl; R5R6 = atoms to form a 3-8 membered (substituted) ring; Q =

bond, CH2, CO, O, S, SO, SO2, NR7, SO2NR7, etc.; R7 = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, (substituted) alkylphenyl, alkylphenyl; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, O, S, SO, SO2, alkylcarbonyl, etc.; G = (substituted) alkyl, cycloalkyl, phenylene, 3-8 membered (fused) (aromatic) heterocyclyl; J = bond, NR9CO, O, S, SO, SO2, CH2, NR9SO2, etc.; X =

(substituted) Ph, naphthyl, (fused) heteroaryl, were prepared as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl)-2-aminophenylcarboxamide (preparation given), 4-cyanobenzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 70% N-(5-bromo-2-pyridinyl)-2-(4-cyanophenylcarbonyl)aminophenylcarboxamide. The latter in MeOH at 0° was saturated with HCl and stirred overnight followed by solvent evaporation. The residue was refluxed 2 h with NH4OAc in MeOH to give

70%
 N-(5-bromo-2-pyridinyl)-2-(4-amidinophenylcarbonyl)aminophenylcarboxamide.

L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 AN 2001:661392 CAPLUS
 DN 135:210946
 TI Preparation of pyridylamides as Factor Xa inhibitors.
 IN Zhu, Bing-yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Erick; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
 PA Cor Therapeutics, Inc., USA
 SO PCT Int. Appl., 306 pp.
 CODEN: PIXXD2
 Patent
 LA English
 FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001064642	A2	20010907	WO 2001-US6247	20010228
WO 2001064642	A3	20020502		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
			US 2000-185746P	P 20000229
			US 2000-663420	A 20000915

PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FAN 2001:208239				
PI WO 2001019788	A2	20010322	WO 2000-US25196	20000915
WO 2001019788	A3	20010809		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
			AU 2000-74867	A 20000915
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
			WO 2000-US25196	W 20000915
EP 1216228	A2	20020626	EP 2000-963452	20000915
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
			WO 2000-US25196	W 20000915
BR 2000014076	A	20021015	BR 2000-14076	20000915
			US 1999-154332P	P 19990917

L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 JP 2003509406 T2 20030311
 NO 2002001229 A 20020521
 US 2000-185746P P 20000229
 US 2000-US25196 W 20000915
 US 1999-154332P P 19990917
 US 2000-185746P P 20000229
 WO 2000-US25196 W 20000915

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FAN 2001:208248				
PI WO 2001019798	A2	20010322	WO 2000-US25196	20000915
WO 2001019798	A3	20011025		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
			US 1999-154332P	P 19990917
			AU 2000-74866	A 20000915
			US 1999-154332P	P 19990917
			WO 2000-US25196	W 20000915
EP 1216231	A2	20020626	EP 2000-963451	20000915
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
			US 1999-154332P	P 19990917
			BR 2000-14078	B 20000915
			BR 2000-14078	20000915
			US 1999-154332P	P 19990917
			WO 2000-US25196	W 20000915
TR 200201413	T2	20030221	TR 2002-200201413	20000915
			US 1999-154332P	P 19990917
JP 2003509412	T2	20030311	JP 2003-523378	20000915
			US 1999-154332P	P 19990917
			WO 2000-US25196	W 20000915
NZ 517828	A	20031031	NZ 2000-517828	20000915
			US 1999-154332P	P 19990917
			WO 2000-US25196	W 20000915
NO 2002001230	A	20020521	NO 2002-1230	20000915
			US 1999-154332P	P 19990917
			WO 2000-US25196	W 20000915

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FAN 2001:661392				
PI WO 2001064643	A2	20010907	WO 2001-US6255	20010228
WO 2001064643	A3	20020404		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
			WO 2000-US25196	W 20000915
			BR 2000-14076	20000915
			US 1999-154332P	P 19990917

L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1259485 A2 20021127
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 2000-185746P P 20000229
 US 2000-663420 A 20000915
 WO 2001-US6255 W 20010228


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002002183	A1	20020103	US 2001-794225	20010228
US 6376515	B2	20020423		
US 2003162690	A1	20030828	US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
			US 2002-126976	20020422
			US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
US 2004097561	A1	20040520	US 2001-794225	A1 20010228
			US 2003-687334	20031015
			US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
			US 2001-794225	A1 20010228
			US 2002-126976	A1 20020422

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FAN 2002:522631				
PI US 2002091116	A1	20020711	US 2001-794214	20010228
US 6632815	B2	20031014		
US 6720317	B1	20040413	US 1999-154332P	P 19990917
			US 2000-662807	A2 20000915
			US 2000-662807	20000915
			US 1999-154332P	P 19990917
US 6686368	B1	20040203	US 2003-387927	20030312
			US 1999-154332P	P 19990917
			US 2000-662807	A3 20000915
			US 2003-600695	20030620
US 2004116399	A1	20040617	US 1999-154332P	P 19990917
			US 2000-662807	A2 20000915
			US 2001-794214	A1 20010228


OS MARPAT 135:210946
 IT 358659-61-7P 358659-62-8P 358659-63-9P
 358659-64-0P 358659-65-1P 358659-66-2P
 358659-67-3P 358659-68-4P 358659-69-5P
 358659-70-6P 358659-71-7P 358659-72-8P
 358659-73-9P 358659-74-0P 358659-75-1P
 358659-76-2P 358659-77-3P 358659-78-4P
 358659-79-5P 358659-80-6P 358659-81-7P
 358659-82-8P 358659-83-9P 358659-84-0P
 358659-85-1P 358659-86-2P 358659-87-3P
 358659-88-4P 358659-89-5P
 R: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

Patel

L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 (prepn. of pyridylamides as Factor Xa inhibitors)
 RN 358659-61-7 CAPLUS
 CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinyl)methyl]phenyl]methylamino]- (9CI) (CA INDEX NAME)





RN 358659-62-8 CAPLUS
 CN Benzamide, 2-[[[4-(aminoiminomethyl)phenyl]methylamino]-N-(5-chloro-2-pyridinyl)] (9CI) (CA INDEX NAME)




RN 358659-63-9 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino(methylamino)methyl]phenyl]methylamino]- (9CI) (CA INDEX NAME)

<8/14/2004>

L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-64-0 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-65-1 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-morpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-69-5 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-74-2 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-thiomorpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-75-3 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperazinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-76-4 CAPLUS

Patel


L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-66-2 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(dimethylamino)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-67-3 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-68-4 CAPLUS
CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino(4-methyl-1-piperazinyl)methyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-77-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(hexahydro-1H-azepin-1-yl)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-78-6 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)




RN 358659-79-7 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)

<8/14/2004>


L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-80-0 CAPLUS
 CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 358659-81-1 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 358659-82-2 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 358659-87-7 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-88-8 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-83-3 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)




RN 358659-84-4 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-85-5 CAPLUS
 CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R1C(NR3), (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl, etc.; R1-R3 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (alkyl)aryl, (alkyl)heteroaryl, etc.; R1R2 or R2R3 = atoms to form a 3-8 membered (substituted) (heterocyclic) ring; Q = bond, CH2, CO, O, NR7, etc.; R7 = H, alkyl, (alkyl)aryl, (alkyl)heteroaryl, etc.; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, S, SO, SO2, alkoxy, etc.; G = (substituted) alkenyl, cycloalkenyl, phenylene, heterocyclyl, fused cyclic system; J = bond, NR9CO, O, S, SO, SO2, SO2NR9, CH2, NR9, etc.; R9 = H, alkyl, (alkyl)aryl, etc.; X = (substituted) Ph, naphthyl, heteroaryl, fused bicyclic], were prepared as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl)-2-aminophenylcarboxamide (preparation given), 4-[(2-tert-butylamino)phenyl]benzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 85% N-(5-bromo-2-pyridinyl)-2-4-[(2-aminosulfonyl)phenyl]phenylcarboxylaminophenylcarboxamide.

L3 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:565010 CAPLUS
 DN 135:137407
 TI Preparation of 2-aminonicotinamides as VEGF-receptor tyrosine kinase inhibitors
 IN Manley, Paul William; Bold, Guido
 FA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
 SO PCT Int. Appl., 66 pp.
 CODEN: PAXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001055114	A1	20010802	WO 2001-EP835	20010125
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, MY, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001028499	A5	20010807	GB 2000-1930	A 20000127
AU 771626	B2	20040401	AU 2001-28499	20010125
BR 2001007805	A	20021022	WO 2001-EP835	A 20000127
			BR 2001-7805	W 20010125
			GB 2000-1930	A 20000127
			WO 2001-EP835	W 20010125
EP 1259487	A1	20021127	EP 2001-946854	20010125
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003520853	T2	20030708	GB 2000-1930	A 20000127
			WO 2001-EP835	W 20010125
			JP 2001-555056	20010125
			GB 2000-1930	A 20000127
			WO 2001-EP835	W 20010125
NZ 520005	A	20040227	NZ 2001-520005	20010125
			GB 2000-1930	A 20000127
			WO 2001-EP835	W 20010125
NO 2002003218	A	20020916	NO 2002-3218	20020702
			GB 2000-1930	A 20000127
US 2003032656	A1	20030213	US 2002-181005	20020711
US 6624174	B2	20030923		
ZA 2002005988	A	20030728	GB 2000-1930	A 20000127
			WO 2001-EP835	W 20010125
			ZA 2002-5988	20020726
			GB 2000-1930	A 20000127


OS MARPAT 135:137407
 IT 62636-33-3P 352227-86-2P 352227-92-0P
 352228-00-3P

L3 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of 2-aminonicotinamides as VEGF-receptor tyrosine kinase inhibitors)
 RN 62636-33-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[3-(trifluoromethyl)phenyl], monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 352227-86-2 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-[(methylamino)carbonyl]phenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl] (9CI) (CA INDEX NAME)




RN 352227-92-0 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-(4-hydroxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl] (9CI) (CA INDEX NAME)


L3 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 352228-00-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[[[3-(4-hydroxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl] (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; n = 1-6; W = O, S; R1, R3 = H, alkyl, acyl; R2 = (un)substituted cycloalkyl, aryl, mono- or bicyclic heteroaryl comprising one or more ring N atoms and 0-2 heteroatoms selected from O and S; R, R' = H, alkyl; X = (un)substituted aryl, mono- or bicyclic heteroaryl comprising one or more ring N atoms and 0-2 heteroatoms selected from O and S] and their pharmaceutically acceptable salts, useful for therapy of

Patel

L3 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 a disease which responds to an inhibition of the VEGF-receptor tyrosine kinase activity (such as neoplastic disease), were prepd. and formulated. Thus, amidation of 3-aminobenzotrifluoride with 2-chloronicotinoyl chloride followed by reacting 4-pyridineethanamine with the resulting carboxamide afforded I [n = 2; R, R' = H; X = 4-pyridyl; W = O; R1, R3 = H; R2 = 3-(F3C)C6H4].
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



<8/14/2004>

L3 ANSWER 23 OF 37 CAPLUS COPYRIGHT 2004 ACS ON STN
 AN 2000:457059 CAPLUS
 DN 133:89437
 TI Preparation of heteroaryl-substituted aromatic amides as factor Xa inhibitors
 IN Beight, Douglas Wade; Craft, Trelia Joyce; Denny, Carl Penman; Franciskovich, Jeffrey Bernard; Goodson, Theodore, Jr.; Hall, Steven Edward; Herron, David Kent; Joseph, Sajan Pariyadan; Klimkowski, Valentine
 Joseph: Masters, John Joseph; Mendel, David; Milot, Guy; Pineiro-Nunez, Maria Maria; Sawyer, Jason Scott; Shuman, Robert Theodore; Smith, Gerald Floyd; Tebbe, Anne Louise; Tinsley, Jennifer Marie; Weir, Leonard Crayton; Wikel, James Howard; Wiley, Michael Robert; Yee, Ying Kwong
 PA Eli Lilly and Co., USA; Kyle, Jeffrey, Alan; et al.
 SO PCT Int. Appl., 403 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000039118	A1	20000706	WO 1999-US29946	19991215
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2361149	AA	20000706	CA 1999-2361149	19991215
US 1998-113556P				P 19981223
EP 1140903	A1	20011010	WO 1999-US29946	19991215
EP 1140903	B1	20040804	EP 1999-964279	19991215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002533454	T2	20021008	US 1998-113556P	P 19981223
US 6635657	B1	20031021	US 1998-113556P	P 19981223
US 2004029874	A1	20040212	US 1998-113556P	P 19981223
US 6759414	B2	20040706	US 1998-113556P	P 19981223
US 2001-857751			US 1999-US29946	W 19991215
US 2001-857751			US 2001-857751	A3 20010608

OS MARPAT 133:89437
 IT 200769-65-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological)

L3 ANSWER 23 OF 37 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 [prep. of heteroaryl-substituted arom. amides as factor Xa inhibitors]
 RN 280769-65-5 CAPLUS
 CN Benzamide,
 2-[[[4-(acetylamino)phenyl]methyl]amino]-5-chloro-N-[5-chloro-2-pyridinyl]- (9CT) (CA INDEX NAME)



GI



II

AB The title compds. [I; A3-A6, together with the two carbons to which they are attached, complete a substituted benzene in which A3 = CR3, A4 = CR4, A5 = CR5, and A6 = CR6 (wherein R3 = H, Me, MeO, etc.; one of R4 and R5 = H, alkyl, halo, etc.; the other of R4 and R5 = H; R6 = H, Me, F, etc.);
 L1 = CONH; Q1 = 2-pyridinyl (un)substituted at the 5-position, 3-pyridinyl (un)substituted at the 6-position, 2-pyrimidinyl (un)substituted at the 5-position, etc.; R2 = L2Q2 (L2 = NHCO, NHCH2, OCH2, etc.; Q2 = (un)substituted piperidinyl, piperazinyl, Ph, etc.) and their pharmaceutically acceptable salts, useful as inhibitors of factor Xa (no data), were prepared and formulated. E.g., a multi-step synthesis of
 II.HCl
 was given. In general, compds. I are effective at 0.01-1000 mg/kg/day.
 RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 37 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

L3 ANSWER 24 OF 37 CAPLUS COPYRIGHT 2004 ACS ON STN
 AN 2000:33588 CAPLUS
 DN 132:347491
 TI Preparation of N-aryl(thio)anthranilic acid amides as VEGF receptor tyrosine kinase inhibitors
 IN Altmann, Karl-Heinz; Bold, Guido; Furet, Pascal; Manley, Paul William; Wood, Jeanette Marjorie; Ferrari, Stefano; Hofmann, Francesco; Meston, Jürgen; Huth, Andreas; Krüger, Martin; Seidelmann, Dieter; Menrad, Andreas; Haberey, Martin; Thierauch, Karl-Heinz
 PA Novartis A. G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Schering Aktiengesellschaft
 SO PCT Int. Appl., 77 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000027820	A1	20000518	WO 1999-EP8545	19991108
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2346898	AA	20000518	CA 1999-2346898	19991108
GB 1998-24579				A 19981110
BR 9915210	A	20010724	WO 1999-EP8545	W 19991108
BR 1999-15210				A 19981110
TR 200101237	T2	20010821	WO 1999-EP8545	W 19991108
EP 1129075	A1	20010905	TR 2001-200101237	19991108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002529453	T2	20020910	GB 1998-24579	A 19981110
AU 758230	B2	20030320	WO 1999-EP8545	W 19991108
NZ 511339	A	20030725	AU 2000-13811	19991108
NO 2001001894	A	20010704	GB 1998-24579	A 19981110
ZA 2001003290	A	20030123	WO 1999-EP8545	W 19991108
US 2002019414	A1	20020214	ZA 2001-3290	20010423
US 6448277	B2	20020910	GB 1998-24579	A 19981110
			US 2001-850434	20010507
			GB 1998-24579	A 19981110
			WO 1999-EP8545	W 19991108

L3 ANSWER 24 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 ZA 2001004673 A 20020909 ZA 2001-4673 20010607
 US 2003064992 A1 20030403 GB 1998-24579 A 19981110
 US 2002-180289 20020626
 GB 1998-24579 A 19981110
 WO 1999-EP8545 W 19991108
 US 2001-850434 A3 20010507

PATENT FAMILY INFORMATION:
 FAN 2000.335387
 PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2000027819 A2 20000518 WO 1999-EP8478 19991109
 WO 2000027819 A3 20000817

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TH, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MM, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

GB 1998-24579 A 19981110
 DE 1999-19910396 A 19990303
 DE 1999-19910396 19990303

DE 19910396 A1 20000907
 DE 19910396 C2 20011213
 BR 9915553 A 20010814

BR 1999-15553 19991109
 GB 1998-24579 A 19981110
 DE 1999-19910396 A 19990303
 WO 1999-EP8478 W 19991109
 EP 1999-953967 19991109

EP 1129074 A2 20010905
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

GB 1998-24579 A 19981110
 DE 1999-19910396 A 19990303
 WO 1999-EP8478 W 19991109

TR 200101307 T2 20020521
 TR 2001-200101307 19991109

GB 1998-24579 A 19981110
 DE 1999-19910396 A 19990303
 JP 2000-580999 19991109

JP 2002529452 T2 20020910
 GB 1998-24579 A 19981110
 DE 1999-19910396 A 19990303
 WO 1999-EP8478 W 19991109

EE 200100258 A 20021216
 EE 2001-258 19991109

GB 1998-24579 A 19981110
 DE 1999-19910396 A 19990303
 WO 1999-EP8478 W 19991109

NZ 511413 A 20040130
 NZ 1999-511413 19991109
 GB 1998-24579 A 19981110
 DE 1999-19910396 A 19990303


WO 1999-EP8478 W 19991109
 AU 2000-10454 19991109
 GB 1998-24579 A 19981110

DE 1999-19910396 A 19990303
 WO 1999-EP8478 W 19991109
 NO 2001002245 A 20010710 NO 2001-2245 20010507


L3 ANSWER 24 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 prepn. of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity is claimed. Thus, a mixt. of 4-pyridinecarboxaldehyde and 2-amino-N-(4-(trifluoromethylphenyl)benzamide (prepn. given) in MeOH contg.
 HOAc was treated with NaBH3CN followed by 16 h stirring to give 2-[(4-pyridyl)methyl]amino-N-(4-(trifluoromethylphenyl)benzamide.
 Tested
 I inhibited Flt-1 VEGF receptor tyrosine kinase with IC50 = 0.18-0.56 µM.
 RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 24 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 GB 1998-24579 A 19981110
 DE 1999-19910396 A 19990303
 WO 1999-EP8478 W 19991109
 BG 105588 A 20020430 BG 2001-105588 20010611
 GB 1998-24579 A 19981110
 DE 1999-19910396 A 19990303
 WO 1999-EP8478 W 19991109

OS MARPAT 132.347491
 IT 269390-99-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-aryl(thio)anthranilic acid amides as VEGF receptor tyrosine kinase inhibitors)
 RN 269390-99-0 CAPLUS
 CN Benzamide, 2-[(5-quinolinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




GI




AB Use of title compds. I; W = O, S; X = NR8; Y = CR9R10(CH2)n, SO2; R9, R10 = H, alkyl; n = 0-3; R1 = aryl; R2 = mono- or bicyclic heteroaryl with the exception that R2 cannot = 2-phthalimidyl, and when Y = SO2 cannot represent 2,1,3-benzothiadiazol-4-yl; R3-R6 = H, substituent; R7, R8 = H, alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof, for the

L3 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1999.409260 CAPLUS
 DN 131.73440
 TI Preparation of aromatic amide derivatives as ACC inhibitor
 IN Igawa, Hiroshi; Nishimura, Masato; Okada, Keiji; Nakamura, Takashi
 PA Fujirebio, Inc., Japan
 SO Jpn. Kokai Tokkyo Koho, 72 pp.
 CODEN: JKKXAF
 DT Patent
 LA Japanese
 FAN.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI JP 11171848 A2 19990629 JP 1998-270721 19980925
 JP 1997-277942 19970926

OS MARPAT 131.73440
 IT 228580-97-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of aromatic amide derivs. as ACC inhibitor)
 RN 228580-97-0 CAPLUS
 CN Benzoic acid, 2-[(2-[(phenylethynyl)amino]-5-(phenylethynyl)benzoyl]amino]- (9CI) (CA INDEX NAME)




IT 228580-60-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of aromatic amide derivs. as ACC inhibitor)
 RN 228580-60-7 CAPLUS
 CN Benzoic acid, 2-[(2-[(phenylethynyl)amino]benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




IT 228580-61-0P 228580-84-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)

<8/14/2004>


L3 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(prepn. of arom. amide deriva. as ACC inhibitor)
RN 228580 61-8 CAPLUS
CN Benzoic acid, 2-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 228580 84-5 CAPLUS
CN Benzoic acid, 2-[[2-[(3-phenylpropyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)



GI



AB Title compds. [I; R = 3-CF3C6H4, C6H5(CH2)2, C6H5, CH3(CH2)5, CH3(CH2)3, CH3(CH2)2, CH3CH2, CH3, C6H5(CH2)3, etc.; R1 = H, CH3(CH2)4, 5-CH3(CH2)SCC, 5-CH3CH2CC, 5-(CH3)3CC, 4-C6H5CH2O, 4-C6H5CC, 3-C6H5CC, 3-(4-NO2C6H4)CC, 3-(4-NCC6H4)CC, 3-(4-HOC6H4)CC, etc.; R2 = 5-OH, 5-Cl, 5-OMe, 5-Me, 5-Br, etc.; R3 = H, CH3, etc.; R4 = CO2H, AcNHCO2, CH3(CH2)4CONHCO2, 4-CF3C6H4CONHCO2, PhCONHCO2, (CH3)3CONHCO2, CH3(CH2)2NHCONHCO2, etc.; X = CH, N; dotted bond = single, double] are prepared and tested as ACC (acetyl-CoA carboxylase) inhibitors in treatment of lipids oxidation related diseases, such as myocardial infarction, cerebral infarction, and diabetes. The title compound I (R = 3-CF3C6H4; R1 = H; R2 =

L3 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:236274 CAPLUS
DN 128:282780
TI Preparation of heterocyclic inhibitors of microsomal triglyceride transfer protein
IN Biller, Scott A.; Dickson, John K.; Lawrence, R. Michael; Magnin, David R.; Poon, Michael A.; Sulsky, Richard B.; Tino, Joseph A.
PA Bristol-Myers Squibb Co., USA
SO U.S., 185 pp., Cont.-in-part of U.S. Ser. No. 391,901, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN: CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5739135	A	19980414	US 1995-472067	19950606
			US 1993-117362	A2 19930903
			US 1994-284808	B2 19940805
			US 1995-391901	B2 19950221
CA 2091102	AA	19930907	CA 1993 2091102	19930305
HU 67962	A2	19950529	US 1992-847503	A 19920306
HU 218419	B	20000828	HU 1993-627	19930305
JP 06038761	A2	19940215	US 1992-847503	A 19920306
			JP 1993-46499	19930308
			US 1992-847503	A 19920306
EP 584446	A2	19940302	EP 1993-103697	19930308
EP 584446	A3	19950426		
EP 584446	B1	20020619		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
SE AT 219514	E	20020715	US 1992-847503	A 19920306
			AT 1993-103697	19930308
PT 584446	T	20020930	US 1992-847503	A 19920306
			PT 1993-103697	19930308
ES 2178640	T3	20030101	US 1992-847503	A 19920306
			ES 1993-103697	19930308
AU 670930	B2	19960808	US 1992-847503	A 19920306
AU 9334064	A1	19930909	AU 1993-34064	19930309
US 5595872	A	19970121	US 1992-847503	A 19920306
			US 1993-117362	19930903
			US 1992-847503	B2 19920306
			US 1993-15449	B2 19930222
US 5789197	A	19980804	US 1995-486924	19950607
			US 1992-847503	B2 19920306
			US 1993-15449	B2 19930222
			US 1993-117362	A3 19930903
US 6492365	B1	20021210	US 1995-486929	19950607
			US 1992-847503	B2 19920306
			US 1993-15449	B2 19930222
			US 1993-117362	A3 19930903
US 5712279	A	19980127	US 1996-548811	19960111
			US 1995-391901	B2 19950221
			US 1995-472067	A2 19950606
IL 116917	A1	20000831	IL 1996-116917	19960126
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
TW 486469	B	20020511	TW 1996-85100978	19960126

Patel

L3 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
H; R3 = H; X = CH; dotted bonds were double bonds) was prepd. with 72% yield from 3-EtO2CC6H4NH2 and 3-(2-HO2CC6H4NH)C6H4CF3.

CA 2213466	AA	19960829	US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			CA 1996-2213466	19960201
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
WO 9626205	A1	19960829	WO 1996-US824	19960201
W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AU 9647631	A1	19960911	US 1995-391901	A 19950221
AU 699865	B2	19981217	US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
CN 1176640	A	19980318	CN 1996-192015	19960201
CN 1108301	B	20030514		
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
EP 886637	A1	19981230	EP 1996-903604	19960201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, NZ				
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
JP 11500442	T2	19990112	JP 1996-525679	19960201
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
NZ 302055	A	20000228	NZ 1996-302055	19960201
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
PL 185443	B1	20030530	PL 1996-322003	19960201
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
ZA 9601340	A	19970911	ZA 1996-1340	19960220
			US 1995-391901	A 19950221
US 5883099	A	19990316	US 1997-896872	19970721
			US 1993-117362	A2 19930903
			US 1994-284808	B2 19940805
			US 1995-391901	B2 19950221
			US 1995-472067	A3 19950606
US 6034098	A	20000307	US 1997-898304	19970721
			US 1993-117362	A2 19930903
			US 1994-284808	B2 19940805
			US 1995-391901	B2 19950221
			US 1995-472067	A3 19950606
US 6066650	A	20000523	US 1997-898303	19970721
			US 1993-117362	A2 19930903
			US 1994-284808	B2 19940805
			US 1995-391901	B2 19950221
			US 1995-472067	A1 19950606
FI 9703416	A	19970820	FI 1997-3416	19970820
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201

<8/14/2004>


L3	ANSWER 26 OF 37	CAPLUS	COPYRIGHT 2004 ACS on STN	(Continued)
NO 9703821	A	19970820	US 1997-3821	19970820
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
LT 4367	B	19980825	WO 1996-US824	W 19960201
			LT 1997-152	19970919
LV 11951	B	19981120	US 1995-391901	A 19950221
			LV 1997-171	19970919
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
US 2003166590	A1	20030904	US 2001-933593	20010821
			US 1992-847503	B2 19920306
			US 1993-15449	B2 19930222
			US 1993-117362	A3 19930903
			US 1995-486929	A3 19950607
PATENT FAMILY INFORMATION:				
FAN	1995:568500			
PI	EP 643057	A1	19950315	EP 1994-113800
SE	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,			19940902
	CA 2091102	AA	19930907	US 1993-117362
				CA 1993-2091102
	ZA 9301601	A	19931005	US 1992-847503
				ZA 1993-1601
	HU 67962	A2	19950529	US 1992-847503
	HU 218419	B	20000828	HU 1993-627
	JP 06038761	A2	19940215	US 1992-847503
				JP 1993-46499
	EP 584446	A2	19940302	US 1992-847503
	EP 584446	A3	19950426	EP 1993-103697
	EP 584446	B1	20020619	19930308
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,			
SE	AT 219514	E	20020715	US 1992-847503
				AT 1993-103697
	PT 584446	T	20020930	US 1992-847503
				PT 1993-103697
	ES 2178640	T3	20030101	US 1992-847503
				ES 1993-103697
	AU 670930	B2	19960808	US 1992-847503
	AU 9334064	A1	19930909	AU 1993-34064
				US 1992-847503
	US 5595872	A	19970121	US 1993-117362
				US 1992-847503
				US 1993-15449
	CA 2131430	AA	19950304	CA 1994-2131430
				US 1993-117362
	FI 9404048	A	19950304	FI 1994-4048
				US 1993-117362
	NO 9403260	A	19950306	NO 1994-3260
				US 1993-117362

L3	ANSWER 26 OF 37	CAPLUS	COPYRIGHT 2004 ACS on STN	(Continued)
AU 9471642	A1	19950316	AU 1994-71642	19940902
AU 690125	B2	19980422		
ZA 9406772	A	19950403	US 1993-117362	A 19930903
			ZA 1994-6772	19940902
JP 07165712	A2	19950627	US 1993-117362	A 19930903
			JP 1994-210057	19940902
CN 1106003	A	19950802	US 1993-117362	A 19930903
			CN 1994-115640	19940902
HU 70613	A2	19951030	US 1993-117362	A 19930903
			HU 1994-2542	19940902
US 5789197	A	19980804	US 1993-117362	A 19930903
			US 1995-486929	19950607
			US 1992-847503	B2 19920306
			US 1993-15449	B2 19930222
			US 1993-117362	A3 19930903
US 6492365	B1	20021210	US 1995-486929	19950607
			US 1992-847503	B2 19920306
			US 1993-15449	B2 19930222
US 2003166590	A1	20030904	US 1993-117362	A3 19930903
			US 2001-933593	20010821
			US 1992-847503	B2 19920306
			US 1993-15449	B2 19930222
			US 1993-117362	A3 19930903
			US 1995-486929	A3 19950607
PATENT NO. KIND DATE APPLICATION NO. DATE				
FAN	1996:641305			
PI	WO 9626205	A1	19960829	WO 1996-US824
SE	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			19960201
	CA 2091102	AA	19930907	US 1995-391901
				US 1995-472067
	HU 67962	A2	19950529	CA 1993-2091102
	HU 218419	B	20000828	US 1992-847503
	JP 06038761	A2	19940215	HU 1993-627
				US 1992-847503
	EP 584446	A2	19940302	JP 1993-46499
	EP 584446	A3	19950426	US 1992-847503
	EP 584446	B1	20020619	EP 1993-103697
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,			19930308
SE	AT 219514	E	20020715	US 1992-847503
				AT 1993-103697
	PT 584446	T	20020930	US 1992-847503
				PT 1993-103697
	ES 2178640	T3	20030101	US 1992-847503
				ES 1993-103697
	AU 670930	B2	19960808	US 1992-847503
	AU 9334064	A1	19930909	AU 1993-34064
				19930309
				US 1992-847503
				A 19920306

L3	ANSWER 26 OF 37	CAPLUS	COPYRIGHT 2004 ACS on STN	(Continued)
US 5739135	A	19980414	US 1995-472067	19950606
			US 1993-117362	A2 19930903
			US 1994-284808	B2 19940805
AU 9647631	A1	19960911	US 1995-391901	B2 19950221
AU 699865	B2	19981217	AU 1996-47631	19960201
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
EP 886637	A1	19981230	EP 1996-903604	19960201
IE	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
JP 11500442	T2	19990112	US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
NZ 302055	A	20000228	NZ 1996-302055	19960201
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
PL 185443	B1	20030530	WO 1996-US824	W 19960201
			PL 1996-322003	19960201
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
ZA 9601340	A	19970911	WO 1996-US824	W 19960201
			ZA 1996-1340	19960220
FI 9703416	A	19970820	US 1995-391901	A 19950221
			FI 1997-3416	19970820
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
NO 9703821	A	19970820	WO 1996-US824	W 19960201
			NO 1997-3821	19970820
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
			LT 1997-152	19970919
			US 1995-391901	A 19950221
LT 4367	B	19980825	US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
			LT 1997-152	19970919
			US 1995-391901	A 19950221
PATENT NO. KIND DATE APPLICATION NO. DATE				
FAN	1998:115356			
PI	US 5712279	A	19980127	US 1996-548811
				US 1995-391901
				US 1995-472067
	CA 2091102	AA	19930907	CA 1993-2091102
				US 1992-847503
	HU 67962	A2	19950529	A 19920306
	HU 218419	B	20000828	HU 1993-627
	JP 06038761	A2	19940215	US 1992-847503
				JP 1993-46499
	EP 584446	A2	19940302	US 1992-847503
	EP 584446	A3	19950426	EP 1993-103697
	EP 584446	B1	20020619	19930308
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,			
SE	AT 219514	E	20020715	US 1992-847503
				AT 1993-103697


L3	ANSWER 26 OF 37	CAPLUS	COPYRIGHT 2004 ACS on STN	(Continued)
PT 584446	T	20020930	US 1992-847503	A 19920306
			PT 1993-103697	19930308
ES 2178640	T3	20030101	US 1992-847503	A 19920306
			ES 1993-103697	19930308
AU 670930	B2	19960808	US 1992-847503	A 19920306
AU 9334064	A1	19930909	AU 1993-34064	19930309
US 5739135	A	19980414	US 1992-847503	A 19920306
			US 1995-472067	19950606
			US 1993-117362	A2 19930903
			US 1994-284808	B2 19940805
ZA 9601340	A	19970911	US 1995-391901	B2 19950221
LT 4367	B	19980825	LT 1997-152	19970919
			US 1995-391901	A 19950221
OS	MARPAT 128:282780			
IT	182429-79-4P			
	RL: RAC (Biological activity or effector, except adverse); BSU			
	(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);			
	BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(preparation of heterocyclic inhibitors of microsomal triglyceride			
	transfer protein)			
	RN 182429-79-4 CAPLUS			
	CN 9H Fluorene-9-carboxamide,			
	9-[4-[[[2-[[[phenylmethyl]amino]benzoyl]amino]-			
	1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)			

PAGE 1 A



L3 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I-V; Q = C(O), S(O)2; X = CHR8, C(O), CHR9CHR10, CR9; CR10 (wherein R8-R10 = H, alkyl, alkenyl, etc.); Y = (CH2)m, C(O) (m = 2-3); R1 = alkyl, alkenyl, alkynyl, etc.; R2-R4 = H, halo, alkyl, etc.;

R5 = alkyl, alkenyl, alkynyl, etc.; R6 = H, C1-4 alkyl, C1-4 alkenyl which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases such as hyperglycemia and obesity, were prepared. Thus, reaction of 1-(3,3-diphenylpropyl)-4-piperidinamine.HCl (preparation described) with benzoyl chloride in the presence of Et3N in CH2Cl2 afforded 84% the title compound III.HCl [Q = C(O); R1 = 3,3-diphenylpropyl; R5 = Ph; R6 = H]. Compds. I-V are effective at 5-500 mg/day.

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1996:641305 CAPLUS

DN 125:275663

TI Preparation of 9-(piperidinoalkyl)fluorene-9-carboxamides and analogs as microsomal triglyceride transfer protein inhibitors
IN Wetterau, John R. II; Sharp, Daru Young; Gregg, Richard E.; Biller, Scott A.; Dickson, John A.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Robl, Jeffrey A.; et al.

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 427 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9626205	A1	19960829	WO 1996-US824	19960201
W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA				
RM: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2091102	AA	19930907	US 1995-391901	A 19950221
HU 67962	A2	19950529	US 1995-472067	A 19950606
HU 218419	B	20000828	CA 1993-2091102	A 19930305
			US 1992-847503	A 19920306
JP 06038761	A2	19940215	HU 1993-627	19930305
EP 584446	A2	19940302	US 1992-847503	A 19920306
EP 584446	A3	19950426	JP 1993-46499	19930308
EP 584446	B1	20020619	US 1992-847503	A 19920306
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			EP 1993-103697	19930308
AT 219514	E	20020715	US 1992-847503	A 19920306
PT 584446	T	20020930	AT 1993-103697	19930308
ES 2178640	T3	20030101	US 1992-847503	A 19920306
AU 670930	B2	19960808	PT 1993-103697	19930308
AU 9334064	A1	19930909	US 1992-847503	A 19920306
US 5739135	A	19980414	ES 1993-103697	19930308
			US 1992-847503	A 19920306
AU 9647631	A1	19960911	AU 1993-34064	19930309
AU 699865	B2	19981217	US 1992-847503	A 19920306
			US 1995-472067	19950606
EP 886637	A1	19981230	US 1993-117362	A2 19930903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE			US 1994-284808	B2 19940805
			US 1995-391901	B2 19950221
			AU 1996-47631	19960201
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
			EP 1996-903604	19960201

L3 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

JP 11500442	T2	19990112	US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
			JP 1996-525679	19960201
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			NO 1996-US824	W 19960201
NZ 302055	A	20000228	NZ 1996-302055	19960201
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			PL 1996-322003	19960201
PL 185443	B1	20030530	US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
			ZA 1996-1340	19960220
ZA 9601340	A	19970911	US 1995-391901	A 19950221
			US 1995-472067	A 19950606
FI 9703416	A	19970820	FI 1997-3416	19970820
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
NO 9703821	A	19970820	NO 1997-3821	19970820
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
LT 4367	B	19980825	LT 1997-152	19970919
			US 1995-391901	A 19950221

PATENT FAMILY INFORMATION:

FAN 1995:568500

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 643057	A1	19950315	EP 1994-113800	19940902
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				

CA 2091102	AA	19930907	US 1993-117362	A 19930903
ZA 9301601	A	19931005	CA 1993-2091102	A 19930305
HU 67962	A2	19950529	US 1992-847503	A 19920306
HU 218419	B	20000828	ZA 1993-1601	A 19930305
			US 1993-117362	A 19930903
JP 06038761	A2	19940215	HU 1993-627	A 19930305
EP 584446	A2	19940302	US 1992-847503	A 19920306
EP 584446	A3	19950426	JP 1993-46499	19930308
EP 584446	B1	20020619	US 1992-847503	A 19920306
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			EP 1993-103697	19930308
AT 219514	E	20020715	US 1992-847503	A 19920306
PT 584446	T	20020930	AT 1993-103697	19930308
ES 2178640	T3	20030101	US 1992-847503	A 19920306
AU 670930	B2	19960808	PT 1993-103697	19930308
AU 9334064	A1	19930909	US 1992-847503	A 19920306
			AU 1993-34064	19930309
			US 1992-847503	A 19920306

L3 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

US 5595872	A	19970121	US 1993-117362	19930903
			US 1992-847503	B2 19920306
			US 1993-15449	B2 19930222
CA 2131430	AA	19950304	CA 1994-2131430	19940902
			US 1993-117362	A 19930903
FI 9404048	A	19950304	FI 1994-4048	19940902
			US 1993-117362	A 19930903
NO 9403260	A	19950306	NO 1994-3260	19940902
AU 9471642	A1	19950316	US 1993-117362	A 19930903
AU 690125	B2	19980423	AU 1994-71642	19940902
ZA 9406772	A	19950403	US 1993-117362	A 19930903
			ZA 1994-6772	19940902
JP 07165712	A2	19950627	US 1993-117362	A 19930903
			JP 1994-210057	19940902
CN 1106003	A	19950802	US 1993-117362	A 19930903
			CN 1994-115640	19940902
HU 70613	A2	19951030	US 1993-117362	A 19930903
US 5789197	A	19980804	HU 1994-2542	19940902
			US 1993-117362	A 19930903
			US 1995-486924	19950607
			US 1992-847503	B2 19920306
US 6492365	B1	20021210	US 1993-15449	B2 19930222
			US 1992-847503	B2 19920306
			US 1993-15449	B2 19930222
			US 1993-117362	A3 19930903
US 2003166590	A1	20030904	US 2001-933593	20010821
			US 1992-847503	B2 19920306
			US 1993-15449	B2 19930222
			US 1993-117362	A3 19930903
			US 1995-486929	A3 19950607

FAN	1998:115356	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5712279	A	19980127	US 1996-548811		19960111
				US 1995-391901	B2	19950221
				US 1995-472067	A2	19950606
	CA 2091102	AA	19930907	CA 1993-2091102		19930305
				US 1992-847503	A	19920306
	HU 67962	A2	19950529	HU 1993-627		19930305
	HU 218419	B	20000828			
				US 1992-847503	A	19920306
	JP 06038761	A2	19940215	JP 1993-46499		19930308
				US 1992-847503	A	19920306
EP 584446	A2	19940302	EP 1993-103697		19930308	
EP 584446	A3	19950426				
EP 584446	B1	20020619				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT						

Patel


<8/14/2004>

L3	ANSWER 27 OF 37	CAPLUS	COPYRIGHT 2004 ACS on STN	(Continued)
AU	9334064	A1	19930909	
US	5739135	A	19980414	US 1992-847503 A 19920306 US 1995-472067 A 19950606 US 1993-117362 A2 19930903 US 1994-284808 B2 19940805 US 1995-391901 B2 19950221 ZA 1996-1340 A 19960220 US 1995-391901 A 19950221 LT 1997-152 A 19970919 US 1995-391901 A 19950221
PAN	1998:236274			
PATENT NO.		KIND	DATE	APPLICATION NO.
PI	US 5739135	A	19980414	US 1995-472067 A 19950606 US 1993-117362 A2 19930903 US 1994-284808 B2 19940805 US 1995-391901 B2 19950221 CA 1993-2091102 A 19930305 US 1992-847503 A 19920306 HU 1993-627 A 19930305
CA	2091102	AA	19930907	US 1992-847503 A 19920306 JP 1993-46499 A 19930308 US 1992-847503 A 19920306 EP 1993-103697 A 19930308
HU	67962	A2	19950529	
HU	218419	B	20000828	
JP	06038761	A2	19940215	
EP	584446	A2	19940302	
EP	584446	A3	19950426	
EP	584446	B1	20020619	
SE		R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,	
AT	219514	E	20020715	US 1992-847503 A 19920306 AT 1993-103697 A 19930308 US 1992-847503 A 19920306 PT 1993-103697 A 19930308 US 1992-847503 A 19920306 ES 1993-103697 A 19930308 AU 670930 B2 19960808 AU 9334064 A1 19930909
US	5595872	A	19970121	US 1992-847503 A 19920306 US 1993-117362 A 19930903 US 1992-847503 B2 19920306 US 1993-15449 B2 19930222 US 1995-486924 A 19950607 US 1992-847503 B2 19920306 US 1993-15449 B2 19930222 US 1993-117362 A3 19930903 US 1995-486929 A 19950607 US 1992-847503 B2 19920306 US 1993-15449 B2 19930222 US 1993-117362 A3 19930903 US 1996-548811 A 19960111 US 1995-391901 B2 19950221 US 1995-472067 A2 19950606 IL 1996-116917 A 19960126 US 1995-391901 A 19950221
US	5789197	A	19980804	
US	6492365	B1	20021210	
US	5712279	A	19980127	
IL	116917	A1	20000831	




L3	ANSWER 27 OF 37	CAPLUS	COPYRIGHT 2004 ACS on STN	(Continued)
TW	486469	B	20020511	US 1995-472067 A 19950606 TW 1996-85100978 A 19960126 US 1995-391901 A 19950221 US 1995-472067 A 19950606 CA 1996-2213466 A 19960201 US 1995-391901 A 19950221 US 1995-472067 A 19950606 WO 1996-US824 A 19960201 W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA RM: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
CA	2213466	AA	19960829	US 1995-391901 A 19950221 US 1995-472067 A 19950606 WO 1996-US824 W 19960201 CN 1996-192015 A 19960201
WO	9626205	A1	19960829	US 1995-391901 A 19950221 US 1995-472067 A 19950606 WO 1996-US824 W 19960201 CN 1996-192015 A 19960201
AU	9647631	A1	19960911	US 1995-391901 A 19950221 US 1995-472067 A 19950606 AU 1996-47631 A 19960201
AU	699865	B2	19981217	US 1995-391901 A 19950221 US 1995-472067 A 19950606 WO 1996-US824 W 19960201 CN 1996-192015 A 19960201
CN	1176640	A	19980318	US 1995-391901 A 19950221 US 1995-472067 A 19950606 CN 1996-192015 A 19960201
CN	1108301	B	20030514	US 1995-391901 A 19950221 US 1995-472067 A 19950606 EP 1996-903604 A 19960201
EP	886637	A1	19981230	US 1995-391901 A 19950221 US 1995-472067 A 19950606 WO 1996-US824 W 19960201 JP 1996-525679 A 19960201 US 1995-391901 A 19950221 US 1995-472067 A 19950606 WO 1996-US824 W 19960201 NZ 1996-302055 A 19960201 US 1995-391901 A 19950221 US 1995-472067 A 19950606 WO 1996-US824 W 19960201 PL 1996-322003 A 19960201 US 1995-391901 A 19950221 US 1995-472067 A 19950606 WO 1996-US824 W 19960201 ZA 1996-1340 A 19960220 US 1995-391901 A 19950221 US 1997-896872 A 19970721 US 1993-117362 A2 19930903 US 1994-284808 B2 19940805 US 1995-391901 B2 19950221 US 1995-472067 A3 19950606 US 1997-898304 A 19970721 US 1993-117362 A2 19930903 US 1994-284808 B2 19940805 US 1995-391901 B2 19950221 US 1995-472067 A3 19950606 US 1997-898303 A 19970721 US 1993-117362 A2 19930903 US 1994-284808 B2 19940805
IE				
JP	11500442	T2	19990112	
NZ	302055	A	20000228	
PL	185443	B1	20030530	
ZA	9601340	A	19970911	
US	5883099	A	19990316	
US	6034098	A	20000307	
US	6066650	A	20000523	

L3	ANSWER 27 OF 37	CAPLUS	COPYRIGHT 2004 ACS on STN	(Continued)
FI	9703416	A	19970820	US 1995-391901 B2 19950221 US 1995-472067 A1 19950606 FI 1997-3416 A 19970820 US 1995-391901 A 19950221 US 1995-472067 A 19950606 WO 1996-US824 W 19960201 NO 1997-3821 A 19970820 US 1995-391901 A 19950221 US 1995-472067 A 19950606 WO 1996-US824 W 19960201
NO	9703821	A	19970820	LT 1997-152 A 19970919 US 1995-391901 A 19950221 LV 1997-171 A 19970919 US 1995-391901 A 19950221 US 1995-472067 A 19950606 US 2001-933593 A 20010821 US 1992-847503 B2 19920306 US 1993-15449 B2 19930222 US 1993-117362 A3 19930903 US 1995-486929 A3 19950607
LT	4367	B	19980825	
LV	11951	B	19981120	
US	2003166590	A1	20030904	

OS MARPAT 125:275663
IT 182429-79-4P 182433-96-1P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 9-[(piperidinoalkyl)fluorene-9-carboxamides and
analogues as
microsomal triglyceride transfer protein inhibitors)
RN 182429-79-4 CAPLUS
CN 9H-Fluorene-9-carboxamide,
9-[4-[[2-[(phenylmethyl)amino]benzoyl]amino]-
1-piperidiny]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




L3	ANSWER 27 OF 37	CAPLUS	COPYRIGHT 2004 ACS on STN	(Continued)
RN	182433-96-1	CAPLUS		
CN	9H-Fluorene-9-carboxamide, 9-[4-[[1-oxido-4-[[2-[(phenylmethyl)amino]benzoyl]amino]-1-piperidiny]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)			




GI

L3 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)





AB R5Z2NR6 [R = piperidyl group Q1; R5 = alkyl, alkoxy, (hetero)aryl, etc.; R6 = H, alk(en)yl; R5R6 = atoms to form a benzannellated ring; Z3 = CO or SO2; 1 of Z4,Z5 = NR1 and the other = CH2; R1 = e.g., (un)substituted aryl group Q2; R12 = H, (halo)alkyl, heteroaryl, etc.; Z = bond, O, S, alkylimino, etc.; Z1,Z2 = bond, O, SO2, CO, etc.; Z11 = bond, alkylene, arylene, etc.] were prepared as microsomal triglyceride transfer protein inhibitors (no data). Thus, N-propyl-9-fluorene-carboxamide (preparation given) was alkylated by 1(CH2)4OSiMe2CMe3 (preparation given) and the deprotected and iodinated product aminated by 2-(4-piperidinyl)-2,3-dihydro-1H-isoindol-1-one (preparation given) to give title compound I.

L3 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1992:571361 CAPLUS
 DN 117:171361
 T1 Synthesis of biologically active 4(3H)-quinazolinonium perchlorates
 AU Chernobrovina, N. I.; Kozhevnikov, Yu. V.; Morozova, G. E.; Chernobrovina, T. A.
 CS Perm. Farm. Inst., Perm, Russia
 SO Khimiko-Farmatsevticheskii Zhurnal (1992), 26(3), 48-51
 CODEN: KHFZAN; ISSN: 0023-1134
 DT Journal
 LA Russian
 IT 139602-64-5P 139602-66-7P 139602-67-8P
 139602-68-9P 139602-69-0P 139602-71-4P
 139602-72-5P 139602-73-6P 143424-22-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and acetylation of)
 RN 139602-64-5 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-phenyl]- (9CI) (CA INDEX NAME)




RN 139602-66-7 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 139602-67-8 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 139602-68-9 CAPLUS
 CN Benzamide, N-(4-chlorophenyl)-2-[[[(2,4-dimethoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 139602-69-0 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-phenyl]- (9CI) (CA INDEX NAME)




RN 139602-71-4 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




L3 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 139602-72-5 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 139602-73-6 CAPLUS
 CN Benzamide, N-(4-chlorophenyl)-2-[[[(3,4-dimethoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 143424-22-0 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




AB Title salts I (R = H, 3-Me, 4-Me, 4-MeO, 4-Cl; R1 = OMe, R2 = H; R1 = H, R2 = OMe) were prepared by condensation of anthranililides with dimethoxybenzaldehydes, followed by borohydride reduction of the imine group, N-acetylation, and acid cyclization. The acute toxicity and anticonvulsant, analgesic, and antimicrobial activities of some I were tested.


L3 ANSWER 29 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1992:128388 CAPLUS
 DN 116:128388
 TI Arylamides of N-(p-2',4'- or -3',4'- dimethoxybenzyl)anthranilic acid
 IN Chernobrovina, N. I.; Kozhevnikov, Yu. V.; Zalesov, V. S.; Semenova, Z. N.
 PA Perm Pharmaceutical Institute, USSR
 SO U.S.S.R.
 From: Otkrytiya, Izobret. 1991, (28), 258.
 CODEN: URXXAF
 DT Patent
 LA Russian
 FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI SU 1156162	A1	19910730	SU 1983-3573020	19830217
IT 139602-64-5			139602-65-6	139602-66-7
139602-67-8			139602-68-9	139602-69-0
139602-70-3			139602-71-4	139602-72-5
139602-73-6				

RL: RCT (Reactant); RACT (Reactant or reagent)
 (intermediate for quinoxalinonium perchlorate deriva.)
 RN 139602-64-5 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)





RN 139602-65-6 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 139602-66-7 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 29 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139602-67-8 CAPLUS
 CN Benzamide, 2-[[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 139602-68-9 CAPLUS
 CN Benzamide, N-(4-chlorophenyl)-2-[[[(2,4-dimethoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)





RN 139602-69-0 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)


L3 ANSWER 29 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139602-70-3 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 139602-71-4 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 139602-72-5 CAPLUS
 CN Benzamide, 2-[[[(3,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 29 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139602-73-6 CAPLUS
CN Benzamide, N-(4-chlorophenyl)-2-[[[(3,4-dimethoxyphenyl)methyl]amino]-
(9CI) (CA INDEX NAME)



GI



AB The title compds. (I; R = H, Me, p-Cl; R1 o-OMe, m-OMe) are intermediates for biol. active 1-(2',4'- or -3',4'-dimethoxybenzyl)-2-methyl-3-aryl-4 (3H)-quinazolinonium perchlorates.

L3 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

US 1990-579001	A	19900906
US 1990-600390	A <th>19901019</th>	19901019
AU 9066732	A1	19910523
AU 630251	B2	19921022
US 1989-438923	A <td>19891117</td>	19891117
US 1990-579001	A <td>19900906</td>	19900906
US 1990-600390	A <td>19901019</td>	19901019
ZA 9009246	A	19920729
JP 04257584	A2	19920911
JP 2539116	B2	19961002
US 1989-438923	A <td>19891117</td>	19891117
US 1990-579001	A <td>19900906</td>	19900906
US 1990-600390	A <td>19901019</td>	19901019
HU 59407	A2	19920528
HU 214595	B	19980428
US 1990-579001	A <td>19900906</td>	19900906
US 1990-600390	A <td>19901019</td>	19901019
RU 2040527	C1	19950725
US 1989-438923	A <td>19891117</td>	19891117
US 1990-579001	A <td>19900906</td>	19900906
US 1990-600390	A <td>19901019</td>	19901019
US 1993-91418	A <td>19930713</td>	19930713
US 1989-340970	B2	19890420
US 1989-372974	B2	19890628
US 1989-438923	B2	19891117
US 1990-579001	B2	19900906
US 1990-600390	B2	19901019
US 1991-740828	B1	19910805
US 1994-279464	B2	19940722
US 1989-340970	B2	19890420
US 1989-372974	B2	19890628
US 1989-438923	B2	19891117
US 1990-579001	B2	19900906
US 1990-600390	B2	19901019
US 1991-740828	B1	19910805
US 1993-91418	A3	19930713
HK 1011025	A1	20000420
US 1989-438923	A <td>19891117</td>	19891117
US 1990-579001	A <td>19900906</td>	19900906
US 1990-600390	A <td>19901019</td>	19901019

PATENT FAMILY INFORMATION:

FAN 1991:102069

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 393529	A1	19901024	EP 1990-107098	19900412
EP 393529	B1	19930630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 91128	E	19930715	US 1989-340970	A 19890420
			AT 1990-107098	A 19900412
			US 1989-340970	A 19890420
			EP 1990-107098	A 19900412
ES 2058656	T3	19941101	ES 1990-107098	A 19900412
			US 1989-340970	A 19890420
CA 2014771	AA	19901020	CA 1990-2014771	A 19900418
CA 2014771	C	20000801		
JP 03063276	A2	19910319	US 1989-340970	A 19890420
JP 2851913	B2	19990127	JP 1990-104379	A 19900419
			US 1989-340970	A 19890420

L3 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1991:514559 CAPLUS

DN 115:114559

TI Preparation of 5,11-dihydro-6H-dipyrido [3,2-b:2',3'-e](1,4) diazepines and their use in the prevention or treatment of HIV infection

IN Hargrave, Karl D.; Schmidt, Guenther; Engel, Wolfhard; Trummlitz, Guenther; Eberlein, Wolfgang

PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Thomae, Dr. Karl, G.m.b.H.

SO Eur. Pat. Appl., 42 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 429987	A2	19910605	EP 1990-121954	19901116
EP 429987	A3	19920122		
EP 429987	B1	19990317		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 1989-438923	A	19891117		
US 1990-579001	A	19900906		
US 1990-600390	A	19901019		
CA 2030056	AA	19910518	CA 1990-2030056	19901115
CA 2030056	C	19951017		
US 1989-438923	A	19891117		
US 1990-579001	A	19900906		
FI 9005674	A	19910518	FI 1990-5674	19901116
FI 94529	B	19950615		
FI 94529	C	19950925		
US 1989-438923	A	19891117		
US 1990-579001	A	19900906		
US 1990-600390	A	19901019		
NO 9004986	A	19910521	NO 1990-4986	19901116
NO 175478	B	19940711		
NO 175478	C	19941019		
US 1989-438923	A	19891117		
US 1990-579001	A	19900906		
US 1990-600390	A	19901019		
HU 56103	A2	19910729	HU 1990-7186	19901116
HU 208139	B	19930830		
US 1989-438923	A	19891117		
JP 04178386	A2	19920625	JP 1990-311230	19901116
JP 2912007	B2	19990628		
US 1989-438923	A	19891117		
IL 96367	A1	19970218		
US 1989-438923	A	19891117		
IL 1990-96367	A	19901116		
US 1989-438923	A	19891117		
IL 1990-94883	A0	19900627		
US 1990-579001	A	19900906		
US 1990-600390	A	19901019		
AT 1990-121954	E	19990415	AT 1990-121954	19901116
US 1989-438923	A	19891117		
US 1990-579001	A	19900906		
US 1990-600390	A	19901019		
ES 1990-121954	T3	19990701	ES 1989-438923	19891117

L3 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

US 1993-91418	A	19930713
US 1989-340970	B2	19890420
US 1989-372974	B2	19890628
US 1989-438923	B2	19891117
US 1990-579001	B2	19900906
US 1990-600390	B2	19901019
US 1991-740828	B1	19910805
US 1994-279464	B2	19940722
US 1989-340970	B2	19890420
US 1989-372974	B2	19890628
US 1989-438923	B2	19891117
US 1990-579001	B2	19900906
US 1990-600390	B2	19901019
US 1991-740828	B1	19910805
US 1993-91418	A3	19930713
US 1989-340970	B2	19890420
US 1989-372974	B2	19890628
US 1989-438923	B2	19891117
US 1990-579001	B2	19900906
US 1990-600390	B2	19901019
US 1991-740828	B1	19910805
US 1993-91418	A3	19930713
HK 1011025	A1	20000420
US 1989-438923	A <td>19891117</td>	19891117
US 1990-579001	A <td>19900906</td>	19900906
US 1990-600390	A <td>19901019</td>	19901019

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 410148	A1	19910130	EP 1990-112072	19900626
EP 410148	B1	19940406		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 1989-372974	A	19890628		
CA 2019812	AA	19901228	CA 1990-2019812	19900626
CA 2019812	C	20001121		
US 1989-372974	A	19890628		
DD 295849	A5	19911114	DD 1990-342100	19900626
US 1989-372974	A	19890628		
AT 103918	E	19940415	AT 1990-112072	19900626
US 1989-372974	A	19890628		
EP 1990-112072	A	19900626		
ES 1990-112072	A	19900626		
US 1989-372974	A	19890628		
NO 1990-2851	A	19900627		
US 1989-372974	A	19890628		
HU 1990-4021	A	19900627		
US 1989-372974	A	19890628		
JP 1990-169663	A	19900627		
US 1989-372974	A	19890628		
ZA 1990-4991	A	19900627		
US 1989-372974	A	19890628		
FI 92828	B	19940930	FI 1990-3225	19900627
FI 92828	C	19950110		
US 1989-372974	A	19890628		
IL 94883	A1	19941007	IL 1990-94883	19900627
US 1989-372974	A	19890628		
AU 9057921	A1	19910103	AU 1990-57921	19900628
AU 620724	B2	19920220		
US 1989-372974	A	19890628		
RU 2024522	C1	19941215	RU 1992-5011432	19920427
US 1989-372974	A	19890628		
US 1993-91418	A	19930713		
US 1989-340970	B2	19890420		
US 1989-372974	B2	19890628		
US 1989-438923	B2	19891117		
US 1990-579001	B2	19900906		

LJ ANSWER 30 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

US 5620974 A 19970415



US 1990-600390 R2 19901019
US 1991-740828 R1 19910805
US 1994-279464 19940722
US 1989-340970 B2 19890420
US 1989-372974 R2 19890628
US 1989-438923 B2 19891117
US 1990-579001 B2 19900906
US 1990-600390 B2 19901019
US 1991-740828 B1 19910805
US 1993-91418 A3 19930713

OS MARPAT 115:114559

IT 132312-45-9P 132362-76-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of antiviral dihydropyridodiazepines)


RN 132312-45-9 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 132362-76-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



GI

LJ ANSWER 31 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1991:449732 CAPLUS

DN 115:49732

TI Preparation of

5,11-dihydro-6H-dipyrro[3,2-b:2',3'-e][1,4]diazepin-6-ones and thiones and their use in the prevention or treatment of AIDS

IN Schmidt, Guenther; Engel, Wolfhard; Trummlitz, Guenter; Eberlein, Wolfgang; Hargrave, Karl D.

PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Thomae, Dr. Karl, G.m.b.H.

SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW

DT Patent



LA English

FAN CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 410148	A1	19910130	EP 1990-112072	19900626
EP 410148	B1	19940406		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2019812	AA	19901228	US 1989-372974	A 19890628
CA 2019812	C	20001121	CA 1990-2019812	19900626
DD 295849	A5	19911114	US 1989-372974	A 19890628
			DD 1990-342100	19900626
			US 1989-372974	A 19890628
AT 103918	E	19940415	AT 1990-112072	19900626
			US 1989-372974	A 19890628
			EP 1990-112072	A 19900626
ES 2063202	T3	19950101	ES 1990-112072	19900626
			US 1989-372974	A 19890628
NO 9002851	A	19910102	NO 1990-2851	19900627
NO 174468	B	19940131		
NO 174468	C	19940518		
HU 55017	A2	19910429	US 1989-372974	A 19890628
HU 206504	B	19921130	HU 1990-4021	19900627
JP 03115283	A2	19910516	US 1989-372974	A 19890628
JP 2911967	B2	19990628	JP 1990-169663	19900627
ZA 9004991	A	19920325	US 1989-372974	A 19890628
			ZA 1990-4991	19900627
FI 92828	B	19940930	US 1989-372974	A 19890628
FI 92828	C	19950110	FI 1990-3225	19900627
IL 94883	A1	19941007	US 1989-372974	A 19890628
			IL 1990-94883	19900627
AU 9057921	A1	19910103	US 1989-372974	A 19890628
AU 620724	B2	19920220	AU 1990-57921	19900628
RU 2024522	C1	19941215	US 1989-372974	A 19890628
			RU 1992-5011432	19920427
			US 1989-372974	A 19890628
US 5366972	A	19941122	US 1993-91418	19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1993-91418	A3 19930713

Patel

LJ ANSWER 30 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB Title compds. I (Z = O, S, :NCR, :NOR; R1-R8 = various subsets of groups selected from H, alkyl, cycloalkyl, fluoroalkyl, aryl, tetrahydrofuryl, alkanoyl, trinalomethyl, alkoxyacarbonyl, halo, amino, and many more; R9 = Cl, 3 alkyl; numerous provisions and exceptions) were prepared for prevention and treatment of HIV-1 infection. For example, 2-hydroxy-4-methyl-3-nitropyridine was converted by chlorination with POCl3 and reduction to 3-amino-2-chloro-4-methylpyridine, which underwent amidation with 2-chloronicotinoyl chloride and condensation with EtNH2 to give (chloromethylpyridinyl) (ethylamino)pyridinecarboxamide II. Cyclization of II by NaH in DMF at reflux temperature gave I (Z = O, R1 = R3 = R4 = R6-R8 = H, R2 = Et, R5 = Me) (III). At 3 µg/mL, III gave 100% inhibition of HIV-1 replication in a human T-cell culture assay. III also gave 100% inhibition of HIV-1 reverse transcriptase at 10 µg/mL in vitro; no activity was seen for I against 2 related enzymes, indicating high specificity. Three formulations, 77 synthetic examples, and addnl. test results including cytotoxicity are given.

LJ ANSWER 31 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

US 5620974 A 19970415

US 1994-279464 19940722
US 1989-340970 B2 19890420
US 1989-372974 B2 19890628
US 1989-438923 B2 19891117
US 1990-579001 B2 19900906
US 1990-600390 B2 19901019
US 1991-740828 B1 19910805
US 1993-91418 A3 19930713

PATENT FAMILY INFORMATION:

FAN 1991:102069

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 393529	A1	19901024	EP 1990-107098	19900412
EP 393529	B1	19930630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 91128	E	19930715	US 1989-340970	A 19890420
			AT 1990-107098	19900412
			US 1989-340970	A 19890420
			EP 1990-107098	A 19900412
ES 2058656	T3	19941101	ES 1990-107098	19900412
CA 2014771	AA	19901020	US 1989-340970	A 19890420
CA 2014771	C	20000801	CA 1990-2014771	19900418
JP 03063276	A2	19910319	US 1989-340970	A 19890420
JP 2851913	B2	19990127	JP 1990-104379	19900419
US 5366972	A	19941122	US 1989-340970	A 19890420
			US 1993-91418	19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1993-91418	A3 19930713

US 5620974 A 19970415

US 1994-279464 19940722
US 1989-340970 B2 19890420
US 1989-372974 B2 19890628
US 1989-438923 B2 19891117
US 1990-579001 B2 19900906
US 1990-600390 B2 19901019
US 1991-740828 B1 19910805
US 1993-91418 A3 19930713

PATENT FAMILY INFORMATION:

FAN 1991:514559



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 429987	A2	19910605	EP 1990-121954	19901116
EP 429987	A3	19920122		
EP 429987	B1	19990317		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2030056	AA	19910518	US 1989-438923	A 19891117
CA 2030056	C	19951017	US 1990-579001	A 19900906
			US 1990-600390	A 19901019
			CA 1990-2030056	19901115
FI 9005674	A	19910518	US 1989-438923	A 19891117
FI 94529	B	19950615	US 1990-579001	A 19900906
FI 94529	C	19950925	FI 1990-5674	19901116

<8/14/2004>


LS	ANSWER 31 OF 37	CAPLUS	COPYRIGHT 2004 ACS on STN	(Continued)
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
NO 9004986	A	19910521	NO 1990-4386	19901116
NO 175478	B	19940711		
NO 175478	C	19941019		
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
HU 56103	A2	19910729	HU 1990-7186	19901116
HU 208139	B	19930830		
			US 1989-438923	A 19891117
JP 04178356	A2	19920625	JP 1990-311230	19901116
JP 2912007	B2	19990628		
			US 1989-438923	A 19891117
IL 96367	A1	19970218	IL 1990-96367	19901116
			US 1989-438923	A 19891117
			IL 1990-94883	A0 19900627
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
AT 177744	E	19990415	AT 1990-121954	19901116
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
ES 2130114	T3	19990701	ES 1990 121954	19901116
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
AU 9066732	A1	19910523	AU 1990-66732	19901119
AU 630251	B2	19921022		
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
ZA 9009246	A	19920729	ZA 1990-9246	19901119
			US 1989-438923	A 19891117
JP 04257584	A2	19920911	JP 1991-211068	19910822
JP 2539116	B2	19961002		
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
HU 59407	A	19920528	HU 1991-2865	19910904
HU 214595	B2	19980428		
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
RU 2040527	C1	19950725	RU 1992-5011559	19920506
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
US 5366972	A	19941122	US 1993-91418	19930711
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
US 5620974	A	19970415	US 1994-279464	19940723

13	ANSWER 31 OF 37	CAPLUS	COPYRIGHT 2004 ACS ON STN	(Continued)
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1993-91418	A3 19930713
HK 1011025		A1	20000420	HK 1998-112090
				US 1989-438923
				US 1990-579001
				US 1990-600390
				US 1991-740828

OS	MARPAT 115:49732	US 1990 600390	A 19901019
IT	132312-45-9P		
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)		
	(preparation and reaction of, in preparation of drug for treatment of		
AIDS			
RN	132312-45-9 CAPLUS		
CN	3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl) 2-[[4-(methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)		





GI




AB The title compds. I [Z = O, S; R1 = H, (substituted) alkyl, arylmethyl,

L3 ANSWER 31 of 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
etc.; R2 = H, (substituted) alkyl, alkenyl, etc.; R3-R8 = H, or 1 of
R3-R8
alkyl, alkoxy, alkylthio, etc., and the remaining 5 of R3-R8 are each
H, or R3-R5 are H, alkyl with the proviso that at least one is H or 1 of
R3-R5 is Bu with the remaining 2 being H; and R6-R8 are H, alkyl with the
proviso that at least 1 is H, or 1 of R6-R8 is Bu with the remaining 2
being H; with the proviso that when R1 and R2 are H, alkyl and R3-R8 are
all H then Z is S] were prepd. A mixt. of
5.11 6-hydroxy-11-ethyl S-methyl-
6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one and Lawesson's reagent in
toluene was refluxed for 2.5 h to give 1 (R1 = Me; Z = S; R2 = Et; R3 =
R4 = R5 = R6 = R7 = R8 = H), which at 10 µg/mL gave 100% in vitro
inhibition of reverse transcriptase.

LJ ANSWER 32 OF 37 CAPLUS COPYRIGHT 2004 ACS ON STN
AN 1991:449642 CAPLUS
DN 115:49642
TI Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1.
Tricyclic pyridobenz- and dipyriddiazepinones
AU Hargrave, Karl D.; Proudfoot, John R.; Grozingier, Karl G.; Cullen,
Ernest;
Kapadia, Suresh R.; Patel, Usha R.; Fuchs, Victor U.; Mauldin, Scott C.;
Vicous, Jana; et al.
CS Boehringer Ingelheim Pharm., Inc., Ridgefield, CT, 06877, USA
SO Journal of Medicinal Chemistry (1991), 34(7), 2231-41
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 115:49642
IT 132312-45-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
Preparation and reductive intramol. cyclocondensation of,
dipyriddiazepinone from)
RN 112312-45-9 CAPLUS
CN 3-Pyridinecarboxamide, N- (2-chloro-3-pyridinyl)- 2-[[{(4-
methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



GI



AB Novel pyrido[2,3-b][1,4]benzodiazepinones, pyrido[2,3-b][1,5]benzodiazepinones, and dipyrdo[3,2-b:2',3'-e][1,4]diazepinones e.g., I (X = N, X1 = CH; X = CH; X1 = N) and II inhibited human immunodeficiency virus type 1 reverse transcriptase in vitro at concns.

<8/14/2004>

L3 ANSWER 32 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 low as 35 nM. In all three series, small substituents (e.g., Me, Et, Ac) are preferred at the lactam nitrogen, whereas slightly larger alkyl moieties (e.g., Et, cyclopropyl) are favored at the other (N-11) diazepinone nitrogen. In general, lipophilic substituents are preferred on the A ring, whereas substitution on the C ring generally reduces potency relative to the corresponding compds. with no substituents on the arom. ring. Max. potency is achieved with Me substitution at the position ortho to the lactam nitrogen atom; however, in this case an unsubstituted lactam nitrogen is preferred. Addnl. substituents on the A ring can be readily tolerated. II (BI-RG 587) is a potent (IC50 = 84 nM) and selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, and has been chosen for preclin. development. It is noncytotoxic except at high doses and effective against all clin. isolates of HIV-1, including those which are AZT-resistant. It is specific for HIV-1, ineffective against HIV-2, inactive against simian and feline reverse transcriptase, and does not inhibit DNA polymerases.

L3 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1991:102069 CAPLUS
 DN 114:102069
 TI Preparation of
 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
 as drugs for prevention or treatment of AIDS
 IN Schmidt, Guenther; Engel, Wolfhard; Trummelitz, Guenter; Eberlein, Wolfgang; Hargrave, Karl D.
 PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Thomae, Dr. Karl, G.m.b.H.
 SO Eur. Pat. Appl., 21 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN CWT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 193529	A1	19901024	EP 1990-107098	19900412
EP 193529	B1	19930630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 91128	E	19930715	US 1989-340970	A 19890420
			AT 1990-107098	19900412
			US 1989-340970	A 19890420
			EP 1990-107098	A 19900412
ES 2058656	T3	19941101	ES 1990-107098	A 19900412
			US 1989-340970	A 19890420
CA 2014771	AA	19901020	CA 1990-2014771	19900418
CA 2014771	C	20000801		
JP 03063276	A2	19910319	US 1989-340970	A 19890420
JP 2851913	B2	19990127	JP 1990-104379	19900419
			US 1989-340970	A 19890420
			US 1993-91418	19930713
			US 1989-340970	B2 19890628
			US 1989-372974	B2 19891117
			US 1989-438923	B2 19900906
			US 1990-579001	B2 19901019
			US 1991-740828	B1 19910805
			US 1994-279464	19940722
US 5620974	A	19970415	US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1993-91418	A3 19930713

PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 410148	A1	19910130	EP 1990-112072	19900626
EP 410148	B1	19940406		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2019812	AA	19901228	CA 1990-2019812	19900626

L3 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2019812	C	20001121		
DD 295849	A5	19911114	US 1989-372974	A 19890628
			DD 1990-342100	19900626
AT 103918	E	19940415	US 1989-372974	A 19890628
			AT 1990-112072	19900626
			US 1989-372974	A 19890628
ES 2063202	T3	19950101	EP 1990-112072	A 19900626
			ES 1990-112072	A 19900626
NO 9002851	A	19910102	US 1989-372974	A 19890628
NO 174468	B	19940131	NO 1990-2851	19900627
NO 174468	C	19940518		
HU 55017	A2	19910429	US 1989-372974	A 19890628
HU 206504	B	19921130	HU 1990-4021	19900627
JP 03115283	A2	19910516	US 1989-372974	A 19890628
JP 2911967	B2	19990628	JP 1990-169663	19900627
ZA 9004991	A	19920325	US 1989-372974	A 19890628
			ZA 1990-4991	19900627
FI 92828	B	19940930	US 1989-372974	A 19890628
FI 92828	C	19950110	FI 1990-3225	19900627
IL 94883	A1	19941007	US 1989-372974	A 19890628
			IL 1990-94883	19900627
AU 9057921	A1	19910103	US 1989-372974	A 19890628
AU 620724	B2	19920220	AU 1990-57921	19900628
RU 2024522	C1	19941215	US 1989-372974	A 19890628
			RU 1992-5011432	19920427
US 5366972	A	19941122	US 1989-372974	A 19890628
			US 1993-91418	19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1993-91418	A3 19930713
US 5620974	A	19970415	US 1989-372974	A 19890628
			US 1989-372974	A 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1993-91418	A3 19930713

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 429987	A2	19910605	EP 1990-121954	19901116
EP 429987	A3	19920122		
EP 429987	B1	19930117		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2030056	AA	19910518	US 1989-438923	A 19891117
CA 2030056	C	19951017	US 1990-579001	A 19900906
			US 1990-600390	A 19901019
			CA 1990-2030056	19901115



L3 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FI 9005674	A	19910518	US 1990-579001	A 19900906
FI 94529	B	19950615	FI 1990-5674	19901116
FI 94529	C	19950925		
NO 9004986	A	19910521	US 1989-438923	A 19891117
NO 175478	B	19940711	US 1990-579001	A 19900906
NO 175478	C	19941019	US 1990-600390	A 19901019
			NO 1990-4986	19901116
HU 56103	A2	19910729	US 1989-438923	A 19891117
HU 208139	B	19930830	US 1990-579001	A 19900906
JP 04178386	A2	19920625	US 1990-600390	A 19901019
JP 2912007	B2	19990628	JP 1990-311230	19901116
IL 96367	A1	19970218	US 1989-438923	A 19891117
			IL 1990-96367	19901116
			US 1989-438923	A 19891117
			IL 1990-94883	A0 19900627
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
AT 177744	E	19990415	AT 1990-121954	19901116
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
ES 2130114	T3	19990701	ES 1990-121954	19901116
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
AU 9066732	A1	19910523	US 1990-600390	A 19901019
AU 630251	B2	19921022	AU 1990-66732	19901119
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
ZA 9009246	A	19920729	ZA 1990-9246	19901119
JP 04257584	A2	19920911	US 1989-438923	A 19891117
JP 2539116	B2	19961002	JP 1991-211068	19910822
			US 1990-579001	A 19900906
HU 59407	A2	19920528	US 1990-600390	A 19901019
HU 214595	B	19980428	HU 1991-2865	19910904
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
RU 2040527	C1	19950725	RU 1992-5011559	19920506
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
US 5366972	A	19941122	US 1993-91418	19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1994-279464	19940722


<8/14/2004>

L3 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 US 1989-340970 B2 19890420
 US 1989-372974 B2 19890628
 US 1989-438923 B2 19891117
 US 1990-579001 B2 19900906
 US 1990-600390 B2 19901019
 US 1991-740828 B1 19910805
 US 1993-91418 A3 19930713
 HK 1011025 A1 20000420 HK 1998-112090 19981117
 US 1989-438923 A 19891117
 US 1990-579001 A 19900906
 US 1990-600390 A 19901019

OS MARPAT 114:102069
 IT 132312-45-9P 132362-76-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as intermediate for dipyrindiazepinone reverse
 transcriptase inhibitor)
 RN 132312-45-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[4-(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 132362-76-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[4-(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)




GI

L3 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1984:611088 CAPLUS
 DN 101:211088
 TI Studies of 4[3H]-quinazolinone. XII. Synthesis and biological activity of 1-benzyl (4'-nitrobenzyl)-2-methyl-3-alkyl (aryl)-4(3H)-quinazolinone perchlorates
 AU Chernobrovin, N. I.; Kozhevnikov, Yu. V.; Zalesov, V. S.; Gradel, I. I.
 CS Perm. Pharm. Inst., Perm, USSR
 SO Khimiko-Farmatsevticheski Zhurnal (1984), 18(7), 830-3
 CODEN: KHFZAN; ISSN: 0023-1134
 DT Journal
 LA Russian
 IT 92944-76-8P 92944-77-9P 92944-78-0P
 92944-79-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or Reagent)
 (preparation and acetylation of)
 RN 92944-76-8 CAPLUS
 CN Benzamide, N-(2,4-dimethylphenyl)-2-[[4-(4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 92944-77-9 CAPLUS
 CN Benzamide, N-(4-methoxyphenyl)-2-[[4-(4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 92944-78-0 CAPLUS
 CN Benzamide, N-(4-methoxyphenyl)-2-[[4-(4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




AB The title compds. (I; R1, R2 = H, C1-5 alkyl), were prepared. Thus, N-(2-chloro-3-pyridinyl)-2-[[4-(4-methoxyphenyl)methyl]amino]-3-pyridinecarboxamide (preparation given) was refluxed 8 h with NaH in DMF to give 50% 5,11-dihydro-11-[[4-(4-methoxyphenyl)methyl]-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, which was converted to title compound II in 3 steps. II at 10 µg/mL gave 100% inhibition of HIV-I reverse transcriptase. Dosage formulations were prepared containing I (R1 = H, R2 = Pr).


L3 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 92944-79-1 CAPLUS
 CN Benzamide, N-(4-ethoxyphenyl)-2-[[4-(4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




GI




L3 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 AB The title compds. I (R = 2,4-xylyl, 4-MeOC₆H₄, Bu, hexyl, R₁ = H; R = 4-MeOC₆H₄, 4-ClOC₆H₄, R₁ = NO₂) were prepared in 58.6-83.4% yields by acetylation of o-RNHCOC₆H₄NR₂CH₂CH₂CH₂CH₂NR₁ (II, R₂ = H) to give 61.3-98.1% I (R₂ = Ac) which were cyclized by refluxing in MeOH containing 5% HClO₄. I (R = 4-MeOC₆H₄, R₁ = NO₂) was an effective antispasmodic for white mice at 150 mg/kg dosage.

L3 ANSWER 35 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1984:34516 CAPLUS
 DN 100:34516
 TI New syntheses of 11-acyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones and related studies
 AU Kovac, T.; Oklobdzija, M.; Comisso, G.; Decorte, E.; Fajdiga, T.; Moimas, F.; Angeli, C.; Zonno, F.; Tomo, R.; Sunjic, V.
 CS Chem. Res. Co., San Giovanni, Italy
 SO Journal of Heterocyclic Chemistry (1983), 20(5), 1339-49
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 OS CASREACT 100:34516
 IT 88369-73-7P 88369-74-8P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 88369-73-7 CAPLUS
 CN Benzamide, N-(2-chloro-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 88369-74-8 CAPLUS
 CN Benzamide, N-(2-chloro-1-oxido-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI)
 (CA INDEX NAME)




GI

L3 ANSWER 35 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




AB 11-Acyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones I (R = 4-methylpiperazino, imidazolo, 2-methylimidazolo) were prepared via N-α-chloroacetylation and aminolysis. Other attempts at cyclization to form I are also reported.

L3 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1977:171214 CAPLUS
 DN 86:171214
 TI Synthesis and pharmacological properties of 2-aminonicotinamide derivatives
 AU Zhmurenko, L. A.; Borisenko, S. A.; Salimov, R. M.; Glozman, O. M.; Zagorevskii, V. A.
 CS Nauchno-Issled. Inst. Farmakol., Moscow, USSR
 SO Fiziologicheskii Aktivnyye Veshchestva (1976), 8, 89-92
 CODEN: FAVUAI; ISSN: 0533-1153
 DT Journal
 LA Russian
 IT 62636-33-3P 62636-39-9P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and pharmacol. properties of)
 RN 62636-33-3 CAPLUS
 CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 62636-39-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-(2-methoxyphenyl)-2-[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

GI



AB The title compds. I (R = H, m-F₃CC₆H₄, o-MeOC₆H₄, NR₂ = HOCH₂CH₂NH,

<8/14/2004>


L3 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
PhCH2NH, 4-methyl-1-piperazinyl, 4-(2-hydroxyethyl)-1-piperazinyl,
piperidino], useful as sedatives and muscle relaxants, were obtained in
56-98% yields by amination of chloronicotinamides with R21NH.

L3 ANSWER 37 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1971:76431 CAPLUS
DN 74:76431
TI 3-Substituted picolinyl penicillins and cephalosporins, useful as animal
feed supplements and in germicidal preparations employed as surface
disinfectants
IN Schwarz, J. S. Paul; Sheehan, John T.
PA E. R. Squibb and Sons, Inc.
SO U.S., 11 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION No.	DATE
PI US 3553203	A	19710105	US 1969-834157	19690617
BR 6915314	A0	19730419	BR 1969-215314	19691219
CA 963003	A1	19750218	US 1969-834157	19690617
DE 2028830	A	19710107	CA 1970-85025	19700609
CH 517116	A	19711231	US 1969-834157	19690617
FR 2052982	A1	19710416	DE 1970-2028830	19700611
FR 2052982	A5	19710416	US 1969-834157	19690617
			CH 1970-517116	19700616
			US 1969-834157	19690617
			FR 1970-22345	19700617
			US 1969-834157	19690617

IT 30861-03-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(Preparation of)
RN 30861-03-1 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[3-
(benzylamino)picolinamido]-3,3-dimethyl-7-oxo-, monosodium salt (BCI)
(CA
INDEX NAME)

Absolute stereochemistry.



● Na

AB The title compds. were prepared Thus, ClCO2Et was added to an ice-cold
solution of 3-benzylxy-2-picolinic acid-HCl sesquihydrate in CHCl3
containing

L3 ANSWER 37 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Et3N; after 10 min, ice-cold 6-aminopenicillanic acid and Et3N in CHCl3
was added and the soln. kept 12 hr to give, after alk. addn., Na
6-(3-benzylxy-2-picolinamido)penicillanate. Prepd. similarly were: Na
7-(3-benzylxy-2-picolinamido)cephalosporanate, Na 6-(3-hydroxy-2-
picolinamido)penicillanate, and Na 7-(3-hydroxy-2-picolinamido)-
cephalosporanate.

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

297.84

453.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-27.20

-27.20

STN INTERNATIONAL LOGOFF AT 10:07:02 ON 14 AUG 2004

L Number	Hits	Search Text	DB	Time stamp
1	5221	("514/183,188,277,352,354,356").CCLS	USPAT	2003/07/02 09:57
2	1355	("546/304,315,345").CCLS	USPAT	2003/07/02 09:58
3	189	((("514/183,188,277,352,354,356").CCLS) and (("546/304,315,345").CCLS)	USPAT	2003/07/02 09:58
4	37	((("514/183,188,277,352,354,356").CCLS) and (("546/304,315,345").CCLS)) and cancer	USPAT	2003/07/02 09:58

police
51365
812404

BEST AVAILABLE COPY

812404

L Number	Hits	Search Text	DB	Time stamp
1	5373	("514/183,188,277,352,354,356").CCLS	USPAT	2003/11/06 14:34
2	1372	("546/304,315,345").CCLS	USPAT	2003/11/06 14:35
3	194	("514/183,188,277,352,354,356").CCLS) and ("546/304,315,345").CCLS)	USPAT	2003/11/06 14:35
4	12075	("514/183,188,277,352,354,356").CCLS) and ("546/304,315,345").CCLS)) and 2-amino-pyridine-3 carboxamide	USPAT	2003/11/06 14:36
5	0	L:3 and (("514/183,188,277,352,354,356").CCLS) and ("546/304,315,345").CCLS)) and 2-amino-pyridine-3 carboxamide) and KDR	USPAT	2003/11/06 14:37
6	7	("514/183,188,277,352,354,356").CCLS) and ("546/304,315,345").CCLS)) and (("514/183,188,277,352,354,356").CCLS) and ("546/304,315,345").CCLS)) and 2-amino-pyridine-3 carboxamide) and 2-amino-pyridine-3 carboxamide) and cancer	USPAT	2003/11/06 14:38
7	0	("514/183,188,277,352,354,356").CCLS) and ("546/304,315,345").CCLS)) and ("514/183,188,277,352,354,356").CCLS) and ("546/304,315,345").CCLS)) and 2-amino-pyridine-3 carboxamide) and KDR	USPAT	2003/11/06 14:39

Handwritten signature
8/1/04